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Tumour necrosis factor (TNF) a  is a pleiotropic cytokine essential to the immune 
response within chronic inflammatory respiratory diseases. In lung parenchymal cells, TNFa 
induces the upregulation of cytokines, chemokines, adhesion molecules and inflammatory 
mediators, which are all important molecules within the immune response of the lung. The 
role of individual phosphoinositide 3-kinase (PI3K) isoforms within these processes is 
unknown at present. After carrying out initial experiments to determine the effect of PI3K 
inhibitors on a primary murine lung preparation, A549 lung epithelial cells were chosen as an 
adequate model for subsequent experimentation. Small interfering (si) RNA technology was 
employed to explore the role of specific PI3K isoforms. After validation of this technique 
through mRNA and protein quantitation, the impact of siRNA-mediated PI3K silencing on 
basic cell functions was analysed by determining the ability of A549 cells to heal wounds and 
survive under basal conditions. During the course of these experiments, PI3K class Ila- 
siRNA treated cells were unable to survive; while class lip- and pllOp-siRNA treated cells 
possessed a delayed wound healing response. Using PI3K isoform-specific inhibitors and 
siRNA on A549 cells, the role of PI3K isoforms in TNFa-induced cell signalling and 
functions was then determined. Under TNFa-stimulated conditions, pi 105-specific inhibition, 
by siRNA or by the p i 1 OS-specific inhibitor IC87114, decreased the levels of cyclooxygenase 
(COX)-2 and its consequent prostaglandin (PG) E2 upregulation. Studies into the 
phosphorylation levels of different transcription factors thought to be active during COX-2 
production, led to the determination that p i 108 activity is also important in cJun activation, an 
important promoter of COX-2 gene expression. Furthermore, using a specific peptide 
inhibitor of cJun amino-terminal kinase, it was determined that cJun activity is important for 
TNFa-induced COX-2 and PGE2 upregulation. Mitogen activated protein kinase signalling 
(extracellular signal-regulated kinase and cJun N-terminal kinase) was not affected by PI3K 
inhibition, while Class I p i 10p-specific siRNA or a pi 10p/pl 105 inhibitor TGX-121 
donwregulated Akt (a downstream mediator of PI3K activity) phosphorylation induced by 
TNFa. IC87114 or siRNA specific for p i 10a or p i 108, had no effect in Akt activation. With 
regards to other cell functions, ICAM-1 expression was not affected by PI3K inhibition, but 
proved to be dependent on mammalian target of rapamycin (mTOR) activity; while 
interleukin-8 upregulation was PI3K- and mTOR-independent. The findings herein described 
suggest that class IA pllOP is the main isoform involved in TNFa-induced Akt 
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In t r o d u c t o r y  S e c t io n
Chapter 1 - Introduction
Chapter 1 -  Introduction
Chronic lung inflammation is a long existing topic of medical interest. Ancient 
Chinese healers used the herb Ephedra sinica, which contains ephedrine, to ease the symtoms 
of chronic lung diseases thousands of years before Western physicians formally recognised 
this group of diseases. It was the Roman physician Galen (130-201 BC) that discovered that 
asthma was due to bronchial obstruction. Over 2000 years later, and a literature search using 
scientific publication engines that limit their scope to articles published in the last 50 years 
clearly shows that the vast majority of contemporary research into lung inflammation has 
focused on the roles played by immune cells. Although the importance of leukocytes within 
these processes remains unquestionable, there is also a growing body of research that 
indicates that many important functions are also being played by lung parenchymal cells 
(Medina-Tato et al., 2007).
The defining characteristics of chronic respiratory diseases include inflammatory cell 
recruitment, inflammatory mediator expression, tissue remodelling, and altered airway 
smooth muscle contraction. Central to these events is a complex interplay between the 
inflammatory immune cell that has been recruited to the site of inflammation, and the lung 
parenchymal cell that initiates the cascades of events leading up to the recruitment of 
leukocytes, after coming in contact with a noxious agent.
Within many of the processes of the inflammatory response, one of the main families 
of kinases involved in the signalling of these disease functions is phosphoinositide 3-kinase 
(PI3K). As chronic respiratory diseases are very common (Lugogo and Kraft, 2006; Avecillas 
et al., 2006), and novel drugs are required to cover the unmet needs of patients, recent 
advances point to the modulation of PI3K as a possible therapeutic target. With this research, 
the analysis of the possible implications that the modulation of PI3K activity could have in 
certain disease mechanisms within the parenchymal lung cell was undertaken.
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1.1 C hronic Lung Inflam m ation
Defence against pathogens and repair o f damage caused by injury and infection are 
indispensable to the survival o f all multicellular organisms. In humans, the basis o f this 
defence is the innate immune system and, if  required, the adaptive immune system. The 
innate immune system acts as the first line o f  defence, as it quickly develops a non-specific 
maximal response against noxious agents, as well as generating the necessary signals to 
instruct the adaptive immune system to mount a more powerful, but delayed, agent-specifc 
response. Thus, the primary biological function o f these systems is to preserve the health and 
survival o f  the host, by responding to foreign challenge or tissue injury, and restoring tissue 
structure and function (Dower and Qwamstrom, 2003).
Lung Inflammation ✓ \
*
C hronic  in flam m atory  
d isease  state
T issue repair 
and return  to function
\
Fibrosis o r tissue 
destruction  (em physem a)
Figure 1.1: From inflammation  
to chronic respiratory disease.
After initial contact with a 
noxious agent, the lung will 
respond through inflammatory 
mechanism s to isolate and 
eliminate the insulting element. If 
after this inflam matory response, 
the noxious agents have been 
eliminated and cleared from the 
parenchyma, repair o f  the lung 
tissue will ensue with respiratory 
functionality being restored. If, as 
in the case o f chronic respiratory 
diseases, the immune mechanisms 
are unable to remove the causative 
agent, the first response o f 
inflammation will elicit further 
and stronger inflammatory 
mechanisms. This continuous 
positive feedback inflammation 
system will then limit and damage 
lung function, causing the 
defining characteristics o f 
inflam matory lung disease. This 
prolonged inflam matory state can 
also cause perm anent changes to 
lung tissue, either by causing cell 
transformations, including
abnormal growth or dysplasias, or 
by tissue destruction and fibrosis. 
Images modified from 
w ww .resptherapy.com .
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As seen in figure 1.1, lung inflammation is a reaction of the pulmonary 
microcirculation that is characterized by the movement of plasma proteins and leukocytes 
from the blood to the extravascular respiratory tissue. Dilation of the microvasculature in the 
affected area increases regional blood flow to the inflamed area and with an increase in 
vascular endothelial permeability results in the loss of fluid and plasma proteins into the 
tissue. Simultaneously, there is an upregulation of adhesion molecule expression and a release 
of chemotactic factors by parenchymal cells, which enables the adherence of circulating 
leukocytes to the vascular endothelium and their consequent migration into the affected area. 
Phagocytic cells in the inflamed area degrade foreign material and cell debris by the of release 
hydrolytic and proteolytic enzymes, as well as by the generation of reactive oxygen species 
that eliminate and digest exogenous agents (Dower and Qwamstrom, 2003). This cascade of 
mechanisms leads to the elimination of the noxious elements in the lung, and it is normally 
followed by the restoration of tissue structure and functions.
In chronic inflammation, the causative agent persists or recurs withstanding the 
defence activity performed by the immune system. A breakdown in the regulating 
mechanisms for immunity and inflammation ensues, with the immune system in place to 
protect the host, ending up being the main culprit of the associated with chronic respiratory 
diseases (Heaney et a l, 2007).
1.1.1 Respiratory diseases
Within the diversity of chronic respiratory diseases, asthma, chronic obstructive 
pulmonary disease (COPD), acute lung injury (ALI) - adult respiratory distress syndrome 
(ARDS) and lung fibrotic diseases represent clinical entites that pose a significant therapeutic 
challenge. The main characteristics of these respiratory diseases are summarised in table 1.1.
1.1.1.1 Asthma
Asthma is one of the most common chronic diseases in the world. It is estimated that 
around 300 million people currently have asthma and that it accounts for about 1 in every 250 
deaths worldwide. Furthermore, it is estimated that there could be an additional 100 million 
people with asthma by 2025 (Masoli et al., 2004). Bronchial asthma is characterized by lung 
eosinophilia, goblet cell hyperplasia, mucus hypersecretion, and airway hyperresponsiveness 
to allergens and other stimuli (Kay, 1991). In individuals with an allergic predisposition, T 
cells exposed to allergen on the surface of antigen presenting cells mature preferentially 
towards the T-helper (Th) 2 subtype. These cells, through the production of a diverse array of
4
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inflammatory mediators, recruit and activate mast cells, granulocytes, B cells and 
parenchymal cells, including airway epithelial and smooth muscle cells. Collectively, these 
processes lead to the pathological events that define this disease (Heijink and Van Oosterhout, 
2005).
Most patients have mild to moderate asthma that responds adequately to inhaled 
corticosteroids and other drugs. However, there is a subpopulation of patients with severe 
asthma, approximately 10% of the patients suffering from asthma, whose symptoms and 
respiratory control are largely unresponsive to the commonplace treatment, including high 
doses of inhaled and systemic corticosteroids. The care of these individuals remains very 
difficult and novel therapeutic agents that can satisfactorily treat these patients are long 
overdue (Wenzel and Busse, 2007).
Disease Major cell types 
involved
Defining characteristics Associated risks




Airflow limitation is usually reversible 
Airway hyperresponssiveness 
Episodes o f  coughing, wheezing and dyspnea 
Onset early in life
Allergy, rhinitis or eczema 
Family history o f  asthma




Airflow limitation is progressive and largely irreversible 
Atypical responses to noxious particles 






Lung endothelial and 
epithelial cells
Interstitial pulmonary oedema
Associated with left atrial o f  pulmonary hypertension
Varying degrees o f  hypoxemia
Pulmonary dysfunction is progressive, but reversible











Chronic fibrosing interstitial pneumonia 
Limited to the lung
Dyspnea with worsening o f  pulmonary function 
Pulmonary dysfunction is progressive and irreversible 
Onset late in life
Unknown
Table 1.1: Main characteristics of chronic inflammatory lung diseases. Table data synthesised from 
information obtained in references for asthma (Heijink and Van Oosterhout, 2005), COPD (Celli and 
MacNee, 2004), ALI-ARDS (Ware and Matthay, 2000; Yum et al., 2001) and pulmonary fibrosis 
(Gross and Hunninghake, 2001).
1.1.1.2 COPD
COPD is a leading cause of chronic morbidity and mortality worldwide, with the 
World Health Report listing COPD as the fifth leading cause of death in the world (Celli and 
MacNee, 2004). COPD is a disease associated with an abnormal inflammatory response of the 
lungs to noxious particles or gases, like those primarily associated with tobacco smoke. 
COPD is characterized by progressive airflow limitation, which is not fully reversible (Celli 
and MacNee, 2004). The term COPD includes a spectrum of diseases inducing chronic
5
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bronchitis and emphysema, and a variety of difficult to classify intermediate states. The fact 
that none of the drugs which are currently used for the treatment of COPD are able to 
adequately reverse the airflow limitation clearly states the necessity for new therapeutic 
agents that could revert the changes in the lung caused by this disease.
The cell types that are characteristically involved within the pathogenesis of COPD 
are cluster of differentiation (CD)8+ T cells, macrophages and neutrophils with certain lung 
parenchymal cells, such as epithelial cells, also activated (Ulbrich et al., 2003). Despite the 
fact that macrophages accumulate in the alveoli and bronchioli of smokers and of COPD 
patients, with a positive association between their numbers and the degree of disease, their 
role is still debated (Tetley, 2002). On the other hand, neutrophils are found in high levels in 
the airways of smokers and patients with COPD. Furthermore, in animal models neutrophil 
elastase is able to reproduce many of the features of this syndrome (Stockley, 2002). 
However, studies demonstrating that neutrophil numbers can be inversely related to the 
severity of emphysema, suggest that other cell types contribute to the pathology of this 
disease (Tetley, 2002).
1.1.1.3 ALI-ARDS
The ocurrence of ALI-ARDS in intensive care units approximates 7% of all 
admissions and 15% of patients receiving more than 24 h of mechanical ventilation. Overall, 
the mortality of patients diagnosed with ARDS was approximately 55% (Brun-Buisson et al.,
2004), highlighting the lack of adequate therapeutic options for the treatment of this clinical 
entity. ALI-ARDS is characterized by increased expression of inflammatory cytokines, 
development of interstitial pulmonary oedema and neutrophil accumulation in the lungs that 
cannot be explained by left atrial or pulmonary capillary hypertension (Ware and Matthay, 
2000; Yum et al., 2001).
The distinction between ALI and ARDS is the degree of hypoxemia. ARDS 
represents the subset of patients which are at the severe end of hypoxemia (Bernard et al., 
1994), characterized by a diffuse inflammation of lung parenchyma. ALI-ARDS is caused by 
an uncontrolled systemic inflammatory response resulting from clinical events including 
major surgery, trauma, severe bums, sepsis, prolonged mechanical ventilation and others 
(Puneet et al., 2005). The initial insult on the lung tissue results in the release of inflammatory 
mediators by local macrophages, epithelial and endothelial cells. This array of chemical 
agents, in conjunction with surface expression of adhesion molecules by parenchymal cells, 
activates and recruits neutrophils and T lymphocytes into the inflamed lungs, which secrete
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even more inflammatory mediators. This further amplifies the inflammation, creating a 
positive feedback loop in which inflammation generates greater inflammation, leading 
inexorably to lung tissue destruction and fibrosis (Belperio et al., 2006).
1.1.1.4 Idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is characterized by progressive breathing 
difficulty and worsening of pulmonary function (Gross and Hunninghake, 2001). The 
prevalence of this disease increases with age, with an incidence of 250 cases per 100,000 in 
the elderly (Perez et al., 2003). IPF is a fatal disease, with approximately 30% of patients 
surviving 5 years after diagnosis. There is no treatment that can modify the natural course and 
usual terminal outcome of this disease.
Pathophysiologically, IPF is caused by dysregulated tissue and vascular remodelling 
with fibroproliferation and deposition of extracelluar matrix. Although the presence of 
eosinophils, mast cells and fibroblasts, and increased amounts of interleukin (IL)-4 and IL-13 
has been reported (Gross and Hunninghake, 2001), there is still no clear understanding of the 
pathological mechanisms underlying to this disease. However, research has identified 
potential culprits for the clinical manifestations of this disease, as a circulating population of 
cells with both leukocyte and mesenchymal markers called fibrocytes could play a role in IPF, 
as they are recruited to fibrotic lungs in an animal model of the disease (Phillips et al., 2004). 
However, the disease mechanisms and aetiology of this entity remain unclear.
1.1.2 Disease mechanisms
Of all the different disease mechanisms highlighted in the previous section, special 
mention is required for those cellular functions that were studied throughout the course of this 
research. Therefore, in this section a more detailed review is carried out on the roles played in 
respiratory disease by arachidonic acid metabolites, specifically cyclooxygenase-2; adhesion 
molecules, highlighting intercellular adhesion molecule-1; and chemoattractant production, 
with emphasis on IL-8.
1.1.2.1 Arachidonic acid metabolites
A variety of metabolites are derived from arachidonic acid which are important in the 
adequate development of the immune response. As seen in figure 1.2, arachidonic acid can be 
metabolized by 2 different groups of enzymes: by cyclooxygenases in order to produce 
prostaglandins and thromboxane, and by lipooxygenases to produce leukotrienes and lipoxins.
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Leukotrienes (LTs) are very important agents in the inflammatory response, as 
exemplified by their many activities in chronic respiratory disease: smooth muscle 
contraction, mucus secretion, inflammatory cell recruitment, cytokine production, and 
induction o f structural changes in the airway (Ogawa and Calhoun, 2006). Consequently, for 
many years the treatment o f asthma and other chronic inflammatory respiratory conditions has 
been carried out successfully through the use o f several LT receptor antagonists, including 
montelukast and zafirlukast (Drazen et al., 1999).
Phospholipase A2







LTA, C 3  LTB4
Leukotrienes
Figure 1.2: Arachidonic acid metabolite pathway. Arachidonic acid can be metabolized by 
5-lipoxygease for the synthesis o f  leukotrienes, by cyclooxygenases for the production o f 
prostaglandins and by 15-lypoxygenase for the synthesis o f  lipoxins. O f particular interest, the 
synthesis, metabolism, and signalling o f  the major prostaglandins (PGs; PG I2, PGE2, PGD, PGA2, 
PGF2ct, and thromboxane A2 [TXA]) are tightly regulated by cell type-specific and PG-specific 
pathways/isomerases. 15-hydroperoxyeicosatetraenoic acid (15-HPETE), lipoxins (LPs; LPA and 
LPB), 5-hydroperoxyeicosatetraenoic acid (5-HPETE), and leukotrienes (LTs; LTA4, LTB4, LTC4, 
LTD4 and LTE4).
Lipoxins, the other family o f molecules produced by lipooxygenases, are 
characterized by carrying out opposing actions to those effected by LTs. Lipoxins display 
several pro-resolving actions, including inhibition in vivo o f eosinophil activation, cytokine 
release and angiogenesis (Levy, 2005). Furthermore, it has been shown that lipoxins
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generated in respiratory tissues block airway inflammation and hyperresponsiveness in an 
experimental model of asthma (Levy et a l, 2002).
Of the inflammatory molecules produced by cyclooxygenases, prostaglandins (PGs) 
are critical small molecule lipid mediators of allergic inflammation. PGs bind specific G 
protein-coupled receptors (GPCRs) and can mediate their effects in an autocrine manner, a 
paracrine manner, or both. Arachidonic acid metabolites, including PGD2, PGF2a, PGI2, TXA, 
LTC4, LTD4 and LTE4, contribute to the regulation of the airflow by constricting bronchial 
smooth muscles, increasing mucous secretion and microvascular leakage, as well as by acting 
as chemoattractant factors for inflammatory cells (Rolin et a l, 2006).
PGE2 is considered the foremost inflammatory eicosanoid. Many studies have 
implicated PGE2 in the pathophysiology of a diversity of illnesses, including arthritis (Honda 
et a l, 2006), fever (Ivanov and Romanovsky, 2004), chronic pain (Mabuchi et a l, 2004), 
bone-loss associated with inflammation (Ha et a l, 2006), bum injury (Hahn and Gamelli,
2000), inflammatory bowel disease (Subbaramaiah et a l, 2004), as well as carcinogenic 
processes such as tumour-assocaited angiogenesis and neovascularisation (Backlund et a l, 
2005; Namkoong et al., 2005). However, PGE2 has also been found to have inflammation 
many resolving properties. PGE2 augments cAMP and induces IL-1 in smooth muscle cells, 
causing relaxation and inhibiting proliferation (Libby et a l, 1988). PGE2 also reduces 
inflammatory activation of macrophages by suppressing the expression of tumour necrosis 
factor (TNF)a, IL-12 and interferon (IFN)y (van der Pouw Kraan et al., 1996), as well as 
various chemokines (Takayama et a l, 2002).
Depending upon context, PGE2 exerts homeostatic, inflammatory, or in some cases 
antiinflammatory effects by regulating the function of endothelial cells, smooth muscle, 
macrophages, T and B lymphocytes (Chung, 2005). The pleiotropic effects that PGE2 has on 
inflammation are likely due, in part, to the contextual expression of the four known PGE2 
receptors, EP1, EP2, EP3, and EP4, which have specific cell-signalling functions. In vitro, 
EP1 and EP3 signalling generally opposes EP2 and EP4 signalling. EP3-deficient, but not 
EP1-, EP2-, or EP4-deficient mice exhibit enhanced allergic inflammation in an ovalbumin 
model, and a selective EP3 agonist suppressed augmented inflammation (Kunikata et al.,
2005). These results suggest that signalling through EP3 is responsible for the ability of PGE2 
to downregulate allergic inflammation. Therefore, the activity of PGE2 through the EP3 
receptor is of importance in limiting respiratory disease mechanisms. This is further supported 
by in vivo studies, both in human subjects and in animals, that demonstrate that PGE2 inhibits 
allergic responses in the lung by inducing airway bronchodilation and by blocking allergen-
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induced bronchoconstriction and inflammatory mediator release (Moore and Peebles, Jr.,
2006).
PGs are derived from arachidonic acid by cyclooxygenase (COX) enzymes. Two 
COX enzyme isoforms, COX-1 and COX-2, convert arachidonic acid liberated from the 
membrane phospholipids to an unstable PGG2 intermediate by a COX activity, and then 
convert PGG2 to PGH? by an endoperoxidase activity (Smith et al., 1996). Both COX-1 and 
COX-2 are expressed in the respiratory epithelium and in inflammatory cells in the lung. 
COX-1 is expressed constitutively, whereas COX-2 expression is induced in inflammation. 
Induction o f COX-2 in antigen-presenting cells, such as macrophages and dendritic cells, is 
thought to be important for PG production in the setting o f allergic lung inflammation (Moore 
and Peebles, Jr., 2006).
NF-kB,
-100
SP-1 NF-kB, AP-2 C/EBP NF-IL6
•100
CRE TATA-Box
Figure 1.3: Human COX-2 promoter region. Schematic representation o f the human COX-2 
prom oter region. W ithin this gene prom oter region there are two nuclear factor-KB (NF-kB) 
transcription factor binding sites: promoter-distal NF-kB1 and prom oter-proximal NF-kB2. There are 
also SP-1, activator protein (AP)-2, CCAAT/enhancer binding protein (C/EBP), NF-IL6 and a CRE 
transcription factor binding site. Image modified from reference (Kaltschmidt et al., 2002).
Since upregulation o f COX-2 is a hallmark o f many inflammatory diseases, 
understanding the mechanisms involved in regulating this enzyme may prove important in 
identifying potential therapeutic targets for chronic inflammatory diseases. Previous studies 
have implicated members o f the mitogen activated protein kinase (MAPK) (Chen et al., 
2001a) as well as the PI3K (Gustin et al., 2001) families in the regulation o f COX-2 
expression and PG synthesis in different cell types. Furthermore, as seen in figure 1.3, several
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enhancer elements present in the COX-2 promoter region have shown to be activated by 
inflammatory mediators (Inoue et al., 1995; Schroer et al., 2002). Previous studies have 
shown binding of c-Jun, cyclic adenosine monophosphate response element (CRE) binding 
protein (CREB), activating transcription factor (ATF)2, CCAAT/enhancer binding protein 
(C/EBP) p, and nuclear factor (NF)-kB p65 to their respective sites (i.e. cJun, ATF2 and 
CREB bind to the CRE site; while NF-Kb and C/EBP bind to their homonymous sites) in the 
COX-2 promoter region (Deng et al., 2003; Vaillancourt et a l, 2007).
1.1.2.2 Adhesion molecule expression
Leukocyte migration requires interaction with the endothelial lining of blood vessels 
within inflamed tissue and organs. There are several families of adhesion molecules involved 
in adherence of leukocytes to the endothelium (see Table 1.2). Selectins initiate the leukocyte- 
endothelial cell interaction and bind to carbohydrate ligand structures. When the leukocyte is 
rolling on the endothelium, its receptors engage with chemoattractants leading to increased 
affinity of leukocyte integrins. This in turn leads to leukocyte adhesion to the endothelium via 
interaction of integrins with their cognate endothelial cell adhesion molecules, which are 
members of the immunoglobulin superfamily (Vanderslice et al., 2004). Leukocyte adhesion 
is followed by a process called transendothelial migration, and it encompasses the 
extravasation of the leukocyte from the blood vessel into the inflamed tissue. Finally, the 
leukocyte migrates towards the source of the chemoattractant, the site of inflammation, in a 
process called chemotaxis (Ward, 2004).
Intercellular adhesion molecule (1CAM)-1 is an especially important molecule, as 
certain cytokines of importance in respiratory disease, such as IL-4 and TNFa, interact with 
immune and structural cells to upregulate its expression, in order to promote the recruitment 
of leukocytes to the lung (Barnes, 2003b; Berry et al., 2007). Furthermore, elevated ICAM-1 
levels have been reported in lung tissue and broncho-alveolar lavage fluid in clinical samples 
from patients suffering from chronic lung disease (Goodman et al., 2003; Barnes, 2003b; 
Berry et al., 2007).
There has been a considerable effort to exploit the importance of adhesion in 
leukocyte migration in the design of new therapeutics for inflammatory diseases. As cellular 
adhesion molecule interaction is crucial for exocytosis, cytokine production and respiratory 
burst, antagonism of these molecules is therapeutically attractive for reasons other than 
inhibition of leukocyte migration (Vanderslice et al., 2004). Unfortunately, with a few 
exceptions, the outcome of clinical trials with adhesion molecule blockers has been variable
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and largely disappointing (2006). Nevertheless, the concept of pharmacological interference 
of leukocyte adhesion remains a popular avenue for development of novel 
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Table 1.2: Adhesion molecules involved in leukocyte interactions. The selectin family is named 
according to the cells in which they were originally discovered. L-selectin for leukocytes, E-selectin for 
endothelial cells, P-selectin for platelets. Glycosylation-dependent cell adhesion molecule 
(GlyCAM)-l, intercellular adhesion molecule (ICAM), very late antigen (VLA)-5, lymphocyte- 
function associated molecule (LFA), vascular cell adhesion molecule (VCAM) and platelet-endothelial 
cell adhesion molecule (PECAM).
1.1.2.3 Chemoattractant production
As stated in the previous section, chemoattractants are essential during chemotaxis in 
the final steps of leukocyte recruitment as the extravasated leukocyte migrates towards the 
site of inflammation (Wu, 2005). Chemoattractants vary greatly, from the superfamily of 
chemokines, which are small, inducible, secreted proteins, to lipid chemoattractants such as 
leukotriene B4 , PGD2 and sphingosine-1-phosphate (SIP). Although structurally diverse, all 
these chemoattractants signal through GPCRs (Luster and Tager, 2004).
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Chemokines are a large family of small molecular weight proteins that primarily 
function to direct leukocyte cell migration, although they also influence cell survival and 
other cell functions (Zlotnik and Yoshie, 2000). Structurally, chemokines are classified into 
four families based on a conserved cystein motif as follows: C, CC, CXC and CX3C. 
Consequently, chemokine receptors are classified into CR, CCR, CXCR and CX3CR 
families, determined by the class of their ligand (Zlotnik and Yoshie, 2000). Chemokines are 
remarkably diverse, both in terms of individual proteins and their production by different cells 
and tissues. Most chemokines were originally characterised as leukocyte chemoattractants, 
although many chemokines have important roles in hematopoiesis, lymphocyte development, 
and promote organisation and function of secondary lymphoid organs in mature organisms 
(Cyster, 2005).
The chemokine IL-8 , also called CXCL8 , is an important chemotactic and activating 
factor for neutrophils, one of the cell types thought to play a predominant role in COPD, 
ALI-ARDS and pulmonary fibrosis. The IL-8 -induced effects in neutrophils are 
predominantly mediated by CXCR1 (Green et al., 1996), one of the two receptors that bind to 
IL-8 . CXCR1 and CXCR2 are highly homologous but functionally different chemokine 
receptors, with the promiscuous CXCR2 binding six different chemokines and CXCR1 
preferentially binding granulocyte chemotactic protein 2, also called CXCL6 , and IL- 8  with 
high affinity (Holmes et al., 1991).
IL- 8  is known to play an important part within chronic respiratory diseases. Patients 
with COPD have been shown to express higher levels of IL- 8  than healthy subjects (Pignatti 
et al., 2005). Furthermore, CXCR1 and CXCR2 messenger (m)RNA are increased in 
bronchial biopsy specimens of COPD patients with an exacerbation of the disease (Qiu et al.,
2003). A CXCR1/CXCR2 antagonist has been shown to abrogate airway neutrophilia in an 
ARDS animal model (Gordon et al., 2005). Although ARDS is very different from COPD and 
pulmonary fibrosis, they share neutrophilia as one of their key features, suggesting that this 
antagonist could prove to be useful for a broad range of pulmonary illnesses.
1.1.3 Inflammatory cytokines
The immunological and inflammatory responses of the lung are especially tightly 
regulated, since the respiratory system is exposed to a large variety of infectious agents as 
well as a diverse group of noxious elements during the process of gas exchange (Toews, 
2001). Cytokines are extracellular signalling proteins that are involved in the regulation of
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homeostatic and immunological processes throughout the body. Cytokines do not induce 
inflammatory states individually, rather they work coordinately in patterns characteristic of 
certain immune responses. In the lung, when these responses persist, specific groups of 
cytokines are upregulated for a prolonged period of time inducing the defining characteristics 
of chronic respiratory diseases (Chung, 2001). As seen in table 1.3, different patterns of 
cytokines are associated with different respiratory diseases.
Respiratory disease Associated cytokines
Asthma IL-3, IL-4, IL-5, IL-13, Eotaxin (CCL11), TNFa, TFGp
COPD IL-ip, IL- 8  (CXCL8 ), MCP-1 (CCL2), RANTES (CCL5), 
Eotaxin (CCL11), TNFa, TFGp, EGF
ALI-ARDS IL-1 P, IL- 8  (CXCL8 ), MCP-1 (CCL2), RANTES (CCL5), 
GROa (CXCL1), ENA78 (CXCL5), TNFa
IPF IL-4, TNFa, TFGP, PDGF, IFNy, IGF-1, endothelin-1
Table 1.3: Cytokines associated with chronic inflammatory lung diseases. Transforming growth 
factor (TGF)P, monocyte chemoattractant protein (MCP)-l, regulated upon activation, normal T-cell 
expressed and secreted (RANTES), epidermal growth factor (EGF), growth-regulated protein (GRO)a, 
epithelial-derived neutrophil-attracting protein (ENA)78, platelet-derived growth factor (PDGF), 
interferon (IFN)y, and insulin-like growth factor (IGF)-l. Table data synthesised from information 
obtained in references for asthma (Chung, 2001), COPD (Chung, 2001), ALI-ARDS (Martin, 1999) 
and IPF (Allen and Spiteri, 2002).
1.1.3.1 IL-1 (3
IL-1 is a pleiotropic cytokine that was first described as an endogenous pyrogen with 
activating properties on monocytes, macrophages, osteoblasts, fibroblasts, muscle cells, 
endothelial cells, epithelial cells, T and B lymphocytes. Scientists later determined that IL-1 
was actually two distinct proteins, named IL-1 a  and IL-1 (3 (Dinarello, 1997). Despite a low 
homology of the primary protein structures, the similar three-dimensional structures of the 
essential domains explains the similar functions of IL -la and IL-1 P (Arend, 2002). The major 
sources of IL-1 p are activated cells of the monocyte-phagocytic system, and its production 
can be rapidly induced by bacterial lipopolysaccharides (LPS), TNFa, IFNs (a, P and y), and 
IL-1 P itself (Dinarello, 1997; Arend, 2002). Both IL-1 proteins show similar binding capacity 
to the two known IL-1 receptors. The 80 kDa type I receptor mediates cell activation by 
subsequent phosphorylation of the IL-1 receptor-associated kinase. In contrast, the 60 kDa 
type 2 receptor lacks cell activating properties and acts as a decoy receptor (Moller and 
Villiger, 2006).
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IL-1 p induces the release of other cytokines such as interleukins -1, -2, -3, -4, -5, -6 , 
-8 , regulated upon activation, normal T-cell expressed and secreted (RANTES), epithelial 
cell neutrophil activator (ENA)-78, monocyte chemotactic peptide (MCP)-l, macrophage 
inflammatory peptide (M lP)-la, IFNy, ICAM-1, TNFa and platelet-derived growth factor 
(PDGF) from a wide range of cells (Chung, 2001; Goodman et al., 2003). Because of this 
production of a variety of chemotactic cytokines and its ability to induce adhesion molecule 
expression in parenchymal cells, IL-1 p is considered to be a prominent cytokine in the 
inflammatory cascade, as it induces leukocytosis by the release of neutrophils from the bone 
marrow and their recruitment to the inflammatory site. IL-1 P can also induce fibroblasts to 
proliferate, increase PG secretion, and upregulate synthesis of fibronectin and collagen 
(Chung, 2001). Furthermore, chronic production of IL-ip in respiratory epithelial cells of 
adult mice causes lung inflammation, enlargement of distal airspaces, mucus metaplasia, and 
airway fibrosis (Lappalainen et al., 2005), all very important disease mechanisms in fibrotic 
and obstructive respiratory diseases
Several investigators have identified the presence of IL-1 in bronchoalveolar lavage 
(BAL) fluid from patients with ARDS (Siler et al., 1989; Suter et al., 1992; Goodman et al., 
1996; Park et al., 2001). Despite the complexities of the IL-1 system, in clinical fluids there 
are strong relationships between IL-1 p with clinical lung injury severity and outcome in 
patients with ARDS (Park et al., 2001). These clinical studies indicate that the interplay 
between IL-1 (3 and its family of counter-regulatory ligands and receptors probably have an 
important role in the pathogenesis of ALI and ARDS.
IL-1 p production has also been documented in stable COPD, with further increases 
during exacerbations of the illness (Chung, 2001). Alveolar macrophages and peripheral 
blood mononuclear cells from smokers produce more IL-1 than those from nonsmokers (Lim 
et al., 2000; Zeidel et al., 2002). When exposed to cigarette smoke, human bronchial 
epithelial cells from patients with COPD respond with a greater increase of IL-1 production 
than those of nonsmokers (Rusznak et al., 2000). BAL fluid from smokers contains higher 
levels of IL-1 (3 than fluid from nonsmokers, and the levels of IL-1 p are related to the lung 
function of the smokers (Ekberg-Jansson et al., 2001). Furthermore, increased expression of 
IL-1 by bronchial epithelium, increased numbers of IL-1-producing macrophages in the 
bronchial submucosa, and elevated levels of IL-1 in BAL fluid as well as in tracheal biopsy 
samples have been reported in asymptomatic and symptomatic individuals with asthma 
(Borish et al., 1992; Sousa et al., 1996).
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1.1.3.2 IL-13
Human IL-13 is a 17 kDa glycoprotein predominantly produced by Th2-polarized 
CD4+ T cells, although it is also produced by a variety of cell types including Thl CD4+ T 
cells and CD8 + T cells, natural killer T cells, mast cells, basophils, and eosinophils (Wills- 
Karp, 2004). It has also been shown that immunoglobulin (Ig)E-sensitized human airway 
smooth muscle cells produce IL-13 (Grunstein et al., 2002). Various cytokines and mediators 
have been implicated in the regulation of IL-13 production including IL-5, IL-9, IL-25, 
histamine, adenosine, and endothelin-1 (Wills-Karp, 2004). This suggests that IL-13 
production is regulated by a variety of inflammatory mediators and cytokines that may lead, 
especially under disease conditions, to a sutained Th2 immune response.
IL-13 mediates its actions via a complex receptor system that includes the IL-4 
receptor a  (IL-4Ra) chain and at least two other IL-13-binding proteins that have been 
designated as IL-13Ral and IL-13Ra2. IL-13Ral by itself binds IL-13 with low affinity, 
however, in the presence of the IL-4Ra chain, IL-13Ral binds IL-13 with high affinity. The 
heterodimeric complex formed by the IL-4Ra chain and the IL-13Ral chain is thought to 
constitute the functional IL-13 receptor. The ability of this receptor complex to bind IL-13 
and IL-4 explains the redundancies in function observed between these cytokines. The IL-13R 
(IL-4R/IL-13Ral) is expressed on both hematopoietic and nonhematopoietic cells such as B 
cells, monocytes/macrophages, dendritic cells, eosinophils, basophils, fibroblasts, endothelial 
cells, airway epithelial cells and airway smooth muscle (ASM) cells.
In contrast to IL-13Ral, IL-13Ra2 alone binds IL-13 with high affinity (Wills-Karp, 
2004). IL-13Ra2 is generally not thought to initiate IL-13 signalling, as it has a short 
cytoplasmic tail that is devoid of signalling motifs (Zurawski et al., 1995). Furthermore, the 
inability of IL-13Ra2 expression to confer IL-13 responsiveness in cells lines (Donaldson et 
al., 1998), along with the finding of soluble IL-13Ra2 in vivo (Zhang et a l, 1997), has led to 
speculation that IL-13Ra2 is a decoy receptor, and as such could help to regulate net IL-13 
activity. Moreover, Rahaman et al. demonstated that the short cytoplasmic domain of 
IL-13Ra2 can bind to the IL-4Ra cytoplasmic domain inhibiting IL-4 and IL-13- mediated 
signal transduction and gene expression (Rahaman et al., 2002). A role for IL-13Ra2- 
mediated modulation of inflammation in asthma is suggested by the IL-13- and IL-4- 
dependent upregulation of IL-13Ra2 in primary bronchial epithelial cells and the 
demonstration that overexpression of IL-13Ra2 in bronchial derived cells decreases IL-13- 
dependent signalling (Yasunaga et al., 2003). The IL-13Ra2 chain has been shown to be 
present in a variety of tissues such as the testis, brain, liver, and thymus. Of particular
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relevance to allergic airway disease, the IL-13Ra2 chain has been observed on ASM and 
epithelial cells (Graber et al., 1998).
There is growing evidence of the importance of IL-13 in causing several of the key 
features of asthma such as goblet cell hyperplasia, mucus hypersecretion, eosinophilia, airway 
fibrosis, and airway hyperresponsiveness. Furthermore, pulmonary overexpression of IL-13 
causes an increase in airway eosinophilia and a marked increase in eotaxin synthesis (Zhu et 
al., 1999). Eotaxin has a potent and selective effect in mobilizing bone marrow eosinophils 
into the blood (Palffaman et al., 1998b). When IL-13 is administered to IL-5- and eotaxin- 
deficient mice, the asthmatic characteristics generally induced by IL-13 treatment are 
attenuated compared with wild-type animals, suggesting a partial dependence of IL-13 on 
these cytokines (Yang et al., 2001).
IL-13 has also been linked to airway hyperresponsiveness by several lines of 
evidence. Overexpression of IL-13 in murine airway epithelial cells was associated with 
airway hyperresponsiveness (Zhu et al., 1999). Exogenous IL-13 also evokes 
hyperresponsiveness, whereas the systemic administration of an IL-13 antagonist inhibits 
allergen-induced airway hyperreactivity in mice (Wills-Karp et al., 1998). Finally, IL-13‘” 
mice fail to develop allergen-induced airway hyperresponsiveness, but this trait was restored 
by the administration of recombinant IL-13 (Walter et a l, 2001).
1.1.3.3 T N Fa
As analysed in more depth in the section 1.2, TNFa is an important inflammatory 
mediator implicated in the pathogenesis of inflammatory lung diseases including ARDS, 
COPD and asthma (Goodman et al., 2003; Barnes, 2003b; Berry et al., 2007). Furthermore, 
TNFa is produced both by immune and parenchymal cells of known importance within 
respiratory disease (Thomas, 2001).
TNFa is a chemoattractant of neutrophils and eosinophils in the airways, as shown 
previously in a diversity of animal models (Lukacs et al., 1995; White et al., 1997). TNFa 
also increases the cytotoxic effect of eosinophils on endothelial cells (Slungaard et al., 1990). 
Furthermore it is involved both in the activation of T cells, and in their concomitant cytokine 
release (Scheurich et al., 1987). TNFa also increases expression of adhesion molecules such 
as ICAM-1 and VCAM-1 (Lassalle et al., 1991), which play an important role in the 
recruitment of immune cells to the lung and in the subsequent development of airway 
hyperresponsiveness. In the airways, TNFa interacts with immune and structural cells to
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generate a highly inflammatory environment through the increased release and production of 
inflammatory cytokines and chemokines, as well as by upregulating adhesion molecules 
(Barnes, 2003b; Berry et al., 2007). As well as enhancing migration and recruitment of 
immune cells to the lung, airway epithelial cells respond to TNFa by producing arachidonic 
acid metabolites, through the induction of COX-2 (Petrovic et al., 2006).
As predicted from all of its cellular functions, TNFa has been implicated in the 
pathogenesis of inflammatory lung diseases including ARDS, COPD and asthma. Elevated 
TNFa levels have been reported in lung tissue and BAL fluid in clinical samples from patients 
with lung disease (Goodman et a l, 2003; Barnes, 2003b; Berry et al., 2007). Moreover, the 
administration of inhaled recombinant TNFa to healthy subjects has led to the development 
of airway hyperresponsiveness and neutrophilia (Thomas et al., 1995); while the 
administration of TNFa to asthmatic patients leads to an increase in airway 
hyperresponsiveness (Thomas and Heywood, 2002). Furthermore, in animal models of 
asthma, genetic deletion of TNFa or TNFa receptors, or treatment with anti-TNFa antibody 
result in important reductions in airway hyperresponsiveness and eosinophilia (Rudmann et 
al., 2000; Zuany-Amorim et al., 2004). TNFa also has several properties that make it a key 
factor in severe refractory asthma, including: induction of glucocorticoid resistance 
(Franchimont et al., 1999), myocyte proliferation (Amrani et al., 1996), and fibroblast growth 
and maturation (Desmouliere et al., 1993; Sullivan et al., 2005).
1.1.4 Lung epithelial cells in inflammation and homeostasis
In adults, type 1 and type 2 alveolar epithelial cells (AEC) constitute the epithelial 
component of the alveoli. Type 1 AEC, which cover more than 90% of the alveolar surface 
area of the peripheral lung, are flattened cells that interface with pulmonary capillaries, 
providing an intact surface of minimal thickness readily permeable to gases. Type 2 AEC, 
morphologically appearing as large rounded cells, are found in the comers of alveoli and are 
in close proximity to mesenchymal cells lying beneath them. They are multifunctional cells 
that synthesize and secrete pulmonary surfactant, serve as progenitor cells for type 1 AEC, 
and directionally transport sodium from apical to basolateral cell surfaces to minimize 
alveolar fluid. These cells also play an essential role within the disease mechanisms of 
respiratory illnesses by regulating the effector phase of the immune response by producing a 
variety of different cytokines involved in host defense during lung inflammation (Shannon 
and Hyatt, 2004).
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During homeostasis and in response to lung damage, type 2 AEC serve as progenitor 
cells. Type 1 AEC are vulnerable to injury, whereas the type 2 AEC are more resistant and 
can therefore function as progenitor cells for regeneration of the alveolar epithelium after 
injury. These cells proliferate and migrate to recover the denuded basement membrane by 
forming a layer of cuboidal epithelial cells. Then, they differentiate to reestablish both type 1 
and type 2 AEC into a functional alveolar epithelium (Selman and Pardo, 2006). Reddy et al. 
suggested that type 2 AEC isolated from injured lungs could be segregated into at least two 
subpopulations, based on their E-cadherin expression levels (Reddy et al., 2004). Importantly, 
E-cadherin-negative AEC were damage resistant, proliferative, and exhibited high levels of 
telomerase activity, suggesting that they might represent a transiently amplifying progenitor 
subpopulation of type 2 AEC responsible for repopulation and repair of damaged alveolar 
epithelium (Reddy et al., 2004).
An increase in the number of epithelial cells and a remarkable disturbance in the 
integrity of the alveolar epithelium with presence of several altered phenotypes is a striking 
feature of the lungs from patients suffereing chronic respiratory inflammatory diseases. In this 
context, alveolar reepithelialization appears severely disturbed in the final stages of chronic 
lung inflammation, when tissue fibrosis takes place (Selman and Pardo, 2006). The reasons 
and significance of the aberrant reaction of AEC in these conditionsare unknown, but some of 
them may result directly from the chemical agents that caused the initial insult (e.g. tobacco 
smoke) whereas others may be the consequence of a prolonged period of accelerated 
epithelial cell proliferation and migration.
The A549 cell line, widely used through this research project, was initiated in 1972 
by Giard et al. through explant culture of lung carcinomatous tissue from a 58-year old 
Caucasian male (Giard et al., 1973). Initial experiments on A549 cells demonstrated that they 
were capable of carrying out pulmonary surfactant synthesis and secretion (Shapiro et al., 
1978; Nardone and Andrews, 1979). Subsequent research has shown that A549 cells have 
many morphologic and biochemical characteristics of type 2 AECs (Balis et al., 1984; Foster 
et al., 1998), with many researchers since then using them as a model for type 2 AEC function 
(Smith, 1977; Rothman et al., 1990; Seagrave and Nikula, 2000; Marcet et al., 2007).
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1.2 TNFa signalling
More than three decades ago, TNF was identified as a protein produced by the 
immune system that played a major role in suppression of tumor cell proliferation (Carswell 
et al., 1975). Since then, research has revealed that TNF is a major mediator of inflammation, 
viral replication, tumor metastasis, transplant rejection, rheumatoid arthritis, respiratory 
disease and septic shock. Currently there are approximately twenty different members of the 
TNF superfamily that have been identified. Although TNF is primarily considered a key 
mediator of the innate immune response, most of the members of the TNF superfamily have 
also been found to mediate a wide variety of disease mechanisms in a range of illnesses 
including cancer, asthma, arthritis, bone resorption, diabetes, atherosclerosis, COPD, 
myocardial infarction, and acquired immune deficiency disease (Aggarwal et al., 2002).
TNFa, the first member identified from the TNF superfamily, is an important 
mediator of the immune response (Russo and Polosa, 2005). Moreover, it is produced by 
immune (e.g. macrophages, dendritic cells, lymphocytes, neutrophils, mast cells and 
eosinophils) and lung parenchymal (e.g. fibroblasts, epithelial cells and smooth muscle cells) 
cells (Thomas, 2001). TNFa is initially produced as a biologically active 26 kDa 212 amino 
acid-long type II transmembrane precursor protein, which is subsequently cleaved, principally 
by the metalloprotease TNFa-converting enzyme (Zheng et al., 2004), to release the 17 kDa 
free protein. This protein forms biologically active 51 kDa homotrimers that exert their 
plethora of functions by interacting with their membrane receptors: the constitutively and 
widely expressed TNFR1 and the tightly-regulated leukocyte-restricted TNFR2 (Grell et al., 
1995). It is through coupling with these receptors, that TNFa causes intracellular signalling 
leading to phosphorylation of various transcription factor elements, which interact with the 
DNA chromatin structure to increase transcription of proinflammatory genes such as COX-2, 
ICAM-1, IL-8 , IL- 6  and TNFa (Chen and Goeddel, 2002).
TNFa exerts a wide spectrum of biological activities, with most cells showing at least 
some TNFa responsiveness. In general, TNFa is considered a major proinflammatory 
mediator with the capacity to induce apoptosis (Wajant et a l, 2003). Moreover, TNFa has 
also been reported as playing a role in downregulating the immune system after a successful 
immune response (Kollias et al., 1999). Therefore, in pathophysiological situations TNFa 
would appear to be strongly engaged in the initiation, perpetuation and termination of the 
inflammatory response. The accrued research would then seem to suggest that the very 
different actions carried out by TNFa depend on a variety of characteristics, with the cellular
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context, TNFR tissue expression, timing and duration o f T N F a production, all being 
important parameters determining the net effect o f T N Fa activity in vivo.
1.2.1 TN Fa-induced gene regulation
T N Fa coupling to its receptors leads to the activation o f various intracellular 
signalling cascades, culminating in the activation o f transcription factors and several 
inflammatory genes. In the following sections, the transcription factor molecules known to 
play important roles in TNFa-induced signalling and their role within respiratory disease will 
be highlighted.
1.2.1.1 N F -k B
NF-kB comprises a group o f dimeric transcription factors consisting o f various 
members. NF-kB proteins are involved in the transcriptional activation o f a huge number of 
inflammatory-related genes in response to a variety o f cytokines, bacterial products and some 
forms o f physical stress, including ultraviolet radiation or reactive oxygen species (Wajant et 
al., 2003). NF-kB pathway activation is illustrated in figure 1.4.
Figure 1.4. NF-kB pathway.
After receptor coupling, a wide 
variety o f  docking proteins are 
recruited to the intracellular 
domain o f  the receptor, which 
eventually lead to the activation o f 
the IkB kinase (IKK) complex. 
The IKK complex is composed o f 
IkB kinases (IK K a and IKK0), 
the regulatory protein NEM O, as 
well as other molecules (Zandi et 
al., 1997; Yamaoka et a l,  1998; 
Chen et a l ,  2002). The activated 
IKK complex phosphorylates the 
I-kB family proteins, which marks 
them for proteasome-mediated 
degradation, liberating the NF-kB 
complex. After being 
phosphorylated, which is essential 
for full activation, the NF-kB 
subunits translocate to the nucleus 
and regulate gene expression 
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In mammalian cells, five distinct members of N F-kB are known: N F-kB l/p50, NF- 
KB2/p52, c-Rel, RelA/p65 and RelB (Verma et al., 1995). The inhibitory counterpart of this 
family of factors is the I-kB protein family, which includes I-kB(x, I-kBP, I-kB y, I-kB c, Bcl- 
3, pl05 and plOO (Perkins, 2000). In a resting state, I-kB proteins interact with NF-kB factors 
concealing the nuclear location sequence, and preventing transcription initiation (Verma et 
a l, 1995).
With regards to N F-kB activation downstream of TNFR, after TNFa-TNFR 
coupling, TRAFs are recruited to the TNFR1 signalling complex through its interaction with 
the adapter protein TRADD (Liu and Han, 2001). One of these associated factors, TRAF2, 
plays an important role in TNFR 1-mediated N F-kB activation (Hsu et a l, 1996b). Another 
critical component of the TNFR1 signalling complex, RIP, has also been also found to be 
recruited to the receptor complex by TRADD, and to be a key effector of TNFa-induced 
N F-kB activation (Hsu et a l, 1996a). Furthermore, it has been shown that TRAF2 is 
sufficient to recruit the IKK complex into the TNFR1 signalling complex; whereas RIP is 
necessary for the activation of the IKK complex (Devin et a l, 2000). Thus, a pathway model 
for TNFa-induced NF-kB  activation comprises TRAF2, acting as a receptor proximal adaptor 
that recruits the IKK complex to the TNFR1 signalling complex, hence enabling RIP to 
activate the kinases of the IKK complex. The key roles of TRAF2 and RIP in TNFa-induced 
N F-kB activation have been confirmed by genetic disruption in animal models (Yeh et a l, 
1997; Kelliher etal., 1998).
In order for full NF-kB activation to be obtained, additional phosphorylation of 
NF-kB p65 at Ser529 and Ser536 appears to be required. This can be accomplished by 
constitutively active kinases like casein kinase II, which is able to phosphorylate Ser529 of 
NF-kB p65 after its release from I-kB proteins (Wang et a l, 2000), or by the serine-threonine 
kinase Akt upon TNFa stimulation via an IKK-dependent pathway (Sizemore et a l, 2002). 
TNFa has been shown to be able to stimulate Akt in a cell type-specific manner via the PI3K 
pathway in a number of different experimental settings (Hanna et al., 1999; Ozes et al., 1999; 
Reddy et al., 2000). Moreover, PTEN inhibits TNFa-induced NF-kB-regulated gene 
transcription (Gustin et al., 2001; Mayo et al., 2002), further supporting the importance of 
PI3K in this pathway.
There are many important inflammatory mediators associated with chronic 
respiratory diseases which are induced by TNFa stimulation of NF-kB transcription factor
22
Chapter 1 -  Introduction
activity. TNFa stimulates the production of matrix metalloproteinases, which play a crucial 
role in tissue remodelling in chronic lung diseases, and IL- 8  in eosinophils in an NF-kB 
dependent manner (Schwingshackl et a l,  1999; Fujihara et al., 2002). Moreover, there is a 
report indicating that NF-kB mediates the production of survival proteins that protect 
eosinophils from cytotoxic effects when stimulated by TNFa (Fujihara et al., 2002). In ASM 
cells, there is evidence indicating that TNFa could help induce, through NF-kB activation, 
ASM hyperresponsiveness to allergens (Amrani et al., 2000). Furthermore, there is a recent 
report that indicates that the induction by TNFa of ICAM-1, IL-6 , IL-8 , RANTES, MCP-1 
and ENA-78 upregulation in human ASM cells, were all dependent on NF-kB activity (Catley 
et al., 2006). Curiosly, in this same system TNFa-induced COX-2 upregulation was not 
NF-kB dependent.
1.2.1.2 Activating Protein-1
Activating Protein (AP)-l collectively describes a group of structurally and 
functionally related members of the Jun protein family (cJun [also called Jun], JunB and 
JunD) and Fos protein family (c-Fos [also called Fos], FosB, Fra-1 and Fra-2). Additionally, 
some members of the ATF (ATFa, ATF2 and ATF3) and Jun dimerization protein (JDP; JDP- 
1 and JDP-2) subfamilies, which share structural similarities and form heterodimeric 
complexes with Jun proteins, can also bind to sequences found in AP-1 sites. Each of these 
proteins is differentially expressed and regulated, which means that different cell types have a 
particular mixture of AP-1 dimers with subtly different functions (Mechta-Grigoriou et al., 
2001).
The individual Jun and Fos proteins have significantly different activation potentials. 
Whereas Jun, Fos and FosB are considered strong transcription activators; JunB, JunD, Fra-1 
and Fra-2 exhibit only weak activity potential. Under specific circumstances, the ‘weak 
activator’ group could dampen gene transcription activity by competing for binding to 
transcription sites or by forming less active heterodimers with Jun, Fos or FosB (Hess et al.,
2004). Some factors from the AP-1 family, including cJun, have shown to be able to bind 
CRE sites in different systems (Ghosh et al., 2005), as is the case in the COX-2 promoter 
region (Deng et al., 2003).
The activity of this group of transcription factors is regulated by a wide range of 
physiological and pathological stimuli, including cytokines, growth factors, stress signals and 
infection metabolites. Regulation of transcription factor activity can be achieved through 
modulation in expression of genes encoding the transcription factors, control of the stability
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of their mRNAs, post-translational processing, and by specific interactions between 
transcription factor proteins with other transcription elements (Hess et a l, 2004). The 
regulation mechanism that has been most extensively analysed in the case of the AP-1 
transcription factors is the activation of cJun through the JNK cascade. Activation of the 
MAPK cascade by a variety of cytokines leads to the translocation of JNK, where it 
phosphorylates Ser63 and Ser73 of cJun, enhancing its transcription activity (Wajant et a l, 
2003). However, several groups have also reported JNK-independent activation of cJun 
(Besirli and Johnson, Jr., 2003; Adiseshaiah et a l, 2006).
The importance of this family of transcription factor molecules in respiratory diseases 
has been clearly suggested by previous research. Many genes of importance in lung illnesses 
have been shown to posses AP-1 binding sites, including inflammatory cytokines (Rooney et 
a l, 1995; Mori et a l, 2000), adhesion molecules (Korenaga et al., 1997), growth factors 
(Hata et a l, 2000) and protein components of airway mucus (Van, I et a l, 2000). 
Furthermore, a study in which a small molecule inhibitor of AP-1 activity was used in the 
context of an ovalbumin model of asthma, showed that the inhibition of this group of 
transcription factors leads to reductions in airway eosinophilia, mucus production and airway 
hyperresponsiveness (Henderson, Jr. et a l, 2002).
1.2.1.3 ATF/CREB family o f transcription factors
All the members of the activating ATF/CREB family of transcription factors share 
identical or homologous consensus sequences and encode proteins with the basic leucine 
zipper (bZip) DNA binding domain. Around 20 different mammalian members of this family 
have been described, with their members being grouped into subgroups on the basis of their 
amino acid similarity: CREB (including CREB and ATF1), CRE-BP1 (including ATF2 and 
ATFa), ATF3, ATF4, ATF6  and B-ATF subgroups. Proteins within each subgroup share 
significant similarity inside and outside the bZip domain, although proteins from different 
subgroups do not share much similarity other than the bZip domain (Hai and Hartman, 2001). 
There is mounting evidence that indicates that ATF/CREB proteins form selective 
heterodimers with each other, and with other bZip proteins such as the AP-1 and C/EBP 
families of proteins (Chinenov and Kerppola, 2001). Moreover, C/EBP possesses intrinisic 
histone acetyltransferase activity that can be activated when bound to other transcription 
molecules (Chen et al., 2001b). Inflammatory mediator gene expression can also be regulated 
by histone acetylation, and an increase in histone acetylation has been implicated to be 
important in chronic respiratory diseases, like asthma (Barnes et al., 2005).
24
Chapter I  -  Introduction
Activation of some of the members of this transcription factor family, including 
CREB and ATF2, has been demonstrated to occur downstream of TNFa signalling. The 
likely culprit responsible for the association between TNFR1 coupling and CREB and ATF2 
activation would seem to be p38 MAPK (Brinkman et al., 1999; Wajant et al., 2003). 
However, as seen with other transcription molecules, the signalling pathways that regulate 
specific transcription molecules vary between the different experimental settings, therefore 
the participation of other intracellular signalling pathways within the activation cascade of 
CREB or ATF2 cannot be discarded.
Interestingly, a recent report has implicated phosphorylation levels of CREB in the 
pathophysiology of asthma. In this study, increased levels of phosphorylated CREB were 
found in the bronchial epithelium and submucosa of untreated or steroid-dependent asthmatic 
patients; while levels in asthmatic patients treated with inhaled steroids were no different 
when compared to control subjects (Chiappara et al., 2007). These research findings support 
the idea that CREB plays an important role within the disease mechanisms of chronic lung 
illnesses.
1.2.1.4 C/EBP
The mammalian C/EBP family of transcription factors belong to the bZIP class of 
basic domain transcription factors and it is composed of six members: C/EBPa, (3, y, 5, e and 
C,. All members of the C/EBP family have similar basic region DNA-binding sequences, with 
the exception of C/EBP^ which lacks DNA-binding activity. The leucine zipper region is 
conserved between the different family members, whereas the amino-terminal activation 
domain is heterogeneous. As was the case in the ATF/CREB family, the leucine zipper 
domain in the C/EBP family is involved in the formation homo- and heterodimers (Cassel and 
Nord, 2003). Three of the C/EBP members have been demonstrated to be expressed in lung: 
C/EBPa, P, and 8  (Cao et al., 1991).
C/EBPp has been shown to be regulated by a diverse set of signal transduction 
pathways, as it carries multiple phosphorylation sites that have demonstrated importance in 
the regulation of the activity of this transcription factor. The p38 MAPK cascade causes 
C/EBPP phosphorylation on Ser105, increasing its transactivation potential (Engelman et al., 
1998). The same amino acid residue has also been shown to be a target for PKC 
phosphorylation (Trautwein et al., 1993). In opposition, other researchers have described 
other phosphorylation sites that decrease transactivation potential by inhibiting DNA binding 
(Mahoney et al., 1992).
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C/EBP factors have been demonstrated to be important regulators of different aspects 
of differentiation, including proliferation, cell cycle arrest, and gene expression (Cassel and 
Nord, 2003). When challenged with inflammatory mediators, C/EBPp and 5 levels are 
increased in the lung (Alam et a l, 1992). After lung injury, inflammatory mediators such as 
IL-1 (3, TNFa and IL- 6  and ICAM-1 are upregulated. All of these genes have been shown to 
be at least partly regulated by C/EBP activity in certain experimental settings (Chini et al., 
1998; Poli, 1998; Fan et a l, 2001). Furthermore, important agents involved in models of 
chronic lung inflammation, like bleomycin, also increase the levels of C/EBPP and 8  in the 
lung (Alam et al., 1992; Sugahara et al., 1999). All of this data suggests an important role for 
C/EBP, specifically the P and 8  isoforms, in the inflammatory reaction to lung injury and the 
subsequent immune response.
1.2.2 Intracellular signalling downstream of TNFR
To initiate intracellular signalling processes TNFR1 and TNFR2 can bind membrane- 
integrated TNFa (memTNFa) as well as soluble TNFa (sTNFa). As mentioned at the 
beginning of section 1.2, TNFR1 is constitutively expressed in many different tissues, while 
expression of TNFR2 is regulated being found mostly in cells of the immune system. 
Therefore, in most cells, TNFR1 appears to be the key mediator TNF signalling, whereas in 
the immune system, TNFR2 seems to play a major role. Interestingly, TNFR2 can only be 
fully activated by memTNFa, but not sTNFa (Grell et al., 1995).
The extracellular domains of both receptors can be proteolytically cleaved, yielding 
soluble receptor fragments with potential neutralizing capacity (Wajant et al., 2003). TNFR2 
is cleaved by TNFa-converting enzyme, the same molecule charged with cleaving TNFa 
(Solomon et al., 1999). The enzyme responsible for TNFR1 cleavage remains unknown, but 
TNFR1 cleavage is an important step in the regulation of cellular TNF responsiveness, as 
mutations producing a cleavage-resistant TNFR1 have been associated with dominantly 
inherited autoinflammatory syndromes, known as TNFR 1-associated periodic syndromes 
(Solomon et al., 1999).
The two receptors display no significant homology in their intracellular domains, 
suggesting that the two receptors elicit different intracellular signals. Genetically engineered 
TNFR1'7' mice are moderately resistant to a lethal dose of LPS but highly susceptible to 
Listeria monocytogenes infection (Pfeffer et al., 1993). On the other hand, TNFR2’7' mice are
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moderately resistant to lethal concentrations of TNFa itself (Erickson et al., 1994). Various 
studies show that mice with double knockout of TNFR1 and TNFR2 show a sum of these 
phenotypic effects (Liu and Han, 2001). This data would suggest that the two TNF receptors 
have different functions in vivo.
The first step of TNFa-induced signalling is believed to be ligand-induced 
oligmerization of the receptor molecules. Signalling initiation occurs by recruitment of 
cytosolic effector proteins that associate with the cytoplasmic domains of the TNF receptors. 
TNFR1 contains a protein-protein interaction domain, called death domain (DD), therefore in 
TNFR1 signalling, one of the first molecules to be recruited is a death-domain-containing 
adaptor protein known as TRADD (Hsu et al., 1995). The intrinsic property of the death 
domain of TNFR1 to aggregate and therefore to signal independent of ligand is masked in 
preassembled TNFR1 complexes by binding of the silencer of death domain (SODD) protein 
(Jiang et al., 1999). After ligand binding, SODD dissociates from TNFR1 complexes and the 
death domain-containing adaptor protein TRADD and other death domain-containing proteins 
are recruited to the death domain of TNFR1 by homophilic interactions with the death 
domains (Hsu et al., 1995). Some of these non-TRADD death domain-containing proteins 
couple to the death receptors for caspase activation and apoptosis (Schulze-Osthoff et al., 
1998). TRADD subsequently recruits other effectors, such as members of the TNF receptor- 
associated factor (TRAF) family to the TNFR1 complex. These effector proteins then mediate 
the activation of proteases, phospholipases, protein kinases and transcription factors (Liu and 
Han, 2001). TNFR2 also recruits members of the TRAF family, induces gene expression and 
intensively crosstalks with TNFRl(Wajant et al., 2003).
1.2.2.1 Activation o f M APKs
MAPKs are serine/threonine-specific protein kinases that respond to extracellular 
stimuli in order to regulate a myriad of cellular activities, including gene expression, mitosis, 
differentiation, chemotaxis, and cell survival/apoptosis (Pearson et al., 2001). There are four 
different groups of MAPK: extracellular signal-regulated kinases (ERK; also called p44/p42 
MAPK) 1 and 2; c-Jun N-terminal kinases (JNK; also referred to as stress-activated protein 
kinases or p54/p46 MAPK); p38 MAPKs; and other MAPKs (including ERK3, ERK5, ERK7, 
etc). As seen in figure 1.5, mitogens and other inflammatory mediators lead to the activation 
MAPKs via a signalling cascade where MAPK kinase (MKK or MAP2K) and MAPK kinase 
kinase (MKKK or MAP3K) lie sequentially upstream of MAPKs (Pearson et al., 2001). 
Therefore, extracellular stimuli would induce phosphorylation of MAP3K, with MAP3K then 
phosphorylating MAP2K, and finally with MAP2K phosphorylating the targeted MAPK.
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Figure 1.5 MAPK signalling pathway. The signalling cascade starts from the plasma membrane 
where the agonist binds to its enzyme-linked receptor, leading to phosphorylation o f  the intracellular 
parts o f  the receptor, which activates guanine exchange factors (GEF). GEFs are attached to the 
receptor by adaptor proteins such as She and Grb-2. GEFs promote the exchange o f  GDP to GTP on 
GTPases such as Ras, which leads to the activation o f the molecule. M AP3Ks, such as Raf, are 
activated on the plasma membrane by Ras-GTP. MAP3K.S then phosphorylate M AP2Ks (e.g. mitogen- 
activated kinase 1/2), which activates M APKs (e.g. ERK, JNK). The MAPKs then phosphorylate a 
variety o f  downstream targets, including transcription factor such as cJun, which results in changes in 
gene expression, and eventually in changes in cell function. Inactivation o f  the pathway occurs because 
Ras-GTP is constantly inactivated by GTPase activating proteins which promote the intrinsic GTPase 
activity o f  Ras. This leads to hydrolyzation o f GTP to GDP and, subsequently to inactivation o f  Ras 
GTPase.
The p38 MAPK, ERK and JNK pathways have all been reported to be activated by 
T N Fa coupling to its receptors (Liu and Han, 2001), although through very different 
pathways. TNFa-induced activation o f ERK is in most cells absent or only moderate when 
compared to TNFa-induced activation o f JNK (Van et al., 1992) or compared to mitogenic- 
induced activation o f ERK through receptor tyrosine kinase (RTK) pathways (Vietor et al., 
1993). Instead, a negative feedback system o f T N Fa on ERK activation through RTK has 
been observed in several cell lines (Muller et al., 1998). When present, the link between TNF 
receptors and ERK has been associated to a protein containing a domain with low DD
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homology termed MADD that binds to the DD of TNFR1 and is able to activate MAPK 
pathways (Schievella et al., 1997). Another possible culprit, the adapter protein Grb2, is also 
known to bind to TNFR1, linking this receptor to ERK (Hildt and Oess, 1999).
In the case of JNK, TNFa-induced activation of the JNK pathway occurs through a 
TRAF2-dependent pathway, as determined from genetically-manipulated mice studies (Lee et 
al., 1997; Yeh et al., 1997). Furhtermore, studies involving embryonic fibroblasts from 
MKK7'7' and MKK4‘A mice suggest that MKK7 is essentially involved in TNFa-induced JNK 
activation, whereas MKK4 contributes to optimal TNFa-mediated JNK activation, but is 
unable to evoke JNK activation on its own (Toumier et al., 2001). The distinct roles of 
MKK7 and MKK4 in TNFa-induced JNK activation possibly reflect the different substrate 
specificities of these kinases. Previous studies have shown that MKK7 preferentially acts on 
Thr180 of JNK (Lawler et al., 1998), whereas MKK4 phosphorylates Tyr182 (Toumier et al.,
2001). Therefore, TNFa-induced activation of JNK seems not to depend on dual JNK 
phosphorylation, as phosphorylation of Thr180 by MKK7 is sufficient to activate JNK in 
response to TNFa, while MKK4 enhances TNFa-MKK7-mediated JNK activation by its 
activity on Tyr182. Remarkably, TNFa seems to mainly activate MKK7 demonstrating that 
basal levels of MKK4 activity are sufficient to allow maximal activation of JNK in response 
to TNFa (Moriguchi et al., 1997).
After being activated, JNK translocates into the nucleus and enhances the 
transcriptional activity of transcription factors, (e.g. cJun and ATF2) by phosphorylation of 
their amino-terminal activation domains (Wajant et al., 2003). TNFa-induced JNK activation 
and c-Jun phosphorylation have been implicated in upregulation of many cellular proteins, 
including collagenases, the chemoattractant MCP-1, E-selectin and many others. However, 
JNK also has cellular functions that are not related to cJun phosphorylation (Wajant et al., 
2003).
Many characteristics of TNF-induced JNK activation are very similar for 
TNFa-induced activation of the p38-MAPK cascade. Both JNK and p38 MAPK are 
transiently activated by TNFa, but show prolonged activation under apoptotic conditions. 
Moreover TRAF2, which has been implicated in TNFa-induced JNK activation, is also an 
important component of the p38 MAPK cascade (Carpentier et al., 1998). Nevertheless, there 
is also clear evidence that differences exist between JNK and p38 activation. For example, 
mouse embryonic fibroblasts from MKK3' ' mice demonstrate a strong reduction in TNFa- 
induced activation of p38 MAPK, but no effect on JNK activation (Wysk et al., 1999).
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Furthermore, TNFa-elicited production of IL-1 and IL- 6  is almost completely blocked in the 
embryonic fibroblasts from MKK3'7' mice (Wysk et al., 1999), suggesting a role for p38 
MAPK in this process. The p38 MAPK signalling cascade also activates various transcription 
factors including ATF2, CREB and NF-kB (Wajant et al., 2003).
1.2.2.2 Activation o f mammalian target o f rapamycin
The mammalian target of rapamycin (mTOR) is a 289 kDa PI3K-related kinase that is 
implicated in the regulation of cellular growth and the activity of the translation machinery 
(Workman et al., 2006). Research has shown that mTOR forms at least two distinct 
complexes: the mTOR complex 1 (mTORCl) is composed of mTOR, mammalian LST8 /G- 
protein (3-subunit like protein (mLST8 /GpL) and regulatory associated protein of mTOR 
(Raptor); whereas mTORC2 consists of mTOR, mLST8/G|3L, rapamycin-insenstivie 
companion of mTOR (Rictor) and mammalian stress-activated protein kinase interacting 
protein 1 (Abraham, 2002). Although mTORCl is responsible for sensing nutrient signals, 
mTORC2 has been implicated in the organization of actin (Tsang et al., 2007).
Rapamycin is the founding member of the family of mTOR inhibitors. Rapamycin 
includes two separated moieties, the TOR-binding and the FKBP 12-binding regions. To be 
active biologically, rapamycin must form a complex with mTOR and FKBP 12. Therefore, 
rapamycin acts to induce the dimerization of mTOR and FKBP 12. The rapamycin-FKBP12 
complex binds directly to mTOR and inhibits the function of mTOR and the mTOR-mediated 
signalling network. Rapamycin interacts with and inhibits mTORCl, but not mTORC2 
(Tsang et al., 2007).
Activation of the mTOR pathway downstream of TNFa coupling to its receptors has 
been shown under certain experimental conditions. Consistent with a role in inflammation, 
TNFa-induced IL- 6  expression in vascular endothelial cells has been reported to be blocked 
in cells pretreated with rapamycin (Schreml et al., 2007). Moreover, others have reported on 
the importance of mTOR activity in TNFa-induced ICAM-1 expression in endothelial and 
smooth muscle cells (Voisard et al., 2007).
An increasing number of human diseases have been linked to the dysregulation of 
mTOR, including immunological, oncological, metabolic, respiratory, cardiovascular and 
neurological diseases. Intriguingly, most of these are due to abnormal hyperactivity of the 
mTOR pathway, which makes inhibitors of mTOR potentially effective therapeutics for the 
treatment of these diseases (Tsang et al., 2007).
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1.2.2.3 PI3K activation
PI3K are a family of kinases that, through the production of lipid mediators, play an 
important role in intracellular signalling within a diversity of homeostatic and, inevitably, 
disease functions. This kinase family is the main target of research of this thesis, and as such, 
information on its background, family structure, homeostatic and disease mechanisms are 
explained in considerable detail in the last section of this introductory chapter. In this section, 
however, TNFa-induced P13K activity in certain cellular fruitions is analysed.
IgA is the predominant immunoglobulin at mucosal surfaces. It has been 
demonstrated that TNFa enhances IgA binding activity of eosinophils from allergic 
asthmatics; while eosinophils from healthy donors failed respond in the same way to TNFa. 
Furthermore, it was shown that the TNFa-induced IgA-binding enhancement in eosinophils 
from asthma patients is dependent on PI3K activity (Bracke et a l, 2000b). This was relatively 
unsurprising, as previous work from the same research group had already shown that 
eosinophil IgA-binding enhancement by another cytokine, IL-5, was dependent on PI3K 
activity (Bracke et al., 2000a).
The phosphatase PTEN, which inactivates PI3K lipid products by dephosphorylation, 
inhibits the transcription of NF-kB -regulated genes elicited by TNFa (Gustin et al., 2001; 
Mayo et al., 2002), implying a role for PI3K activity and its lipid by-products within N F-kB- 
regulated gene expression. Concurrent with this idea, quercetin, a dietary flavonoid that has 
been found to inhibit PI3K activity, was able to block TNFa-induced NF-kB activation in 
cultured human airway epithelial cells. These researchers also reported that pretretament with 
the broad-spectrum PI3K inhibitor LY294002 or quercetin efficiently reduced TNFa-induced 
IL- 8  and MCP-1 expression in these cells (Nanua et al., 2006).
Reactive oxygen species generation downstream of TNFa stimulation in endothelial 
cells has also been shown to be dependent on PI3K activity, specifically the class IB PI3K 
pi lOy catalytic subunit. The activity of pllOy was selectively targeted by using lung 
microvascular endothelial cells from pi 10y'A mice. Furthermore, TNFa-induced NF-kB 
activity and ICAM-1 protein expression were also blocked in p i 10y'/_ mice (Frey et a l, 2006). 
These same authors demonstrated in another report that i.v. infusion of a TAT-fused 
dominant-negative form of the class IA PI3K p85 regulatory subunit successfully reduced 
leukocyte recruitment and microvascular permeability in the lung, using murine models of 
TNFa-induced lung inflammation (Gao et al., 2007).
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1.3 PI3K
PI3K has come a long way since its initial discovery almost twenty years ago. 
Disease has accompanied PI3K from its onset, being copurified with oncoproteins when first 
recognised by Lewis C. Cantley and his team (Whitman et al., 1988). It is now clear that 
PI3K is a family of signalling molecules that not only play a key part in many disease 
processes, but also play essential roles in many of our basic homeostatic mechanisms, like cell 
differentiation and growth.
1.3.1 PI3K family
PI3K is a family of enzymes that functions both as lipid kinases, phosphorylating the 
D3 position of the inositol ring of target lipids, and as protein kinases, phosphorylating serine 
residues of certain protein targets, like the their own p85 regulatory subunits (Rameh and 
Cantley, 1999). As seen in Table 1.4, the PI3K family is divided into three classes based on 
their different isoform structure and substrate specificity. Furthermore, the class I family is 
further subdivided into IA and IB on the basis of their mechanism of activation.
1.3.1.1 Class IA PI3K
Class LA PI3Ks regulate a number of cellular functions including cell proliferation, 
differentiation, transformation, motility, and apoptosis (Cumock et al., 2002). Class IA 
PI3Ks, activated by receptor tyrosine kinases, are cytoplasmic heterodimers composed of a 
110 kDa (pi 10a, -P, or - 6 ) catalytic subunit and an 85kDa (p85, p55 or p50) adaptor protein 
(Rameh and Cantley, 1999).
p i  10a andpllOp
The ubiquitously expressed pi 10a and pi 10(3 catalytic subunits have been difficult to 
study because genetically engineered mice deficient in these isoforms have proven to be lethal 
at an embryonic stage, implying a role for these isoforms during development (Bi et a l, 1999; 
Bi et al., 2002). However, several studies using heterozygous animals and other molecular 









Distribution In vitro lipid products Functions Organisation with licences fo r  
selective inhibitors
I A p i 10a p85a, p85p, 
p55a,p55y, p5 0 a
RTK* Ubiquitous PI(3)Pb, PI(3,4)P2C, 
PI(3,4,5)P3*
D evelopm ent 





















p i 105 p85a, p85p, 
p55a,p55y, p 50a








B- and T-cell antigen receptor
signalling
Smooth muscle tone and 
hypertension
Neutrophil migration and burst
ICOS
PIramed
B pllO y p 101, p87plKAP GPCRsh Myeloid' PI(3)Pb, PI(3,4)P2C, 
PI(3,4,5)P3*
Thymocyte development 
T cell development 
T cell migration 
Neutrophil migration 
Macrophage and dendritic cell 
migration










II C 2a Clathrin RTK*, 
GPCRb, IRk
W idespread PI(3)Pb, PI(3,4)P2C Vesicle trafficking 
Insulin signalling 
Cell survival 
Vascular smooth muscle 
contraction
C2P Clathrin RTK', 
GPCRh, IRk
W idespread PI(3)Pb, PI(3,4)P2C Vesicle trafficking 
Cell migration 
Liver growth
C2y Clathrin ? Hepatic PI(3)Pb, PI(3,4)P2C Liver regeneration
III Vps34p V psl5p TLR1,
constitutive
Ubiquitous PI(3)Pb Toll-like receptor signalling 
Receptor-independent 
membrane trafficking
Table 1.4 Main characteristics of the P13K 
family. Table adapted from the review 
publication (Medina-Tato et al., 2007). The 
original references for the functions of each 
catalytic subunit can also be found in the 
review publication. 
a Tyrosine kinase receptors 
b Phosphatidyl Inositol (3) Monophosphate 
c Phosphatidyl Inositol (3,4) Bisphosphate 
d Deletion associated with defective mouse 
embryonic proliferation and death 
e Phosphatidyl Inositol (3,4,5) Trisphosphate 
f Mutated/amplified in human cancer.
8 Due to the high frequency of PIK3CA 
mutation in human cancer, extensive 
research into selective inhibitors for this 
isoform have been carried out by many other 
institutions (Yamanouchi, Xinxiang Medical 
College, Semafore, Chiron, Zenyaku Kogyo, 
Boehringer, University of British Columbia) 
h G-protein coupled receptors 
1 Mainly, but also expressed in endothelial 
cells and others
1 These are two commercially available 
inhibitors. 
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p l io s
The pi 105 subunit is expressed predominantly in lymphocytes and lymphoid tissues, 
and has therefore been thought to play a more important role in PI3K-mediated signalling of 
immune responses (Chantry et a l, 1997), than the other two member of the Class IA 
subgroup. Both p 1105'/_ (Clayton et al., 2002) and knock-in kinase-dead pi 105 mice 
(Okkenhaug et al., 2002) displayed impaired B cell activation and signalling. Furthermore, in 
vivo administration of IC87114, a novel pi 105 specific inhibitor, reduced neutrophil tethering 
and increased rolling velocities on cytokine-activated microvessels (Puri et al., 2004). Thus, 
p i 105 may be a reasonable therapeutic target in specific inflammatory conditions as blockade 
of its activity reduces B cell activation and neutrophil influx into tissues.
1.3.1.2 Class IB PI3K (p i 10y)
PI3K pllOy is especially abundant in leukocytes and, like pi 105, linked with the 
regulation of immune functions (Wymann and Pirola, 1998). Macrophages and neutrophils 
from pllOy"7" mice displayed reduced migratory capacity in response to certain chemokines 
(Sasaki et al., 2000). These mice also showed impaired T cell development and activation, 
reduced ability to produce reactive oxygen species in neutrophils (Hirsch et al., 2000), 
decreased thromboembolism (Hirsch et al., 2001) and improved heart function (Crackower et 
al., 2002). Moreover, these mice also showed a defective capacity to mount contact 
hypersensitivity and delayed-type hypersensitivity reactions (Del et al., 2004).
1.3.1.3 The p 110y-p 1105 functional association
Since pi 105 and pllOy are predominantly expressed in immune cells, it has been 
suggested that they interact to accomplish certain functions. Stimulation of TNFa-primed 
human neutrophils with N-formyl-methionyl-leucyl-phenylalanine results in a biphasic 
activation of PI3K. The first phase depends on pllOy, while the second one depends on 
p i 105. Interestingly, the pi 105-dependent second phase requires the pllOy-dependent first 
phase (Condliffe et al., 2005). Moreover, pi 105/pl 10y'A mice have shown that the activity of 
both of these isoforms is essential for thymocyte survival, and T cell development and 
production (Webb et al., 2005; Swat et al., 2006). Furthermore, this p i 105-pl lOy association 
also exists in parenchymal cells, like in the endothelium were these isoforms interact to 
express adhesion molecules (Puri et al., 2005).
34
Chapter 1 -  Introduction
1.3.1.4 Class IIP I3K
The class II PI3Ks (a, (3 and y isoforms), which are much larger than class I 
(>200 kDa), are characterized by the presence of a C2 domain at the carboxyl terminal 
(Domin et al., 1997). PI3K-C2a and PI3K-C2P show a widespread distribution, while the 
expression of PI3K-C2y is restriced, principally to the liver (MacDougall et al., 1995). In 
contrast to members of the other PI3K classes, PI3K-C2a is refractory to inhibition by 
wortmannin and LY294002 (Domin et a l, 1997). Although PI3K-C2a and PI3K-C2P are 
concentrated in the trans-Golgi network and are present in clathrin-coated vesicles in the 
endoplasmic reticulum (Domin et al., 2000), their suspected role within vesicle trafficking 
remains largely unknown. PI3K C2a activity has also been suggested to be important in 
insulin signalling (Urso et al., 1999), cell survival (Kang et al., 2005), and vascular smooth 
muscle contraction (Wang et al., 2006), while C2p has been mainly implicated in cell 
migration (Maffucci et al., 2005; Domin et al., 2005). PI3K-C2y remains elusive in regards to 
its possible functions.
1.3.1.5 Class III PI3K
Class III PI3K, originally described in yeast, appears to only utilize 
phosphatidylinositol as a substrate. The catalytic subunit of the human form of class III PI3K 
binds to a 150 kDa binding/regulatory subunit termed p i50 and has been postulated to play a 
role in the regulation of vesicle trafficking similar to that observed in yeast (Panaretou et al., 
1997). Although class III PI3K has also been recently suggested to be important in toll like 
receptor signalling (Kuo et al., 2006), its main role lays in the production of an apparently 
non-signalling inositol lipid.
1.3.2 PI3K  signalling
As seen in figure 1.6, PI3Ks phosphorylate the D-3 position of the inositol ring of 
target lipids. The levels of PI(3,4)P2 and PI(3,4,5)P3 in cells are usually in low abundance in 
resting conditions, but can rise sharply after cell stimulation. These lipids then interact with 
an array of downstream protein effectors via lipid binding domains such as pleckstrin 
homology (PH) and phox homology (PX) domains (Rameh and Cantley, 1999).
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Downstream Kinase Recruitment and Activation
Figure 1.6. PI3K, SHIP and PTEN activity on lipid substrates and products. In vitro experiments 
have shown that class I PI3Ks can phosphorylate PI, PI(4)P, PI(4,5)P2 to produce PI(3)P, PI(3,4)P2 and 
PI(3,4,5)P3, respectively; that class II PI3Ks phosphorylate PI and PI(4)P to produce PI(3)P and 
PI(3,4)P2, respectively; and that class III PI3Ks produce PI(3)P from PI. The effects o f  PI(3,4,5)P3 are 
counteracted by the lipid phosphatases PTEN and SHIP which convert this lipid to PI(4,5)P2 and 
PI(3,4)P2 respectively. PI(3,4,5)P3 and PI(3,4)P2 act as docking sites at the plasma membrane, 
recruiting and activating proteins containing phospholipid-binding domains.
36
Chapter 1 -  Introduction
The downstream PI3K effectors include protein kinases that promote cell growth, 
survival and proliferation, such as Akt, 3’-phosphoinositide-dependent kinase (PDK)l, and 
the Tec family kinases; kinases regulating guanosine triphosphatases that mediate cell 
motility and membrane trafficking, such as P-Rex and Swap70; and scaffolding proteins that 
nucleate the assembly of key signalling complexes, such as Gab2; (Vanhaesebroeck et a l, 
2001; Parry et al., 2007) amongst many other molecules and functions. Therefore, as 
represented in figure 1.7, PI3K is a hub through which many signals are relayed. The 
therapeutic challenge would then be to achieve control of pathological signalling activation, 
by selective inhibition of PI3K activity essential for disease mechanisms, without detrimental 
off-target effects, by non-inhibition of PI3K activity essential for homeostatic processes.
1.3.2.1 Akt
Akt is one of the main downstream effectors of PI3K activity. The ubiquitously 
expressed Akt family of kinases includes three known members: Aktl (PKBa), Akt2 (PKBP) 
and Akt3 (PKBy). Akts are serine/threonine kinases that are activated by two distinct 
phosphorylation events. The enzymatic activity of this family of kinases has been implicated 
as a possible therapeutic target for cancer diseases (Cheng et al., 2005).
The production of P1(3,4,5)P3 through the activation of class I PI3Ks is the first step 
in Akt activation by the majority of activating agents. This PI3K lipid product recruits Akt to 
the cellular plasma membrane through interaction with its N-terminal PH domain. It is 
thought that this interaction induces a change of conformation of Akt that allows PDK1 to 
phosphorylate Akt on Thr308 (in the specific case of Aktl) in its kinase domain. PDK1 seems 
to colocalise with Akt through interaction between its PH domain and PI3K lipid products 
(Datta et al., 1999; Chan et al., 1999; Cheng et al., 2005). A currently unidentified kinase, 
refered to generally as PDK2, phosphorylates Akt on Ser473 (for Aktl) in its C-terminal 
hydrophobic motif. There are certain molecules considered as possible candidates of being 
PDK2 including: Akt itself (through autophosphorylation), integrin-linked kinase, DNA- 
dependent protein kinase, PKC and Rictor, amongst others. In order for Akt to be fully 
activated, both residues must be phosphorylated. After full activation is carried out, Akt tends 
to dissociate from the cellular membrane and translocates to different sites of action 
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Figure 1.7 P13K as a central hub o f signalling in inflammation and homeostasis. This figure aims to be representative o f  the main kinases and proteins involved in 
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Akt has been demonstrated to phosphorylate a number of proteins, particularly those 
involved in regulating glucose metabolism and cell survival, such as glycogen synthase kinase 
(GSK)-3p. Moreover, PDK1, Akt and mTOR contibrute to the activation p70 S6 kinase 
(S6K), an enzyme thought to be important in the regulation of protein synthesis (Datta et a l, 
1999; Cheng et al., 2005). Akt has also been implicated in a variety of other cellular 
functions, such as cell proliferation, angiogenesis, cell survival and migration (Woodgett, 
2005).
1.3.2.2 GSK-3
GSK-3 is a family of multifunctional serine/threonine kinases found in all eukaryotes. 
There are two mammalian GSK-3 isoforms encoded by distinct genes: the 51 kDa GSK-3a 
and the 47 kDa GSK-3 P (Doble and Woodgett, 2003). GSK-3 a  and GSK-3 (3, although 
structurally similar, do not appear to be functionally identical. This is suggested by genetic 
manipulation experiments of the GSK-3 P isoform in mice, which resulted in GSK-3 P“/_ 
animals suffering from embryologic lethality due to massive liver degeneration caused by 
extensive hepatocyte apoptosis (Hoeflich et al., 2000). The inability of GSK-3a activity to 
rescue the GSK-3P-' mice indicates that the degenerative liver phenotype arises from a non- 
redundant function of GSK-3 p.
GSK-3 is an unusual kinase in that it is normally active in cells and is primarily 
regulated through inhibition of its activity. As mentioned at the end of section 1.3.2.1, 
phosphorylation of GSK-3 occurs through a PI3K- and Akt-dependent mechanism. PI3K- 
induced activation of Akt results in Akt-mediated phosphorylation of both GSK-3 isoforms 
(Ser9 of GSK-3P; Ser21 of GSK-3a) (Cross et al., 2001), which inhibits GSK-3 activity. This 
leads to the dephosphorylation of the substrates regulated by GSK-3 activity, resulting in their 
functional activation and consequent increased glycogen and protein synthesis (Doble and 
Woodgett, 2003).
The enzyme is a key regulator of numerous signalling pathways, including responses 
to receptor tyrosine kinases and GPCRs, involved in a wide range of cellular processes, 
ranging from glycogen metabolism to cell cycle regulation. Furthermore, GSK-3P has 
emerged in the last couple of years as one of the most promosing therapeutic targets for the 
treatment of multiple neurological diseases, including Alzheimer's, stroke and bipolar
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disorders, as well as noninsulin-dependent diabetes mellitus and certain inflammatory 
illnesses (Ougolkov and Billadeau, 2006).
1.3.2.3 Ribosomal protein S6
Ribosomes are intracellular organelles in charge of translating mRNA into a 
polypeptide chain, using aminoacids delivered by transfer RNA. Higher eukaryotic ribosomes 
consist of two subunits designated the 40S and 60S subunits. The 40S subunit comprises a 
single molecule of RNA, called 18S ribosomal RNA (rRNA), and 33 proteins. By contrast, 
the 60S subunit has three RNA molecules, called 5S, 5.8S and 28S rRNA, and approximately 
47 proteins (Ruvinsky and Meyuhas, 2006). Of all of the 60S ribosomal proteins, S6 has 
gained much notoriety because it was the first substrate that had been shown to undergo 
inducible phosphorylation (Pende et al., 2004). This phospho-regulation occurs in response to 
numerous physiological and pathological stimuli (Ruvinsky and Meyuhas, 2006).
The phosphorylation sites in S6 have been mapped to five residues: Ser235, Ser236, 
Ser240, Ser244 and Ser247, whose location at the C terminus of higher eukaryotes is 
evolutionarily conserved (Krieg et al., 1988). S6 was the first identified substrate of the S6K 
family. Analysis of S6 phosphorylation in mouse cells deficient in either S6K1 or S6K2 
suggests that both kinases are required for full phosphorylation of S6, yet it is predominantly 
carried out by S6K2. Furthermore, phosphorylation of S6 at Ser235 and Ser236 can still be 
detected, albeit at a much lower level, in cells lacking both of these kinases (Pende et al., 
2004). As described in a previous section, S6 phosphorylation occurs after exposure to a 
variety of external stimuli in a PI3K-dependent manner through the activation of PDK1, Akt 
and mTOR, as these downstream kinases contibrute to the activation of S6K (Datta et al., 
1999; Cheng et al., 2005).
1.3.2.4 Transcription factor signalling
PI3K signalling, through the activation or inactivation (in the case of GSK3(3) of its 
downstream kinases, has been associated with the regulation of a variety of transcription 
factor molecules. It has been recently shown that binding sites for Forkhead family members 
were over-represented among PI3K-dependent genes (Tullai et al., 2004), consistent with 
regulation of Forkhead family members by PI3K-induced signalling (Tran et al., 2003). 
Binding sites for C/EBP were also over-represented within the PI3K-dependent group of 
genes (Tullai et al., 2004), consistent with the regulation of C/EBP transcription activity by 
GSK-3P downstream of PI3K and Akt (Ross et al., 1999). The NF-kB pathway has also been 
implicated downstream of PI3K activation in a diversity of experimental settings (Sliva,
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2004). Moreover, PI3K has been shown to regulate the activation of a variety of other 
transcription molecules under specific experimental conditions, as is the case with the 
ATF/CREB and the cJun pathways (Mayr and Montminy, 2001; Chandrasekar et a l, 2005).
1.3.3 PI3K  silencing tools
The search for cell functions performed by individual PI3K isoforms has been 
difficult. This non-distinction has been due to the poor specificity, hence broad spectrum, of 
the classical pharamacoligcal tools used for studying PI3K function, the inhibitors 
wortmannin and LY294002 (Finan and Thomas, 2004). This impediment is augmented by the 
fact that these inhibitors potently inhibit enzymes that are functionally associated with PI3K, 
like the mTOR and myosin light chain kinase (Ward et al., 2003). However, with the use of 
DNA-RNA manipulation technology, as well as the development of other molecular biology 
tools such as isoform-specific antibodies and short interference RNA, the different roles of 
each one of the members of the PI3K family have begun to be determined.
1.3.3.1 Inhibitors
The majority of small molecule PI3K inhibitors that have been developed to date bind 
to the ATP-binding site of the PI3K molecule, making them ATP-competitive inhibitors. The 
first widely available inhibitors of PI3K to be considered as relatively specific were 
LY294002 and wortmannin (chemical structures shown in Fig. 1.8). Wortmannin is a 
naturally occurring metabolite of Penicillum funiculosum that acts as an irreversible inhibitor 
of PI3K. On the other hand, LY294002, which was derived from the flavonoid quercetin, is a 
reversible inhibitor of PI3K (Ito et al., 2007). Although these compounds have been 
invaluable tools to study the PI3K pathway, they both have a broad inhibitory profile across 
different isoforms of PI3K. The broad inhibitory profile displayed by these compounds 
prevents their use in elucidating isoform-specific functions within disease and homeostasis 
mechanisms within whole cell experimental settings. Furthermore, the fact that both these 
compounds efficiently inhibit other molecules, independently of their homology to PI3K, 
further complicates the interpretation of research data obtained when using them. In this 
sense, LY294002 and wortmannin have been shown to inhibit mTOR and DNA-dependent 
protein kinase, both considered to be highly related molecules to PI3K (Brunn et al., 1996). 
Furthermore, LY294002 also inhibits PI3K-unrelated protein kinases such as casein kinase 2 
and Pim-1 (Davies et al., 2000; Jacobs et al., 2005); while wortmannin inhibits myosin light 
chain kinase and polo-like kinase (Davies et al., 2000; Wipf and Halter, 2005).
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Due to all the specificity disadvantages possessed by LY294002 and wortmannin, and 
since these compounds have poor solubility, high toxicity and low absorption, the need for 
better and novel small molecule inhibitors targeting PI3K activity was evident. Consequently, 
a great number o f patents have been registered, by academic and pharmaceutical institutions 
alike, describing both broad-spectrum and isoform-selective inhibitors (Ruckle et al., 2006; 
lio et al., 2007). The ICOS Corporation has produced several quinazoline derivatives that act 
as highly-selective p i 108 inhibitors, including IC87114 (Sadhu et al., 2003), which has a 
positive impact on airway disease as described in section 1.3.41. Other companies like 
Kinacia Ltd. and PIramed have focused on developing p i 1 0 0 - (e.g. TG X -115 and TGX-121) 
and p i 1 0 a -  (PI-103) selective compounds, respectively. As seen in table 1.4, there are many 
other research institutions that are currently involved in the discovery o f novel PI3K 
inhibitors. The chemical structures o f the compounds mentioned in this section can be seen in 
figure 1.8.
LY2 9 4 0 0 2 PI103 IC87114
H„N
W ortm annin TGX115
Figure 1.8. Small-molecule inhibitors of the PI3K family. LY294002 and wortmannin are broad- 
spectrum inhibitors o f the PI3K family and other molecules. Recent isotype-specific inhibitors such as 
PI 103 (p i lOa-selective), IC87114 (pi 108-selective) and TGX115 (p i 10p/pl 108-selective) have been 
developed and are now being used to determine the specific roles o f  individual PI3K isoforms in a 
variety o f  cellular processes. Image adapted from reference (Stokoe, 2005)
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In the clinic, the decision between broad-spectrum inhibitors versus isoform-specific 
compounds seems to be more difficult to answer. Some pharmaceutical companies like 
Semafore Pharmaceuticals Inc. research the possibility that a broad spectrum PI3K inhibitor, 
like their lead compound SF1126, could prove to be useful therapeutical agent against tumor 
development in cancer therapy; while others, including TargeGen, Inc., using their pi 105/y 
selective inhibitor (TGI00-115), which has begun clinical trials for actue myocardial 
infarction (ClinicalTrials.gov Identifier: NCT00103350), research the possibility that 
specificity is the correct approach in the patient.
1.3.3.2 Genetically-engineered animals
The generation and analysis of mice that have been genetically manipulated to 
enhance or abrogate the function of a specific isoform of the PI3K family of kinases have 
shed invaluable data on the roles that these targeted isoforms play within a diverse array of ex 
vivo and in vivo experimental models in which they have been used. Many of the functions 
ascribed to the different PI3K isoforms as reported in Table 1.4 have been the product of 
genetically-manipulated animal work.
The reported importance that p i 10a and p i 10(3 have on growth and development 
partially stems from the fact that pi 10a'A and pllOP'7' animals are embryonic lethal, at 
different stages of development, suggesting that although both are important for development, 
they carry different functions within the development process (Bi et al., 1999; Bi et a l, 2002). 
As seen in previous sections, generation of pi 105'7' mice or mice possessing a point mutation 
on the pi 105 gene rendering the production of a non-functional pi 105 subunit (referred to as 
knockin mice), have demonstrated the importance of this isoform in B cell maturation, 
antibody production, and immune response (Okkenhaug et a l, 2002; Clayton et al., 2002; Jou 
et al., 2002; Puri et a l, 2004; Ali et al., 2004); while p ll0y ‘7‘ and pllOy knockin mice have 
demonstrated the predominant role that this isoforms plays in leukocyte recruitment and 
chemotaxis (Hirsch et a l, 2000; Li et al., 2000; Sasaki et a l, 2000; Laffargue et al., 2002; 
MacDonald et a l, 2004; Patrucco et a l, 2004). Other groups have also genetically 
manipulated the regulatory subunits of the class LA PI3K family, with their results reviewed 
in reference (Vanhaesebroeck et a l, 2005).
There are also important setbacks to using gene manipulation technology. Firstly, as 
seen in the case of p i 10a'7' and p i 10p'/_ animals, if the target is important for development,
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recognition of any other function it may have will not be unveiled. Secondly, as in the case of 
pi lOy'7' mice, elimination of a molecule and not its mere inhibition, leads to potential changes 
in stoichiometry that could have repercussions on cell functions which are not directly 
dependent on the targeted molecule. In the above mentioned example, pllOy'7' mice, but not 
pllOy knockin mice, have increased heart contractility, but this is not due to the kinase 
function of p i lOy. The explanation comes from the fact that pi lOy binds to and controls the 
activity of phosphodiesterase 3B, an important enzyme within heart contractily, independently 
of its catalytic activity (Hirsch et al., 2000; Patrucco et al., 2004). Therefore, any technique 
that eliminates or reduces the presence of a specific molecule, including gene deletion or 
RNA intereference, if not verified by other techniques, could lead to the misinterpretation of 
certain effects observed within the target protein-depleted system.
1.3.3.3 RNA interference
RNA interference (RNAi) is a evolutionary conserved pathway involved in cellular 
defense against viral invasion and post-transcriptional regulation. The functional effector 
molecules of the RNAi pathway, small interference (si) RNA, are a class of 20-25 basepair 
long RNA molecules that may be synthesized by a variety of means and introduced 
intracellularly to effect changes in protein expression (Grunweller and Hartmann, 2005). 
Short interfering (si)RNA was first discovered in plants by David Baulcombe’s group 
(Hamilton and Baulcombe, 1999). Two years later, the use of synthetic siRNA was used to 
induce sequence-specific gene silencing in cultured mammalian cells (Elbashir et al., 2001). 
Subsequent studies have shown that for highly potent siRNAs, the silencing effect is 
relatively stable, persisting through several cell divisions (Grunweller and Hartmann, 2005).
The process of RNA interference is illustrated in figure 1.9. Briefly, once siRNA 
duplexes have been delivered in the cytoplasm, the guide and passengers strands are 
disassociated. The guide strand is in the anti-sense orientation with respect to the targeted 
mRNA and is assembled with other proteins to form the RNA-induced silencing complex 
(RISC). RISC binds mRNA complementary to the guide strand and cleaves it. Once the 
mRNA target is cleaved, RISC dissociates from the cleaved mRNA to repeat the cleavage 
cycle with other mRNA targets (Dykxhoom et al., 2003).
Further potential exists for RNAi beyond basic research. Four years ago, after the first 
publication showing in vivo evidence of RNAi-based therapeutic efficacy in protecting mice 
from an animal model of fulminant hepatitis (Song et al., 2003), the development of siRNA 
as a therapeutic agent took off very rapidly. Since then, three phase I studies directed at
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in v es tig a tin g  R N A i-b ased  d rugs fo r ag e -re la ted  m acu la r d eg en era tio n , a lead in g  cau se  o f  
b lin d n ess , an d  fo r resp ira to ry  sy n cy tia l v iru s  in fec tio n , one  o f  the  lead in g  cau se  o f  p aed ia tric  
h o sp ita liz a tio n s  in the d ev e loped  w orld , h av e  a lread y  b een  co m p le ted  w ith o u t p resen tin g  
p ro h ib itiv e  to x ic ity  (de  F o u g ero lle s  et al., 2007 ). A lth o u g h  th e  qu estio n  o f  therapeu tic  
e ff ic ien cy  still rem ain s, the s tage  is se t fo r s iR N A  to  beco m e  a n ew  o p tio n  in  the trea tm en t o f  
a  d iv e rse  a rray  o f  d iseases.
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Figure 1.9 siRNA-mediated post-transcriptional gene silencing. A. An siRNA is composed o f two 
21 nucleotide (nt) long single short RNA with a 19 nt duplex region. B. The siRNAs are uptaken by the 
RNA-induced silencing complex (RISC). ATP is then hydrolysed to help unwind the siRNA. Hence, 
the siRNA duplex is diassociated into passenger and guide strands. C. The single-stranded antisense 
strand, known as guide strand, directs RISC in order to find the target mRNA. The guide strand 
provides sequence specificity for the target mRNA. Once the target mRNA is recognised, RISC cleaves 
the mRNA in the middle o f the duplex region, 10 nt from the 5'end o f the siRNA Diagram modified 
from reference (Dykxhoom et al., 2003)
1.3.3.4 O ther m olecu lar approaches
O th e r  tech n iq u es fo r m an ip u la tin g  P13K a c tiv ity  have  b een  u sed  by  o th e r au thors. 
M eth o d s  su ch  as m ic ro -in jec tio n  o f  an tib o d ies  o r tran sfe ren ce  o f  do m in an t n ega tive  fo rm s o f  
P I3K  in to  ce lls  have  b een  d esc r ib ed  b e fo re  (B en is tan t e t al., 2000 ; S m ith  et a l ,  2001).
1.3.4 P13K in respiratory disease
A  su m m ary  o f  P I3K  resea rch  done  in lung  d isea se s  can  be found  in  T ab le  1.5.
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Target Disease Model Research Tool Targeting Impact
PI3K ALI-
ARDS
Endotoxin-Induced (in vitro) Inhibitor Reduced expression o f IL-1 p and TNFa in cultured 
neutrophils.
Endotoxin-Induced (in vivo) Inhibitor No reduction in IL-6 or CXCL2 levels
Endotoxin-Induced (in vivo) Inhibitor Decreased oedema, neutrophil infiltration and 
inflammatory cytokine expression
Overventilation (ex vivo) Inhibitor Attenuated filtration coefficients in isolated lungs
Overventilation (in vivo) Inhibitor Diminished IL-6 and CXCL2 release
HC1 lung instillation (in vivo) Inhibitor Reduced neutrophil recruitment to lungs
COPD IL-lp-induced mucin secretion 
(in vitro)
Inhibitor Attenuated mucin secretion in cultured airway epithelial 
cells
Chemotaxis assay (in vitro) Inhibitor Inhibited chemotactic responses to a CXCR3 ligand in 
cultured airway epithelial cells
Nicotine-induced survival and 
transformed phenotype (in vitro)
Inhibitor Prevented transformed phenotype and enhanced survival 
in human airway epithelial cells
Asthma IL-13-induced mucus secretory 
phenotype (in vitro)
Inhibitor Reduced mucus hypersecretory phenotype and goblet 
cell metaplasia in bronchial epithelial cell cultures
Thrombin-, EGF- and PDGF- 
induced (in vitro)
Inhibitor Reduced proliferation o f  cultured airway smooth muscle 
cells
Long-term serum deprivation (in
vitro)
Inhibitor Inhibited the transformation of cultured airway myocytes 
into a contractile phenotype
Methacoline-induced (in vitro) Inhibitor Partially attenuated contraction in cultured airway 
smooth muscle strips
Ovalbumin-induced (in vitro) Inhibitor Decreased bronchial contraction in isolated bronchial 
tissue
Ovalbumin-induced (in vivo) Inhibitor Diminished levels of interleukins (4,5 and 13), lung 
tissue eosinophilia, airway mucus production and AHR
Ovalbumin-induced (in vivo) Inhibitor No improvement in lung eosinophilia or in AHR to 
acetylcholine, attenuated eosinophil levels and 
degranulation in BAL fluid, and AHR to histamine
p85a ALI-
ARDS
TNFa-induced (in vitro) Blocking protein (TAT 
construct)
Attenuated reactive oxygen species production in 
primary granulocytes
TNFa-induced (in vivo) Blocking protein (TAT 
construct)
Reduced microvascular injury and granulocyte 
recruitment to the lung
Asthma Ovalbumin-induced (in vivo) Gene disruption Decreased secretion of interleukins (4 and 5), eosinophil 
and lymphocyte lung infiltration, and AHR
pi 10 Asthma Thrombin-, EGF- induced (in 
vitro)




i.p. E. coli challenge (in vivo) Gene disruption No protection against disease model
Endotoxin-Induced (in vivo) Inhibitor Reduced lung neutrophil accumulation
Endotoxin-Induced (in vivo) Gene disruption Diminished neutrophils recruitment, pulmonary levels of 
IL-1P and TNFa
Endotoxin-Induced (in vivo) Gene disruption Reduced neutrophil recruitment
COPD i.n. chemokine instillation (in 
vivo)
Gene disruption No protection against disease model
Asthma Allergen-IgE-induced (in vitro) Gene disruption and 
Inhibitor
Inhibited degranulation and cytokine release in cultured 
mast cells
Ovalbumin-induced (in vivo) Inhibitor Diminished levels of interleukins (4,5 and 13), leukocyte 
infiltration to the lungs, and IgE and LTC4 release
Ovalbumin-induced (in vivo) Hemopoietic cell- 
restricted gene disruption
Reduced levels o f type 2 cytokines, eosinophil 
recruitment to the lung, airway inflammation and mucus 
production
p i lOy ALI-
ARDS
Overventilation (ex vivo) Gene disruption Attenuated levels of histologic indices and levels o f PKB 
phosphorylation in isolated lungs
Endotoxin-Induced (in vivo) Gene disruption Decreased neutrophil recruitment to the lung
COPD Chemotaxis assay (in vitro) Gene disruption Reduced chemotaxis to CXCR2 ligands in neutrophils
i.n. chemokine instillation (in
vivo)
Gene disruption Diminished neutrophil accumulation in the lung
Asthma Allergen-lgE-adenosine-induced 
(in vitro)
Gene disruption Partially attenuated degranulation and cytokine release 
in cultured mast cells
Table 1.5 PI3Ks as targets in respiratory disease research. Table adapted from reference (Medina- 
Tato et al., 2007), which contains the source references. Airway hyperresponsiveness (AHR), 
immunoglobulin E (IgE), leukotriene C4 (LTC4), bronchoalveolar fluid (BAL).
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1.3.4.1 Asthma
PI3K inhibitors have shown to be highly benefitial in asthma models of disease. 
Initial studies showed that ovalbumin-induced IL-4 and IL-5 levels could be decreased by 
intratracheal administration of PI3K inhibitors (Kwak et al., 2003). Moreover, others have 
demonstrated that intratracheal administration of LY294002 greatly inhibits many of the 
pathological characteristics of a mouse asthma model, including eotaxin levels, lung tissue 
eosinophilia, airway mucus production, airway hyperesponiveness (AHR) to inhaled 
methacholine, IL-5 and IL-13 levels in BAL (Duan et al., 2005).
PI3K and Akt activities are increased after allergen challenge in different models of 
asthma, and it has been shown that Akt activity is sensitive to pretreatment with non-selective 
PI3K inhibitors (Kwak et al., 2003). Unfortunately, these studies do not attempt to distinguish 
the specific PI3K isoform involved. Myou et al., using a dysfunctionalized p85 in the context 
of an asthma model, were the first to demonstrate that class IA PI3K are important in 
leukocyte recruitment to the lungs, antigen-induced airway inflammation and 
hyperresponsiveness, and Th2 cytokine production. Curiosly, p85 blockage did not affect 
BAL fluid levels of the Thl cytokine, IFN-y, suggesting that class LA PI3K is involved in the 
regulation of the balance between Thl and Th2 responses (Myou et a l, 2003).
The role played by pi 108 and pi lOy in the asthmatic response has been determined 
by other studies. Genetic or pharmacologic blockage of pi 108 activity has been shown to 
inhibit mast cell allergen-IgE-induced degranulation and cytokine release in vitro (Ali et al., 
2004). Furthermore, others have demonstrated that intratracheal administration of the pi 108 
specific inhibitor, IC87114, in a mouse asthma model, was able to reduce leukocyte 
accumulation, IgE, LTC4 and Th2 cytokine levels (IL-4, IL-5 and IL-13) in the lungs (Lee et 
al., 2006). On the other hand, pllOy'7' mice have proved to be partially protected from 
anaphylaxis elicited by an intradermal injection of IgE and allergen (Laffargue et al., 2002).
Eosinophils play a critical part in the development of asthma, as shown by the fact 
that BAL eosinophil count in asthmatic patients has often positively correlated with AHR 
(Durham and Kay, 1985; Foresi et al., 1990). Inflammatory mediators activate eosinophils via 
signal transduction pathways involving PI3K (Ezeamuzie et a l, 2001). Moreover, eosinophils 
depend on PI3K activity in order to migrate towards a variety of chemoattractants. Palframan 
et al. have reported that wortmannin inhibited the release of eosinophils from perfused bone 
marrow induced by IL-5 (Palframan et al., 1998a). Others have shown that wortmannin 
reduces eosinophil numbers and eosinophil peroxidase activity in the BAL fluid of
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ovalbumin-challenged animals (Tigani et al., 2001). However, Ezeamuzie et al. have shown 
that LY294002 pretreatment in a model of allergen-induced lung inflammation failed to 
prevent the increase in lung eosinophilia, but succesfully attenuated the increase in bronchial 
eosinophil degranulation and AHR to histamine. This suggests that eosinophil degranulation 
in the lungs, and not solely their accumulation, is important in the development of allergen- 
induced AHR (Ezeamuzie et al., 2001). This is supported by reports of a similar dissociation 
between AHR and pulmonary eosinophilia in asthma-models in guinea pigs (Ishida et al., 
1990; Matsuse et a l, 1991; Heuer et al., 1994).
Parenchymal lung cells also play an important part in asthma, as ASM cells have 
been implicated in airway inflammation and remodelling that occurs in asthma. When 
chronically exposed to a highly inflammatory environment, ASM cells grow and limit the 
flow of air into the lungs (King et al., 1999). These diseased ASM cells also contract more 
intensely and for longer periods further restricting airflow (Halayko et a l, 2004). PI3K 
inhibitors have been shown to attenuate anaphylactic bronchial contraction and to facilitate 
relaxation of constricted airways (Tsang and Fred Wong, 2000), suggesting that PI3K is an 
important regulator ASM cell contraction. Furthermore, in vitro experiments support the 
importance of PI3K in regulating contraction in ASM cells (Gosens et a l, 2004), and in the 
transformation of ASM cells into the contractile phenotype observed in asthma (Halayko et 
al., 2004).
With regards to ASM cell proliferation, PI3K inhibitors reduce proliferation induced 
by thrombin (Krymskaya et a l, 1999; Tsang et a l, 2002), EGF (Krymskaya et al., 1999) and 
PDGF (Walker et a l, 1998). Furthermore, transient expression of constitutively active class 
IA PI3K human, ASM cells do not express the class IB PI3K isoform (Krymskaya et a l, 
2001), induced activation of the cyclin D1 promoter (Orsini et al., 1999), DNA synthesis and 
ASM cell growth. However, inhibition of class IA PI3K did not inhibit mitogen-induced 
DNA synthesis (Krymskaya et al., 2001). The incomplete inhibition of mitogen-induced 
proliferative responses suggests that in human ASM other pathways are also likely to regulate 
this process. Some authors have shown that certain mitogens activate two parallel signalling 
pathways in ASM cells that are crucial for the proliferative response, namely ERK and the 
PI3K pathways (Ammit and Panettieri, Jr., 2001).
Many downstream targets of PI3K activity are associated with protein synthesis, 
including GSK-3(3, PHAS-1/4E-BP and S6K (Halayko et a l, 2004). A critical role for PI3K- 
dependent S6K activation in DNA synthesis elicited by PDGF in bovine tracheal smooth 
muscle cells has been demonstrated (Scott et al., 1996). Others have shown that S6K activity
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is essential for human ASM proliferation (Krymskaya et al., 1999). Expression of a dominant 
p85 negative mutant in ASM cells blocks EGF and thrombin-induced S6K activation and 
DNA synthesis (Krymskaya et al., 1999). Furthermore, it has been proved that PI3K- 
dependent S6K activation leads to the accumulation of contractile apparatus proteins, 
differentiation, and growth of ASM cells (Halayko et al., 2004), clearly suggesting a role for 
these kinases in ASM cell proliferation.
1.3.4.2 COPD
Nicotine, an addictive chemical and a carcinogen precursor that is found in tobacco, 
activates PI3K and leads to the activation of its downstream kinases Akt and GSK-3P in 
human airway epithelial cells in vitro (West et al., 2003). In these experiments, PI3K activity 
led to enhanced survival and the induction of a transformed phenotype, similar to 
premalignant lesions found in smoking-related COPD patients. This data suggests that certain 
chemicals found in tobacco activate PI3K in lung parenchymal cells, and that this activation 
could have repercusions in the establishment of COPD and lung cancer.
The excessive production of mucus in the airway that leads to obstruction of airflow, 
is a hallmark characteristic of certain COPD entities, like chronic bronchitis. TNFa (Levine et 
al., 1995), IL-1 p (Kim et al., 2000) and LPS (Li et al., 1997) upregulate expression of the 
mucin genes inducing mucin hypersecretion. Interestingly, epithelial cells pretreated with a 
PI3K inhibitor, presented an attenuated response towards IL-ip-induced mucin gene 
expression and secretion (Kim et al., 2002). Moreover, when the lung epithelium is 
persistently exposed to inflammatory mediators, it can be transformed to a mucus- 
hypersecreting metaplasia called goblet cell. IL-13, an important cytokine in airway disease, 
induces goblet cell metaplasia thorugh PI3K activation (Atherton et al., 2003).
In COPD and asthma, a denudation of the epithelial lining of the airway also occurs, 
and airway epithelial migration may contribute to airway repair and reconstitution (Erjefalt et 
al., 1995). Shahabuddin et al. have recently demonstrated in vitro that PI3K inhibitors 
potently inhibited the chemotactic responses of a human airway epithelial cell line to 
CXCL11, a CXCR3 ligand (Shahabuddin et a l, 2006). Therefore, despite their potentially 
therapeutic effects on mucus hypersecretion, these types of inhibitors could also have a 
negative effect on some protective mechanisms, including airway lining repair, in airway 
disease.
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PI3K is also central to neutrophil recruitment to the lungs. Neutrophil accumulation 
in the chronically inflamed lung is central to the pathology of several airway diseases, 
including COPD (Bames, 2003a). Researchers have observed that class IB PI3K pllOy'7' 
neutrophils in vitro presented reduced chemotaxis towards keratinocyte-derived chemokine 
(KC, mouse orthologue of human CXCL1) and MIP-2 (also called CXCL2). Furthermore, 
pllOy'7' mice showed reduced accumulation of neutrophils following intranasal instillation of 
these chemokines in vivo; while pi 108 kinase dead mutation mice showed no inhibition in 
either scenario (Thomas et al., 2005).
1.3.4.3 ALI-ARDS
As mentioned in section 1.1.1.3, ALI-ARDS is caused by a unregulated systemic 
inflammatory response resulting from a variety of clinical events including sepsis and 
prolonged mechanical ventilation (Puneet et a l, 2005). The major animal models for ALI- 
ARDS replicate more closely the events of these two causes, as intratracheal instillation of 
LPS or mechanical overventilation of the lungs is commonly used (Shimabukuro et al., 2003; 
Belperio et al., 2006).
Increased ventilation in isolated lungs elicits local and systemic upregulation of 
proinflammatory mediators (von Bethmann et al., 1998), which is comparable with that 
achieved by bacterial endotoxins (Held et al., 2001). Overventilation has been identified as a 
potent physical force that activates PI3K (Kuebler et al., 2003; Uhlig et al., 2004). Some 
studies have shown that overventilation causes a stronger activation of Akt phosphorylation 
than that seen with LPS instillation (Uhlig et a l, 2004). Morevoer, overventilation elicits 
PI3K-dependent production of nitric oxide (Kuebler et a l , 2003) and nuclear translocation of 
NF-kB (Uhlig et a l, 2004). Inhibition of NF-kB translocation through the use of PI3K 
inhibitors, led to impairment of the production of IL-6 and CXCL2, both important mediators 
of ALI-ARDS (Uhlig etal., 2004).
Two recent publications have emphasized further the role of PI3K in ALI-ARDS 
models. Miyahara et al. showed that PI3K inhibition in isolated lungs attenuated 
overventilation-induced lung injury (Miyahara et al., 2007). Moreover, Lioetti et al. 
demonstrated in ex vivo experiments that overventilated lungs from pllOy'7' mice possessed 
diminished levels of histologic indices of lung injury and Akt phosphorylation compared to 
wild type controls (Lionetti et a l, 2006).
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In endotoxin-induced ARDS models, researches have found endotoxin administration 
resulted in the activation of PI3K and Akt in neutrophils that accumulated in the lung; while 
PI3K pretreatment in this model led to a reduction in NF-kB activation, oedema, neutrophil 
infiltration, and proinflammatory cytokine expression in the lungs (Yum et al., 2001). 
Similarly, in a TNFa-induced model of lung inflammation, mice treated with a dominant 
negative form of the PI3K p85 regulatory protein presented reduced microvascular injury and 
granulocyte recrutiment to the lungs. Moreover, in this study it was also demonstrated that 
granulocytes treated in vitro with the p85 construct were prevented from TNFa-induced 
oxidant production (Gao et al., 2007).
Studies researching the roles played by specific PI3K isoforms in ALI-ARDS models 
are few. It has been reported that the pi 108-selective inhibitor, IC87114, showed an important 
reduction in neutrophil recruitment to the lung in an endotoxin-induced model of lung injury 
(Puri et al., 2004). With regards to class IB PI3K, the severity of endotoxemia-induced ALI, 
quantified by lung oedema, nuclear translocation of NF-kB, neutrophil recruitment, and 
pulmonary levels of IL-1 p and TNFa, has been demonstrated to be significantly reduced in 
p 110y"7' mice (Yum et al., 2001). Surprisingly in a model of lung injury induced by 
bacteremia (i.e. intraperitoneal Escherichia coli challenge), p 110y'7' mice presented higher 
levels of oedema and leukocytes in the lung (Ong et al., 2005). A possible explanation for this 
increased infiltration of leukocytes could be the neutrophilia previously observed in pllOy'7' 
mice (Hirsch et al., 2000), however the authors associated this negavitve impact in 
bacteremia-induced lung inflammation with increased expression of CD47 and p3-integrins by 
pllOy'7' leukocytes (Ong et al., 2005). These results suggest that the possible impact of 
targeting PI3K in certain types of ALI-ARDS is still unclear.
A recent report has shown that reconstituting wild type neutrophils in pi 10y"7' mice, 
did not reverse the strong reduction in neutrophil recruitment to the lungs reported for pi 10y'7' 
mice in endotoxemia-induced ALI. The reconstitution of wild type neutrophils was also 
without effect when used in p ll0 8 '77pll0y'7' mice, which possessed even lower levels of 
neutrophil recruitment in the endotoxemic model of ALI (Puri et al., 2005). Collectively, this 
suggests suggests that the activity of classes IA and IB PI3K is needed in the endothelial cells 
to adequately express cytokine-induced adhesion molecules, essential in the recruitment of 
neutrophils. This highlights the importance of parenchymal cell PI3K activity in chronic 
inflammatory diseases of the lung.
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1.4 Aims of the study
As has been established throughout this introductory chapter, parenchymal lung cells 
play an essential part within the pathological mechanisms of inflammatory lung diseases. 
However, parenchymal cells are often overlooked, as research normally focuses on the roles 
played by immune cells. With the work done in the PI3K field within cytokine signalling in 
respiratory diseases being no exception, the aim of this work was to test the hypothesis that 
cytokine-induced cellular responses in lung epithelial cells are regulated by specific members 
of the PI3K family, and selective modulation of individual PI3K isoforms leads to the 
modulation of specific responses. To this effect, the main aims of this research project were:
• To determine the presence of individual PI3K isoforms in lung epithelium
• To validate siRNA-mediated mRNA and protein silencing of specific PI3K 
isoforms in lung alveolar epithelial cells
• To evaluate the impact of siRNA-mediated PI3K silencing on basic cell functions
• To determine the effect on cytokine-induced cell signalling caused by selective 
inhibition of indivual PI3K isoforms
• To analyse the possible effects of targeting individual PI3K isoforms on cytokine- 
induced cell functions
Initial work using the broad-spectrum PI3K inhibitor LY294002 and the 
p i 105-specific inhibitor IC87114 on a primary murine lung preparation produced a limited 
amount of results. Since only limited access was available to the diverse array of 
pharmacological tools that were needed to carry this work forward using this murine model, 
the employment of siRNA technology was decided upon as the next step, using A549 lung 
alveolar epithelial cells as a lung epithelium model. Moreover, in order to establish the 
possible impact that siRNA treatment could have on the basic cellular functions, A549 cells 
treated with the different PI3K isoform-specific siRNAs were assayed for survival and wound 
healing under basal conditions.
The majority of this research project consisted of studying TNFa-induced signalling, 
including Akt, GSK3P, S6, ERK and JNK phosphorylation, and cell functions, including 
COX-2, ICAM-1 and IL-8 upregulation, in siRNA-induced PI3K knockdown cells. After 
gaining access to other isoform-selective inhibitors, the results obtained through RNAi 
technology were validated with these novel small molecule inhibitors. Once PI3K- 
dependency was established for TNFa-induced COX-2 production, a subsequent aim to
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establish the transcription factors involved in this process was established. For this purpose, a 
screening of a variety of transcription molecules involved in COX-2 regulation was done, 
with its consequent validation through the use of inhibitors for both PI3K and JNK.
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Chapter 2 -  Methods & Materials
2.1 Primary Murine Lung Preparation
Murine thoracic tissue from 8-12 weeks old MF1 male mice were obtained from the 
University of Bath Animal House. The lungs and heart were dissected from the animals after 
neck dislocation. The lungs were then profusely perfused with ice-cold phosphate-buffered 
solution (PBS) through the pulmonary veins in order to eliminate erythrocyte and circulating 
leukocyte content. The lungs were then carefully dissected from the heart and washed with 
PBS, before being chopped into fragments of less than 4 mm3 using a scalpel. The treatment 
to follow depended on the different experiments that were carried out in this preparation.
For the procedural steps regarding samples used in cytokine stimulation experiments, 
refer to section 2.6. In the case of samples that were to be used for in vitro lipid kinase studies 
(see section 2.9) or for immunoblotting experiments (see section 2.8) which required no 
cytokine-stimulation, 100 mg of lung fragments were placed in clean eppendorfs containing 
500 pi of ice-cold lysis buffer (50 mM Tris, pH 7.5, 150 nM NaCl, 5 mM ethylenediamine 
tetraacetic acid [EDTA], 1% vol/vol Nonidet P-40, 10 mM sodium fluoride, 1 mM 
phenylmethylsulfonylfluoride, 10 pg/ml leupeptin, 10 fig/ml aprotinin, 1 pg/ml soybean 
trypsin inhibitor, 1 pg/ml pepstatin A, 1 mM sodium orthovanadate, and 1 mM sodium 
molybdate), and homogenised for 30 s using a Power Gen 125 Homogenizer. Lysates were 
then rotated at 4°C for 30 min. The samples were then centrifuged at 12,400 g at 4°C for 
15min to eliminate debris. Supernatants were then passed to clean eppendorfs. For 
immunoblotting samples, protein concentration was determined (section 2.7) and 
immunoblotting with the appropriate antibodies carried out (section 2.8). For in vitro lipid 




Human alveolar epithelial A549 cells were obtained from the European Collection of 
animal cell cultures. A549 cells were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 2 mM glutamine, 10% fetal bovine serum (FBS), and 100 U/ml 
penicillin and 100 pg/ml streptomycin (subsequently referred to as complete DMEM 
medium) at 37°C in a 5% C 02 humidified atmosphere. For cell culture purposes, A549 cells 
were maintained in 175 cm2 flasks.
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To subculture, the medium in the 175 cm2 flasks containing confluent monolayers of 
A549 cells was removed and the cells were washed twice with PBS. The monolayer was then 
washed with 5 ml of a mixture of 0.05% (w/v) Trypsin and 0.02% (w/v) EDTA in Roswell 
Park Memorial Institute (RPMI) 1640 medium. The excess solution was removed and the 
cells were incubated for 3 mins at 37°C or until the cells had detached from the flask. The 
trypsin/EDTA reaction was stopped by the addition of 30 ml of complete DMEM medium, 
the cell suspension was then passed to 50 ml tubes and centrifuged at 1500 g for 5 min at 
room temperature (RT). The supernatant was eliminated and the cell pellet was carefully 
resuspended in complete DMEM medium. Cell number and viability were then determined by 
the Trypan Blue exclusion method (see section 2.4.2). A549 cells were then seeded at 1><107 
cells for 175 cm2 flasks (for subculturing), 6*105 cells per well in 6-well plates (for siRNA 
transfection, section 2.3; cytokine stimulation, section 2.6; wound healing, section 2.10; flow 
cytometry, section 2.11; enzyme-linked immunosorbant assays [ELISA], section 2.13), or 
5><104 cells per well in 96-well plates (for cell adhesion assays, section 2.12). Flasks and 
plates reached confluency after approximately 3-4 days of culturing.
2.2.2 THP1 cells
The THP1 human acute monocytic leukaemia cell line was obtained from the 
European Collection of animal cell cultures. THP1 cells were cultured at 37°C in a 5% CO2 
humidified atmosphere using DMEM/F12 medium supplemented with 2 mM glutamine, 10% 
FBS, and 100 U/ml penicillin and 100 pg/ml streptomycin (subsequently referred to as 
complete DMEM/F12 medium). Cells were grown to a maximum concentration of 
2x 106 cells per ml and diluted with fresh complete medium to 5x10s cells per ml, every three 
or four days. THP1 cells were used in this research exclusively for cell adhesion assays, as 
described in section 2.12.
2.2.3 Jurkat cells
The human leukemic T-cell line Jurkat was obtained from Cancer Research UK. 
Jurkats were maintained in 175 cm2 tissue culture flasks in RPMI 1640 medium supplemented 
with 2 mM glutamine, 10% FBS, and 100 U/ml penicillin and 100 pg/ml streptomycin 
(subsequently referred to as complete RPMI medium). Cultures were maintained at 37°C in a 
5% C 02 humidified atmosphere. Cells were grown to a maximum of 1.5x106 cells per ml and 
diluted with fresh complete medium to 3xl05 cells per ml, every two or three days. Jurkat
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cells were only used for immunoblotting experiments, which required no cytokine 
stimulation, as a positive control in experiments determining the presence of the different 
class I PI3K isoforms in the murine lung preparation. For these experiments, 3*106 cells were 
washed three times in RPMI without FBS, before being lysed in 300 pi of ice-cold lysis 
buffer (described in 2.1). The lysates were then rotated at 4°C for 30 min before being 
centrifuged at 12,400 g at 4°C for 15 min to eliminate debris. Supernatants were then passed 
to clean eppendorfs. Protein concentration was then determined (section 2.7) and 
immunoblotting with the appropriate antibodies was carried out (section 2.8).
2.2.4 Cell storage
Cell lines were frozen in liquid nitrogen tanks to provide cells of a particular age to 
minimise the possibily of transformation of cell lines that has been known to occur with long­
term cell culture. For nitrogen freezing purposes, cells were resuspended at 4><106 cells per ml 
of freeze medium (10% dimethylsulphoxide [DMSO] and 90% FBS). The cell suspension (1 
ml per tube) was transferred to cryotubes and gradually cooled in vapour phase of liquid 
nitrogen overnight and then stored in liquid nitrogen tanks. For thawing of cells, cell were 
rapidly defrosted at 37°C in a water bath, washed with their appropriate medium, resuspended 
in their corresponding complete medium and seeded into 80 cm2 tissue culture flasks. After 2 
or 3 days at 37°C in an atmosphere of in a 5% C 02 humidified atmosphere, tissue 
subculturing was then carried on as described.
2.3 siRNA transfection
In this study, siRNA silencing was used to selectively reduce mRNA, and hence the 
protein levels, of class I and II PI3K catalytic isoforms in order to determine the particular 
role of each isoform within certain cell functions. siRNA is used to carry out post- 
transcriptional gene silencing, as it leads to the cleavage of the mRNA of the target protein. 
For this purpose, in this research work siRNA was delivered into the cell cytoplasm through 
the use of a lipid-based transfection reagent, Lipofectamine 2000.
A549 cells were transfected following the protocol from the manufacturer for 
Lipofectamine 2000. Briefly, the day before transfection, 105 cells per well were seeded in 6- 
well plates in 2 ml of complete DMEM. siRNA duplexes (pre-designed from Dharmacon, 
Erembodegem, Belgium) targeting class I (pi 10a, p i 10P and pi 108) isoforms, class II (C2a 
and C2P) isoforms or non-targeting siRNA formulated at 250 pmol with 5 pi of
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Lipofectamine 2000 in 500 pi of OptiMEM serum-free media were then added to the cells for 
24 h at 37°C in 5% C 02. Afterwards the medium was replaced with fresh complete DMEM 
medium for the remainder of the incubation period, which varied according to the different 
experiments to be carried out.
2.4 Cellular quantification
2.4.1 M icroscopic photography
Since all the class I PI3K isoforms (Benistant et al., 2000; Doepfner et al., 2007) and 
the class Ila  isoform (Kang et al., 2005) have bee implicated in cell survival in a variety of 
different systems, their downregulation by siRNA silencing could lead to cell death in the 
A549 cells transfected with the corresponding isoform siRNA. Therefore, while samples for 
mRNA and protein levels of the targeted catalytic isoforms were being generated, cell 
survival of PI3K isoform-siRNA cells was being analysed. To this effect, all transfected cell 
cultures, independently of the siRNA used, were photographed in a light microscope using 4x, 
lOx and 25x objectives every 24 h for a 96 h period. Photographs were then analysed for 
changes in cell morphology and density.
2.4.2 Dye exclusion method
Live cells with intact cellular membranes are very selective in the compounds that 
enter their intracellular plasma. Most dyes, such as Trypan blue, are unable to trespass the 
cellular membrane of an intact cell. However, the integrity of the cellular membrane in dead 
cells is severely compromised, allowing dyes to enter the cell. Thus, when exposing dead 
cells to Trypan blue, these are shown as a distinctive blue colour under a microscope. Since 
live cells are excluded from staining, this staining method is called the Dye Exclusion 
Method. In this research project, this method was utilised to determine the number of live 
cells at different stages depending on the experiments that were being carried out.
Briefly, A549 cells were removed en2ymatically from flasks or culture dishes as 
described in section 2.2.1. After washing, cells were resuspended in DMEM medium to an 
appropriate volume, normally 200 -  500 pi. Then, equal volumes of 0.4% (w/v) Trypan blue 
and cell suspension were added to an appropriate tube and gently mixed. Incubation at RT for 
5 min followed. Afterwards, 10 pi of stained cell suspension was placed in a haemocytometer, 
and viable cell number was determined under light microscopy. Calculations on the values
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obtained were carried out in order to compensate for the dilutions made, and cell number was 
expressed as cells/ml.
2.5 Reverse transcription and quantitative PCR
To evaluate the knockdown obtained with the use of siRNA technology on A549 
cells, it was imperative to measure the amount of target RNA present in the cells after 
transfection with siRNA. For this purpose, reverse transcription PCR for each of the catalytic 
isoforms of PI3K was carried out. In this process the RNA strand was first reverse transcribed 
into its DNA complement, known as complementary DNA, followed by its amplification 
using real-time PCR.
Total cellular RNA was isolated from A549 cells using RNeasy mini kit (Qiagen Ltd, 
Crawley, UK) according to the manufacture’s instructions. Briefly, 3 x 106 A549 cells were 
lysed in RNeasy Lysis Buffer and homogenised with the QIAshredder™ column. Ethanol 
(70%) was mixed with the lysate and applied to an RNeasy mini column. After removal of 
contaminants, RNA was eluted in RNase free water. The concentration of RNA was 
quantified on a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, USA), using the RNA 
6000 LabChip kit. RNA was reverse transcribed in the presence of TaqMan RT buffer (10X), 
MgCl2 25 mM, dNTP 25 mM, required primers at 50 pM, RNase inhibitor 20 units/pl, and 
RT enzyme 50 units/pl. Reactions were performed in a Biometra UNO II thermocycler 
(Gottingen, Germany) at 25°C for 10 minutes, 48°C for 30 minutes, followed by 5 minutes at 
95°C. Samples were then stored at 4°C prior to quantitative PCR.
For the quantitative PCR assay, each 25 pi of reaction mixture with 40 ng cDNA was 
mixed with 12.5 pi of 2X TaqMan Universal PCR Master Mix, 1.25 pi of primer probe mix 
plus 6.25 pi H20  and briefly centrifuged. The reactions were carried out using the following 
parameters: 50°C for 2 min, 95°C for 10 min, then 40 cycles of 95°C for 15 seconds, 60°C for 
1 min. TaqMan data was analysed using the Sequence Detector Software version 2.1.
2.6 Cytokine stimulation
2.6.1 Primary murine lung preparation
For cytokine-stimulation studies in the primary murine lung preparation, the lung 
fragments were incubated in 24-well culture dishes with RPMI 1640 media without fetal
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bovine serum at 37°C at 5% C 02 overnight. All vehicles, cytokines or inhibitors were diluted 
in RPMI 1640 and were added to the wells for the relevant amount of time. As all the 
cytokine stimulations carried out in this lung preparation were studied using immunoblotting, 
stimulations were terminated at the appropriate times by taking the lung fragments from the 
24-well plate and placing them in clean eppendorfs containing 500 pis of ice-cold lysis buffer. 
Lung sample homogenisation was carried out as described in section 2.1. Samples were then 
assayed to determine their protein concentration (section 2.7.1) and immunoblotted (section 
2 .8).
2.6.2 A549 cells
At confluence, A549 cells were washed and serum-starved overnight prior to 
experimental use. All vehicles, cytokines or inhibitors were diluted in DMEM without FBS 
prior to their addition to the cell monolayers. Growth arrested cells were then treated with 
vehicles, inhibitors or cyokines for the concentration and the time relevant to each 
experimental setting. Depending on the experimental readout, stimulations were terminated 
following different procedures. For receptor expression and cell adhesion assays, after the 
stimulation period, cells were treated as described in sections 2.11 and 2.12, respectively. 
When the samples were to be used for immunobloting, stimulations were terminated by 
removing the supernatant, which was then stored immediately at -20°C for ELISA purposes 
(section 2.13). This was followed by adding 300 pi of ice-cold lysis buffer (described in 
section 2.1) to each well or culture dish. Cell monolayers were then scraped, transferred to 
plastic tubes, and rotated at 4°C for 15 min. Cell debris was removed by centrifugation at 
12,400 g for 15 min. Protein assays (section 2.7.1) followed by immunblotting (section 2.8) 
were then performed.
2.7 Protein quantification and sample preparation
In order to provide similar amounts of protein in the same volume for each sample to 
be used in immunoblotting, quantification of protein followed by homogenisation of protein 
levels between lysate samples were carried out before performing the immunoblotting 
process.
2.7.1 Protein quantification assay
The Bradford protein quantification colorimetric assay was used. This assay is based 
on the fact that the dye Coomassie suffers an absorbance shift when it is bound to arginine
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and certain hydrophobic amino acid residues widely present in proteins (Zor and Selinger, 
1996). A widely known problem of this assay, is that it is linear only over a short range of 
protein concentrations (Zor and Selinger, 1996). Therefore, ten microliters of the lysate 
protein samples, generated as stated in section in 2.6, were diluted in 1:1 dilution with ice- 
cold lysis buffer, before carrying out these experiments. For the standard curve, known 
concentrations of bovine serum albumin were diluted in ice-cold lysis buffer over a range of 
concentrations.
Protein concentrations were estimated using the Bio-Rad protein assay, which is 
based on the Bradford protein quantification assay. Briefly, two microlitres of the standard 
curve or lysate samples were added to each well in a 96-well plate, containing 248 pi of 20% 
Bradford solution. After thorough mixing, the 96-well plates were read at 595 nm on a 
Dynatech MR5000 plate reader. The protein concentrations of the lysate samples were then 
calculated by linear regression from the standard curve, with additional calculations to 
compensate for the dilutions carried out at the start of the assay.
2.7.2 Immunoblotting sample preparation
After determining protein concentrations, lysate samples containing higher 
concentraions of protein were diluted with ice-cold lysis buffer to homogenise the protein 
levels between the lysate samples of that particular experiment. Then, 200 pi of each 
homogenised lysate sample were mixed with 50 pi of 5X sodium dodecyl sulphate sample 
buffer (5% sodium dodecyl sulphate, 50% glycerol, 200 mM Tris-HCl pH 6.8, bromophenol 
blue and 5% 2-mercaptoethanol). Samples were then vortexed for 20 seconds, boiled at 100°C 
for 5 min and briefly centrifuged at 1,500 g. After centrifugation, samples were place in ice 
for 5 min. At this point, these electophoresis samples could be stored at -80°C until needed or 
directly loaded onto an electrophoresis gel to begin immunoblotting.
2.8 Immunoblotting
Immunoblotting, also called Western blotting, is a technique that allows visualisation 
of the relative amounts of specific proteins in a given sample. To begin, the protein samples 
are run through a polyacrylamide gel using electric current, separating the proteins within the 
lysate according to their molecular weight. This profile of proteins is then transferred to a 
membrane of nitrocellulose paper by again using electric current. The membrane can then be 
probed using antibodies raised against specific proteins usually called primary antibodies.
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These primary antibodies can be specific for a certain conformation of the protein of interest, 
such as the phosphorylated form of the protein. Afterwards, another set of antibodies are used, 
called secondary antibodies, that specifically recognise the primary antibodies. The secondary 
antibodies are tagged with the enzyme horseradish peroxidase, which catalyses a reaction that 
enables the antibodies to be detected using photosensitive film.
2.8.1 Electrophoresis
Cell protein lysates were analysed by one dimensional gel electrophoresis, which 
under reducing conditions separates proteins based on their molecular weight. Sodium 
dodecyl sulphate (SDS) -  polyacrylamide gel electrophoresis was carried out using the 
Bio-Rad Mini Protean II system (Bio-Rad Labs, Hemel Hempstead, UK).
Electrophoresis gels were prepared following the recipes described in section 7.1. The 
resolving gel was poured into the gel equipment and overlaid with MilliQ-flltered water to 
create a uniform surface. After 1 h, after the resolving gel had set, the water was withdrawn 
and the stacking gel poured on top of the resolving gel. Combs were inserted into the stacking 
in order to form wells. After 30 min, after the stacking gel had set, the combs were removed 
and the wells were througly cleaned with MilliQ-filtered water before being filled with 
electrophoresis running buffer (192 mM glycine, 25 mM Trizma base, 0.1% [w/v] SDS, 
MilliQ-filtered water). The electrophoresis samples (described in section 2.7.2) were then 
loaded, typically with 40 pg of protein per sample. In one or two of the wells, 5 pi of 
molecular weight markers were loaded to serve as guides to ease protein band identification at 
a later stage. Gels were then run at room temperature at 80 volts until the bromophenol blue 
tracking contained in the lysate samples entered the resolving gel. At that time, the voltage 
was increased to 180 volts. Gels were run until the bromophenol blue dye reached the bottom 
of the resolving gel. Gels were completely removed from the electrophoresis equipment and 
placed into semi-dry transfer buffer (39 mM glycine, 48 mM Trizma base, 0.0375% SDS, 
20% [v/v] methanol, MilliQ-filtered water).
2.8.2 Semi-dry protein transfer
After electrophoresis, samples were transferred onto nitrocellulose membrane before 
antibody probing. For this purpose, the graphite electrodes of the transfer apparatus 
(Pharmacia-Biotech Multiphor II) were dampened with semi-dry transfer buffer, described in
2.8.1. Four pieces of 3MM Whatman paper, of the same size than the gel, soaked in semi-dry
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transfer buffer were placed on the bottom electrode and rolled to gently expel any air bubbles. 
A piece of nitrocellulose membrane, again of the same size than the gel and soaked in semi­
dry transfer buffer, was place on top of the Whatman paper. The electrophoresis gel was then 
placed on top of the nitrocellulose paper. Finally, four pieces of semi-dry transfer buffer 
soaked 3MM Whatman paper were placed on top of the electrophoresis gel. Afterwards, the 
transfer apparatus was assembled and run for 1 h at 0.8 mA/cm2 of membrane, approximately 
40 mA per gel. Once the transfer had finished, the transfer apparatus was disassembled and 
the nitrocellulose paper was placed in Tris buffered saline (TBS; 20mM Tris-HCl pH 7.5, 150 
mM NaCl, MilliQ-filtered water).
2.8.3 Antibody probing and imm unoblot developing
Following the semi-dry transfer, the nitrocellulose membrane was incubated with an 
appropriate protein blocking buffer (see section 7.2) for 1 h at room temperature on a rocking 
platform, in order to block non-specific binding sites on the nitrocellulose membrane. The 
excess blocking buffer was then removed by briefly washing the membrane in TBS-Tween 
0.1% (TBST). The membrane was then incubated overnight at 4°C in a rocking platform in 
the primary antibody diluted in TBST at different concentrations depending on the antibody, 
as stated in section 7.2. Afterwards, the primary antibody dilution was removed and the 
membrane was washed 3 times for 10 min with TBST to remove excess primary antibody left 
on the membrane. The secondary antibody diluted in TBST at different concentrations 
depending on the primary antibody used (for further information see section 7.2), was then 
added to the membrane and left for an incubation period of 3 h on a rocking platform at room 
temperature. The membrane was then washed 3 times for 10 min with TBST and 1 time for 
5 min with TBS. After removing the TBS, 5 ml of Enhanced Chemiluminescent Lumigen 
reagent was added for 1 min and the membranes were then exposed to photosensitive film for 
a period of time ranging from 2 s to 30 min, depending on the exposure required. The film 
was then developed using a RGII Fuji X-ray film developer. Film was later digitalized and 
analysed for optical density using Scion Image software for Windows version 4.O.3.2.
2.8.4 M embrane stripping
In order to probe for a different molecule in the the cell lysate samples of a 
nitrocellulose membrane that had already been used, the used membranes were stripped free 
of antibody before reusing. The membranes were first washed with TBS for 10 min at room 
temperature in a rocking platform, before being placed in sealed container with approximately
63
Chapter 2 -  Methods & Materials
25 ml of stripping buffer (62.5 mM Tris-HCl pH 6.8, 2% [w/v] SDS, 100 mM 
2-mercaptoethanol, MilliQ-filtered water). The container was incubated in a water bath at 
60°C for 30 min. After the incubation period, the stripping buffer was disposed of, and the 
blots were moved to clean containers and washed three times for 15 minutes in TBST. After a 
final 5 min wash in TBS, the membranes were again blocked using an appropriate blocking 
buffer as described at the beginning of section 2.8.3.
2.9 In vitro lipid kinase assay
The lipid kinase activity of PI3K can be measured by an in vitro lipid kinase assay. 
This assay detects the transfer of radiolabeled y-phosphate of ATP to the D-3 position of 
phosphoinositides (PI), resulting in the formation of (y32P)-labelled PI(3)P. This assay was 
used to determine the inhibitory activity of LY294002 and IC87114 on class I PI3K isoforms 
within the primary murine lung preparation. To this end, the targeted isoforms were first 
immunoprecipitated from murine lung lysate, before being incubated with the different 
inhibitors and assayed for lipid kinase activity.
2.9.1 Immunoprecipitation
Lysate samples from the primary murine lung preparations, as described in section
2.1, were pre-cleared with 20 pi of protein G sepharose beads for 1 h at 4°C with constant 
rotation. Samples were then spun at 13,000 g for 1 min and supernatants were transferred into 
clean tubes. Proteins were then immunoprecipitated, by the addition of the adequate amount 
(depending on the antibody used, from 2 to 25 pis, see section 7.3) of antibody against the 
protein of interest, and were rotated at 4°C for 1 h. Forty microlitres of 50% (v/v) suspension 
of the protein G beads were then added, and the samples were again rotated for 1 h at 4°C. 
The beads were captured by centrifugation at 13,000 g for 1 min at 4°C.
2.9.2 Lipid kinase reaction
Immunoprecipitated samples were extensively washed as follows: 3 times in wash 
buffer A (PBS, 1% NP-40, 100 pM sodium vanadate, MilliQ-filtered water), 3 times in wash 
buffer B (100 mM Tris, pH 7.4, 5 mM LiCl, 100 mM sodium vanadate, MilliQ-filtered 
water), 2 times in TNE buffer (10 mM Tris, pH 7.4, 150 mM NaCl, 5 mM EDTA, 100 mM 
sodium vanadate, MilliQ-filtered water). Between each wash, the beads were spun down at
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13,000 g for 30 s at RT. After the removal of the final wash pretreatment with inhibitors, that 
were diluted in 50 pi TNE buffer, was carried out. Control samples were treated with 50 pi 
TNE for the same period of time. Following pretreatment, 10 pi (20 pg) of PI and 10 pi of 
100 mM MgCl2 were added to each pellet of beads. The reactions were started by adding 5 pi 
of ATP reaction buffer (0.88 mM ATP, 20 mM MgCl2, and 5-10 pCi [y32P]-ATP) and were 
allowed to proceed for 10 min. Reactions were terminated by the addition of 20 pi of 5 N HC1 
and 160 pi chloroform:methanol (1:1). Samples were briefly vortexed and phases were 
separated by centrifugation at 10,000 g for 10 min at RT. Fifty microliters of the lower 
chloroform phase were removed and spotted onto 1% potassium oxalate-treated thin layer 
chromatography (TLC) plates. The lipids were resolved by TLC in 
chloroform:methanol:water:ammonium hydroxide (60:47:11.3:2). Radioactive lipids were 
visualised by autoradiography at -80°C for a range of time from 1 day to 1 month. The film 
was then developed using a RGII Fuji X-ray film developer. TLC plates were iodine stained 
to confirm equal loading. The film was later digitalized and analysed for optical density using 
Scion Image software for Windows version 4.0.3.2.
2.10 Wound healing
One of the commonly used techniques used to determine the ability of adherent cells 
to migrate adequately is the wound healing assay. In this procedure, a sterile pipette tip is 
used to score a line through the cell monolayer, and the monolayer is observed during a given 
period of time in order to determine the ability of the cells to repair the wound. Thus, this 
assay was used to analyse the ability of the PI3K isoform-specific knockdown cells to 
migrate.
Twenty-four hours after monolayers of A549 cells in 6-well tissue culture plates were 
transfected with siRNA, wounding with a Gilson p2 pipette tip was carried out under sterile 
conditions. Cells were washed 3 times with fresh serum-free DMEM medium and placed in 
complete DMEM medium for the duration of the observation period (72 h). Wound widths 
and lengths for each monolayer, which were necessary to calculate wound area, were 
measured immediately after the initial wounding and every 24 h afterwards, under 
microscopic vision with a graded eyepiece. Simultaneously, photographs of each wound were 
also taken in a light microscope using 4x, lOx and 25x objectives at each time point.
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2.11 Flow cytometry
One of the cell functions analysed throughout the course of this research was the 
surface expression of ICAM-1 by A549 lung epithelials. In this sense, the determination of 
the possible roles played by PI3K or mTOR kinases in the regulation of expression of this 
adhesion molecule downstream of TNFa was sought. In order to determine the expression 
level of ICAM-1 on TNFa-stimulated A549 cells, a phytoerythrin (PE)-labelled anti-ICAM-1 
antibody was employed. The coupling of this antibody to the membrane surface of A459 cells 
expressing ICAM-1 generated an increase in fluorescence that was detected by flow 
cytometry.
After A549 cells had been incubated with TNFa as explained in section 2.6.2, 
cytokine-stimulation was stopped by completely removing the medium, and adding 500 pi of 
0.05% (w/v) trypsin and 0.02% (w/v) EDTA in RPMI 1640 medium. The excess 
trypsin/EDTA solution was removed and the cells were incubated for 3 min at 37°C or until 
the cells had detached from the dish. The trypsin/EDTA reaction was stopped by the addition 
of 1 ml of complete DMEM medium to the culture dish. The cell suspension was then passed 
to 1.5 ml eppendorf tubes, and washed twice and resuspended in ice cold PBS. Cells were 
incubated for 1 h at 4°C in the dark with 10 pg/ml PE-labelled monoclonal mouse anti-human 
ICAM-1 antibody or PE monoclonal mouse isotype control. Two million cells were also left 
untreated to give a measure of the autofluorescence of the cells. After the incubation period, 
the cells were washed twice in ice-cold PBS and transferred to flow cytometry polyprylene 
tubes. Flow cytometry was performed with a FACSCalibur flow cytometer and analyzed with 
Cell Quest Pro software (Becton Dickinson, MA, USA). Prior to analysis, all samples were 
gated by forward and side scatter to eliminate data interference by dead cells.
2.12 Cell adhesion assay
To further analyse the possible repercussions signalling kinase inhibition might have 
on respiratory disease, the ability of A549 cells to recruit leukocytes, through adhesion 
molecule expression downstream of TNFa stimulation, was studied. For this purpose, the 
THP1 human acute monocytic leukaemia cell line was used to adhere to A549 lung epithelial 
cells. In order to determine the variations in cell adhesion after inhibiting or silencing specific 
kinases, calcein AM-labelling was used. As seen in figure 2.1, tagging monocytes with this
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fluorescent compound allows the user to track the presence o f these cells, and determine 
whether these tagged cells are able to adhere to a TNFa-stim ulated cell line which is attached 
to the bottom o f a tissue-culture plate. As seen at the end o f this section, this compound also 
allows the analysis o f cell viability in the treated adherent cells.
Adhesion assays were performed using Vybrant® Cell Adhesion Assay Kit. Briefly, 
1*107 THP1 cells/plate were suspended in PBS and incubated with 20 pM calcein AM for 
60 min at 37°C. After washing the cells twice to remove the excess dye, T H P ls were 
resuspended at a concentration o f l x 106 cells/ml in warm serum-free medium. Afterwards, 1 
x 105 THP1 cells/well were added to 96-well plates containing siRNA-treated or inhibitor- 
treated A549 cells after a 6 h stimulation with T N Fa (100 ng/ml). After 120 min o f co­
incubation at 37°C, the plates were carefully washed three times with warm PBS to remove 
non-adherent THP1 cells. Fluorescence was then measured at 485 nm excitation and 530 nm 
emission on a Dynatech MR5000 plate reader. Differences in fluorescence values represent 
differences in cell adhesion.
A
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Figure 2.1 Cell adhesion assay. A. A549 adherent cells in 96-well plates were treated with siRNA or 
inhibitors for the appropriate time periods. B. THP1 cells that had been previously labelled with calcein 
AM are added to the treated adherent cells in the 96-well plates. C. A549 adherent lung epithelial cells 
are incubated with THP 1 monocytes, in order for the monocytes to interact with the A549 cells through 
associations with their adhesion molecules. C. After removal of non-adherent monocytes, fluorescence, 
used as an indicator of cell adhesion, was measured in a plate reader. Diagram modified from 
http://probes.invitrogen.com/lit/microplate/pis/15.pdf.
To ensure that any differences in cell survival were not overseen, a control parallel 
96-well plate was treated with T N Fa and the corresponding siRNA or inhibitor in the same 
way as the plate destined for the cell adhesion study. For this control plate, instead o f being
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incubated with calcein AM-labelled THP1 cells for 120 mins, the A549 cells of this control 
plate were directly incubated with 20 pM calcein AM. These calcein AM-labelled A549 cells 
were then washed in the same manner as the other plate and read in the plate reader 
accordingly. Since the A549 cells in this controls plate, did not come in contact with THP1 
cells, but instead were directly labelled with calcein AM, the fluorescence values obtained 
from this plate represented cell viability and not cell adhesion. The values of these control 
plates never differed in more than 3% with each other, ensuring adequate viability between 
the study groups, and that the changes in values observed in the cell adhesion assay 
corresponded to changes in adhesion molecule expression and not cell survival.
2.13 ELISA
Two important cellular functions elicited by TNFa stimulation on A549 lung epithelial 
cells are the increased production of IL-8 and PGE2. In order to measure the impact signalling 
modulation, either by the use of inhibitors or siRNA, has on these processes, ELISAs specific 
for these molecules were carried out.
In the work carried out for these research objectives, the ELISA kits utilised to 
determine IL-8 and PGE2 concentrations were dissimilar. As seen in figure 2.2, the ELISA 
for IL-8 is a classical ‘sandwich’ ELISA, where a capture antibody specific for IL-8 is coated 
onto the microplates. After incubation with the sample supernatant, IL-8 becomes bound to 
the capture antibody, and is later recognised by a secondary antibody specific for IL-8. This 
secondary antibody is labelled with a horse-radish peroxidase enzyme, which enables its 
detection when incubated with an appropriate substrate solution. In this case, the more IL-8 
molecules present in the supernatant, the more pronounced colour change that will occur in 
the solution. For PGE2, this ELISA is based on a competitive binding technique in which 
PGE2 present in the sample competes with a fixed amount of alkaline phosphatase-labelled 
PGE2 for sites on a PGE2-specific mouse monoclonal antibody. Therefore, the less PGE2 
present in the supernatant sample, the more alkaline phosphatase-labelled PGE2 will be bound 
to the monoclonal antibody, and hence, a greater colour change will occur in the substrate 
solution. Thus, the amount of colour change in this technique is inversely proportional to the 
amount of PGE2 in the sample.
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Figure 2.2 ELISA assays for IL-8 and PGE2. A. In the IL-8 ELISA kit, cell supernatant sample is 
added to the IL-8 capture antibody coated-microplates. After the incubation period, when the IL-8 
molecules become bound to the capture antibody, a horse-radish peroxidase-labelled IL-8 antibody is 
added. After further incubation, this latter antibody becomes bound to IL-8, and washing of the wells 
ensues to eliminate excess antibody. A substrate solution is then added in order to determine bound 
horse-radish peroxidase activity. The intensity of the colour generated is directly proportional to the 
concentration of IL-8 in the sample. B. For the PGE2 ELISA procedure, sample supernatants, alkaline 
phosphatase-labelled PGE2 and a mouse anti-PGE2 antibody are added simultaneously to the goat anti­
mouse antibody coated plates. During the incubation, the mouse monoclonal antibody becomes bound 
to the goat anti-mouse antibody coated onto the microplate, while the phosphatase-labelled PGE2 and 
the sample PGE2 compete to bind to the mouse antibody. Following a wash to remove excess conjugate 
and unbound sample, a substrate solution is added to the wells to determine the bound enzyme activity. 
The intensity of the colour generated is inversely proportional to the concentration of PGE2 in the 
sample.
2.13.1 IL-8 ELISA
The kit used in the assay to measure IL-8 concentration was from R&D Systems. 
Known concentations o f IL-8 standard were diluted in DMEM cell culture medium and used 
for a standard curve from 31.2 pg/ml to 1000 pg/ml. Fifty microlitres o f standard or diluted
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(1:5) cell culture supernatant sample were placed in microplates coated with IL-8 capture 
antibody. After a 4 h incubation period and copious washing, 100 pi of horse-radish 
peroxidase-labelled IL-8 antibody was added to each well and incubated for a further 1 h at 
room temperature. The wells were then washed 4 times using using a multi-channel pipette. 
The microplate was then inverted and blotted against clean paper, before the addition of the 
substrate solution (200 pi) and incubation for 30 min at RT in the dark. At the end of this 
incubation period, 50 pi of stop solution (2 N sulphuric acid) was added to each well. The 
optical density at 450 nm was determined within 30 min using a Dynatech MR5000 plate 
reader. The IL-8 concentrations were calculated by comparison to a four parameter logistic 
curve fit generated from the values obtained from the standard curve, using BioLinx software. 
Diluation factors for the cell supernatant samples were taken into consideration in the 
calculations for protein concentration.
2.13.2 PGE? ELISA
For the determination of PGE2 concentrations, a kit from R&D Systems was used. 
Briefly, known concentrations of a PGE2 standard were diluted in DMEM cell culture 
medium and used for a standard curve, ranging from 39 pg/ml to 5000 pg/ml. One-hundred 
microlitres of standard or cell culture supernatant sample were placed in microplates coated 
with goat anti-mouse antibody. To each well, 50 pi of PGE2 conjugated to alkaline 
phophatase and 50 pi of PGE2 antibody solution were added. The plates were covered an 
incubated on a shaking platform overnight at 4°C. After this incubation, the wells were 
aspirated and washed three times with wash buffer using a multi-channel pipette. After the 
last wash, the microplates were inverted and botted against clean paper. Two-hundred 
microlitres of substrate solution was then added to each well and incubated at RT for 20 min, 
while being protected from light. After this incubation, 50 pi of 2 N sulphuric acid was added 
to each well to stabilise the reaction. The optical density at 450 nm was determined within 20 
min using a Dynatech MR5000 plate reader. The PGE2 concentrations were calculated by 
comparison to the sigmoid standard curve using BioLinx software.
2.14 Statistical treatment
ANOVA followed by Dunnett’s or Newman-Keuls post-hoc tests were carried out as 
appropriate to test for statistical significance. A P  value of 0.05 or less was considered as 
statistically significant.
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2.15 M aterials
Material Catalog No. Source
0.05% Trypsin / 0.02% EDTA 
in RPMI medium
25300-054 Gibco (Paisley, UK)
2-Mercaptoethanol M3148 Sigma-Aldrich (Poole, UK)
30% Acrylamide/Bis-acrylamide 
solution
161-0154 Bio-Rad (Hercules, USA)
(32P)y-ATP AA0068 GE Healthcare (Little Chalfont, UK)
Absolute Ethanol E7148 Sigma-Aldrich (Poole, UK)
Adenosine triphosphate A7699 Sigma-Aldrich (Poole, UK)
Agilent RNA 6000 kit 5067-1511 Agilent Technologies (Stockport, UK)
Agilent RNA 6000 reagents 5067-1512 Agilent Technologies (Stockport, UK)
Anti-Aktl antibody sc-1618 Santa Cruz Biotechnology (Santa Cruz, USA)
Anti-COX-1 antibody sc-1752 Santa Cruz Biotechnology (Santa Cruz, USA)
Anti-COX-2 antibody sc-1746 Santa Cruz Biotechnology (Santa Cruz, USA)
Anti-mTOR antibody sc-1550 Santa Cruz Biotechnology (Santa Cruz, USA)
Anti-PI3K pi 10a antibody sc-7174 Santa Cruz Biotechnology (Santa Cruz, USA)
Anti-PI3K pi 10(3 antibody sc-603 Santa Cruz Biotechnology (Santa Cruz, USA)
Anti-PI3K pi lOy antibody sc-7177 Santa Cruz Biotechnology (Santa Cruz, USA)
Anti-P13K pi 105 antibody sc-7176 Santa Cruz Biotechnology (Santa Cruz, USA)
Anti-phosphoSer9-GSK-3|3
antibody
9336 Cell Signalling Technology (Boston, USA)
Anti-phosphoSer73-cJun antibody 9164 Cell Signalling Technology (Boston, USA)
Anti-phophoSerli5-CREB antibody 9198 Cell Signalling Technology (Boston, USA)
Anti-phosphoSer176/180-IKKa/ 
Ser177/181-IKK|3 antibody
2694 Cell Signalling Technology (Boston, USA)
Anti-phosphoSer23^ ^ -S 6  antibody 2211 Cell Signalling Technology (Boston, USA)
Anti-phosphoSer473-Akt antibody 9271 Cell Signalling Technology (Boston, USA)
Anti-phosphoSeri36-p65 antibody 3031 Cell Signalling Technology (Boston, USA)
Anti-phosphoThr7l-ATF2 antibody 9225 Cell Signalling Technology (Boston, USA)
Anti-phosphoThr18j/Tyrl83-JNK
antibody
4671 Cell Signalling Technology (Boston, USA)
Anti-phosphoThr207TyriU4-ERK
antibody
9101 Cell Signalling Technology (Boston, USA)
Anti-phosphoThr235 - 
C/EBPp antibody
3084 Cell Signalling Technology (Boston, USA)
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Anti-PI3K class Ila  antibody 611046 BD Biosciences (Oxford, UK)
Anti-PI3K class lip antibody 611343 BD Biosciences (Oxford, UK)
Ammonium persulphate A9164 Sigma-Aldrich (Poole, UK)
Bovine serum albumin A6003 Sigma-Aldrich (Poole, UK)
Bromophenol blue B8026 Sigma-Aldrich (Poole, UK)
Chloroform C2432 Sigma-Aldrich (Poole, UK)
Dimethyl sulphoxide D8418 Sigma-Aldrich (Poole, UK)
DMEM 31885 Gibco (Paisley, UK)
DMEM/F12 (1:1) 21331 Gibco (Paisley, UK)
Enhanced chemiluminescence 
detection kit for western blotting
RPN2209 GE Healthcare (Little Chalfont, UK)
EDTA ED2SS Sigma-Aldrich (Poole, UK)
FACS polyprylene tubes (5 ml) 352053 BD Biosciences (Oxford, UK)
Foetal bovine serum 10108-165 Gibco (Paisley, UK)
Formaldehyde F8775 Sigma-Aldrich (Poole, UK)
FUJI Medical X-Ray Film 2731261 Fisher Scientific (Loughborough, UK)
Goat anti-mouse peroxidase 
conjugate
P0447 DAKO (Glostrup, Denmark)
Goat anti-rabbit peroxidase 
conjugate
P0448 DAKO (Glostrup, Denmark)
Glycerol G5516 Sigma-Aldrich (Poole, UK)
Glycine 50046 Sigma-Aldrich (Poole, UK)
IC87114 NA ICOS Corporation (Bothell, USA)
IL-ip, recombinant human 200-0 IB Peprotech (London, UK)
IL-8 ELISA kit D8000C R&D Systems (Abingdon, UK)
IL-13, recombinant human 200-13 Peprotech (London, UK)
IL-13, recombinant murine 210-13 Peprotech (London, UK)
JNK I Inhibitor 420116 Calbiochem (San Diego, USA)
L-glutamine (1 OOx) 25030-024 Gibco (Paisley, UK)
Leupeptin 62070 Sigma-Aldrich (Poole, UK)
Lipofectamine 2000 11668 Invitrogen (Carlsbad, USA)
Lithium chloride L9650 Sigma-Aldrich (Poole, UK)
LY294002 L9908 Sigma-Aldrich (Poole, UK)
Marvel non-fat dehydrated milk NA Premier Foods (Birmingham, UK)
Methanol M/4056/17 Sigma-Aldrich (Poole, UK)
Molecular weight markers 161-0373 Bio-Rad (Hercules, USA)
mTOR pre-designed siRNA duplex J-003008-11 Dharmacon (Erembodegem, Belgium)
Nitrocellulose membrane 7031-4502 Fisher Scientific (Loughborough, UK)
Nonidet P-40 56009 Sigma-Aldrich (Poole, UK)
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Non-sterile 96-well plate 260836 NUNC (Roskilde, Denmark)
Non-targeting pre-designed siRNA 
duplex
D-001210-01 Dharmacon (Erembodegem, Belgium)
pi 10a pre-designed siRNA duplex D-003018-07 Dharmacon (Erembodegem, Belgium)
pi 10(3 pre-designed siRNA duplex D-003019-07 Dharmacon (Erembodegem, Belgium)
pi 108 pre-designed siRNA duplex D-006775-04 Dharmacon (Erembodegem, Belgium)
PE-labelled anti-ICAM-1 IgG 
antibody
2011-08-31 BD Biosciences (Oxford, UK)
PE-labelled IgG isotype control 555749 BD Biosciences (Oxford, UK)
Penicillin/Streptomycin 15140-122 Gibco (Paisley, UK)
Phenylmethanesulfonylfluoride P7626 Sigma-Aldrich (Poole, UK)
Phosphate buffered saline (lOx) 3082920A Gibco (Paisley, UK)
Phosphatidylinositol 794003 Sigma-Aldrich (Poole, UK)
PI 103 NA UCB (Slough, UK)
PI3K class Ila  pre-designed 
siRNA duplex
D-006771-01 Dharmacon (Erembodegem, Belgium)
PI3K class lip pre-designed siRNA 
duplex
D-006772-01 Dharmacon (Erembodegem, Belgium)
PGE2 Elisa kit KGE004 R&D Systems (Abingdon, UK)
Protein G Sepharose 4 Fast Flow 17-0618-01 GE Healthcare (Little Chalfont, UK)
Protein Assay Dye Reagent 
Concentrate
500-0006 Bio-Rad (Hercules, USA)
QIAshredder 79654 QIAGEN (Crawley, UK)
Rabbit anti-goad peroxidase 
conjugate
P0449 DAKO (Glostrup, Denmark)
Rapamycin 553210 Calbiochem (San Diego, USA)
RNeasy mini kit 74106 QIAGEN (Crawley, UK)
RPMI 1640 52400 Gibco (Paisley, UK)
Sodium azide S2360 Sigma-Aldrich (Poole, UK)
Sodium chloride S7653 Sigma-Aldrich (Poole, UK)
Sodium dodecyl sulfate L4390 Sigma-Aldrich (Poole, UK)
Sodium fluoride SI 504 Sigma-Aldrich (Poole, UK)
Sodium hydroxide 22,146-5 Sigma-Aldrich (Poole, UK)
Sodium molybdate S6646 Sigma-Aldrich (Poole, UK)
Sodium orthovanadate S6508 Sigma-Aldrich (Poole, UK)
TEMED T9281 Sigma-Aldrich (Poole, UK)
TGX-121 NA UCB (Slough, UK)
Thin layer chromatography plates 4865-821 Fisher Scientific (Loughborough, UK)
Tissue culture (TC) 96-well plate 137101 NUNC (Roskilde, Denmark)
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TC 6-well multidish 140675 NUNC (Roskilde, Denmark)
TC dish 35x10 153066 NUNC (Roskilde, Denmark)
TC flask 175 cm1 178883 NUNC (Roskilde, Denmark)
TNFa, recombinant human 300-01A Peprotech (London, UK)
TNFa, recombinant murine 315-01A Peprotech (London, UK)
Trizma base T-8,760 Sigma-Aldrich (Poole, UK)
Trypan blue (0.4%) T6146 Sigma-Aldrich (Poole, UK)
Tween-20 PI 379 Sigma-Aldrich (Poole, UK)
Vybrant Cell Adhesion Assay Kit V I3181 Invitrogen (Carlsbad, USA)
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The main objective of this research project is to establish the role of PI3K isoforms in 
parenchymal lung cell responses under inflammatory cytokine stimulation. The findings of 
this research are divided into three chapters. This first results chapter deals with the initial 
studies done in a murine lung preparation that contained a diversity of cells, from immune to 
parenchymal. In this system, IL-13 and TNFa-induced signalling, as well as the role that 
PI3K, and specifically pi 105, played within these processes were briefly explored. Due to the 
difficulty in discerning the specific activities carried out by parenchymal cells in this system, 
the research effort was furthered in A549 lung alveolar epithelial cells.
The second and third results chapters revolve around the research carried out on A549 
alveolar cells. The second chapter describes the development of siRNA-induced knockdown 
of all class I and II PI3K isoforms in A549 cells, and documents changes due to this selective 
PI3K knockdown in basal cell activity, including cell survival and spontaneous wound 
closure. This chapter also analyses the effect of selective-isoform siRNA-mediated 
knockdown on cell signalling induced by different inflammatory cytokines.
The third chapter centres on TNFa-induced signalling and cellular responses in lung 
cells. Furthermore, it analyses the effect of isoform-selective silencing, induced by siRNA or 
pharmacologically, on these signalling and functional processes. This chapter details effects 
observed downstream of TNFa stimulation, such as ICAM-1 expression, THP1 cell adhesion, 
IL-8 upregulation, COX-2 expression and PGE2 production as well as cell transduction 
mechanisms, including transcription element, MAPK and PI3K signalling.
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3.1 E xpression  o f  class I PI3K isoform s in prim ary m urine lung cells
This thesis investigates the role o f individual PI3K isoforms in parenchymal lung 
cells under inflammatory conditions. Therefore, it was necessary to first identify the presence 
o f the different isoforms o f PI3K within the lung. For this purpose, immunoblotting o f all 
class I PI3K isoforms was carried out in a heterogeneous primary murine lung sample. This 
lung preparation was obtained after lungs and heart dissection from the thoracic cavity of 
mice, PBS perfusion through the pulmonary veins, lung isolation, fragmentation using a 
scalpel and lysis with solubilisation buffer. The Jurkat leukemic T cell line served as a 
positive control, since work from o f our laboratory had shown these cells express all the class 
I PI3K isoforms.
p l lO a  pi10p pi 105 pllOy
Figure 3.1 PI3K isoforms expression in primary murine lung cells. For each experiment, 2 male 
9-week old MF1 strain mice were culled. Their lungs and heart were obtained and thoroughly washed 
with cold PBS through the pulmonary veins, to grossly eliminate erythrocyte and circulating 
leukocyte content. The lungs were then dissected, and triturated in lysis buffer to obtain a primary 
murine lung whole cell lysate (PL). A cell lysate from 5.0 X 106 Jurkats was also collected (J6). 
Proteins were quantified by Bradford assay and samples were boiled with 5X sample buffer, resolved 
in SDS-PAGE with 25 pg of protein loaded for each sample, transferred to nitrocellulose membranes 
and immunoblotted, using antibodies against pi 10a, pi 1 Op, pi 108 and pllOy, as indicated at the 
bottom of each immunoblot. Arrow (+ ) indicates 110 kDa. Antibodies were detected using ECL. 
Immunoblot is representative of four independent experiments. The corresponding optical density 
values (minus background density) are expressed above each representative immunoblot. Optical 
density values are expressed as mean+SEM from n=4 independent experiments.
As seen in figure 3.1, the primary lung preparation contained all the class I PI3K 
isoforms, as a band o f around 110 kDa was found when the whole cell lysate samples o f  the
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lung preparation were probed using antibodies specific for each member of class I PI3K. 
Although the protein bands detected by the isoform-specific antibodies were different in the 
lung and T cells samples, expression of all four isoforms investigated was also seen in the 
Jurkat leukemic T cell line, used as a positive control. It is impossible to determine the 
difference in quantity of protein between the different isoforms within the same cell sample or 
even of the same isoform between the murine lung preparation and the human T cell line, as 
other factors, like antibody reactivity, would greatly affect the intensity of the band observed. 
Therefore, from these studies it is impossible determine the most or least abundant class I 
PI3K isoform within these preparations or if a particular isoform is more abundant in 
leukocytes compared to parenchymal cells.
3.2 LY294002 and IC87114 on class I PI3K activity
To recognise the role played by PI3K, and its isoforms, on lung cell functions, 
inhibitors that specifically target this family of kinases in a variety of experimental settings 
were used. For the studies in the primary murine lung, the broad spectrum PI3K inhibitor 
LY294002 and the pllOS-selective inhibitor, IC87114, were used. As seen on Table 3.1, the 
inhibitory profiles of these compounds on class I PI3Ks have been previously determined by 
others (Knight et a l, 2006; Ito et al., 2007).
Class IP I3 K  Isoforms
a P Y 5
IC87114 >200 16 61 0.13
LY294002 0.72 0.31 1.3 7.3
Table 3.1: LY294002 and IC87114 IC50 values (pM) on class I PI3K isoforms. Values are based on 
in vitro assays of inhibitor activity against purified protein activity (Knight et al., 2006; Ito et al., 
2007).
Since IC50 values tend to differ slightly between experiments and laboratories, an 
investigation into the inhibitory profiles of LY294002 and IC87114 was carried out before 
using them in the cytokine-signalling studies within the lung cell preparation. In order to 
determine the activity of these inhibitors against different class I PI3K isoforms, in vitro lipid 
kinase assays were carried out. These studies detect the transfer of radiolabeled y-phosphate 
of ATP to the D-3 position of phosphatidyl inositol.
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Figure 3.2 Sensitivity o f PI3K isoforms to LY294002 and IC 87114 in primary murine lung cells.
For each experiment, 8 male 9-week old MF1 strain mice were culled. Their lungs and heart were 
obtained and thoroughly washed with cold PBS through the pulmonary vein to eliminate erythrocyte 
and circulating leukocyte content. The lungs were then dissected, and triturated in lysis buffer to obtain 
a primary murine lung whole cell lysate. Immunoprecipitates (IP) for class I pi 10a, pi 10(3, pi 108 and 
pllOy were obtained from whole cell lysates and assayed for lipid kinase activity after a 30 min 
pretreatment with vehicle (V) or increasing concentrations (1-30 pM) of LY294002 or IC87114. 
Reactions products were extracted, fractionated by thin layer chromatography, and examined by 
autoradiography. Imagess are representative of three independent experiments. The corresponding 
optical density values (minus background density) are shown above each representative image, with 
untreated (white bars), LY294002 (black bars) and IC87114 (grey bars) samples as indicated at the top 
of the figure. Optical density values are expressed as mean+SEM from n=3 independent experiments. 
Statistical significance expressed as (*) for p<0.05 and (**) for p<0.01.
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As ascertained from the initial experiments, the primary murine lung preparation 
contained all four class I PI3K isoforms. By immunoprecipitating the different class I 
isoforms (pi 10a, P, 5 and y) from primary lung whole cell lysates and analysing their ability 
to transfer radiolabeled y-phosphate while under the presence of the inhibitors, the activity of 
these compounds towards specific PI3K isoforms was determined.
As seen in figure 3.2, LY294002 clearly inhibited all four isoforms in a similar 
manner. Its most potent inhibitory effects were displayed against p i 10a and pi 10(3, while 
p i 105 seemed to be the isoform on which it had the least activity. On the other hand, IC87114 
demonstrated selectivity for p i 105 activity, by predominantly inhibiting this isoform, with 
p i 10p and pi lOy only showing a trend towards inhibition at the highest concentration of this 
compound (30 pM).
3.3 IL-13 and TNFa-induced signalling in primary murine lung cells
The signalling cascades induced by cytokine coupling to their receptors on the cell 
surface are of primary importance in understanding lung disease pathophysiology. There is a 
wide array of cytokines that play important parts in respiratory disease, including IL-ip, IL-4, 
IL-5, IL-13, TNFa, etc (Kumar and Foster, 2002; Tetley, 2002). To begin analysing their role 
within PI3K activation, the effect that IL-13 and TNFa stimiulation had on the PI3K pathway 
in primary lung cells was determined by carrying out timecourse and concentration-effect 
studies. As the readout for these studies, Akt phosphorylation as a marker of PI3K activation 
was used. Akt requires phosphorylation on Thr308 and Ser473 for full activation. This phospho- 
regulation is dependent on PI3K activity (Alessi et al., 1996). For these experiments, an 
antibody specific for Ser473 phophorylated Akt, as well as with an Aktl antibody, to act as the 
loading control, were used.
TNFa stimulation at 100 ng/ml resulted in an increase in Akt phosphorylation 
starting at 5 min, peaking 10 min later, and returning close to basal levels an hour after 
stimulation (Fig. 3.3 A). A concentration-effect study was then carried out, using 15 min as 
an adequate timepoint. In these experiments a maximum level of phosphorylation was 
reached with a concentration of TNFa of 100 ng/ml (Fig. 3.3 B). The highest concentration, 
300 ng/ml, showed an increase in phosphorylation levels compared to basal levels, but of less 
intensity than with the immediate lower concentration of 100 ng/ml.
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Figure 3.3 TNFa and IL-13 timecourse and concentration-effect studies on Akt phosphorylation 
in primary murine lung cells. For each experiment, 4 male 9-week old MF1 strain mice were culled. 
Their lungs and heart were obtained and thoroughly washed with cold PBS through the pulmonary 
vein, to grossly eliminate erythrocyte and circulating leukocyte content. The lungs were then dissected 
and segmented using a scalpel. Pooled tissue was then separated into equal groups according to weight. 
Lung samples were cultured in serum-free DMEM at 37°C at 5% C 02 for 1 h. Samples were then 
incubated with vehicle (V), TNFa (A and B) or IL-13 (C and D) at the stated concentrations and for the 
indicated times. Samples were resolved in SDS-PAGE with 25 pg of protein used for each sample, 
transferred to nitrocellulose membranes and immunoblotted, using antibodies against phophoSer473-Akt 
(pAkt) and Aktl with both protein bands detected at 60 kDa. Immunoblots are representative of three 
independent experiments. The corresponding optical density values (minus background density and 
corrected for Aktl optical density values) are shown above each representative image, with untreated 
(white bars), TNFa or IL-13 (black bars) samples as indicated at the top of the figure. Optical density 
values are expressed as mean fold increase compared to control+SEM from n=3 independent 
experiments. Statistical significance expressed as (*) for p<0.05.
IL-13 at 10 ng/ml produced a biphasic response in Akt phosphorylation, peaking at 5 
min, returning to normal levels at 15 min, and increasing again at 30 min post-stimulation 
(Fig. 3.3 Q . Concentration-effect studies at 5 min revealed only a limited increase in Akt 
phosphorylation at 10 and 30 ng/ml, with the rest o f the concentrations remaining unchanged
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from basal (Fig. 3.3 D). These results coincide with previous studies that show that TNFa and 
IL-13 induce Akt activation in the inflamed lung (Atherton et al., 2003; Gao et al., 2007).
3.4 LY294002 and IC87114 inhibition on cytokine signalling
To elucidate the role played by PI3K, and specifically p i 108, in TNFa- and IL-13- 
induced Akt phosphorylation in primary murine lung cells, experiments were carried out 
using the broad spectrum PI3K inhibitor LY294002 and the pi 105-specific inhibitor IC87114 
(For IC50 values see Table 5.1).
TNFa-induced Akt phosphorylation was inhibited by both inhibitors (Fig. 3.4 A and 
B), with LY294002 completely abolishing the response at 10 and 30 pM. IC87114 was unable 
to completely inhibit Akt phosphorylation, but did reduce levels of phosphorylation to basal 
level at its highest concentrations of 10 and 30 pM. With regards to IL-13 signalling (Fig. 3.4 
C and D), LY294002-pretreatment led to a concentration-dependent inhibition, with 30 pM 
showing clear inhibition from stimulated levels, but still above basal. IC87114 was unable to 
inhibit IL-13-induced Akt phosphorylation, with the highest concentrations showing a clear 
tendency towards potentiation of Akt phosphorylation.
These results with LY294002 inhibition indicate a role for PI3K activity in cytokine- 
induced Akt-phosphorylation in the lung, as has previously been described (Atherton et al., 
2003). Furthermore, the different inhibition profile obtained when using the p i 105-selective 
inhibitor on IL-13 and TNFa experiments suggests a differential level of control on cytokine 
signalling in the PI3K family. Thus, pi 108 appears to be the predominant PI3K kinase 
involved in the upregulation of Akt phosphorylation downstream of TNFa in primary murine 
lung cells, as inhibition of this isoform clearly inhibited the phosphorylation response 
observed on Akt. On the other hand, selective inhibition of this isoform seemed to potentiate 
IL-13 signalling. The apparent potentiation of IL-13 signalling during p i 108-inhibition 
suggests a signalling mechanism in which pi 108, possibly through its protein kinase activity, 
regulates the activity of other pi 10 isoforms downstream of IL-13 signalling.
83














IL-13 lOng/ml IL-13 lOng/ml
LY294002(pM) IC87114(pM)
Figure 3.4 Effect of LY294002 and IC87114 pretreatment on T N F a and IL-13-induced Akt 
phosphorylation in primary murine lung cells. For each experiment, 4 male 9-week old MF1 strain 
mice were culled. Their lungs and heart were obtained and thoroughly washed with cold PBS through 
the pulmonary vein, to grossly eliminate erythrocyte and circulating leukocyte content. The lungs were 
then dissected; segmented with a scalpel and pooled. Tissue was then separated into equal groups 
according to weight. Lung samples were cultured in serum-free DMEM at 37°C at 5% C 02 for 1 h. 
Samples were then incubated for 30 min with increasing concentrations of LY294002 (A and C), 
IC87114 (B and D) or vehicle (V), prior to stimulation either with TNFa for 15 min (A and B), IL-13 
for 5 min (C and D) or an appropriate vehicle control (C). Samples were resolved in SDS-PAGE with 
25 pg of protein used for each sample, transferred to nitrocellulose membranes and immunoblotted, 
using antibodies against phophoSer47 -Akt (pAkt) and Aktl with both protein bands detected at 60 kDa. 
Immunoblots are representative of three independent experiments. The corresponding optical density 
values (minus background density and corrected for Aktl optical density values) are shown above each 
representative image, with untreated (white bars), TNFa or IL-13 (black bars), and LY294002 or 
IC87114 (checkered bars) samples as indicated at the top of the figure. Optical density values are 
expressed as mean fold increase compared to control+SEM from n=3 independent experiments. The 
dagger (f) indicates the group to which all others were compared for statistical significance. Statistical 
significance expressed as (*) for p<0.05 and (**) for p<0.01.
84
Chapter 3 - Results I
Chapter 3 - Results I
3.5 Discussion
3.5.1 Class I PI3K isoforms in the lung
To initiate the investigation of the role of PI3K isoforms in the inflamed lung, the 
presence of all four class I isoforms was determined in the primary murine lung preparation. 
PI3K is a family of kinases that is widely expressed across many different species and types 
of cells. Out of the class I PI3K members, pi 10a and pllOP are ubiquitously expressed 
(Rameh and Cantley, 1999); therefore to find these isoforms within the primary murine lung 
preparation (as seen in Fig. 3.1) was to be expected. On the other hand, since pi 108 and 
pi lOy distribution is generally restricted to leukocytes (Rameh and Cantley, 1999), the level 
of presence that these isoforms would have was uncertain. However, both of these isoforms 
were found in the lung preparation, although apparently not in as high concentrations as in the 
Jurkat T cell line. The presence of p i 108 and p i lOy in the lung could be due to the presence 
of certain parenchymal lung cells which are known to express them, like pi 1 0 y in endothelial 
cells (Puri et al., 2005). Moreover the murine lung preparation contains a host of different cell 
types, so resident immune cells of the lung, like mast cells (Zhong et al., 2003), as well as 
residual marginated leukocytes, will also contribute to levels of both pi 108 and pi 1 0 y seen in 
the immunoblot. The greater protein levels of these isoforms detected in the Jurkat T cell line 
is also due to the heterogeneity of the primary lung preparation, as this latter one contains a 
variety of cells, of which only a proportion are known to express pi 108 and pllOy PI3K 
isoforms, while in the Jurkat T cell line, all cells should express high levels of both of these 
isoforms.
3.5.2 Inhibitory profiles o f LY294002 and IC87114 on lung cells
After determining the presence of the different class I PI3K isoforms in the lung 
preparation, a validation of the pharmacological tools to be utilised to discern the roles played 
by PI3K, and specifically p i 108, was carried out. As seen in Table 3.1, other research groups 
have determined the IC50 values for this compounds on the different class I PI3K isoforms 
(Knight et al., 2006; Ito et a l, 2007); however IC50 values tend to differ slightly from one 
study to the next. In order to obtain results that would resemble as closely as possible their 
activity in lung cells, immunoprecipitation of the different PI3K isoforms from primary 
murine lung lysates for the in vitro lipid kinase studies was done. These experiments showed 
that LY294002 had almost no selectivity for any of the class I isoforms. This correlates with 
data that has been previously published by others (Ito et al., 2007), where it was found that
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the difference in IC50 between the most sensitive isoform (pi 10P -  0.31 pM) and the least 
sensitive one (pi 108 ~ 7.3 pM) was around twenty fold, with the results obtained in this 
project showing a similar profile. With regards to the inhibitory profile of IC87114, the 
previously reported selectivity of this compound for pi 105 (Knight et a l, 2006) was 
confirmed, with little effect seen on the activity of the other isoforms. This is due to the 
propensity of this compound for the p i 108, as its selectivity for this isoform is around 1 0 0  
times higher than towards p i 10|3, and even higher for pi lOy (-500 times) and pi 10a (>1500 
times).
3.5.3 PI3K and p l!0 8  in cytokine-induced signalling in primary lung cells
Once the inhibitory profile of the PI3K inhibitors had been examined, the 
investigation was continued by determining the role played by this family of kinases within 
certain events of key importance within respiratory illness. Cytokines are main mediators of 
disease by inducing critical disease functions in parenchymal lung cells. For example, IL-13 
induces chemokine and adhesion molecule expression (Zhu et a l, 1999; Pope et a l, 2001), 
subepithelial fibrosis (Zhu et a l, 1999; Zheng et a l, 2000), mucus hypersecretion (Zhu et a l, 
1999; Venkayya et a l, 2002), reduced mucus clearance (Laoukili et a l, 2001) and airway 
hyperresponsiveness (Venkayya et a l, 2002; Kuperman et a l, 2002); while TNFa increases 
the release and production of inflammatory cytokines and chemokines, upregulates adhesion 
molecule expression and many other effects (Lassalle et a l, 1993; Yamamoto et a l, 1998).
In the murine lung preparation, treatment with either IL-13 or TNFa induced Akt 
phosphorylation, which is a process generally associated with PI3K activity (Shishodia et a l, 
2004; Zhou et a l, 2005). Accordingly, LY294002-pretreatment results indicated that Akt 
phosphorylation downstream of either cytokine was effectively PI3K dependent. Moreover, 
TNFa-induced Akt phosphorylation was more sensitive to LY294002 than phosphorylation 
downstream of IL-13. This could be due to IL-13 possessing a more robust activation of PI3K 
than TNFa, or that IL-13 induces the activation of isoforms which are less sensitive to 
LY294002 than isoforms activated by TNFa. However, the results obtained when using 
IC87114 question this latter possibility, as the pi 108-selective inhibitor inhibited TNFa- 
induced phosphorylation of Akt, suggesting that p i 105, the class I isoform most resistant to 
LY294402 inhibition, is the main isoform involved in this process. Opposing effects were 
observed in IL-13 induced Akt phosphorylation, as pretreatment with IC87114 demonstrated 
a trend towards potentiation of the phosphorylation levels. Isoform-specific regulation of Akt
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phosphorylation downstream of cytokine activation has been described before for pi 108 in 
IL-4 induced signalling in B cells (Bilancio et al., 2006).
3.5.4 From a primary lung cell preparation to an alveolar epithelial cell line
After the results in this chapter were obtained, a decision was made to continue the 
research effort in a type II alveolar epithelial cell line called A549 (results described in 
chapters 4 and 5). The decision was taken in the belief that siRNA experimentation in A549 
cells would provide interesting leads that would help determine the possible cell functions 
that individual PI3K isoforms perform during cytokine stimulation in the lungs. The 
information generated from the A549 cell model would be used to design ex vivo and in vivo 
experiments. The initial experiments to verify the data obtained from the A549 cell line in 
primary lung tissue would include immunohistochemistry targeting signalling molecules (e.g. 
individual PI3K isoforms), phosphorylated forms of kinases (e.g. phosphoSer473-Akt), and 
molecules involved in the inflammatory reaction in the lung (e.g. ICAM-1, TNFR, COX-2). 
Furthermore, experiments in which purification of different cell types from lung tissue would 
also be carried out in order to study primary lung cell signalling and function, and determine 
its differences with the A549 cell line.
Unfortunately, the obtention of useful data for the design of ex vivo and in vivo 
experiments from the A549 cell line was more challenging and time-consuming than 
originally planned. Therefore, the experiments that could link the primary lung work 
described in this chapter and the A549 cell line work described in the following chapters were 
not carried out.
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3.6 Conclusions
In this initial part of the study it was determined that all class I PI3K isoforms were 
present in the murine lung. However, given the nature of the primary lung preparation, it was 
impossible to make any distinction of which type of cell contained which class I PI3K 
isoform. Furthermore, initial studies using LY294002 and IC87114 demonstrated a certain 
specificity for pi 108 in TNFa-induced Akt phosphorylation. While phosphorylation 
downstream of IL-13 proved to be dependent on PI3K activity, no further elucidation was 
possible, as this process was insensitive to IC87114 pretreatment.
At this time, access to other isoforms-selective inhibitors (i.e. TGX-121 and PI103) 
was unavailable; hence this research work could not continue elucidating the roles of other 
isoforms in the primary murine lung preparation described in this chapter. Therefore, 
employment of siRNA technology to further elucidate the roles of different PI3K isoforms 
was decided upon. However, to obtain a clearer picture of the mechanisms at play in 
parenchymal lung cells, and since the primary murine lung preparation contained a wide 
variety of cells, ranging from leukocytes to parenchymal and structural lung cells, it was 
determined that the most feasible way to further this study was in the widely used human lung 
cell line, A549 alveolar epithelial cells.
In summary, in the present chapter the following was determined:
• Primary murine lungs expressed all the class IPI3K isoforms
• LY294002 inhibited all class I PI3K isoforms obtained from murine lung 
cells
• IC87114 selectively inhibited the pi 105 isoform from murine lung cells
• LY294002 blocked IL-13 and TNFa-induced Akt phosphorylation
• IC87114 attenuated TNFa-induced, but not IL-13-induced, Akt 
phosphorylation
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As mentioned in chapter 3, due to the lack of availability of other isoform-selective 
inhibitors, the research work was continued using siRNA technology. For this purpose, A549 
human alveolar epithelial cells were used as a lung parenchyma model. The silencing of PI3K 
isoform-specific mRNA was attempted using synthetically-generated siRNA specific for the 
catalytic isoforms of class LA and II PI3K, but not class IB p i lOy, as it is not present in these 
cells (Patel et al., 2005). This chapter therefore begins with the validation data of the RNAi 
process, using qPCR and immunoblotting techniques to determine mRNA and protein levels, 
respectively.
One of the main objectives in of this research is to determine the role played by PI3K 
isoforms in the signalling cascade downstream of inflammatory cytokines in the lung. Thus, 
with the use of siRNA, in this chapter the elucidation of the individual role of PI3K isoforms 
in the context of IL-lp, IL-13 and TNFa signalling in A549 cells was begun. Before 
evaluating the changes in cytokine signalling, the possible effects that PI3K silencing might 
have on basal cell activity, including cell survival and spontaneous wound closure, were 
determined. This was important to analyse, as changes in the ability of the cell to reproduce or 
survive would have repercussions in the outcomes of future functional studies for these 
knockdown cells and that could lead to misinterpretation of the results.
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4.1 siRNA knockdown of class I and II PI3K in A549 cells
To begin the research work using siRNA technology, validation of the protocol for 
the A549 cell line transfection was required. Initially, observation of siRNA-treated cells for 
changes in morphology or cell number during a period of 96 h was carried out. To this effect, 
photographs of the cells were taken every 24 h at lOx and 25x magnification using a light 
microscope. No obvious changes were detected in either the size or morphology of the 
transfected cells. However, as observed in figure 4.1 A, culture dishes containing cells treated 
with class Ila  isoform-specific siRNA decreased in cell density, with changes becoming 
apparent at 72 h and 96 h. After analysing the data from the viable cell counts performed on 
each sample after microscopic photography (Fig. 4.1 B), it became apparent that at 72 h and 
96 h, cell numbers in class I la  siRNA-treated cells had fallen by 74 and 92%, respectively, 
compared to cells transfected with non-targeting siRNA. At 72 h, class Ila  siRNA-treated 
cells had a concentration of 6.17±0.51xl05 cells/ml, while samples treated with non-targeting 
siRNA possessed a concentration of 2.36±0.18xl06 cells/ml. Furthermore, at 96 h the 
concentration of class I la  siRNA-treated cells was 2.56±0.23xl05 cells/ml while for 
non-targeting siRNA-treated cells it was 3.08±0.22xl06 cells/ml. PI3K class I and class 11(3 
siRNA-treated samples did not demonstrate any significant loss in their cell numbers. This 
finding was not completely unexpected, as class Ila  PI3K has been previously described by 
other groups as important in the signalling of cell survival mechanisms in another cell line 
(Kang et al., 2005).
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Figure 4.1 Cell survival o f A549 cells transfected with class I and II PI3K isoform-specific siRNA.
The day before transfection, 10s cells were seeded in a 35 mm plate in 2 ml of 10% FBS-supplemented 
DMEM. As indicated on the left hand side of the figure, vehicle (Control), pre-designed siRNA 
duplexes targeting class IA pi 10a, pi 1 Op, pi 108, class Ila, lip or non-targeting siRNA (scrambled) 
formulated at 250 pmol with 5 pi of Lipofectamine 2000 in 500 pi of serum-free media was added to 
the cells for 24h at 37°C in 5% CO2 . A. The cells were then observed for a period of 96 h, with 
photographs taken of the cell cultures at lOx magnification every 24 h, as indicated at the top of each 
column. All experiments were performed in duplicate. Images are representative of six independent 
experiments. B. After the photographs were taken for each time point, siRNA-treated A549 cells were 
enzymatically removed from their culture dishes, washed, resuspended and exposed to 0.4% Trypan 
blue for 5 min at room temperature. Viable cell number concentration was then determined using a 
haemocytometer in light microscopy. Values are expressed as mean+SEM from n=6 independent 
experiments. Statistical significance expressed as (**) for p<0.01.
I
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Next, analysis o f the levels o f protein and mRNA o f all class IA and class II isoforms 
in the siRNA-treated cells was done, in order to determine the ability o f siRNA to knockdown 
its intended mRNA and protein target, as well as to verify its specificity by detecting mRNA 
and protein levels o f non-targeted isoforms. As seen in figure 4.2, mRNA levels for each one 
o f the targeted isoforms were significantly (p<0.01) decreased from 24 h to 96 h post­
transfection, except for class I la , as there were not enough cells to generate samples for the 
72 h and 96 h time points. Furthermore, all the mRNA levels for non-targeted isoforms, like 
p i 10(3 mRNA levels in p llO a-siR N A  treated samples, presented no important reductions 
with the use o f any o f  the siRNAs. The only other apparently significant change was an 
increase in p i 105 mRNA levels in pll0 |3-siR N A  treated cells, exclusively 24 h post­
transfection (upper left graph in figure 4.2). This effect is possibly due to compensatory 
mechanisms, as a decrease in p i 10(3 mRNA could induce the cells to overexpress p i 105. 
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Figure 4.2 mRNA levels of class I and II PI3K isoforms in A549 cells transfected with isoform- 
specific siRNA. Cell were transfected as described before, with class IA pi 10a, pi 1 Op, pi 105, class 
Ila, lip or non-targeting (Scrambled) siRNA. Using 24h intervals for a total 96 h, mRNA levels for 
class I pi 10a, pllOp, pi 105, class Ila  (C2a), and 11(3 (C2P), as below each graph, were determined 
using RT-PCR. mRNA levels are expressed as mean fold increases+SEM to GAPDH (a housekeeping 
gene) for n=3 independent experiments. Statistical significance expressed as (*) for p<0.05 and (**) for 
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With regards to protein levels, as seen in figure 4.3 A, pllOa-siRNA treated cells 
showed very small changes in the first 48 h post transfection, with peak inhibition of protein 
expression reached at 72 h. For the other two class IA isoforms, pllOp and pi 105 protein 
silencing was significantly reduced at an earlier time point than for pi 10a, with an important 
decrease observable at 48h and lasting until 96 h. No reduction in protein levels was evident 
for the non-targeted isoforms at any of the time points. For class II PI3K (Fig. 4.3 B), class 
I la  levels start decreasing at 48 h post transfection. Unfortunately, as seen at the beginning of 
this section, class Ila-siRNA treated cells were scarce at the 72 h and 96 h timepoints, with 
generation of whole cell lysates comparable to other siRNA-treated samples becoming 
practically unfeasible. Class lip protein levels were partially decreased at 48 h after 
transfection, however this knockdown effect peaked at 72 h and remained significant at 96 h. 
No reduction in protein levels was evident for the non-targeted isoforms at any of the time 
points.
Immunoblotting studies at 72 h after transfection were performed to determine if any 
off-target modulation of class II PI3K protein levels had been generated by the knockdown of 
class IA PI3K isoforms, and vice versa. As seen in figure 4.3 C, knockdown of pi 10a, pi 10P 
or pi 105 had no significant effects on the protein levels of class Ila  or lip. Moreover, 
knockdown of class lip had no significant effect on the protein levels of the class IA 
isoforms.
Collectively, these data demonstrate that the siRNA used was sufficiently effective to 
reduce levels of both mRNA and proteins, and specific enough to not inhibit the levels of 
mRNA or protein of any of the other isoforms in the PI3K family, rendering it as the ideal 
tool to study the effect of PI3K isoform-selective silencing within these cells in the context of 
inflammatory mediator signalling. Since the levels of the siRNA-targeted protein were 
effectively decreased at 72 h post transfection for all the PI3K isoforms studied (Fig. 4.3 C), 
with the exception of class Ila, this time point was utilised in all subsequent experimentation.
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Figure 4.3 Protein levels of class I and II PI3K isoforms in A549 cells transfected with isoform-specific siRNA. Figure lengendon next page.
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(Figure 4.3 is on the previous page)
Figure 4.3 Protein levels of class I and II PI3K isoforms in A549 cells transfected with isoform- 
specific siRNA. A and B. For each experiment, 4 culture dishes of cells were transfected with either 
vehicle (C), pi 10a (a), p i 10p (P), pi 105 (5), class I la  (2a), class lip (2P) or non-targeting (S) siRNA 
as indicated at the bottom. Whole cell lysates were generated every 24 h for a 96 h period for each 
treatment group. As labelled to the left of the immunoblots, samples were then probed for protein levels 
of p i 10a at 110 kDa, pllOp at 110 kDa, p i 105 at 110 kDa, class I la  (C2a) at 170 kDa, class lip (C2P) 
at 165 kDa, and Aktl at 60 kDa. Cells treated with class I la  siRNA were insufficient to generate whole 
cell lysate samples at 72 and 96 h. A shows class I PI3K; while B shows class II PI3K. Images are 
representative of six independent experiments. The corresponding optical density values (minus 
background density and corrected for Aktl optical density values) are shown above each representative 
image. Optical density values are expressed as mean+SEM from n=6 independent experiments. 
Statistical significance expressed as (*) for p<0.05 and (**) for p<0.01. C. For each experiment, a 
culture dish of cells was transfected with either pi 10a (a), p i 10p (P), pi 105 (5), class lip (2P) or non­
targeting (S) siRNA as indicated at the bottom. Whole cell lysates were generated 72 h after 
transfection. As labelled to the left of the immunoblots, samples were then probed for protein levels of 
pi 10a at 110 kDa, p i 10p at 110 kDa, pi 105 at 110 kDa, class I la  (C2a) at 170 kDa, class lip (C2P) at 
165 kDa, and Aktl at 60 kDa. Images are representative of ten independent experiments. The 
corresponding optical density values (minus background density and corrected for Aktl optical density 
values) are shown above each representative image. Optical density values are expressed as 
mean+SEM from n=10 independent experiments. Statistical significance expressed as (**) for p<0.01.
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4.2 PI3K silencing on spontaneous wound healing
In chronic inflammatory respiratory diseases, denudation of the epithelial airway 
lining of the airway occurs with epithelial migration contributing to airway repair and 
reconstitution (Erjefalt et a l, 1995). It has been previously demonstrated that PI3K plays a 
role in airway epithelial migration (Shahabuddin et a l, 2006), therefore wound healing 
experiments were carried out in siRNA-mediated PI3K knockdown cells. This was important 
to determine the general responsiveness of these cells under basal conditions, before carrying 
out cytokine stimulation experiments. A pipette-tip scratching technique of a confluent 
monolayer and wound closure observation under light microscopy for 72 h was used.
As seen in figure 4.4 A, wound healing occured without delay in cultures treated with 
either p i 10a or p i 108-specific siRNA compared with control cells treated with non-targeting 
siRNA. However, wound healing was delayed in cells treated with either class I pllOP or 
class lip with their wound closure processes remaining incomplete 48 h after scoring.
When analysing the mean wound closure percentage values of these experiments 
(Fig. 4.4 B), p i 10a, pi 108 and non-targeting siRNA had all mean percentages above 90% at 
24 h post scoring; while class Iip-siRNA treated cells were approximately at 81% and class I 
pllOp siRNA-treated cells, which suffered the greatest delay in wound healing, had a mean 
wound closure of just over 70%, with both of this delays having a statistical significance of 
p<0.01. The majority of siRNA-treated monolayers were completely closed at 48 h, however 
pllOP-siRNA treated cells reached a mean closure of only 88% (p<0.05). Class Iip-siRNA 
treated monolayers also presented delayed wound healing at 48h with a mean of 92%, but this 
was not statistically different from control values, generated from non-targeting siRNA 
treated cells. All wounds were completely closed at 72 h.
This study established that siRNA transfection per se in A549 cells had no deleterious 
effects in spontaneous wound healing, a process involving cell reproduction and migration. 
Although class I pi 10p and class lip-knockdown cells had delayed responses to monolayer 
disruption, their basic cell response of wound healing remained, as demonstrated by their 
ability to repair the wound in 72 h. This suggested that the PI3K isoform specific-siRNA 
treated cells, with the exception of class Ila, were not only capable of surviving the PI3K 
knockdown process, but they were able to respond adequately to basic stimuli, like 
mechanical cell-to-cell disruption.
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Figure 4.4 Spontaneous wound healing in A549 cells transfected with PI3K isoform-specific 
siRNA. A. Cells were transfected with class IA pi 10a, pi 10(3, pi 108, class lip (C2P), or non-targeting 
(Scrambled) siRNA. Wounds were initiated 24h post transfection using a pipette tip. Photographs of 
the wounds were taken at lOx magnification at Oh, 24h and 48h as labelled at the top of each column. 
Images are representative of three independent experiments; each experiment was carried out in 
duplicate. B. Graph depicting wound closure percentage means±SEM at 24 h (■) and 48 h ( A)  post­
scoring for cell monolayers treated with PI3K class I pi 10a (a), pi 10(3 (P), pi 105 (8), class lip (C2P) 
or non-targeting (Scrambled) siRNA treated cells. Measurements of each wound were taken at t=0 and 
every 24 h afterwards, for a full period of 72 h. From these measurements, wound area was calculated. 
Zero percent (0%) wound closure was assigned to the area value obtained from the initial measurments 
taken after pipette tip scratching of the monolayer. Full closure of the wound, or wound area of 0, was 
considered 100% wound closure. Data expressed as means ± SEM from n=3 independent experiments; 
each experiment was carried out in duplicate. Statistical significance expressed as (*) for p<0.05 and 
(**) for p<0.01.
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4.3 PI3K silencing on cytokine-induced signalling
In Chapter 3, the effect that pretreatment with the broad spectrum PI3K inhibitor 
LY294002 or the pllOS-selective inhibitor IC87114 had on Akt phosphorylation induced by 
TNFa and IL-13 in primary murine lung cells was analysed. Due to the unavailability of other 
selective PI3K inhibitors, siRNA technology was used to advance this work. After verifying 
the effectiveness and the specificity of siRNA-mediated knockdown, and determining that 
transfected cells were still capable of basic cell responses, an analysis of the differences in 
cytokine-signalling observed in PI3K isoform-specific knockdown cells was carried out.
To begin, it was necessary to determine the optimum incubation period and 
concentration of cytokine for the stimulations. Hence, timecourse and concentration-effect 
studies for the inflammatory mediators that were to be analysed were carried out. In the case 
of A549 cells, the inflammatory cytokine IL-ip, along IL-13 and TNFa, were used. The same 
antibodies that were used in the experiments described in Chapter 3 were employed for these 
experiments.
IL-ip stimulation at 1 ng/ml resulted in an increase in Akt phosphorylation starting at 
10 min and peaking at 15 min, returning to basal levels 30 min after stimulation (Fig 4.5 A). 
In the concentration-effect study, carried out at 15 min post stimulation, IL-lp showed a clear 
concentration-dependent stimulation of Akt phosphorylation, with high levels of 
phosphorylation reached at 100 and 300 ng/ml (Fig 4.5 B).
A549 cell stimulation with IL-13 at 30 ng/ml produced a biphasic response, with a 
trend for upregulation in Akt phosphorylation at 5 min, a decrease at 10 min, and a significant 
increase in phosphorylation at 15 min. Levels of Akt phosphorylation similar to basal were 
apparent 60 min after stimulation (Fig 4.5 C). Concentration-effect studies at 15 min 
demonstrated increase in Akt phosphorylation at 10 and 30 ng/ml, with lower concentrations 
remaining unchanged from basal levels (Fig 4.5 D).
TNFa stimulation at 100 ng/ml induced increased levels of Akt phosphorylation from 
10 to 30 min post stimulation, with 60 min still showing slightly increased levels over basal 
(Fig 4.5 E). Concentration-effect studies at 15 min showed increasing levels of Akt 
phosphorylation in a concentration-dependent manner, with a maximum level of 
phosphorylation reached at 100 ng/ml, with no significant increases at 300 ng/ml (Fig 4.5 F).
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Figure 4.5 IL-ip, IL-13 and TNFa timecourses and concentration-effects on Akt-phosphorylation 
in A549 cells. Confluent A549 cell monolayers in 35 mm culture dishes were left in serum-free 
DMEM at 37°C at 5% C 02 overnight. Samples were then stimulated with vehicle (V), IL-1 (3 (A andB), 
IL-13 (C and D) or TNFa (E and F) at the stated concentrations and incubated for the indicated times. 
Whole cell samples were then generated for electrophoresis, resolved in SDS-PAGE, transferred and 
immunoblotted, using antibodies against phosphoSer473-Akt (pAkt) and Aktl with both protein bands 
detected at 60 kDa. Immunoblots are representative of three independent experiments. The 
corresponding optical density values (minus background density and corrected for Aktl optical density 
values) are shown above each representative image, with untreated (white bars), IL-1 p, IL-13 or TNFa 
(black bars) samples as indicated at the top of the figure. Optical density values are expressed as mean 
fold increase compared to control+SEM from n=3 independent experiments. Statistical significance 
expressed as (*) for p<0.05 and (**) for p<0.01.
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The effect of introducing siRNA into a cell, even when the transfected siRNA is 
designed not to target any potential mRNA sequences, has deleterious effects on the responses 
of the cell (Judge et al., 2005). For this reason, the siRNA studies begun by analysing the 
ability of the cells to respond to cytokine stimulation after being transfected with non­
targeting siRNA compared to the addition of Lipofectamine 2000, the transfection reagent, on 
its own (Fig. 4.6 A). From these experiments, it was observed that non-targeting siRNA 
transfected cells retain their ability to respond to all the cytokines analysed. The only 
difference in Akt phosphorylation between non-targeting siRNA transfected cells and 
Lipofectamine 2000-treated cells was in the IL-13 response, as transfection reagent-treated 
cells possessed a higher level of phosphorylation than siRNA-transfected cells, although both 
groups presented greater phosphorylation levels than basal. Since non-targeting siRNA 
transfected cells resemble more closely the situation in PI3K isoform-specific siRNA 
knockdown cells, this control was chosen as the optimum one for the rest of the experiments.
In class IA PI3K isoform-specific siRNA-transfected cells, pllOp knockdown 
inhibited IL -ip - and TNFa-induced Akt phosphorylation (Fig. 4.6 B and D), while p i 108 
knockdown showed a tendency towards inhibition of IL-ip-induced phosphorylation. IL-13 
phosphorylation remained relatively unchanged in all PI3K knockdown cells (Fig. 4.6 C). As 
seen in figure 4.6 E, class lip knockdown had no significant effects on Akt phosphorylation 
induced by IL-ip, IL-13 or TNFa.
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Figure 4.6 Effect of PI3K-siRNA knockdown on IL-ip, IL-13 and TNFa-induced Akt 
phosphorylation in A549 cells. Cells were stimulated with cytokines or vehicle control 72 h after cells 
were transfected with vehicle control (C), non-targeting (S), class IA pi 10a (a), pi 10P (P), pi 108 (8) 
or with class lip (C2P) siRNA. Samples were then immunoblotted for phosphoSer473-Akt (pAkt) and 
Aktl as indicated to the left of the immunoblots, with both protein bands detected at 60 kDa. The 
corresponding optical density values (minus background and corrected for Aktl optical density values) 
are shown above each representative image, with untreated (white bars), IL-1P, IL-13 or TNFa (black 
bars) samples as indicated at the top. A. Effect of non-targeting siRNA on cytokine-induced Akt 
phosphorylation. Cells were stimulated with IL-ip at 1 ng/ml, IL-13 at 30 ng/ml, TNFa at 100 ng/ml 
or vehicle control for 15 min. Immunoblots representative of 4 experiments. Optical density values are 
expressed as mean fold increase compared to control+SEM from n=4 independent experiments. B, C 
and D. Effect of class IA PI3K siRNA on cytokine-induced Akt phosphorylation. Cells were stimulated 
with IL-1P (B), IL-13 (C) or TNFa (D) at the indicated concentrations for 15 min. Appropriate vehicle 
controls (V) were also carried out for each cytokine for the same period of time. Images representative 
of ten independent experiments. Optical density values are expressed as mean fold increase compared 
to control+SEM from n=10 independent experiments. E. Effect of class lip PI3K siRNA on cytokine- 
induced Akt phosphorylation. Cells were stimulated as in A. Immunoblots representative of six 
independent experiments. Optical density values are expressed as mean fold increase compared to 
control+SEM from n=6 independent experiments. The dagger (f) indicates the group to which all 
others were compared for statistical significance. Statistical significance expressed as (*) for p<0.05.
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In order to further elucidate the signalling mechanisms behind cytokine signalling, 
double PI3K isoform knockdown was attempted. In the initial knockdown experiments that 
were described at the beginning of this section, an siRNA concentration of 250 pmol with 5 pi 
of Lipofectamine 2000 in 500 pi of serum-free media was added to the cell medium for 24h. 
For these double knockdown experiments the same amount of siRNA and transfection reagent 
was used for each isoform. Therefore, the final concentration of siRNA in double knockdown 
samples was of 500 pmol with lOpl of Lipofectamine 2000 in 500pl of serum free media. 
Single knockdown cells used as comparison for double knockdown experiments were treated 
with twice as much siRNA and Lipofectamine 2000, in order to serve as appropriate controls 
for the double knockdown cells.
As seen in figure 4.7 A, cell numbers fell dramatically in A549 cells that were 
transfected with two different siRNAs as cell survival at 72 h was decreased by approximately 
50%. Furthermore, protein recovery from double-knockdown samples (Fig. 4.7 B) was also 
significantly reduced in comparison to single-knockdown samples. This was almost certainly 
due to the effect of the cells lacking two class I PI3K isoforms, instead of just one, as the 
increased levels of transfection reagent and siRNA were shared by all samples. Unfortunately, 
the extremely low protein levels presented by the double knockdown samples made it 
practically unfeasible to carry out any immunoblotting experiments. Therefore, no verification 
that in double knockdown cells both of the targeted isoforms had successfully been silenced 
was obtained.
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Figure 4.7 Effect of double PI3K-siRNA knockdown on cell numbers and whole cell lysate 
protein concentration . As indicated on the botom, vehicle (C), class IA pi 10a(a), pllO p (P), 
pi 108 (8), class lip (IIP) or non-targeting (S) siRNA formulated at 500 pmol or, for the double 
knockdowns, at 250 pmol for individual siRNA (with total siRNA concentration being 500 pmol) with 
Lipofectamine 2000 (10 pi) in 500 pi of serum-free media was added to the cells. After 24 h 
incubation, the media was replaced with 10% FBS-supplemented DMEM and incubated for another 
48 h .A . Seventy-two hours after transfection, siRNA-treated A549 cells were enzymatically removed 
from their culture dishes, washed, resuspended and exposed to 0.4% Trypan blue for 5 min at room 
temperature. Viable cell number concentration was then determined using a haemocytometer in light 
microscopy. B. After quantification of viable cell numbers, ice cold lysis buffer was used to make 
whole cell lysates of the siRNA-treated A549 cells. Proteins concentrations were then determined on 
the samples by the Bradford assay. For A and B, values expressed as mean+SEM from n=10 
independent experiments. Statistical significance expressed as (*) for p<0.05 and (**) for p<0.01.
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4.4 Discussion
4.4.1 siRNA-mediated PI3K isoforms-specific silencing
As shown in the first section of this chapter, targeting class I and IIPI3K isoforms by 
siRNA in A549 cells proved to be both a potent and specific way of silencing, in an isoform- 
specific manner, mRNA and protein levels within the knockdown cells. In A549 cells, an 
important reduction in mRNA levels for all class I and II PI3K isoforms at 24 h post- 
trasfection was obtained. However, at this time-point, the knockdown in protein levels was 
not evident. Previous studies have shown that the suppression of protein levels effected by 
siRNA can begin at different times for different proteins, depending on the half-life of the 
target protein (Alisky and Davidson, 2004). Since mRNA levels were effectively decreased at 
24 h for all PI3K isoforms and these levels remained suppressed throughout the 96 h period 
studied, the appearance of protein knockdown depended completely on depletion of existing 
levels of protein within the cell. For class I pi 10P and pi 105, this depletion became apparent 
48 h post transfection, while for class I pi 10a and class lip, it required 72 h for an effective 
decrease in protein levels. Class Ila  mRNA levels were decreased at 24 h and 48 h post­
transfection, and a slight inhibition in protein levels is apparent at 48 h, but unfortunately 
A549 cells treated with class Ila-specific siRNA were unable to survive to the 72 h time 
point. This data validated that siRNA is a powerful and specific tool for studying protein 
activity as the mRNA and protein levels of the targeted protein were efficiently suppressed, 
while the levels of other related proteins from the same family of PI3K kinases were without 
change.
4.4.2 PI3K in A549 cell survival
As described in section 4.1, class Ila-siRNA treated A549 cells were unable to 
survive to reach adequate knockdown for study, suggesting a role for class Ila  in cell 
survival. This idea is supported by evidence found in a different cell line by another group 
(Kang et al., 2005). In this study, Chinese hamster ovary cells were transfected with antisense 
oligonucleotides specific for class Ila  PI3K, decreasing class Ila  gene expression and causing 
changes in the cell activity indicative of apoptosis, such as nuclear condensation, formation of 
apoptotic bodies and DNA fragmentation. Furthermore, this group also found a reduction in 
class Ila  mRNA levels when cells were incubated in cell media deficient in growth factors,
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establishing a possible mechanism for the activity this isoform displayed in cell survival, by 
being a prominent PI3K isoform involved in growth factor signalling.
A549 cells treated with siRNA specific for one class I isoform cells suffered no 
apparent decrease in cell number, as seen in the first section of this chapter. However, cells 
treated with two siRNAs targeting different class I isoforms suffered important decreases in 
cell numbers, as reflected by the amount of protein obtained from their corresponding cell 
lysate samples, seen in the last section of this chapter. Interestingly, the lowest protein levels 
obtained for samples treated with siRNA targeting only one isoform were for cells treated 
with p i 10P-specific siRNA. Furthermore, double knockdown samples had lower levels of 
protein if one of the targeted isoforms was p i 10p (i.e. pllO a-pllO P and pi 10P-pl 105 
knockdowns), with the p ll0 a -p ll0 5  double knockdown sample having the highest level of 
protein for any of the double knockdown samples. This would implicate that the activities of 
class I PI3K isoforms, especially of pllOp, are also involved in cell survival, but to a lesser 
extent than class Ila. Previous reports have implicated all three class LA PI3K isoforms in 
survival-regulating mechanisms. PI3K pi 10a has been previously implicated in cell survival 
(Benistant et al., 2000) as well as in the regulation of cell proliferation, as it is mutated in 
human cancer with high frequency (Lee et al., 2005), while pllOp and pi 105 have been 
implicated in cell survival downstream of insulin-like growth factor stimulation in acute 
myeloid leukaemia cells (Doepfner et a l, 2007).
4.4.3 PI3K in spontaneous wound healing
PI3K has been implicated by other researchers in the process of wound healing, a 
process that encompasses cell proliferation and migration. A recent paper has determined that 
PI3K activity is essential for adequate wound healing in cultured human skin fibroblasts (Cao 
et al., 2006), while findings from other research seem to suggest that this could be a preserved 
mechanism, as PI3K signalling has been shown to be essential in wound repair in other cell 
types (Rieck et al., 2001). In A549 cells, although all the different type of knockdown cells 
studied were able to close the gap created by the pipette tip at 72 h post-wounding, class I 
pi 10p and class lip possessed a delayed response in comparison to cells with siRNA-induced 
knockdown for other members of the PI3K family, implying a role for these isoforms in 
wound healing.
It could be inferred that the delayed response observed for pi 10P-knockdown cells 
could be partly due to the diminished ability of these cells to survive/proliferate. Furthermore,
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there is a previous report where pllOp was shown to regulate lamellipod extension, an 
essential activity in epithelial cell migration (Yip et a l, 2004). However, in this report it was 
the overexpression of pllOP which caused inhibition of epidermal growth factor-stimulated 
lamellipod extenstion and not its inhibition, as observed in the results described in this 
project. Opposing reports exist for a role in cell migration for class lip. Class IIP'7' mice 
display normal epidermal growth, differentiation and wound healing (Harada et al., 2005), 
while on the other hand, class Up has been implicated in cell migration and in lamellipod 
extension formation in vitro (Maffucci et al., 2005; Domin et al., 2005). This would seem to 
indicate that these responses might be cell or context dependent.
Our main intention with this research was to determine the role of individual PI3K 
isoforms in inflammatory cytokine signalling and function in the lung, while cell viability and 
wound healing were only investigated to determine the ability of knockdown cells to respond 
to basic signals, such as cell-to-cell disruption and survival signals. Although interesting 
characteristics of cell survival and wound healing capabilities were learnt during the study of 
the different knockdown cells, the primary interest of this research project was not in 
apoptosis, survival-related mechanisms, or cell migration. Therefore a decision was taken not 
to pursue with the characterization of the mechanisms involved in the cell death induced by 
PI3K silencing or in its ability to inhibit wound healing in this specific cell line. Hence work 
was continued directed at the objectives set out initially for this project, commencing the 
study into inflammatory cytokine signalling.
4.4.4 PI3K in cytokine-induced signalling
When cytokine stimulation was carried out in PI3K isoform-specific knockdown 
cells, pllOp proved to be the main isoform involved in TNFa and IL-ip-induced Akt 
phosphorylation, while IL-13 stimulation of Akt was preserved regardless of the PI3K 
isoform being targeted. The increased levels of Akt phosphorylation in response to any of the 
three cytokines used remained unchanged in p i 10a or class lip knockdown cells.
For IL-ip, pi 108-knockdown cells also showed decreased levels of Akt 
phosphorylation, however pllOp exerted a more important inhibition than pi 105 silencing. 
This would suggest that the residual phosphorylation level observed in pllOp knockdown 
cells are due to pi 108 activity, and vice versa. Cytokine-induced Akt phosphorylation 
dependent on a specific PI3K isoform has been previously reported for pi 108, as this PI3K
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kinase is the predominant isoform involved in Akt activation downstream of IL-4 (Bilancio et 
a l, 2006).
The fact that TNT a  and IL-ip-induced Akt phosphorylation was dramatically 
blocked by pllOP silencing suggests that this isoform plays an important part on cell 
functions elicited by these cytokines. As shown in table 1.4, pllOp has previously been 
associated with a diversity of roles including development, insulin signalling and 
phagocytosis. Therefore, as described in the chapter 5, extensive work was carried out into 
discovering cytokine-inducted cell functions that were dependent on pi 10p and Akt activity.
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4.5 Conclusions
In this chapter, through the use of siRNA technology, the analysis of the different 
roles that the different PI3K isoforms play in A549 lung alveolar epithelial cells was begun. 
Class II PI3Ks, which are often overlooked, demonstrated their importance in cell survival 
(Ila) and wound healing (II|3). Meanwhile, p i 10(3 proved to be the pivotal isoform for the 
class I isoforms as shown by its importance in a variety of processes, including wound 
healing, cell survival, and signalling downstream of TNFa and IL-lp. Class I pi 105 
demonstrated a somewhat smaller role in IL-ip-induced Akt phosphorylation.
With the results described in this chapter, it was discovered that individual PI3K 
isoforms possess specialized functions in comparison to the other isoforms of the same family 
of kinases. As described in chapter 5, to carry forward the results from cytokine-induced cell 
signalling described in this chapter into cytokine-induced cell functions, the study of cell 
functions downstream of TNFa was done using isoform-specific siRNA and verified with 
isoform-selective inhibitors.
In summary, in the present chapter the following was determined:
• siRNA treatment selectively reduced mRNA and protein levels of target PI3K 
isoforms in A549 cells
• PI3K class I la  A549-knockdown cells failed to survive for more than 48 h 
after transfection
• Knockdown of two class I isoforms results in impaired cell survival, 
especially when one of the isoforms targeted is p i 10p
• PI3K class lip or pi 10p-knockdown cells presented delayed spontaneous 
wound healing responses
• PI3K pi 10P-knockdown cells possessed an abrogated Akt phosphorylation 
response to TNFa or IL-lp, but not IL-13
• PI3K pi 105-knockdown cells have a reduced Akt phosphorylation response 
to IL-ip, but not IL-13 or TNFa
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In this third and final chapter in the results section, the role of PI3K isoforms in 
TNFa-induced signalling in A549 lung alveolar epithelial cells is studied in more depth. The 
phosphorylation levels of other known downstream kinases of the PI3K family, as well as of 
signalling molecules belonging to the MAPK family were analysed and, the effect of PI3K 
isoform-specific silencing in cell functions downstream of TNFa stimulation was researched. 
Hence, an analysis into TNFa-induced COX-2 and PGE2 expression, IL-8 production, and 
ICAM-1 upregulation and its consequent effects on cell adhesion, can be found in the latter 
sections of this chapter. All of these processes are important cell functions in the pathological 
mechanisms in chronic respiratory disease (Lassalle et al., 1993; Yamamoto et al., 1998; 
Petrovic et al., 2006).
Due to certain results obtained during the investigation, the individual role played by 
PI3K isoforms in COX-2 transcription factor signalling was also determined. To understand 
further COX-2 promoter activation, the role played by the JNK member of the MAPK family 
in TNFa-induced COX-2 upregulation and transcription factor signalling was also studied. 
Furthermore, some of the results from TNFa-induced cell functions directed the research 
away from PI3K and towards mTOR activity. Correspondingly, the role of mTOR was 
researched through the use of siRNA and rapamycin.
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5.1 P I3K  in T N F a-in d u ced  sign allin g
Before determining the possible effects o f  PI3K silencing on TN Fa-induced cell 
functions, an analysis into the signalling mechanisms elicited by T N F a was carried out. 
Therefore, a broader scope into cell signalling was adopted by examining the phosphorylation 
levels o f other well known downstream kinases o f  the PI3K family, including GSK-3P and 
ribosomal protein S6, as well as some o f the members o f the MAPK family, including ERK 
and JNK, that are known to be dependent on PI3K activity under certain conditions (Moule 
and Denton, 1997; Chandrasekar et al., 2005; Robertson et al., 2005). In these T N Fa- 
signalling studies, the dual p i 10p/pl 105 selective inhibitor TGX-121 was now available, as 
well as IC87114, allowing the comparison o f their effects to siRNA-treated cells.
5.1.1 Signalling molecules donw stream  of PI3K
To begin the study into TN Fa-induced activation o f GSK-3p and S6, a comparison of 
the phosphorylation levels o f these molecules to those corresponding to Akt in timecourse and 
concentration-effect studies was carried out. In figure 5.1 A, it can be observed that S6 and 
GSK-3P phosphorylation levels increased in a similar fashion to Akt, with S6 levels receding 
quickly after peaking at 15 min, while GSK-3P phosphorylation persisted until 60 min, by 
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Figure 5.1 TNFa timecourses and concentration-effects on Akt, GSK-3P and S6 phosphorylation 
in A549 cells. Confluent A549 cell monolayers in 35 mm culture dishes were left in serum-free 
DMEM at 37°C at 5% CO2 overnight. Cells were then stimulated with vehicle (V) or TNFa at the 
stated concentrations and incubated for the indicated times. Whole cell samples were then generated for 
electrophoresis, resolved in SDS-PAGE, transferred and immunoblotted, using antibodies against 
phosphoSer473-Akt (pAkt) at 60 kDa, phosphoSer9-GSK-3P (pGSK-3P) at 46 kDa, phosphoSer235 236-S6 
(pS6) at 32 kDa and Akt l at 60 kDa. Immunoblots are representative of three independent experiments.
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As the phosphorylation levels for the different signalling molecules are all elevated at 
15 min, concentration-effect studies at this time point were carried out (Fig. 5.1 B ). Akt and 
S6 phosphorylation increased with 30 ng/ml o f  TN Fa, and peaked at 100 ng/ml. On the other 
hand, GSK-3(3 phosphorylation is increased with 3 ng/ml, and peaked with 10 ng/ml, with 
higher concentrations having no incremental effect on phosphorylation levels. The fact that all 
three molecules are phosphorylated at similar times suggests dependence on a common 
activating signal, like PI3K-derived phosphoinositides. However, the different T N Fa 
concentration required for phosphorylation suggests that each one o f the molecules might be 
important for different cellular pathways, and hence, require different concentration of 
initiation signal to induce phosphorylation.
To determine if  PI3K activity is essential for GSK-3P and S6 phosphorylation, as it is 
for Akt, the effect o f LY29002 pretreatment on TNFa-induced signalling was studied. As 
shown in figure 5.2, TNFa-induced S6 phosphorylation was inhibited in a concentration- 
dependent manner by LY294002, with phosphorylation remaining unchanged from basal with 
a 10 pM pretreatment, and even demonstrating lower levels o f phosphorylation than basal at 
30 pM. GSK-3P phosphorylation was only partially reduced with LY294002 pretreament, 
obtaining maximal inhibition at 3 pM with higher concentrations offering no further reduction 
in phosphorylation.
TNFa 1 OOng/ml 
LY294002(pM) 
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pA kt —► ----------
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Figure 5.2 Effect of LY294002 pretreatment on TNFa-induced Akt, GSK-30 and S6 
phosphorylation in A549 cells. Confluent A549 cell monolayers in 35 mm culture dishes were left in 
serum-free DMEM at 37°C at 5% C 02 overnight. Cells were incubated for 30 min with increasing 
concentrations of LY294002 or vehicle (V), prior to 15 min stimulation with TNFa or an appropriate 
vehicle control (C). Whole cell samples were then generated for electrophoresis, resolved in SDS- 
PAGE, transferred and immunoblotted, using antibodies against phosphoSer473-Akt (pAkt) at 60 kDa, 
phosphoSer9-GSK-3(3 (pGSK-3p) at 46 kDa, phosphoSer235/236-S6 (pS6) at 32 kDa and Aktl at 60 kDa. 
Immunoblots are representative of three independent experiments.
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Figure 5.3 Role of Class IA PI3K isoforms in TNFa-induced Akt, GSK-3p and S6 
phosphorylation in A549 cells. A. Seventy-two hours after cells were transfected with class IA pi 10a 
(a), pi 10p (P), pi 105 (8), or non-targeting (S) siRNA, cells were stimulated for 15 min with TNFa or 
vehicle (V). Immunoblots are representative of eight independent experiments. B and C. A549 cell 
monolayers in 35 mm culture dishes were left in serum-free DMEM at 37°C at 5% C 02 overnight. 
Cells were incubated for 30 min with increasing concentrations of TGX-121 (B), IC87114 (C) or 
vehicle (V), prior to 15 min stimulation with TNFa or an appropriate vehicle control (C). Immunoblots 
are representative of three independent experiments. For both siRNA (A) and inhibitor experiments (B 
and C), after stimulation whole cell samples were generated for electrophoresis, resolved in SDS- 
PAGE, transferred and immunoblotted, using antibodies against phosphoSer473-Akt (pAkt) at 60 kDa, 
phosphoSer9-GSK-3p (pGSK-3P) at 46 kDa, phosphoSer235/236-S6 (pS6) at 32 kDa and Aktl (Aktl) at 
60 kDa. Immunoblots are representative of three independent experiments.
In order to determine the role o f individual Class IA PI3K isoforms in these signalling 
processes, PI3K isoform-selective inhibitors and siRNA-induced knockdown cells were used. 
As previously seen in chapter 4, p i 10(3 knockdown completely inhibited TN Fa-induced Akt 
phosphorylation. However, GSK-3P and S6 phosphorylation remained unchanged in pl lOP 
knockdown cells (Fig 5.3 A). In samples treated with TGX-121, the p i 10p/pl 105 dual 
inhibitor, Akt phosphorylation elicited by T N Fa stimulation is inhibited in a concentration- 
dependent manner (Fig 5.3 B), reducing it below basal levels. IC87114, the p i 105 selective
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inhibitor, had a partial inhibitory effect on Akt phosphorylation and was unable to completely 
inhibit TNFa-induced phosphorylation (Fig 5.3, Q . Neither isoform-selective inhibitor had 
any effect on GSK-3(3 or S6 phosphorylation levels (Fig 5.3 B and Q . GSK-3P immunoblots 
will sometimes have two bands as seen in these figures, this is due to the crossreactivity of the 
antibody with the phosphorylated form of GSK-3a at 51 kDa.
The initial observation from siRNA experiments implicating pllOp as the specific 
PI3K isoform involved in TNFa-induced Akt phosphorylation has been verified by the use of 
isoform-specific inhibitors. As seen in Table 5.1, TGX-121 is reported to have the same level 
of specificity for both pi 10P and pi 105, therefore the inhibition of Akt phosphorylation seen 
with this compound could theoretically be due to its activity on either isoform. However, 
IC87114 is over 100 times more selective for p i 105 than pllOp and this compound only 
presented a limited inhibition of TNFa-induced Akt phosphorylation, discarding the 
possibility of p i 105 activity as the main isoform involved in this process. Hence, the 
inhibitory effect of TGX-121 on pllOp must be responsible for the inhibition of this 
signalling activity.
Class IP I3 K  Isoforms Class I I  
Isoforms
a P Y 5 C2a C23
PI-103 0.008 0.088 0.15 0.048 ~1 0.026
TGX-121 >5 0.05 >50 0.05 ND ND
IC87114 >200 16 61 0.13 >100 >100
LY294002 0.72 0.31 1.3 7.3 19 6.9
Table 5.1: IC5o values (pM) for isoform-selective PI3K inhibitors. Values are based on in vitro 
assays of inhibitor activity against purified protein activity (Domin et al., 1997; Arcaro et al., 1998; 
Knight et a l,  2006; Ito et a l,  2007).
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5.1 .2 P13K s i l en c ing  on M A P K  f a m i l y  s ign a l l in g
In order to study the role o f PI3K in the activation o f other kinases in the context of 
T N F a signalling, timecourse and concentration-effect studies on the phosphorylation levels of 
the MAPKs ERK and JNK were carried out. Phosphorylation levels o f ERK and JNK are 
represented by two bands on immunoblotting as seen in figure 5.4.
A TNFa 1 OOng/ml B
Time (min) | 0 5
pE R K  ^  pE R K  = *
30 60 V
TNFa (ng/ml) at 15 min 





Figure 5.4 T N F a timecourses and concentration-effect studies on ERK and JNK phosphorylation  
in A549 cells. Confluent A549 cell monolayers in 35 mm culture dishes were left in serum-free 
DMEM at 37°C at 5% C 02 overnight. Cells were then stimulated with vehicle (V) or TNFa at the 
stated concentrations and incubated for the indicated times. Whole cell samples were then generated for 
electrophoresis, resolved in SDS-PAGE, transferred and immunoblotted, using antibodies against 
phosphoThr202/Tyr204-ERK (pERK) at 44 and 42 kDa, phosphoThrl83/Tyrl85-JNK (pJNK) at 54 and 
46 kDa, and Aktl at 60 kDa. Immunoblots are representative of three independent experiments. The 
corresponding optical density values (minus background density and corrected for Aktl optical density 
values) are shown above each representative image, with untreated (white bars), and TNFa (black bars) 
samples as indicated at the top. Optical density values are expressed as mean fold increase compared to 
control+SEM from n=3 independent experiments. Statistical significance expressed as (*) for p<0.05.
In figure 5.4 A, it can be observed that ERK and JNK phosphorylation levels peaked 
between 10 and 15 min after stimulation. At the 15 min time point, concentration-effect 
studies demonstrated that JNK phosphorylation required slightly lower concentrations of 
T N Fa than those required for ERK phosphorylation, as JNK levels began increasing at 10 
ng/ml becoming significant around 30 ng/ml, while ERK levels increased at 30 ng/ml and
116
Chapter 5 -  Results III
became significant at 100 ng/ml (Fig.5.4 B ). Since both signalling molecules had elevated 
levels o f phosphorylation at 100 ng/ml, this concentration was used for experiments involving 
LY294002.
Although the activity o f ERK and JNK has been demonstrated to be downstream of 
PI3K in certain systems (Chandrasekar et al., 2005; Robertson et al., 2005), there are also 
numerous examples where these MAPKs are completely independent o f PI3K activity 
(Shepherd et al., 1997; Igishi et al., 1999; Guo and Rothstein, 2005). To determine PI3K 
dependence in this system, experiments using LY294002 were carried out. In figure 5.5 it can 
be clearly observed that LY294002 pretreatment did not inhibit the phosphorylation o f either 
JNK or ERK elicited by TNFa. Thus, it would seem that in A549 epithelial alveolar cells, 
TN Fa-induced JNK and ERK phosphorylation is PI3K independent.
Figure 5.5 Effect o f LY294002 pretreatment on T N Fa- 
induced ERK and JNK phosphorylation in A549 cells.
A549 cell monolayers were left in serum-free DMEM at 
37°C at 5% C 02 overnight. Cells were incubated for 30 min 
with increasing concentrations of LY294002 or vehicle (V), 
prior to 15 min stimulation with TNFa or an appropriate 
vehicle control (C). Whole cell samples were then generated 
for electrophoresis, resolved in SDS-PAGE, transferred and 
immunoblotted, using antibodies against 
phosphoThr202/Tyr204-ERK (pERK) at 44 and 42 kDa, 
phosphoThrl83/Tyrl85-JNK (pJNK) at 54 and 46 kDa, and 
Aktl at 60 kDa. Immunoblots represent three independent 
experiments.
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5.2 TNFa-induced COX-2 and PGE? upregulation
TNFa is not only important in the migration and recruitment of immune cells to the 
lung, which are activities normally associated with ICAM-1 and IL-8 upregulation, but airway 
epithelial cells also respond to TNFa by producing arachidonic acid metabolites through the 
induction of COX-2 (Petrovic et al., 2006). Although the upregulation of COX-2 as a 
consequence of TNFa stimulation in A549 cells is well-known (Mitchell et al., 1994; Billich 
et al., 2005; Tong et al., 2006), the potential role of PI3K within this process had not been 
explored.
In the initial studies determining the 24 h timecourse of COX-2 and PGE2 expression 
after TNFa stimulation (Fig 5.6 A andB), it was shown that an increase in COX-2 levels was 
significant from 2 h onwards, while PGE2 upregulation was not significant until 4 h after 
treatment with TNFa at 100 ng/ml. Thereafter, both COX-2 and PGE2 increased in a time- 
dependent manner until reaching a maximum level of stimulation at 12 h for COX-2 and at 
24 h for PGE2. TNFa concentration-effect, from 1 to 1000 ng/ml, studies (Fig 5.6 C andD ) at 
6 h showed a significant increase in COX-2 and PGE2 concentrations with 1 ng/ml of TNFa, 
with higher concentrations of TNFa increasing levels of COX-2 and PGE2. Levels of PGE2 
continued increasing up to 1000 ng/ml, while COX-2 levels peaked at 100 ng/ml. A 6 h- 
stimulation with TNFa at 100 ng/ml was used for subsequent experiments.
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Figure 5.6 T N F a timecourse and concentration-effect studies on COX-2 and PGE2 expression in 
A549 cells. Confluent A549 cell monolayers were left in serum-free DMEM at 37°C at 5% C 02 
overnight. Cells were then stimulated with vehicle (V) or TNFa at the stated concentrations and 
incubated for the indicated times. A and C. Supernatants were then taken from cell cultures dishes and 
analysed for PGE2 concentration by ELISA. Data expressed as mean+SEM for n=3 independent 
experiments. Statistical significance expressed as (*) for p<0.05 and (**) for p<0.01. B and D. Whole 
cell samples were generated from treated cell monolayers, resolved by electrophoresis, transferred and 
immunoblotted, using antibodies against COX-2 at 70 kDa, COX-1 at 72 kDa and Aktl at 60 kDa. 
Immunoblots are representative of three independent experiments.
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Figure 5.7 Effect of LY294002 or Rapamycin pretreatment on TNFa-induced COX-2 and PGE2 
expression in A549 cells. Confluent A549 cell monolayers were left in serum-free DMEM at 37°C at 
5% CO2 overnight. Afterwards, cells were incubated with vehicle (V) or increasing concentrations of 
LY294002 (A and B) or rapamycin (C and D). Cells were then stimulated with an appropriate vehicle 
control (C) or TNFa at 100 ng/ml and incubated for 6 h. A and C. Supernatants were then taken from 
cell cultures dishes and analysed for PGE2 concentration by ELISA. Data expressed as mean+SEM for 
n=3 independent experiments. The dagger (t) indicates the group to which all others were compared 
for statistical significance. Statistical significance expressed as (*) for p<0.05 and (**) for p<0.01. B 
and D. Whole cell samples were generated from treated cell monolayers, resolved by electrophoresis, 
transferred and immunoblotted, using antibodies against COX-2 at 70 kDa, COX-1 at 72 kDa and Aktl 
at 69 kDa. Immunoblots are representative of three independent experiments.
To determine the role o f PI3K within TN Fa-induced COX-2 and PGE2 upregulation, 
pretreatment of A549 cells for 30 min with increasing concentrations o f LY294002, from 1 to 
30 pM, was carried out prior to T N Fa stimulation (Fig. 5.7 A and B). PGE2 levels from 
supernatants collected from these experiments showed a significant decrease at 10 and 30 pM 
LY294002, with a concentration-dependent downregulation o f COX-2 production becoming 
apparent with LY294002-pretreatment at 3 pM through to 30 pM. Protein levels o f  the 
constitutively expressed COX-1 remained unaffected.
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In order to eliminate the possibility o f  any involvement o f  mTOR in the results 
obtained with LY294002, rapamycin pretreatment o f A549 cells was also carried out (Fig. 5.7 
C and D ). In these studies, incubation with rapamycin had no significant effect on PGE2 or 
COX-2 levels. These results clearly indicated an important function for PI3K, but not mTOR, 
in TN Fa-induced COX-2 upregulation.
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Figure 5.8 Effect o f PI3K Class I and II isoform s-specific knockdown on TN Fa-induced COX-2 
and PGE2 expression in A549 cells. A. Seventy-two hours after cells were transfected with class IA 
pi 10a (a), pi 1 Op (P), pi 105 (5), class Up (C2P) or non-targeting (S) siRNA, cells were stimulated for 
6 h min with 100 ng/ml TNFa(+) or vehicle (-). Whole cell samples were generated for 
immunoblotting and antibodies against COX-2 at 70 kDa, COX-1 at 72 kDa and Aktl at 60 kDa were 
used. Immunoblots representative of five independent experiments. B. Supernatants were taken from 
cell cultures dishes after stimulation, as described in A, and analysed for PGE2 concentration by 
ELISA. Data expressed as mean+SEM for n=5 independent experiments. Statistical significance 
expressed as (**) for p<0.01.
To further elucidate the roles o f each o f the PI3K class IA and II isoforms within 
TNFa-induced COX-2 and PGE2 upregulation, isoform-specific siRNA and inhibitors were 
used. With regards to siRNA treatment (Fig. 5.8), it was demonstrated that class I p i 10a, 
p llO p  and class lip-specific knockdown cells showed no significant decrease in PGE2 and 
COX-2 levels after 6 h-stimulation with T N F a when compared to cells transfected with 
non-targeting siRNA (scrambled). Only the p i 105-specific knockdown cells showed a 
significant decrease in stimulated COX-2 and PGE2 levels when compared to the control 
siRNA group (scrambled). Although unstimulated or basal levels o f COX-2 also seem to be 
lower in p ll05-siR N A  treated cells (Fig. 5.8 A), basal PGE2 levels are not significantly 
decreased when compared with those from non-targeting siRNA treated cells (Fig. 5.8 B ). 
Surprisingly, p 1105-knockdown cells also possessed a lower level o f COX-1, independently 
o f  T N Fa stimulation, with Aktl expression remaining unaltered (last two lanes o f the 
immunoblots in figure 5.8 A).
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With regards to the PI3K-isoform specific inhibitors (Fig. 5.9), the PI-103 compound, 
a compound with a slight preference for the p i 10a had very little effect in these experiments. 
Only the highest concentration of PI-103, that is not specific for pi 10a (as shown in Table 
5.1), was able to exert a partial inhibitory effect on PGE2 production (Fig. 5.9 A andB). TGX- 
121, the p i 10p/pl 105 inhibitor, also had a consistent, although not statistically significant, 
effect on both TNFa-induced COX-2 and PGE2 production (Fig. 5.9 C andD). This was not 
unexpected, as this compound is equipotent for both the p i 10(3 and p i 108 isofoms. As 
predicted from the siRNA data, the pi 105-selective inhibitor IC87114 had a clear inhibitory 
effect on both PGE2 and COX-2 production (Fig. 5.9 E and F ). COX-1 and Aktl levels 
remained unchanged throughout all the experiments. Taken together, the isoform-specific 
siRNA and inhibitor results suggested that the p i 105 isoform is the primary PI3K isoform 
involved in TNFa-induced COX-2 and PGE2 upregulation.
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Figure 5.9 Effect of PI103, TGX-121 or IC87114 pretreatment on TNFa-induced COX-2 and 
PGE2 expression in A549 cells. Confluent A549 cell monolayers were left in serum-free DMEM at 
37°C at 5% C 0 2 overnight. Afterwards, cells were incubated with vehicle (V) or increasing 
concentrations o f PI 103 (A and B), TGX-121 (C  and D ) or IC87114 (E and F). Cells were then 
stimulated with an appropriate vehicle control (C) or T N F a at 100 ng/ml and incubated for 6 h. A, C 
and E. Supernatants were then taken from cell cultures dishes and analysed for PGE2 concentration by 
ELISA. Data expressed as mean+SEM for n=3 independent experiments. The dagger (f )  indicates the 
group to which all others were compared for statistical significance. Statistical significance expressed 
as (**) for p<0.01. B, D and F. Whole cell samples were generated from treated cell monolayers, 
resolved by electrophoresis, transferred and immunoblotted, using antibodies against COX-2 at 70 kDa, 
COX-1 at 72 kDa and A ktl at 60 kDa. Immunoblots are representative o f  three independent 
experiments.
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5.3 PI3K in TNFa-induced COX-2 transcription
To determine the mechanism through which pi 108 regulates COX-2 expression, the 
phosphorylation levels of transcription molecules involved in COX-2 expression were 
studied. Various transcription sites have been shown to be important for COX-2 promoter 
activation by inflammatory mediators. These include a CRE, a C/EBP element and 2 NF-kB 
sites (Inoue et al., 1995; Schroer et a l, 2002).
Previous studies have shown binding of cJun, CREB, C/EBPp, and NE-kB p65 to 
their respective sites in this region (Deng et al., 2003; Vaillancourt et al., 2007). In 
accordance with a role for the PI3K pathway in transcription factor activation by TNFa, it has 
been found that the phosphatase PTEN, which inactivates PI3K lipid products by 
dephosphorylating them, inhibits the transcription of NF-KB-regulated genes elicited by 
TNFa (Gustin et al., 2001; Mayo et al., 2002) However, the role played by individual PI3K 
isoforms in TNFa-induced activation of inflammatory molecule transcription factors in 
alveolar epithelial lung cells had not been explored. Therefore, to elucidate the mechanism 
through which pi 108 carries out COX-2 regulation, phosphorylation levels of transcription 
factors involved in COX-2 induction were examined, including the NF-kB kinases RelA/p65 
and IKKa/p, ATF2, c-Jun, CREB, and C/EBPp. For this purpose, timecourse studies using 
TNFa to increase phosphorylation levels of these transcription molecules were done. To 
begin, the NF-kB family was examined, by specifically studying IKKa/p and p65 
phosphorylation within this system (Fig. 5.10 A). After stimulation with TNFa 100 ng/ml, the 
phosphorylation levels of both of these proteins rose sharply, peaking at 5 min, with levels 
disappearing almost completely after 10 min for IKKa/p. Although decreasing 
phosphorylation levels for p65 were apparent after 5 min, phosphorylation remained slightly 
elevated 1 h after stimulation, compared to basal levels. The 5 min time point was chosen as 
optimum for subsequent experiments.
In order to determine the role PI3K within TNFa-induced NF-kB signalling, a 30 min 
LY294002-pretreatment, from 1 to 30 pM, was carried out, prior to the stimulation of cells 
samples with TNFa at 100 ng/ml for 5 min (Fig. 5.10 B). The phosphorylation levels of these 
molecules seemed to be completely unaffected by PI3K inhibition even at the highest 
concentration (30 pM) of LY294402, demonstrating that PI3K seems to play no important 
part within this process.
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Figure 5.10 Effect of LY294002 pretreatment and TNFa timecourse studies on transcription 
element phosphorylation in A549 cells. A. Confluent A549 cell monolayers were left in serum-free 
DMEM at 37°C at 5% C 02 overnight. Afterwards, cells were stimulated with TNFa at 100 ng/ml and 
incubated for the time indicated on the upper part of the blot. Whole cell samples were generated from 
treated cell monolayers, resolved by electrophoresis, transferred and immunoblotted, using antibodies 
against phosphoSer176 l80-IKKa/Ser177/l8l-IKKp (pIKKa/p) at 87 and 85 kDa, phosphoSer 36-p65 
(pP65) at 75 kDa, phosphoSer73-cJun (pcJun) at 48 kDa, phosphoThr235-C/EBPp (pC/EBPP) at 38 kDa, 
phophoSerl33-CREB (pCREB) at 43 kDa, phosphoThr71-ATF2 (pATF2) at 70 kDa and Aktl at 60 kDa. 
Immunoblots representative of three independent experiments. B and C. Overnight serum-starved A549 
cells were incubated for 30 min with increasing concentrations of LY294402 or vehicle (V). Cells were 
then stimulated with an appropriate vehicle control (C) or with TNFa 100 ng/ml for either 5 min (B) or 
15 min (C). Whole cell samples were generated and immunoblotted in the same manner as in A. 
Immunoblots shown are representative of three independent experiments.
C/EBP transcription elements have also been highlighted as important in regulating 
the activity o f the COX-2 promoter (Inoue et al., 1995). There are two forms o f  C/EBPP, the 
38 kDa liver activating protein (LAP) and the 20 kDa liver inhibitory protein (LIP) which 
may be a product o f alternative translation. The 38 kDa LAP protein is a transcriptional 
activator while LIP may act as an inhibitor o f C/EBPP transcriptional activity (Calkhoven et
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a l, 2000). Using TNFa-stimulation in A549 cells, only the 38 kDa LAP isoform of C/EBPp 
displayed any increase in its phosphorylation levels, with no apparent protein bands appearing 
at 20 kDa. In the timecourse studies, LAP-C/EBPp phosphorylation levels increased slowly, 
appearing at 10 min post-stimulation and returning to basal after 30 min (Fig. 5.10 4^). When a 
30 min LY294002 pretreatment was tested with a 15 min stimulation period with TNFa, the 
phosphorylation levels of LAP-C/EBPp remained unaltered (Fig. 5.10 C).
The CRE site can bind a variety of different transcription elements. Amongst these 
are members of the activator protein-1 family of transcription factors, including cJun, and 
ATF2, as well as CREB, all of which have been previously shown to regulate COX-2 
expression (Sorli et al., 1998; Guo et a l, 2001). The phosphoSer133-CREB antibody also 
detects the phosphorylated form of the CREB-related protein ATF1 at 29 kDa. During the 
timecourse experiments, CREB and cJun phosphorylation patterns were almost identical, with 
levels increasing after 10 min of stimulation, peaking at 15 min, and returning to basal levels 
at 60 min. The ATF2 timecourse was very similar, except that increases in phosphorylation 
started at 5 min (Fig. 5.10 A). The 15 min time point was decided upon for all subsequent 
experiments. Phosphorylation levels for CREB and ATF2 remained completely unaffected 
with LY294002-pretreatment (Fig. 5.10 C). Out of all the transcription molecules studied, 
only cJun phosphorylation decreased in a concentration-dependent manner when incubated 
with LY294002 (Fig. 5.10 Q . A decrease in phosphorylation level can be observed from the 
3 pM concentration, with higher concentrations further decreasing it. However, even at the 
highest LY294002 concentration, residual levels of phosphorylation above basal can be 
observed, implying that although PI3K activity is important in cJun phosphorylation, it is not 
the only molecule involved in the upkeep of this signal.
To determine the role of specific PI3K isoforms in cJun phosphorylation, experiments 
involving Class I and II isoform-specific siRNA-treated cells were carried out (Fig. 5.11 A). 
Class I pi 10a and pi 1 Op and class 11(3 knockdown cells had cJun phosphorylation levels 
comparable to those found in non-targeting siRNA-treated cells. However, pi 108-knockdown 
cells showed a significant inhibition of cJun phosphorylation, with levels in p i 105- 
knockdown cells similar to those found at basal level.
To further support the data obtained with siRNA technology, isoform-selective 
inhibitors were used. A549 cells treated with a range of concentrations of either PI 103 (Fig. 
5.11 B) or TGX-121 (Fig. 5.11 C) responded no differently to TNFa-induced cJun 
phosphorylation than samples that had been treated with appropriate vehicle controls. As
126
Chapter 5 -  Results III
expected, cells incubated with the p i 108-selective inhibitor IC87114 at 30 pM inhibited cJun 
phosphorylation levels (Fig. 5.11 D). Simlilarly to the results obtained with the broad 
spectrum inhibitor LY294002, cJun phosphorylation levels remained above basal even after 
treating the cells with the highest concentration o f IC87114, supporting the idea o f an 
alternate activation pathway for cJun. Collectively, this data indicates a prominent role for 
PI3K, and more specifically for PI3K class I p i 105, in the regulation o f cJun phosphorylation 
downstream o f TNFa.
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Figure 5.11 Role of Class IA and II PI3K isoforms in TNFa-induced cJun phosphorylation in 
A549 cells. A. Seventy-two hours after cells were transfected with class IA pi 10a (a), pllOP (P), 
pi 105 (8), class lip (C2P) or non-targeting (S) siRNA, cells were stimulated for 15 min with TNFa or 
vehicle (V). B, C andD. A549 cell monolayers in 35 mm culture dishes were left in serum-free DMEM 
at 37C at 5% C 02 overnight. Cells were incubated for 30 min with increasing concentrations of PI 103 
(B), TGX-121 (C), IC87114 (D) or vehicle (V), prior to 15 min stimulation with TNFa at 1 OOng/ml or 
an appropriate vehicle control (C). For both siRNA (A) and inhibitor experiments (B, C and D), after 
stimulation whole cell samples were generated, resolved by electrophoresis, transferred and 
immunoblotted, using antibodies against phosphoSer73-cJun (pcJun) and Aktl. Immunoblots are 
representative of three experiments. The corresponding optical density values (minus background 
density and corrected for Aktl optical density values) are shown above each representative image, with 
untreated (white bars) and TNFa (black bars) samples as indicated at the top. Optical density values are 
expressed as mean fold increase compared to control+SEM from n=3 independent experiments. 
Statistical significance expressed as (*) for p<0.05. The dagger (t) indicates the group to which all 
others were compared for statistical significance.
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5.4 JN K  in T N F a -in d u ced  C O X -2 upregulation  and transcription
The association between cJun and COX-2 upregulation has been previously described 
in a diversity o f systems (Bennett et al., 2001; Billack et al., 2002; Grau et al., 2006). In the 
majority o f these studies, cJun phosphorylation is effected by the JNK member o f the MAPK 
family. To determine if inhibition o f cJun phosphorylation could be directly linked to COX-2 
upregulation, a specific peptide JNK inhibitor (JNKi, reported IC5o ~  1 pM) that specifically 
inhibits the activity o f JNK on cJun phosphorylation was used.
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Figure 5.12 Effect of JNKi pretreatment on TNFa-induced COX-2 and PGE2 expression in A549 
cells. Confluent A549 cell monolayers were left in serum-free DMEM at 37°C at 5% C 02 overnight. 
Afterwards, cells were incubated with vehicle (V) or increasing concentrations of JNKi. Cells were 
then stimulated with an appropriate vehicle control (C) or TNFa at 100 ng/ml and incubated for 6 h. 
A. Supernatants were then taken from cell cultures dishes and analysed for PGE2 concentration by 
ELISA. Data expressed as mean+SEM for n=3 independent experiments. The dagger (t) indicates the 
group to which all others were compared for statistical significance. Statistical significance expressed 
as (*) for p<0.05. B. Whole cell samples were generated from treated cell monolayers, resolved by 
electrophoresis, transferred and immunoblotted, using antibodies against COX-2 at 70 kDa, COX-1 at 
72 kDa and Aktl at 60 kDa. Immunoblots are representative of three independent experiments. The 
corresponding optical density values (minus background density and corrected for Aktl optical density 
values) are shown above each representative image, with untreated (white bars) and TNFa (black bars) 
samples as indicated at the top. Optical density values are expressed as mean fold increase compared to 
control+SEM from n=3 independent experiments. Statistical significance expressed as (*) for p<0.05. 
The dagger (f) indicates the group to which all others were compared for statistical significance.
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In order to carry out these experiments, A549 cells were pretreated with increasing 
concentrations o f JNKi before being stimulated with T N Fa for a 6 h period. Incubation of 
cells with JNKi at 10 and 30 pM inhibited TNFa-induced COX-2 upregulation, without 
affecting levels o f COX-1 or Aktl (Fig 5.12 B). With regards to PGE2 levels, JNKi 
concentrations o f 10 and 30 pM were capable o f significantly reducing PGE2 levels in cell 
supernatants (Fig 5.12 A). However, the use o f this inhibitor even at its highest concentration 
could not inhibit PGE2 levels to basal levels, this effect is also seen at protein level, where 
increased levels o f COX-2 are clearly present in cells treated with high concentrations of 
JNKi. This significant, but incomplete, inhibition o f  this inflammatory mediator upregulation 
suggests that JNK is an important molecule in TN Fa-induced COX-2 and PGE? upregulation, 
but that its activity is complementary to that o f another signalling pathway.
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Figure 5.13 Effect of JNKi pretreatment and TNFa timecourse studies on transcription element 
phosphorylation in A549 cells. Confluent A549 cell monolayers were left in serum-free DMEM at 
37°C at 5% C 02 overnight. Cells were then incubated for 30 min with increasing concentrations of 
JNKi or vehicle (V). Afterwards, cells were stimulated with an appropriate vehicle control (V) or 
TNFa 100 ng/ml and incubated for 5 min (A) or 15 min (B). Whole cell samples were generated from 
treated cell monolayers, resolved by electrophoresis, transferred and immunoblotted, using antibodies 
against phosphoSerl76/l80-IKKa/Serl77/18,-IKKp (pIKKa/p) at 87 and 85 kDa, phosphoSer536-p65 
(pP65) at 75 kDa, phosphoSer73-cJun (pcJun) at 48 kDa, phosphoThr235-C/EBPp (pC/EBPP) at 38 kDa, 
phophoSer133-CREB (pCREB) at 43 kDa, phosphoThr71-ATF2 (pATF2) at 70 kDa and Aktl at 60 kDa. 
Immunoblots are representative of three independent experiments.
For the validation o f the ability o f JNKi to inhibit selectively cJun phosphorylation, 
studies into transcription molecule phosphorylation using this inhibitor were done. As shown 
in figure 5.13 A, a 5 min stimulation with T N Fa was capable o f inducing phosphorylation of 
NF-kB molecules, regardless of pretreatment with JNKi. Likewise, in figure 5.13 B, a 15 min 
stimulation with T N Fa induced phosphorylation o f ATF2, LAP-C/EBPP and CREB without 
any apparent inhibition in JNKi-treated cells. As expected, cJun phosphorylation was highly
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sensitive to JNKi incubation, with 10 and 30 pM causing a strong inhibition of TNFa- 
induced phosphorylation (Fig. 5.13 B). This not only corroborates the selectivity of JNKi for 
its target molecule, but it also highlights the fact that JNK activity in this system is very 
important for cJun phosphorylation. Furthermore, JNKi is able to inhibit TNFa-induced cJun 
phosphorylation almost completely, but is unable to fully inhibit COX-2 or PGE2 levels in 
TNFa-stimulated cells. This would suggest that neither cJun nor JNK regulate expression of 
these inflammatory mediators in an absolute manner. Hence, other transcription molecules 
could play prominent roles in the regulation of TNFa-induced COX-2 and PGE2 
upregulation.
In order to determine if PI3K class IA pi 105 and JNK were affecting cJun 
phosphorylation through the same mechanism, combination experiments using submaximal 
concentrations of IC87114 and JNKi were carried out. At 10 pM concentration both inhibitors 
were able to diminish cJun phosphorylation, COX-2 and PGE2 upregulation, without 
completely inhibiting these responses, therefore 10 pM was used for these experiments. As 
seen in figure 5.14 A and B, each compound used alone significantly inhibits TNFa-induced 
COX-2 and PGE2 production to similar levels, without abolishing the response. When used in 
combination, no added inhibitory effect was observed. Similar results were seen when 
analysing the level of cJun phosphorylation after pretreatment with either or both compounds 
(Fig. 5.14 C). Collectively, this data suggests that JNK and pi 105 are exerting their influence 
through a similar pathway in cJun phosphorylation, and in COX-2 and PGE2 upregulation.
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Figure 5.14 Pretreatment with IC87114 with/or JNKi on TNFa induced COX-2 and PGE2 
upregulation, and cJun phoosphorylation in A549 cells. A. Confluent A549 cell monolayers were 
left in serum-free DMEM at 37°C at 5% C 02 overnight. Cells were then incubated for 30 min with a 
vehicle control (-) or 10 fiM IC87114 (+) as well as with a vehicle control (-) or 10 pM JNKi (+). 
Supernatants were then taken from cell cultures dishes and analysed for PGE2 concentration by ELISA. 
Data expressed as mean+SEM for n=3 independent experiments. Statistical significance expressed as 
(***) for p<0.001. B. Cells were treated as described in A, with inhibitor and stimulation use indicated 
at the top of the immunoblot. Whole cell samples were generated from treated cell monolayers, 
resolved by electrophoresis, transferred and immunoblotted, using antibodies against COX-2 at 70 kDa, 
COX-1 at 72 kDa and Aktl at 60 kDa. Immunoblots are representative of three independent 
experiments. C. Overnight serum-starved cells were incubated with IC87114 with/or JNKi as described 
in A. Afterwards, cells were stimulated with vehicle control (-) or TNFa 100 ng/ml (+) for 15 min. 
Whole cell samples were then generated from treated cell monolayers, resolved by electrophoresis, 
transferred and immunoblotted, using antibodies against phosphoSer73-cJun (pcJun) at 48 kDa, and 
Aktl at 60 kDa. Immunoblots are representative of three independent experiments.
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5.5 TNFa-induced ICAM-1 expression and cell adhesion
In the context of respiratory disease, one of the main functions of TNFa is to interact 
with parenchymal cells in order to generate a highly inflammatory environment through the 
upregulation of adhesion molecules, like ICAM-1 (Lassalle et al., 1993; Yamamoto et al., 
1998). Previous work has reported an important role for PI3K activity in TNFa-induced 
ICAM-1 upregulation and leukocyte cell adhesion in A549 cells (Huang and Chen, 2005). 
Therefore, this work was aimed at elucidating the specific roles played by individual PI3K 
isoforms in this process.
5.5.1 PI3K in TNFa-induced ICAM-1 expression and cell adhesion
This study begun by establishing an ICAM-1 timecourse in response to TNFa at 
100 ng/ml during a 24 h period (Fig. 5.15 4^). A 2 h-stimulation proved to be sufficient for a 
significant increase in ICAM-1 expression from basal levels, with longer time points 
possessing increasing ICAM-1 levels. In similar conditions, calcein AM-labelled THP1 
adhesion assays were carried out (Fig 5.15 B), which shows a different response curve to the 
one observed for ICAM-1 expression, with just a 1 h-stimulation sufficing in significantly 
increasing leukocyte adhesion. Again, adhesion increased in a time-dependent manner, with 
the highest levels of adhesion found 24 h post-stimulation.
Additionally, TNFa concentration-effect studies from 0.1 to 1000 ng/ml at 6 h for 
ICAM-1 upregulation and THP1 cell adhesion were carried out. In both experiments 
(Fig. 5.15 C and D), TNFa concentration had a concentration-dependent relation, with the 
lowest concentration of 0.1 ng/ml being sufficient to significantly increase ICAM-1 
expression, while the slightly higher concentration of 1 ng/ml was required for a significant 
increase in cell adhesion. Therefore a 6 h-stimulation with 1 ng/ml was to be the lowest 
concentration used in all subsequent experiments, with 100 ng/ml being the highest.
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Figure 5.15 TNFa timecourse and concentration-effect studies on ICAM-1 upregulation and 
THP1 cell adhesion in A549 cells. A and C. Confluent A549 cell monolayers were left in serum-free 
DMEM at 37°C at 5% C 02 overnight. Cells were then stimulated with vehicle (V) or TNFa at the 
stated concentrations and incubated for the indicated times. Cell were then removed enzymatically 
from culture dishes and labelled with 10 pg/ml PE-labelled monoclonal mouse anti-human ICAM-1 
antibody or PE monoclonal mouse isotype control. After washing the cells, flow cytometry was 
performed and analyzed with Cell Quest Pro software. B and D. 1 x 105 calcein AM-labelled THP1 
cells/well were added to 96-well plates containing A549 cells treated with vehicle (V) or TNFa at the 
stated concentrations and incubated for the indicated times. After 120 min of co-incubation at 37°C, the 
plates were carefully washed to remove non-adherent THPls. Fluorescence was then measured at 485 
nm excitation and 530 nm emission. For A, B, C and D, data expressed as mean+SEM for n=3 
independent experiments. Statistical significance expressed as (*) for p<0.05 and (**) for p<0.01.
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To verify the previously published importance of PI3K in this process, cells were 
pretreated with increasing concentrations of LY294002 froom 1 to 30 pM for 30 min prior to 
a 6 h stimulation with a range of concentrations, from 1 to 100 ng/ml, of TNFa (Fig. 5.16) 
and adhesion molecule expression and leukocyte adhesion measurements. Although 
stimulation with TNFa at 100 ng/ml significantly increased ICAM-1 expression over basal 
level (p<0.001), the values for LY294002-treated samples were unable to significantly inhibit 
ICAM-1 expression, even at the highest concentration of this inhibitor (Fig 5.16 A). Lower 
concentrations of TNFa at 1 and 10 ng/ml were attempted at the same time point using the 
same concentrations of LY294002, from 1 to 30 pM, with similar results (Fig 5.16 C andE). 
Furthermore, cell adhesions assays using calcein AM labeled-THPl human monocytes 
yielded similar results to those found in ICAM-1 expression experiments, with no inhibition 
being observed with LY294002 pretreatment (Fig 5.16 B, D and E). Parallel studies on cell 
signalling were done to validate inhibitor potency.
Since a previous report established a role for PI3K in ICAM-1 expression (Huang and 
Chen, 2005) and that a trend towards inhibition was found at the highest concentrations of 
LY294002, experiments using PI3K isoform-specific siRNA-treated A549 cells both for 
ICAM-1 expression and cell adhesion using a range of TNFa concentrations, from 1 to 100 
ng/ml, were carried out. As seen in figure 5.17 A, the changes observed in class I and II PI3K 
knockdown cells in TNFa-induced ICAM-1 expression were not significantly different to 
those which were observed in cells treated with non-targeting (scrambled) siRNA. The results 
for the leukocyte adhesion assay (Fig. 5.17 B) in these PI3K knockdown cells emulate the 
values obtained in the ICAM-1 expression experiments, with no significant results to report.
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Figure 5.16 Effect of LY294002 pretreatment on TNFa-induced ICAM-1 upregulation and THP1 
cell adhesion in A549 cells. A, C and E. Confluent A549 cell monolayers were left in serum-free 
DMEM at 37°C at 5% C 02 overnight. Cells were incubated for 30 min with vehicle (V) or with 
increasing concentrations of LY294002 (1-30 pM) and then stimulated with an appropriate volume 
control (C) or TNFa at the stated concentrations at the top of each graph and incubated for 6 h. Cells 
were then removed enzymatically from culture dishes and labelled with PE-labelled monoclonal mouse 
anti-human ICAM-1 antibody or PE-labelled monoclonal mouse isotype control. After washing the 
cells, flow cytometry was performed and analyzed with Cell Quest Pro software. B, D and F. 1 x 105 
calcein AM-labelled THP1 cells/well were added to 96-well plates containing A549 cells that had been 
incubated for 30 min with vehicle (V) or LY294002 (1-30 pM) and then treated for 6h with a vehicle 
control (C) or TNFa (1-100 ng/ml). After 120 min of co-incubation at 37°C, the plates were carefully 
washed to remove non-adherent THPls. Fluorescence was then measured at 485 nm excitation and 
530 nm emission. For A, B, C, D, E and F  data expressed as mean+SEM for n=3 independent 
experiments. The dagger (t) indicates the group to which all others were compared for statistical 
significance.
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Figure 5.17 Role of PI3K isoforms in TNFa-induced ICAM-1 upregulation and THP1 cell 
adhesion in A549 cells. A. Seventy-two hours after cells were transfected with class IA pi 10a, pi 10(3, 
pi 108, class lip or non-targeting (scrambled) siRNA, cells were stimulated with vehicle (Vehicle) or 
TNFa (1-100 ng/ml) for 6 h. Cells were then removed enzymatically from culture dishes and labelled 
with PE-labelled monoclonal mouse anti-human ICAM-1 antibody or PE monoclonal mouse isotype 
control. After washing the cells, flow cytometry was performed and analyzed with Cell Quest Pro 
software. Data expressed as mean+SEM for n=4 independent experiments. B. 1 x 105 calcein AM- 
labelled THP1 cells/well were added to 96-well plates containing A549 cells that had been transfected 
seventy-two hours before hand with class IA pi 10a, pi 1 Op, pi 108, class lip or non-targeting 
(scrambled) siRNA and then treated for 6 h with a vehicle control (Vehicle) or TNFa (1-100 ng/ml). 
After 120 min of co-incubation at 37°C, the plates were carefully washed to remove non-adherent 
THPls. Fluorescence was then measured at 485 nm excitation and 530 nm emission. Data expressed as 
mean+SEM for n=3 independent experiments.
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5.5.2 mTOR in TNFa-induced ICAM-1 expression and cell adhesion
LY294002 was designed as a PI3K inhibitor that competitively binds to the ATP site 
in the catalytic isoforms of this family of kinases. Unsurprisingly, considering the structural 
homology between the catalytic domains of PI3K and mTOR, LY294002 has been shown to 
inhibit mTOR with similar potency as it does PI3K, with the an IC50 for mTOR activity of 
around 5 pM (Brunn et al., 1996). Since LY294002 had a limited inhibition of TNFa-induced 
ICAM-1 expression while PI3K isoform-specific knockdown cells had none, complementary 
work was done to determine the role mTOR played within this TNFa-induced cell function.
To elucidate the role of mTOR in ICAM-1 production, pretreatment with a range of 
concentrations, from 0.3 to 10 pM, of the specific mTOR inhibitor rapamycin was used in 
TNFa-stimulated A549 cells. As shown in figure 5.18 A, C and E, rapamycin at 10 pM 
significantly inhibited ICAM-1 expresion induced by the range of the concentrations used of 
TNFa, from 1 to 100 ng/ml. Furthermore, rapamycin pretreatment inhibited in a 
concentration-dependent manner THPl-cell adhesion in a significant manner when cells were 
stimulated with 100 ng/ml of TNFa (Fig. 5.18 B). The highest concentration of rapamycin of 
10 pM was also capable of inhibiting cell adhesion induced by lower concentrations of 
TNFa, as seen in figure 5.18 D andE.
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Figure 5.18 Effect o f Rapamycin pretreatm ent on TNFa-induced ICAM-1 upregulation and 
THP1 cell adhesion in A549 cells. A, C and E. Confluent A549 cell monolayers were left in serum- 
free DMEM at 37°C at 5% C 02 overnight. Cells were incubated for 30 min with vehicle (V) or with 
increasing concentration of rapamycin (0.3-10 pM) and then stimulated with an appropriate volume 
control (C) or TNFa at the stated concentrations and incubated for 6 h. Cells were then removed
enzymatically from culture dishes and labelled with PE-labelled monoclonal mouse anti-human
ICAM-1 antibody or PE monoclonal mouse isotype control. After washing the cells, flow cytometry 
was performed and analyzed with Cell Quest Pro software. B, D and F. 1 x 105 calcein AM-labelled 
THP1 cells/well were added to 96-well plates containing A549 cells that had been incubated for 30 min 
with vehicle (V) or rapamycin (0.3-10 pM) and then treated for 6 h with a vehicle control (C) or TNFa 
(1-100 ng/ml). After 120 min of co-incubation at 37°C, the plates were carefully washed to remove 
non-adherent THPls. Fluorescence was then measured at 485 nm excitation and 530 nm emission. For 
A, B, C, D, E and F  data expressed as mean+SEM for n=3 independent experiments. The dagger (t) 
indicates the group to which all others were compared for statistical significance. Statistical
significance expressed as (**) for p<0.01.
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To corroborate the results obtained with rapamycin, siRNA targeting specifically 
mTOR was used to silence the production o f this molecule in A549 cells. Transfection was 
carried out in the same way as used for siRNA targeting PI3K sisoforms. As shown in figure 
5.19, mTOR knockdown begins 24 h after transfection, although it does not reach near 
complete silencing o f mTOR until 72 h post-transfection, thus this time point was chosen for 
all further experimentation.
24h 48h 72h 96h
mTOR —►
Aktl —►
siRNA | C S M C S M  C S M  C S M
Figure 5.19 mTOR protein levels in A549 cells transfected with mTOR-specific siRNA. Four 
culture dishes of cells were transfected with vehicle (C), mTOR (M) or non-targeting (S) siRNA. 
Whole cell lysates were generated every 24 h for a 96 h period for each treatment group. Samples were 
then probed for protein levels of mTOR at 220 kDa and Aktl at 60 kDa, as a loading control. Images 
are representative of three independent experiments.
The ability o f mTOR-knockdown cells to upregulate ICAM-1 surface expression after 
T N F a stimulation was severely compromised. As seen in figure 5.20 A, mTOR knockdown 
cells had significantly lower levels o f ICAM-1 expression by around 40% when compared to 
non-targeting siRNA-treated cells regardless o f  the concentration o f T N F a used. 
Correspondingly, cell adhesion assays demonstrated a clear and significant inhibition in 
mTOR knockdown cells after T N Fa stimulation with 10 or 100 ng/ml (Fig. 5.20 B ).
These results indicate that a previously reported role o f  PI3K determined by using 
LY294002 pretreatment in TNFa-induced ICAM-1 upregulation in A549 cells (Huang and 
Chen, 2005), is probably due to the inhibitory effect that LY294002 has on other signalling 
pathways, most likely mTOR.
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Figure 5.20 Role of mTOR in TNFa-induced ICAM-1 upregulation and THP1 cell adhesion in 
A549 cells. A. Seventy-two hours after cells were transfected with mTOR or non-targeting (scrambled) 
siRNA, cells were stimulated with vehicle (Vehicle) or TNFa (1-100 ng/ml) for 6 h. Cells were then 
removed enzymatically from culture dishes and labelled with PE-labelled monoclonal mouse anti­
human ICAM-1 antibody or PE-labelled monoclonal mouse isotype control. After washing the cells, 
flow cytometry was performed and analyzed with Cell Quest Pro software. B. 1 x 105 calcein AM- 
labelled THP1 cells/well were added to 96-well plates containing A549 cells that had been transfected 
seventy-two hours beforehand with mTOR or non-targeting (scrambled) siRNA and then treated for 6 h 
with a vehicle control (Vehicle) or TNFa (1-100 ng/ml). After 120 min of co-incubation at 37°C, the 
plates were carefully washed to remove non-adherent THPls. Fluorescence was then measured at 
485 nm excitation and 530 nm emission. For A and B data expressed as mean+SEM for n=3 
independent experiments. Statistical significance expressed as (**) for p<0.01 and (***) for p<0.001.
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5.6 TNFa-induced IL-8 upregulation
TNFa is a multifunctional cytokine that induces the expression of certain 
chemoattractants in parenchymal lung cells, like IL-8. IL-8 is a selective chemokine for 
neutrophils that is found in high levels in COPD patients, with IL-8 levels in induced sputum 
correlating with the extent of neutrophilic inflammation and disease severity (Keatings et al., 
1996; Yamamoto et al., 1997). Previous reports have implicated a role for PI3K within 
TNFa-induced upregulation of IL-8 in other systems (Osawa et al., 2002), hence research 
work into the possible roles of PI3K within this process in alveolar epithelial lung cells was 
done.
Initially, a timecourse using TNFa at 100 ng/ml was carried out to determine the 
optimum time for stimulation in A549 cells (Fig. 5.21 A). IL-8 levels in A549 supemantants 
did not increase in a significant manner until 6 h of stimulation (Fig. 5.21 B). Therefore, for 
subsequent experiments TNFa stimulation for 6h was used. In concentration-effect studies, 
all the concentrations used for TNFa, from 1 to 1000 ng/ml, significantly increased IL-8 
expression over basal at 6 h stimulation. However, IL-8 values peaked with a concentration of 
TNFa of 100 ng/ml.
T NFa 1 OOng/ml g
Time (h) TNFa (ng/ml) for 6h
Figure 5.21 TN Fa timecourse and concentration-effect studies on IL-8 upregulation in A549 
cells. Confluent A549 cell monolayers were left in serum-free DMEM at 37°C at 5% C 02 overnight. 
Cells were then stimulated with vehicle (V) or TNFa at the stated concentrations and incubated for the 
indicated times. Supernatants were then taken and analysed for IL-8 concentration using an IL-8 
ELISA. For A and B data expressed as mean+SEM for n=3 independent experiments. Statistical 
significance expressed as (**) for p<0.01.
In order to determine the importance of PI3K, a 30 min LY294002 incubation before 
TNFa stimulation was carried out. To discard any possible mTOR activity in this process,
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rapamycin inhibition was used on another group o f cells. With T N F a stimulation of 
100 ng/ml, LY294002-pretreatment had no effect on IL-8 expression (Fig. 5.22 A). W hen the 
highest concentration o f LY294404 was tested against a range o f concentrations o f  TN Fa, 
from 1 to 1000 ng/ml, there were still no apparent inhibitory effects (Fig. 5.22 B). 
Experiments were done using rapamycin pretreatment, and similar results were obtained with 
no significant effects to describe (Fig. 5.22 C and D). This data indicates that in A549 cells, 
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Figure 5.22 Effect of LY294002 or Rapamycin pretreatment on TNFa-induced IL-8 upregulation 
in A549 cells. A and C. Confluent A549 cell monolayers were left in serum-free DMEM at 37°C at 
5% CC>2 overnight. Cells were incubated for 30 min with vehicle (V) or with increasing concentrations 
of LY294002 (1-30 pM, A) or rapamycin (0.3-10 pM, C). Then the cells were stimulated with an 
appropriate control (C) or TNFa at 100 ng/ml. Supernatants were then taken and analysed for IL-8 
concentration by an IL-8 ELISA. Data expressed as mean+SEM for n=3 independent experiments. The 
dagger (+) indicates the group to which all others were compared for statistical significance. B and D. 
A549 cell were incubated for 30 min with vehicle, 30 pM LY294002 (B) or 10 pM rapamycin (D). 
Cells were then stimulated with increasing concentrations of TNFa (1-1000 ng/ml) for 6 h. 
Supernatants were then taken and analysed for IL-8 concentration by an IL-8 ELISA. Data expressed as 
mean+SEM for n=3 independent experiments.
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5.7 Discussion
5.7.1 PI3K class I pllOB in TNFa-induced signalling
TNFa is a potent pleiotropic cytokine that is essential to the immune response by 
regulating inflammation and repair mechanisms in the body, displaying a prominent role in 
inflammatory diseases such as asthma, rheumatoid arthritis and others (Babu et al., 2004). 
TNFa exerts its plethora of functions by interacting with its membrane receptors, however, 
the signalling molecules involved between the TNFa receptor and its downstream effectors 
remain unclear. Previous studies have implicated PI3K activity (Huang and Chen, 2005), as 
well as members of the MAPK family (Chen et a l, 2001a), in the regulation of TNFa- 
induced cell functions, including ICAM-1 expression and PG sysnthesis in different cell 
types.
In order to begin studying TNFa signalling in lung parenchymal cells, an analysis of 
the phosphorylation levels of two different groups of molecules was performed: the first type 
is associated with PI3K activity, while the second group refers to kinases belonging to the 
MAPK family. The objective in studying these two groups of signalling molecules was to 
elucidate the hierarchy possessed by PI3K within the signalling events initiated by TNFa. It 
was observed that TNFa stimulation of A549 cells causes an increase in phosphorylation 
levels of all the molecules studied, testament to the robustness of the signal initiated by this 
inflammatory cytokine. With the exception of GSK-3|3, the phosphorylation levels for all 
these molecules peaked at 15 min, with levels receding near to basal levels 60 min post­
stimulation. This would suggest some similarity in the mechanism of activation for all these 
kinases. Furthermore, the concentration-effect studies for each molecule demonstrated similar 
profiles, with most phosphorylation signals peaking at 100 ng/ml.
When LY294002 was used to determine PI3K dependency on the phosphorylation of 
each kinase, only the molecules generally associated with PI3K activity seemed affected. Of 
these, only Akt phosphorylation was abrogated by LY294002 pretreatment. S6 
phosphorylation remained at pre-stimulation levels, while GSK-3P was partially inhibited but 
remained above basal levels even at the highest concentrations of the inhibitor. For Akt, the 
complete abrogation suggests that this phosphorylation event is completely dependent on 
PI3K activity, as it has been shown previously by others (Alessi et al., 1996). On the other 
hand, the reduced dependency on PI3K activity found in S6 and GSK-3P indicates that either
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PI3K isoforms which are highly resistant to LY294002 inhibition, like class Ila, play a major 
role in the phospho-regulation of these molecules, or that other signalling pathway are 
involved in the regulation of the activity of these kinases. Reports advocating a principal role 
for PI3K in S6 and GSK-3P phosphorylation abound (Cross et a l, 1994; Cross et al., 1995; 
Belham et al., 1997); however many other reports suggest the participation of other pathways 
in the regulation of these molecules (Kanda et al., 1997; Manoukian and Woodgett, 2002). 
The dependency would appear to vary greatly between experimental models and the stimulus 
used, although some authors have found both PI3K dependent and independent mechanisms 
using the same system and stimulant (Somwar et al., 1998).
The observation that MAPK phosphorylation levels were independent of PI3K was 
not unexpected, as many other reports indicate independence of PI3K activity for the 
regulation of these kinases (Molton et al., 2003; Guo and Rothstein, 2005). However, 
signalling events appear to vary depending on the specific experimental settings. Thus, others 
have previously shown that MAPK kinases can be found downstream of PI3K activity in 
certain circumstances (Go et al., 1998; Orr et al., 2002; Chandrasekar et al., 2005), while 
some have indicated that PI3K directly antagonises MAPK activation (Murakami et al.,
2005).
To elucidate the isoforms involved in the phospho-regulation of Akt, S6 and GSK-3(3, 
experiments with siRNA and isoform-selective inhibitors were carried out, with class I p i 10(3, 
the isoform generally associated with insuling signalling (Brachmann et al., 2005), proving to 
be essential for TNFa-induced Akt phosphorylation. The phosphorylation levels of S6 and 
GSK-3p remained unperturbed when using isoform-specific inhibitors or siRNA, suggesting 
that TNFa does not only activate pi 10(3, as the Akt data would indicate, as other PI3K 
isoforms must be activated in order to upregulate the phosphorylation levels of S6 and 
GSK-3P under isoform-specific inhibition. The difference in the results obtained with the 
isoform-specific inhibitors and LY294002 demonstrates that the level of control for kinases 
downstream of PI3K is different for each one, with Akt activity mainly regulated by one 
isoform (pllOP), while S6 and GSK-3P phosphorylation are regulated, at least partly, by the 
activity of two or all three Class LA isoforms. Isoform-specific level of control for Akt 
phosphorylation has been reported by others previously, as pi 108 was the main isoform 
involved in Akt regulation in IL-4 induced signalling (Bilancio et al., 2006).
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5.7.2 PI3K class I p i  108 in TNFa-induced COX-2 and PGE? upregulation
Airway epithelial cells respond to TNFa by producing PGs, through the induction of 
COX-2 (Petrovic et al., 2006). PGs are implicated in many lung disease processes, such as 
inflammation, oedema and bronchoconstiction; as well as in many homeostatic cellular 
activities (Mitchell et al., 1995; Portanova et al., 1996). Here, it has been demonstrated that in 
A549 alveolar epithelial cells, TNFa stimulation leads to COX-2 and PGE2 upregulation in a 
PI3K-dependent manner. Although upregulation of COX-2 downstream of TNFa stimulation 
in A459 cells had been well documented by previous work (Billich et a l, 2005; Tong et al.,
2006), the potential role of PI3K had yet to be explored. Furthermore, recent work supports 
the role for PI3K in COX-2 upregulation by a diverse variety of factors (Sheu et a l, 2005; 
Hsieh et a l, 2006; Rodriguez-Barbero et a l, 2006; Cao et a l, 2007), including inflammatory 
mediators like IL-1|3 (Chen et al., 2007).
Previous studies had implicated PI3K (Gustin et al., 2001), as well as members of the 
MAPK (Chen et a l, 2001a) and PKC (Chen et a l, 2000) familes, in the regulation of TNFa- 
induced COX-2 expression and PG synthesis in different cell types. Even though PI3K 
proved to be important, specific targeting of the signalling activities carried out by MAPK or 
PKC was not done, therefore these molecules could play a significant part in COX-2 
upregulation in A549 cells. This is further supported by the results that show that even when 
employing the highest concentration of LY294002 there is still residual COX-2 upregulation 
that cannot be suppressed by PI3K inhibition.
Through isoform-specific silencing, it has been elucidated that the class I pi 105 
isoform of the PI3K family is the main isoform involved in TNFa-induced COX-2 
upregulation in A549 cells. Class I pi 105 is one of the most researched within the PI3K 
family, owing to the fact that animals possessing a genetically-disrupted pi 105 isoform are 
viable (Okkenhaug et a l, 2002), in contrast with pi 10a'A or pi 10p /_ animals (Bi et a l,  1999; 
Bi et a l, 2002). Roles for the pi 105 isoforms have been clearly shown in B (Okkenhaug et 
al., 2002) and T-cell development (Webb et a l, 2005), cell proliferation (Sujobert et al.,
2005) and smooth muscle tone, as well as IL-4-receptor signalling (Bilancio et al., 2006). In 
this latter study, pi 105 silencing led to inhibition of IL-4-induced antiapoptotic effects, as 
well as IL-4 induced Akt phosphorylation (Bilancio et al., 2006). This pattern differs from the 
results obtained in this project, as the key isoform involved in cellular signalling is not 
implicated in the discovered PI3K-dependent cell function. As previously described in section 
5.1.1, pllOp, not pi 105, is the main PI3K isoform responsible for Akt phosphorylation
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downstream of TNFa receptor coupling while p i 108 is the main regulator of TNFa-induced 
COX-2 production.
This discrepancy between signalling and function signifies that the PI3K activity 
necessary for COX-2 upregulation is not exerted through Akt phosphorylation, or even 
through GSK3J3, S6, or MAPK phosphorylation, as all of the phosphorylation levels for these 
molecules remained unchanged in the p i 108-knockdown and IC87114-treated cells. This 
means that the downstream signalling regulation that is dependent on p i 108 is via a molecule 
that was not considered in these experiments or that at present remains unknown. Another 
possible explanation would be that the regulatory effect is not exerted through lipid 
phosphorylation. Aside from their lipid kinase activity, PI3K class LA isoforms also possesses 
protein kinase activity which mainly serves as an autoregulatory system involving 
phosphorylation of their adapter subunit, which in turn inhibits the lipid kinase activity of the 
catalytic subunit (Vanhaesebroeck et a l, 1999; Beeton et al., 2000). However, it has been 
reported that class LA P3K isoforms also phosphorylate exogenous substrates including 
insulin receptor substrate 1 (Lam et al., 1994) and phosphodiesterase 3b (Rondinone et al., 
2000). Therefore, the non-redundant activity played by pi 108 in TNFa-induced COX-2 
upregulation could be due to a specific protein target for its protein kinase activity that it does 
not share with other members of the PI3K class LA.
5.7.3 PI3K class I pllO S in TNFa-induced cJun phosphorylation
In order to elucidate further the mechanism through which pi 108 regulates COX-2 
expression, the transcription molecules involved in COX-2 expression were analysed. CRE, 
C/EBP and 2 NF-kB sites (Inoue et al., 1995; Schroer et al., 2002) have been shown to be 
important for COX-2 promoter activation by inflammatory mediators, hence the 
phosphorylation levels of the molecules directly involved in the function of these sites were 
used as markers of activity for these gene promoter sites.
Initially, it was established that all the transcription elements analysed were 
phosphorylated following TNFa stimulation. This has been shown before, with many papers 
highlighting the importance of NF-kB (Gustin et al., 2001; Mayo et al., 2002), ATF2 
(Brinkman et al., 1999), C/EBPp (Deng et al., 2007), cJun (Bennett et al., 2001; Billack et al., 
2002; Grau et al., 2006) and CREB (Ono et al., 2004) in TNFa-induced gene transcription. 
When the cells were pretreated with a broad spectrum PI3K inhibitor, TNFa-upregulation of 
phosphorylation levels remained for all of the transcription molecules, except for cJun, which
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demonstrated an LY294002 concentration-dependent inhibition of its activity. This is 
interesting as a role for PI3K in NF-kB activity has been studied in a diversity of systems 
(Gustin et al., 2001; Mayo et al., 2002; Osawa et al., 2002) and NF-kB activity is associated 
with COX-2 upregulation (Newton et al., 1997; Ke et al., 2007), hence an impact on NF-kB 
activity was expected after PI3K inhibition. However, similar relationships between PI3K 
activity and all the COX-2-associated transcription molecules can be found in different 
experimental settings (Kang et al., 2003; Chandrasekar et al., 2005; Caravatta et al., 2007).
In order to determine if PI3K-dependent cJun phosphorylation was specifically 
dependent on p i 108 function, as the COX-2 results would suggest, experiments using 
isoform-selective inhibitors and knockdown cells were carried out. This experiments led to 
the determination that cJun phosphorylation levels were effectively inhibited by pi 105 
silencing. The association between cJun, which is a transcription element that binds to the 
COX-2 CRE promoter site, and COX-2 upregulation has been previously described in other 
systems (Bennett et al., 2001; Billack et a l, 2002; Grau et al., 2006). In the majority of these 
studies, cJun phosphorylation is effected by a member of the MAPK family called JNK. 
Moreover, there is a report that in the signalling pathway involved in IL-18-induced CXCL16 
expression in smooth muscle cells, PI3K lies upstream of JNK and cJun activation, and 
downstream of the TNF receptor-associated factor 6 (Chandrasekar et al., 2005). However, 
according to the results described in section 5.1.2, PI3K does not seem to be upstream of JNK 
activity, as PI3K inhibition had no effect on the phosphorylation levels of JNK. This is 
compatible with previous research done by several groups showing that cJun phosphorylation 
can occur independently of JNK activity (Besirli and Johnson, Jr., 2003; Adiseshaiah et al.,
2006). In fact, one group showed that TNFa-induced cJun phosphorylation in pulmonary 
epithelial cells was shown to be completely independent of JNK (Adiseshaiah et a l, 2006). 
However, in the studies carried out in this research project, cJun phosphorylation is not 
completely dependent on PI3K activity, as inhibition even at the highest concentrations of 
either IC87114 or LY294002 was not able to completely inhibit the TNFa-induced 
upregulation in cJun phosphorylation levels. This data suggests that another kinase, like JNK, 
could have an important role in the regulation of cJun activity.
5.7.4 JNK  in TNFa-induced cJun phosphorylation and COX-2 upregulation
The role played by JNK in inflammatory respiratory disease has been the focus of 
recent research. Using the JNK inhibitor SP600125 researchers have shown that JNK is a key 
signalling molecule involved in acute eosinophil and lymphocyte recruitment to the lung and
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allergen-induced bronchial hyperresponsiveness (Nath et al., 2005). In chronic models of 
allergic inflammation, SP600125 was also able to reduce DNA incorporation into ASM and 
epithelial cells (Eynott et al., 2003). With this previous work in mind, and the fact that one of 
the main targets of this molecule, cJun, was demonstrating importance within this system, a 
direct analysis of the importance of JNK was undertaken.
The peptide inhibitor JNKi that specifically inhibits the activity of JNK on cJun 
phosphorylation was used to investigate the role of JNK activity in cJun phosphorylation and 
TNFa-induced COX-2 expression. In these experiments, it was determined that JNK activity 
has a prominent role in COX-2 and PGE2 upregulation downstream of TNFa stimulation. 
Furthermore, it was shown that pretreatment with JNKi blocks phosphorylation of cJun 
completely, without affecting phosphorylation levels for any other of the transcription 
molecules monitored. This demonstrates that JNK activity plays an important part in the 
regulation of cJun, and that JNK is also a signalling molecule of importance within TNFa- 
induced COX-2 and PGE2 upregulation.
In an attempt to clarify the particular roles played by PI3K class LA. pi 108 and JNK 
in COX-2 upregulation and cJun phosphorylation, experiments using IC87114 and JNKi in 
combination were carried out. These results indicate a system where TNFa-induced cJun 
phosphorylation and its activation of the COX-2 CRE promoter site is dependent on both 
PI3K pi 108 and JNK, as inhibition with either JNKi or IC87114 prevents COX-2 and PGE2 
upregulation, as well as cJun activity. Furthermore, since there is no greater inhibition when 
these compounds are used in conjunction, it can be concluded that the activities of both 
kinases are necessary for cJun activation, but are not complementary to each other.
5.7.5 mTOR in TNFa-induced ICAM-1 expression and cell adhesion
Coupling of TNFa to its receptor on the surface of parenchymal cells leads to the 
upregulation of adhesion molecules, which is an important event in leukocyte cell recruitment 
and the acute phase inflammatory response within respiratory diseases (Lassalle et al., 1993; 
Yamamoto et al., 1998; Huang and Chen, 2005). Within the experiments carried out for this 
project, this function was not dependent on PI3K activity, as shown by the experiments using 
the broad-spectrum PI3K inhibitor LY294002 and siRNA-induced PI3K-isoform silencing. In 
fact, it was discovered that in the experimental model used in this research, ICAM-1 
upregulation was dependent on mTOR, a kinase that is highly related to PI3K, in as much that
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some authors consider it within another class of the PI3K family (class IV PI3K), also
referred to as PI3K-like kinases (Workman et a l,  2006).
The finding that TNFa-induced ICAM-1 expression in A549 cells was independent 
of PI3K activity is surprising, as another group had already published a report suggesting a
predominant role for PI3K activity in this scenario (Huang and Chen, 2005). Two
methodological differences exist between the studies; Huang and Cheng used an ELISA to 
determine ICAM-1 expression and preferred U937 monocytes in their cell adhesion assay. 
According to their results, a 10 pM concentration of LY294002 significantly decreased 
ICAM-1 expression and TNFa-induced cell adhesion. Furthermore, they employed luciferase 
based promoter activity assays, to determine that LY294002 inhibited ICAM-1 promoter 
activity. In the experimental settings used in this work, LY294002 was tested against a range 
of concentrations of TNFa, with only the highest concentration of the inhibitor showing a 
limited inhibition in ICAM-1 expression and THP1 monocyte cell adhesion. Furthermore, 
studies carried out in PI3K isoform-specific knockdown cells showed no difference for either 
of the measured responses. With these results, and since LY294002 is a known inhibitor of 
mTOR (Brunn et al., 1996), the possibility that this signalling molecule was the responsible 
kinase for ICAM-1 expression downstream of TNFa in A549 cells was investigated.
The inhibition of mTOR, either by siRNA or rapamycin, significantly inhibited 
TNFa-induced ICAM-1 expression and THP1 cell adhesion. Since the results using mTOR- 
targeting tools proved far superior in inhibiting ICAM-1 expression, and the consequent cell 
adhesion, than those targeting PI3K, it was determined that mTOR holds a predominant role 
over PI3K in this experimental model. This idea is further supported by others who have 
reported on the importance of mTOR activity in TNFa-induced ICAM-1 expression in 
endothelial and smooth muscle cells (Voisard et al., 2007).
Methodological differences, like flow cytometry instead of ELISA and THPls instead 
of U937s, cannot easily explain the divergence observed in the results obtained in this part of 
this research project compared with those resultant of the work of others (Huang and Chen, 
2005). In this case LY294002 had a small but reproducible effect on TNFa-induced ICAM-1 
expression, however this effect could be mainly due to the activity of this compound on 
mTOR and not on PI3K. Unfortunately, Huang and Chen chose no other pharmacological tool 
to inhibit PI3K activity to corroborate their results. In the same fashion, the work herein 
described could be criticised for not carrying out siRNA-mediated silencing of pi 10, without 
specificity for any catalytic isoform, to corroborate that this process was independent of PI3K.
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However, during this investigation, two different techniques were employed to reduce mTOR 
activity, and in both this protein kinase was demonstrated to play an important role in the 
regulation of adhesion molecule expression downstream of TNFa.
5.7.6 PI3K and mTOR-independent TNFa-induced IL-8 upregulation
IL-8 is one of the most potent chemoattractants of neutrophils, one of the cell types 
thought to play a predominant role in COPD (Pignatti et al., 2005). Furthermore, it has been 
recently shown in asthma that a rapid withdrawal of corticosteroid-treatment leads to 
exacerbations that are preceded by an upregulation of neutrophils and IL-8 concentrations in 
sputum (Maneechotesuwan et al., 2007). TNFa plays a central role in the initiation and 
maintenance of the acute and chronic inflammatory responses in the lung. TNFa stimulates 
lung epithelial cells to increase the production of cytokines such as IL-8 (Babu et al., 2004). 
In accordance to this, in this study A549 cells stimulated with TNFa were capable of 
upregualting production of IL-8 in a time- and concentration-dependent fashion, in a similar 
manner to that shown by others before in the same cells (Kwon et al., 1994; Fiedler et al., 
1998; Rahman et al., 2002).
The sites responsible of IL-8 promoter activation downstream of TNFa stimulation 
have been widely studied in A549 cells, with the NF-kB and AP-1 sites proving key players 
within this gene activation (Fiedler et al., 1998; Rahman et al., 2002). Not withstanding the 
work performed on transcription factors, the signalling cascades controlling the activity of 
these promoters has been generally overlooked. While attempting to elucidate the signalling 
pathways regulating TNFa-induced IL-8 production, it was determined that neither PI3K nor 
mTOR had any roles of importance within TNFa-induced IL-8 expression in A549 cells. This 
was surprising, as previous work by others has shown that TNFa-induced IL-8 production in 
a variety of cell systems is dependent on PI3K (Osawa et al., 2002; Xu et al., 2007) or mTOR 
(Charreau et al., 2000) activity. However, as is the case with signalling processes, these tend 
to be specific for the cell type or experimental model used, with other publications supporting 
the independence of the activity of these signalling molecules in IL-8 production (Wu et al., 
2004; Schreml et al., 2007).
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5.8 Conclusions
In this final part of the study, it was determined that p i 10(3 is the principal class I 
PI3K isoform involved in Akt phosphorylation downstream of TNFa-stimulation while S6, 
another PI3K-dependent molecule, was resistant to single PI3K isoform-selective inhibition. 
With regards to TNFa-induced cell functions, p i 105 was the main PI3K molecule involved in 
TNFa-induced COX-2 and PGE2 production, while a PI3K-related molecule, mTOR, 
demonstrated its importance in TNFa-induced ICAM-1 production. Furthermore, it was 
shown that PI3K pi 108 and the MAPK JNK play significant roles in the phospho-regulation 
of the transcription factor cJun. JNK activity also proved to be important in TNFa-induced 
COX-2 and PGE2 upregulation.
In summary, in the present chapter the following was determined:
• LY294002 reduced TNFa-induced Akt and S6, but not GSK-3P, JNK or
ERK, phosphorylation
• TGX-121 or pi 1 Op-siRNA treatment blocked TNFa-induced Akt, but not S6 
or GSK-3P, phosphorylation
• TNFa-induced ICAM-1 expression, and it consequent cell adhesion, was 
blocked by rapamycin or mTOR-siRNA treatment
• TNFa-induced IL-8 upregulation occured independently of PI3K or mTOR 
activity
• LY294002, but not rapamycin, blocked TNFa-induced COX-2 and PGE2
upregulation
• JNKi, IC87114 or pi 108-siRNA treatment attenuated TNFa-induced COX-2 
and PGE2 upregulation
• JNKi, IC87114 or pi 108-siRNA treatment inhibited TNFa-induced cJun 
phosphorylation
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6.1 General Conclusions
6.1.1 PI3K in homeostatic and cytokine-induced cell processes
Throughout the course of this research the main interest has resided with the roles that 
the PI3K family play within the epithelial cells of the lung under inflammatory mediator 
stimulation. To do this, succesful use of siRNA technology, as validated by mRNA and 
protein levels, in order to silence every isoform of the class LA and II of the PI3K family was 
carried out. Furthermore validation of the results that implicated class IA isoforms was 
obtained, by using inhibitors that selectively target individual isoforms of this group. Using 
these research tools, it was possible to determine that these kinases are involved in a wide 
range of cellular functions, from cell survival to the regulation of COX-2 expression.
Initially, it was determined that class II PI3K, a commonly overlooked class of PI3K, 
plays a crucial role in A549 cells, with the I la  isoform proving to be important for cell 
survival while the II|3 isoform demonstrating key relevance in spontaneous wound healing. 
Furthermore, class LA pllOp also proved to be important in these cell functions. When 
studying basic cell responses, pllOp knockdown cells were impaired in their ability to 
survive, although to a much lesser extent than Ila, and possessed delayed wound healing 
responses, in a similar fashion to II(3-knockdown cells.
The cytokine-induced signalling in A549 cells contrasted with those observed for the 
primary murine lung preparation. In the lung preparation, TNFa-induced Akt phosphorylation 
was sensitive to pretreatment with the p i 105-selective inhibitor IC87114, implying an 
important role for pi 108 within that system. However, in pi 105-knockdown or IC87114- 
pretreated A549 cells, Akt phosphorylation downstream of TNFa remained unchanged when 
compared with control samples. Meanwhile, A549 treated with pi 10P-specific siRNA or 
incubated with the p 11 Op/p 1108-selective inhibitor TGX-121 prevented TNFa-induced 
upregulation of Akt phosphorylation levels. Therefore, in the primary murine lung preparation 
pi 108 appears to be the important isoform in TNFa-induced Akt phospho-regulation, while 
in A549 cells the same function is prerformed by pllOp. The reasons for this discrepancy 
could be that the murine lung preparation is of a heterogeneous nature, with a diversity of cell 
types participating in the signalling of that model, while A549 cells represent a much more 
homogenous system, with only one cell type being stimulated by TNFa. Therefore, the data 
obtained from A549 cells suggests that TNFa-induced Akt phosphorylation in alveolar
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epithelial cells is p i 105-independent and pi 10p-dependent. Meanwhile this same function in 
the primary lung preparation could be mainly acheived by a cell type that is dependent on 
p i 105 activity, overshadowing any activity that might remain in alveolar epithelial cells or 
any other pi 105-independent cells in this system. In contrast, IL-13 studies in A549 cells and 
the primary murine lung preparation were unaffected by selective inhibition or silencing of 
any of the PI3K isoforms. This data suggests that IL-13 uses more than one isoform to exert 
its activity.
The key finding of this thesis is the role of PI3K pi 105 in TNFa-induced COX-2 and 
PGE2 upregulation in A549 alveolar epithelial cells. PI3K pi 105-knockdown or pretreatment 
with IC87114 in A549 cells blocked the upregulation of COX-2 and PGE2 elicited by a 6 h 
incubation with TNFa. In elucidating the mechanism through which pi 105 regulates this 
process, it was discovered that p i 105 silencing, either by IC87114 or siRNA, inhibited the 
phosphorylation of the transcription activator cJun downstream of TNFa stimulation. 
Moreover, cJun has been shown to bind to the COX-2 CRE promoter site, upregulating COX- 
2 production (Bennett et a l, 2001; Billack et al., 2002; Grau et al., 2006). However, the 
mechanism through which pi 105 regulates cJun phosphorylation is unknown. JNK, the 
kinase that regultes cJun activity in a diversity of systems, appeared to be the perfect target 
for PI3K-regulated activity. Furthermore, in the experiments carried out in this research 
project, JNK inhibition not only completely inhibited cJun phosphorylation, but it also 
reduced COX-2 and PGE2 levels after TNFa stimulation. However, it was also shown that 
JNK phosphorylation occurred independently of PI3K activity, eliminating the possibility of 
this kinase operating downstream of p i 105. Therefore, pi 105 must affect cJun 
phosphorylation through a JNK-independent mechanism. Curiously, combined inhibition of 
p i 105 and JNK does not have increased effects over inhibition with a single compound, 
suggesting that although pi 105 and JNK activities are not complementary to each other, both 
pathways are required for adequate cJun activation.
Through this research project, no cytokine-induced cellular functions were discovered 
for class I p i 10a, pllOp or either of the class II isoforms. However, the inability to analyse 
any possible functions carried out by Ila  in these experiments must be recognised, as cells 
lacking this isoform failed to survive, and therefore no experiments under cytokine- 
stimulation in Ila  knockdown cells were carried out. In the case of pllOp, this isoform 
proved to be involved in Akt phosphorylation downstream of IL-ip and TNFa. However, this 
inhibition in Akt signalling was not reflected in any of the TNFa-induced functions that were
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studied. Nevertheless, due to the fact Akt signalling has been shown to be important in a 
variety of processes including cell survival (Datta et ah, 1999), insulin signalling (Dummler et 
al., 2006; Doepfner et al., 2007), and respiratory disease mechanisms (Bodine et al., 2001; 
Miyahara et al., 2007), this pi 10p-mediated Akt phosphorylation inhibition in A549 cells 
must have repercussions in the cellular function of A549 cells.
Unfortunately, after obtaining the results described in chapters 4 and 5 in A549 cells, 
no further experimentation was carried out to discern the possible association between the 
results obtained in A549 cells and the primary murine lung (discussed in chapter 3). As 
mentioned in section 3.5.4, there was insufficient time within this research project to carry out 
appropriate experiments that could link the results obtained in these two distinct models. The 
experiments that should have been carried out for this purpose included 
immunohistochemistry in primary lung tissue targeting a variety of molecules associated with 
the inflammatory response (e.g. PI3K, Akt, COXs, etc), as well as experiments involving 
primary lung cells purified from whole lung preparations.
6.1.2 mTOR regulates TNFa-induced ICAM-1 up regulation
Not all TNFa-induced cell functions were dependent on PI3K activity. TNFa- 
induced ICAM-1 upregulation showed only moderate reduction with LY294002 with no 
effects seen in PI3K knockdown cells. As this compound is a known inhibitor of mTOR 
(Brunn et al., 1996), it was necessary to determine if the effect observed with LY294002 
pretreatement was mTOR-dependent. Inhibition of mTOR, either by the use of rapamycin or 
siRNA, successfully reduced ICAM-1 expression and its consequent cell adhesion. 
Unfortunately neither the signalling mechanism through which mTOR is activated 
downstream of TNFa receptor coupling, nor the transcription molecules regulated by mTOR 
for this functions were investigated, as PI3K activity was the main interest in this project.
Similarly, IL-8 production downstream of TNFa stimulation was shown to be 
independent of either mTOR or PI3K activity. Although many potential signalling molecule 
candidates for this IL-8 induction have been reported (Hoffmann et al., 2002; Henriquet et al.,
2007), they were outside the main focus of this research project and remained uninvestigated.
6.1.3 Clinical implications
Whether COX-2 and PGE2 inhibition would be clinically desirable, has a direct 
bearing on the possible therapeutical uses for the prototypical PI3K, p i 108, JNK or cJun
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inhibitors that are currently under development. With regards to respiratory disease (A549 
cells are alveolar epithelial cells), two different classes of prostanoids are produced in the 
lung, bronchoconstrictive PGs, such as PGD2 and PGD2, and bronchoprotective PGs, such as 
PGE2 and PGI2 (Holgate et a l, 1984; Kroegel and Matthys, 1993). In the specific case of 
PGE2, this PG has been shown to inhibit mast cell (Peters et al., 1982) and eosinophil (Kita et 
al., 1991) degranulation, chemotaxis, and cytokine-stimulated survival (Alam et al., 1993). 
More importantly, PGE2 inhalation can inhibit pulmonary responses to inhaled allergen in 
asthmatic subjects (Gauvreau et al., 1999). Furthermore, COX-2'7' animals (Gavett et al., 
1999) or mice treated with a selective COX-2 inhibitor (Peebles, Jr. et al., 2002) had 
significantly higher airway hyperresponsiveness and higher levels of IL-13 than wildtype or 
untreated mice, respectively. At the time of these studies, targeting of COX-2 in the airways 
had appeared to be a reasonable therapeutic target, as PGD2 is a powerful bronchoconstrictor. 
However, blocking COX-2 activity not only inhibits PGD2 activity, but it also impairs PGE2 
production and, as described previously by others, this prostaglandin acts a bronchodilator in 
the lungs. Hence, it seems that neither COX-2 nor PGE2 are desirable drug targets in chronic 
respiratory diseases.
For cancer (A549s were derived from a human lung carcinoma), the idea of blocking 
COX-2 and PGE2 productions seems more favourable. Transgenic mice overexpressing 
COX-2 in mammary glands developed focal mammary gland hyperplasia, dysplasia and 
metastatic tumors (Liu et al., 2001). Transgenic mice overexpressing COX-2 in gastric 
epithelial cells developed metaplasia, hyperplasia and malignant growths in their stomach 
(Oshima et al., 2004); while COX-2'7' animals have markedly reduced levels of intestinal 
tumours and skin papillomas (Chulada et al., 2000; Tiano et al., 2002). This experimental 
data is further supported by epidemiologic finding that inhibitors of COX protect against a 
wide range of tumours (Jayaprakash et al., 2006; Kwan et al., 2007), and in some cases it 
seems to be clearly related to COX-2 expression (Chan et al., 2007).
In the case of the possible clinical implications of the mTOR regulation of ICAM-1 
levels, the need to answer these questions is to an extent a more pressing one than those 
concerning PI3K acitivity, as rapamycin, known in the clinic as Sirolimus, is a currently used 
immunosuppressive drug in the context of organ transplantation (Augustine et al., 2007). In 
this scenario, an inhibition of ICAM-1 expression downstream of inflammatory mediator 
stimulation, and hence a reduction in the recruitment of leukocytes, could work to the benefit 
of the patient as it would further reduce the possibility of an adverse immunological reaction 
to the transplanted tissue. Furthermore, the inhibition that rapamycin has on TNFa-induced 
ICAM-1 expression has been studied before in the context of arterial vessel drug eluting
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stents, where application of the compound successfully inhibited restonosis (Voisard et al.,
2007). However some authors argue that the use of rapamycin, and its effects on cellular 
adhesion, could cause these stents to increase the risk of thrombosis (Shuchman, 2006).
6.1.4 In a nutshell
As illustrated in figure 6.1, the results of this research project demonstrate that PI3K 
pllOp is the main isoform involved in Akt phosphorylation downstream of TNFa- 
stimulation, while p i 105 is the main isoform in TNFa-induced COX-2 and PGE2 production 
in A549 human alveolar epithelial cells. PI3K pi 105 is also important in cJun 
phosphorylation, and inhibition of cJun phosphorylation by the use of a specific JNK inhibitor 
also leads to downregulation of PGE2 and COX2 levels. The regulatory activity of p i 105 and 
JNK appear to act on the same pathway as the inhibition of both kinases does not seem to 
enhance the downregulation caused by the inhibition of either molecule on its own.
Not all TNFa-induced cell functions depend on PI3K activity. Upregulation of 
ICAM-1, and the consequent increase in monocyte adhesion that it conveys, was dependent 
on mTOR activity, but not PI3K. Moreover, IL-8 production downstream of TNFa appeared 
to be completely independent of both PI3K and mTOR activity.
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C O X l
Figure 6.1 Model of PI3K and mTOR activity in TNFa-induced cell functions. Through the work 
carried out for this thesis, certain roles for PI3K downstream o f T N F a receptor coupling have been 
defined. In the signalling pathway model PI3K is important for S6, GSK-3P and Akt phosphorylation, 
with Akt being mostly dependent on pl i op activity. With regards to transcription molecule, PI3K 
(specifically pi 108) and JNK activity are important for cJun phosphorylation, and both kinases are 
important in the upregulation o f  COX-2 and PGE2 production. Many other transcription molecules are 
also activated downstream o f T N Fa, with the signalling cascades that regulate them and the role that 
they play in COX-2 increase remaining unclear. ICAM-1 expression, and its consequent increase in cell 
adhesion, is mainly regulated by mTOR and not PI3K; while TN Fa-induced IL-8 expression is 
controlled by neither PI3K nor mTOR, with its regulatory cascade continuing to be unknown.
158
Chapter 6 -  General Conclusions & Future Work
6.2 Future Work
The logical next step for the research described herein, is to determine their 
reproducibility initially as ex vivo experiments, and then as in vivo animal models of 
respiratory and oncologic diseases. As it was determined in the course of this work, important 
differences exist depending on the experimental settings used. Thus, pi 105 inhibition in the 
primary lung preparation sufficed to inhibit TNFa-induced Akt phosphorylation, while in 
A549 cells the main kinase ascribed to this function was pllOp. Therefore, animal model 
experiments can be carried out to elucidate further the importance of PI3K and COX-2 in 
chronic inflammatory conditions. This could be acheived by using the same research tools 
that were used in this research project, as tracheal inhalation of nude siRNA has previously 
been shown to be effective in silencing protein targets specifically in the lung in an in vivo 
model of acute injury (Lomas-Neira et al., 2005). This proposed research in animal models 
could potentially generate important data for the novel drug targets in lung illnesses.
Further work can also be carried out within A549 cells. This research should be 
focused on determining the signalling mechanism through which PI3K interacts and regulates 
cJun activation. To this purpose, some studies have associated PI3K downstream kinases in 
the regulation of transcription factor activation (Wu and Janknecht, 2002; Bilancio et a l, 
2006; Salazar et al., 2006). Moreover, gene promoter assays should also be carried out to 
determine which of all of the transcription molecules which are activated downstream of 
TNFR1 coupling are responsible for the induction of COX-2 expression, aiding to clearly 
establish the role of cJun in COX-2 upregulation. Furthermore, the importance in cell function 
of the IL-ip- and TNFa-pl 10P-Akt signlling axes should be analysed. Even more 
fundamental questions pertaining to signalling research can also be addressed in the A549 cell 
model, such as the exact way that TNFR1 activates PI3K, which is a very important question 
that is yet to be answered.
Some of research done also briefly highlighted roles for other PI3K isoforms as well 
as other kinases in both cytokine-induced and spontaneous cell activities in A549 cells. A 
further insight into the signalling mechanisms behind the roles played by pllOp and lip in 
spontaneous wound healing is required, as well as determining the importance of these 
kinases in chemokine-stimulated wound healing. More profound investigation is also required 
into the signalling mechanisms behind IL-8 upregulation and into mTOR-regulated ICAM-1 
expression.
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Finally, a very interesting finding in this research project should not go without 
further mention. The fact that PI3K class I la  silencing was able in itself to completely inhibit 
cell survival in a lung cancer cell line should prompt an investigation into the possibility that 
this occurrence could be a widespread phenomenon in cancer cell lines, and hence a possible 
cancer drug target. The type of cell death elicited by I la  inhibition, and the signalling cascade 
that Ila  silencing disrupts should also be analysed, in order to gauge the possible 
consequences of regulating this survival mechanism.
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6 6.5 7 7.5 8 10 12 15 4 5
30% Acrylamide-Bis 
acrylamide Solution (ml)
3.0 3.25 3.5 3.75 4 5 6 7.5 ~  T . V T " 1.67
MilliQ-filtered H20 (ml) 6.35 6.1 5.85 5.6 5.35 4.35 3.35 1.85 6.36 6.0
IM  Tris pH  8.8 (ml) 5.6 5.6 5.6 5.6 5.6 5.6 5.6 5.6 1.25 1.25
10% SDS (ml) 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.15 0.15
Just before pouring, gel ingredients should be mixed with 50 pi o f 10% (w/v) ammonium 
persulphate solution and 20 pi o f TEMED. Refer to section 2.8.1 for further information.
1 Ingredient volumes for Running Gels are sufficient for three I mm thick mini gels.
~ Ingredient volumes for Stacking Gels are sufficient for four 1 mm thick mini gels.
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12  Im m unoblotting  conditions for prim ary antibodies
















Aktl Goat 60 5% 1:1000 1:10000
Cyclooxygenase-1 Goat 70 5% 1:1000 1:10000
Cyclooxygenase-2 Goat 72 5% 1:700 1:10000
mTOR Goat 220 5% 1:500 1:10000
phosphoSer9-GSK-3/3 Rabbit 46 5% 1:1000 1:10000
phosphoSer73-cJun Rabbit 48 5% 1:700 1:7000
phophoSerl 33-CREB Rabbit 43 5% 1:700 1:7000
phosphoSerl 76/180- 
lKKa/Serl 77/181-IKK/3
Rabbit 87 and 85 5% 1:700 1:10000
phosphoSer235/236-S6 Rabbit 32 5% 1:1000 1:10000
phosphoSer4 73-A kt Rabbit 60 1% 1:700 1:7000
phosphoSer536-p65 Rabbit 75 5% 1:1000 1:10000
phosphoThr71-A TF2 Rabbit 70 5% 1:700 1:10000
phosphoThrl83/Tyrl85-JNK Rabbit 54 and 46 5% 1:1000 1:10000
phospho Thr202/Tyr204-ERK Rabbit 44 and 42 5% 1:1000 1:10000
phospho Thr235-C/EBP/3 Rabbit 38 5% 1:700 1:7000
PI3K class Ila Mouse 170 5% 1:700 1:10000
PI3 K  class 11(3 Mouse 165 5% 1:700 1:10000
P13K p i  10a Rabbit 110 5% 1:700 1:10000
PI3Kpi 10/3 Rabbit 110 5% 1:200 1:7000
PI3K p i  10S Rabbit 110 3% 1:700 1:7000
Refer to section 2.8.3 for further information.
1 Expressed as percentage (w/v) non-fat milk diluted w/v in TBST
2 Diluted v. v in 0.01% (w/v) sodium azide TBST
3 Diluted v. v in 1% (w/v) non-fat milk in TBST
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7.3 A ntibody volum es used for im m unoprecip itation




PI3K p i 10a 5
PI3K p llO p 25
PI3K p i  10/ 5
P13K.pl 108 2
Refer to section 2.9.1 for further information.
164
Chapter 8 - References
Chapter 8 -  References
(2006) The trials and tribulations of Tysabri. Lancet Neurol 5: 373.
Abraham, R. T. (2002) Identification of TOR signaling complexes: more TORC for the cell growth 
engine. Cell 111: 9-12.
Adiseshaiah, P., Kalvakolanu, D. V., and Reddy, S. P. (2006) A JNK-independent signaling pathway 
regulates TNF alpha-stimulated, c-Jun-driven FRA-1 protooncogene transcription in pulmonary 
epithelial cells. JImmunol 177: 7193-7202.
Aggarwal, B. B., Shishodia, S., Ashikawa, K., and Bharti, A. C. (2002) The role of TNF and its family 
members in inflammation and cancer: lessons from gene deletion. Curr Drug Targets Inflamm Allergy 
1: 327-341.
Alam, R., Dejamatt, A., Stafford, S., Forsythe, P. A., Kumar, D., and Grant, J. A. (1993) Selective 
inhibition of the cutaneous late but not immediate allergic response to antigens by misoprostol, a PGE 
analog. Results of a double-blind, placebo-controlled randomized study. Am Rev Respir Dis 148: 1066- 
1070.
Alam, T., An, M. R., and Papaconstantinou, J. (1992) Differential expression of three C/EBP isoforms 
in multiple tissues during the acute phase response. J  Biol Chem 267: 5021-5024.
Alessi, D. R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P. et al. (1996) Mechanism 
of activation of protein kinase B by insulin and IGF-1. EM BO J15: 6541-6551.
Ali, K., Bilancio, A., Thomas, M., Pearce, W., Gilfillan, A. M., Tkaczyk, C. et al. (2004) Essential role 
for the p i lOdelta phosphoinositide 3-kinase in the allergic response. Nature 431: 1007-1011.
Alisky, J. M. and Davidson, B. L. (2004) Towards therapy using RNA interference. Am J  
Pharmacogenomics 4: 45-51.
Allen, J. and Spiteri, M. (2002) Growth factors in idiopathic pulmonary fibrosis: relative roles. 
Respiratory Research 3: 13.
Ammit, A. J. and Panettieri, R. A., Jr. (2001) Invited review: the circle of life: cell cycle regulation in 
airway smooth muscle. J  Appl Physiol 91: 1431-1437.
Amrani, Y., Chen, H., and Panettieri, R. A., Jr. (2000) Activation of tumor necrosis factor receptor 1 in 
airway smooth muscle: a potential pathway that modulates bronchial hyper-responsiveness in asthma? 
Respir Res 1: 49-53.
Amrani, Y., Panettieri, R. A., Jr., Frossard, N., and Bronner, C. (1996) Activation of the TNF alpha- 
p55 receptor induces myocyte proliferation and modulates agonist-evoked calcium transients in 
cultured human tracheal smooth muscle cells. Am J  Respir Cell Mol Biol 15: 55-63.
Arcaro, A., Volinia, S., Zvelebil, M. J., Stein, R., Watton, S. J., Layton, M. J. et al. (1998) Human 
phosphoinositide 3-kinase C2beta , the role of calcium and the C2 domain in enzyme activity. J  Biol 
Chem 273: 33082-33090.
Arend, W. P. (2002) The balance between IL-1 and IL-IRa in disease. Cytokine Growth Factor Rev 13: 
323-340.
Atherton, H. C., Jones, G., and Danahay, H. (2003) IL-13-induced changes in the goblet cell density of 
human bronchial epithelial cell cultures: MAP kinase and phosphatidylinositol 3-kinase regulation. Am 
J  Physiol Lung Cell Mol Physiol 285: L730-L739.
Augustine, J. J., Bodziak, K. A., and Hricik, D. E. (2007) Use of sirolimus in solid organ 
transplantation. Drugs 67: 369-391.
166
Chapter 8 -  References
Avecillas, J. F., Freire, A. X., and Arroliga, A. C. (2006) Clinical epidemiology of acute lung injury 
and acute respiratory distress syndrome: incidence, diagnosis, and outcomes. Clin Chest Med 27: 549- 
557.
Babu, K. S., Davies, D. E., and Holgate, S. T. (2004) Role of tumor necrosis factor alpha in asthma. 
Immunol Allergy Clin North Am 24: 583-595.
Backlund, M. G., Mann, J. R., and Dubois, R. N. (2005) Mechanisms for the prevention of 
gastrointestinal cancer: the role of prostaglandin E2. Oncology 69: 28-32.
Balis, J. U., Bumgarner, S. D., Paciga, J. E., Paterson, J. F., and Shelley, S. A. (1984) Synthesis of lung 
surfactant-associated glycoproteins by A549 cells: description of an in vitro model for human type II 
cell dysfunction. Exp Lung Res 6: 197-213.
Barnes, P. J. (2003a) Chronic obstructive pulmonary disease * 12: New treatments for COPD. Thorax 
58: 803-808.
Barnes, P. J. (2003b) Cytokine-directed therapies for the treatment of chronic airway diseases. Cytokine 
Growth Factor Rev 14: 511-522.
Barnes, P. J., Adcock, I. M., and Ito, K. (2005) Histone acetylation and deacetylation: importance in 
inflammatory lung diseases. Eur Respir J 25: 552-563.
Beeton, C. A., Chance, E. M., Foukas, L. C., and Shepherd, P. R. (2000) Comparison of the kinetic 
properties of the lipid- and protein-kinase activities of the pi lOalpha and p i lObeta catalytic subunits of 
class-Ia phosphoinositide 3-kinases. BiochemJ 350: 353-359.
Belham, C. M., Scott, P. H., Twomey, D. P., Gould, G. W., Wadsworth, R. M., and Plevin, R. (1997) 
Evidence that thrombin-stimulated DNA synthesis in pulmonary arterial fibroblasts involves 
phosphatidylinositol 3-kinase-dependent p70 ribosomal S6 kinase activation. Cell Signal 9: 109-116.
Belperio, J. A., Keane, M. P., Lynch, J. P., Ill, and Strieter, R. M. (2006) The role of cytokines during 
the pathogenesis of ventilator-associated and ventilator-induced lung injury. Semin Respir Crit Care 
Med 27: 350-364.
Benistant, C., Chapuis, H., and Roche, S. (2000) A specific function for phosphatidylinositol 3-kinase 
alpha (p85alpha-pl lOalpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha- 
p l lObeta) in de novo DNA synthesis of human colon carcinoma cells. Oncogene 19: 5083-5090.
Bennett, B. L., Sasaki, D. T., Murray, B. W., O'Leary, E. C., Sakata, S. T., Xu, W. etal. (2001) 
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U SA  98: 
13681-13686.
Bernard, G. R., Artigas, A., Brigham, K. L., Carlet, J., Falke, K., Hudson, L. et al. (1994) The 
American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, 
and clinical trial coordination. Am J  Respir Crit Care Med 149: 818-824.
Berry, M., Brightling, C., Pavord, I., and Wardlaw, A. (2007) TNF-alpha in asthma. Curr Opin 
Pharmacol 7: 279-282.
Besirli, C. G. and Johnson, E. M., Jr. (2003) JNK-independent activation o f c-Jun during neuronal 
apoptosis induced by multiple DNA-damaging agents. J  Biol Chem 278: 22357-22366.
Bi, L., Okabe, I., Bernard, D. J., and Nussbaum, R. L. (2002) Early embryonic lethality in mice 
deficient in the p i lObeta catalytic subunit of PI 3-kinase. Mamm Genome 13: 169-172.
Bi, L., Okabe, I., Bernard, D. J., Wynshaw-Boris, A., and Nussbaum, R. L. (1999) Proliferative defect 
and embryonic lethality in mice homozygous for a deletion in the p i lOalpha subunit of 
phosphoinositide 3-kinase. JBiol Chem 274: 10963-10968.
167
Chapter 8 -  References
Bilancio, A., Okkenhaug, K., Camps, M., Emery, J. L., Ruckle, T., Rommel, C. et al. (2006) Key role 
of the pi lOdelta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of 
genetic and pharmacologic interference with p i lOdelta function in B cells. Blood 107: 642-650.
Billack, B., Heck, D. E., Mariano, T. M., Gardner, C. R., Sur, R., Laskin, D. L. et al. (2002) Induction 
of cyclooxygenase-2 by heat shock protein 60 in macrophages and endothelial cells. Am J  Physiol Cell 
Physiol!83: C1267-C1277.
Billich, A., Bomancin, F., Mechtcheriakova, D., Natt, F., Huesken, D., and Baumruker, T. (2005) Basal 
and induced sphingosine kinase 1 activity in A549 carcinoma cells: function in cell survival and IL- 
lbeta and TNF-alpha induced production of inflammatory mediators. Cell Signal 17: 1203-1217.
Bodine, S. C., Stitt, T. N., Gonzalez, M., Kline, W. O., Stover, G. L., Bauerlein, R. et al. (2001) 
Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle 
atrophy in vivo. Nat Cell Biol 3: 1014-1019.
Borish, L., Mascali, J. J., Dishuck, J., Beam, W. R., Martin, R. J., and Rosenwasser, L. J. (1992) 
Detection of alveolar macrophage-derived IL-1 beta in asthma. Inhibition with corticosteroids. J  
Immunol 149: 3078-3082.
Brachmann, S. M., Ueki, K., Engelman, J. A., Kahn, R. C., and Cantley, L. C. (2005) Phosphoinositide 
3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin 
sensitivity in mice. Mol Cell Biol 25: 1596-1607.
Bracke, M., Nijhuis, E., Lammers, J. W., Coffer, P. J., and Koenderman, L. (2000a) A critical role for 
PI 3-kinase in cytokine-induced Fcalpha-receptor activation. Blood 95: 2037-2043.
Bracke, M., van de, G. E., Lammers, J. W., Coffer, P. J., and Koenderman, L. (2000b) In vivo priming 
of FcalphaR functioning on eosinophils of allergic asthmatics. JLeukoc Biol 68: 655-661.
Brinkman, B. M., Telliez, J. B., Schievella, A. R., Lin, L. L., and Goldfeld, A. E. (1999) Engagement 
of tumor necrosis factor (TNF) receptor 1 leads to ATF-2- and p38 mitogen-activated protein kinase- 
dependent TNF-alpha gene expression. J  Biol Chem 274: 30882-30886.
Brun-Buisson, C., Minelli, C., Bertolini, G., Brazzi, L., Pimentel, J., Lewandowski, K. et al. (2004) 
Epidemiology and outcome of acute lung injury in European intensive care units. Results from the 
ALIVE study. Intensive Care Med 30: 51-61.
Brunn, G. J., Williams, J., Sabers, C., Wiederrecht, G., Lawrence, J. C., Jr., and Abraham, R. T. (1996) 
Direct inhibition of the signaling functions of the mammalian target of rapamycin by the 
phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EM BO J15: 5256-5267.
Calkhoven, C. F., Muller, C., and Leutz, A. (2000) Translational control of C/EBPalpha and 
C/EBPbeta isoform expression. Genes Dev 14: 1920-1932.
Cao, C., Sun, Y., Healey, S., Bi, Z., Hu, G., Wan, S. et al. (2006) EGFR-mediated expression of 
aquaporin-3 is involved in human skin fibroblast migration. Biochem J 400: 225-234.
Cao, Z., Liu, L. Z., Dixon, D. A., Zheng, J. Z., Chandran, B., and Jiang, B. H. (2007) Insulin-like 
growth factor-I induces cyclooxygenase-2 expression via PI3K, MAPK and PKC signaling pathways in 
human ovarian cancer cells. Cell Signal 19: 1542-1553.
Cao, Z., Umek, R. M., and McKnight, S. L. (1991) Regulated expression of three C/EBP isoforms 
during adipose conversion of 3T3-L1 cells. Genes Dev 5: 1538-1552.
Caravatta, L., Sancilio, S., di, G., V, Rana, R., Cataldi, A., and Di, P. R. (2007) PI3-K/Akt-dependent 
activation of cAMP-response element-binding (CREB) protein in Jurkat T leukemia cells treated with 
TRAIL. J  Cell Physiol in press.
168
Chapter 8 -  References
Carpentier, I., Declercq, W., Malinin, N. L., Wallach, D., Fiers, W., and Beyaert, R. (1998) TRAF2 
plays a dual role in NF-kappaB-dependent gene activation by mediating the TNF-induced activation of 
p38 MAPK and IkappaB kinase pathways. FEBSLett 425: 195-198.
Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., and Williamson, B. (1975) An 
endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A l l :  3666- 
3670.
Cassel, T. N. and Nord, M. (2003) C/EBP transcription factors in the lung epithelium. Am J  Physiol 
Lung Cell Mol Physiol 285: L773-L781.
Catley, M. C., Sukkar, M. B., Chung, K. F., Jaffee, B., Liao, S. M., Coyle, A. J. et al. (2006) Validation 
of the anti-inflammatory properties of small-molecule IkappaB Kinase (IKK)-2 inhibitors by 
comparison with adenoviral-mediated delivery of dominant-negative IKK1 and IKK2 in human 
airways smooth muscle. Mol Pharmacol 70: 697-705.
Celli, B. R. and MacNee, W. (2004) Standards for the diagnosis and treatment of patients with COPD: 
a summary of the ATS/ERS position paper. Eur Respir J  23: 932-946.
Chan, A. T., Ogino, S., and Fuchs, C. S. (2007) Aspirin and the risk of colorectal cancer in relation to 
the expression of COX-2. N Engl J  Med 356: 2131-2142.
Chan, T. O., Rittenhouse, S. E., and Tsichlis, P. N. (1999) Akt/PKB and other D3 phosphoinositide- 
regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annual Review o f 
Biochemistry 68: 965-1014.
Chandrasekar, B., Mummidi, S., Valente, A. J., Patel, D. N., Bailey, S. R., Freeman, G. L. et al. (2005) 
The pro-atherogenic cytokine interleukin-18 induces CXCL16 expression in rat aortic smooth muscle 
cells via MyD88, interleukin-1 receptor-associated kinase, tumor necrosis factor receptor-associated 
factor 6, c-Src, phosphatidylinositol 3-kinase, Akt, c-Jun N-terminal kinase, and activator protein-1 
signaling. J  Biol Chem 280: 26263-26277.
Chantry, D., Vojtek, A., Kashishian, A., Holtzman, D. A., Wood, C., Gray, P. W. et al. (1997) 
p i lOdelta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is 
expressed predominantly in leukocytes. J  Biol Chem 211: 19236-19241.
Charreau, B., Coupel, S., Goret, F., Pourcel, C., and Soulillou, J. P. (2000) Association of 
glucocorticoids and cyclosporin A or rapamycin prevents E-selectin and IL-8 expression during LPS- 
and TNFalpha-mediated endothelial cell activation. Transplantation 69: 945-953.
Chen, C. C., Sun, Y. T., Chen, J. J., and Chang, Y. J. (2001a) Tumor necrosis factor-alpha-induced 
cyclooxygenase-2 expression via sequential activation of ceramide-dependent mitogen-activated 
protein kinases, and IkappaB kinase 1/2 in human alveolar epithelial cells. Mol Pharmacol 59: 493- 
500.
Chen, C. J., Deng, Z., Kim, A. Y., Blobel, G. A., and Lieberman, P. M. (2001b) Stimulation of CREB 
binding protein nucleosomal histone acetyltransferase activity by a class of transcriptional activators. 
Mol Cell Biol 21: 476-487.
Chen, C. C., Sun, Y. T., Chen, J. J., and Chiu, K. T. (2000) TNF-{alpha}-induced cyclooxygenase-2 
expression in human lung epithelial cells: Involvement of the phospholipase C-{gamma}2, protein 
kinase C-{alpha}, tyrosine kinase, NF-{kappa}B-inducing kinase, and I-{kappa}B kinase 1/2 pathway. 
J  Immunol 165: 2719-2728.
Chen, G., Cao, P., and Goeddel, D. V. (2002) TNF-induced recruitment and activation of the IKK 
complex require Cdc37 and Hsp90. Mol Cell 9: 401-410.
Chen, G. and Goeddel, D. V. (2002) TNF-R1 signaling: a beautiful pathway. Science 296: 1634-1635.
169
Chapter 8 -  References
Chen, K. H., Weng, M. S., and Lin, J. K. (2007) Tangeretin suppresses IL-1 beta-induced 
cyclooxygenase (COX)-2 expression through inhibition of p38 MAPK, JNK, and AKT activation in 
human lung carcinoma cells. Biochem Pharmacol 73: 215-227.
Cheng, J. Q., Lindsley, C. W., Cheng, G. Z., Yang, H., and Nicosia, S. V. (2005) The Akt/PKB 
pathway: molecular target for cancer drug discovery. Oncogene 24: 7482-7492.
Chiappara, G., Chanez, P., Bruno, A., Pace, E., Pompeo, F., Bousquet, J. et al. (2007) Variable p- 
CREB expression depicts different asthma phenotypes. Allergy 62: 787-794.
Chinenov, Y. and Kerppola, T. K. (2001) Close encounters of many kinds: Fos-Jun interactions that 
mediate transcription regulatory specificity. Oncogene 20: 2438-2452.
Chini, B. A., Fiedler, M. A., Milligan, L., Hopkins, T., and Stark, J. M. (1998) Essential roles of NF- 
kappa B and C/EBP in the regulation of intercellular adhesion molecule-1 after respiratory syncytial 
virus infection of human respiratory epithelial cell cultures. J  Virol 72: 1623-1626.
Chulada, P. C., Thompson, M. B., Mahler, J. F., Doyle, C. M., Gaul, B. W., Lee, C. et al. (2000) 
Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer 
Res 60: 4705-4708.
Chung, K. F. (2001) Cytokines in chronic obstructive pulmonary disease. Eur Respir J  Suppl 34: 50s- 
59s.
Chung, K. F. (2005) Evaluation of selective prostaglandin E2 (PGE2) receptor agonists as therapeutic 
agents for the treatment of asthma. Sci STKE 2005: e47.
Clayton, E., Bardi, G., Bell, S. E., Chantry, D., Downes, C. P., Gray, A. et al. (2002) A crucial role for 
the p i lOdelta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J  Exp Med 
196:753-763.
Condliffe, A. M., Davidson, K., Anderson, K. E., Ellson, C. D., Crabbe, T., Okkenhaug, K. et al.
(2005) Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst 
of human but not murine neutrophils. Blood 106: 1432-1440.
Crackower, M. A., Oudit, G. Y., Kozieradzki, I., Sarao, R., Sun, H., Sasaki, T. et al. (2002) Regulation 
of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 110: 737-749.
Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M., and Hemmings, B. A. (1995) Inhibition of 
glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378: 785-789.
Cross, D. A., Alessi, D. R., Vandenheede, J. R., McDowell, H. E., Hundal, H. S., and Cohen, P. (1994) 
The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat 
skeletal muscle cell line L6 is blocked by wortmannin, but not by rapamycin: evidence that wortmannin 
blocks activation of the mitogen-activated protein kinase pathway in L6 cells between Ras and Raf. 
Biochem J 303: 21-26.
Cross, D. A., Culbert, A. A., Chalmers, K. A., Facci, L., Skaper, S. D., and Reith, A. D. (2001)
Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones 
from death. JNeurochem  77: 94-102.
Cumock, A. P., Logan, M. K., and Ward, S. G. (2002) Chemokine signalling: pivoting around multiple 
phosphoinositide 3-kinases. Immunology 105: 125-136.
Cyster, J. G. (2005) Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid 
organs. Annu Rev Immunol 23:127-59.: 127-159.
Datta, S. R., Brunet, A., and Greenberg, M. E. (1999) Cellular survival: a play in three Akts. Genes 
Dev 13: 2905-2927.
170
Chapter 8 -  References
Davies, S. P., Reddy, H., Caivano, M., and Cohen, P. (2000) Specificity and mechanism of action of 
some commonly used protein kinase inhibitors. Biochem J 351: 95-105.
de Fougerolles, A., Vomlocher, H. P., Maraganore, J., and Lieberman, J. (2007) Interfering with 
disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6: 443-453.
Del, P. A., Vermi, W., Dander, E., Otero, K., Barberis, L., Luini, W. et al. (2004) Defective dendritic 
cell migration and activation of adaptive immunity in PI3Kgamma-deficient mice. EMBO J23: 3505- 
3515.
Deng, W. G., Montero, A. J., and Wu, K. K. (2007) Interferon-{gamma} suppresses cyclooxygenase-2 
promoter activity by inhibiting c-Jun and C/EBP {beta} binding. Arterioscler Thromb Vase Biol in 
press.
Deng, W. G., Zhu, Y., and Wu, K. K. (2003) Up-regulation o f p300 binding and p50 acetylation in 
tumor necrosis factor-alpha-induced cyclooxygenase-2 promoter activation. J  Biol Chem 278: 4770- 
4777.
Desmouliere, A., Geinoz, A., Gabbiani, F., and Gabbiani, G. (1993) Transforming growth factor-beta 1 
induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent 
and growing cultured fibroblasts. J  Cell Biol 122: 103-111.
Devin, A., Cook, A., Lin, Y., Rodriguez, Y., Kelliher, M., and Liu, Z. (2000) The distinct roles of 
TRAF2 and RIP in IKK activation by TNF-R1: TRAF2 recruits IKK to TNF-R1 while RIP mediates 
IKK activation. Immunity 12: 419-429.
Dinarello, C. A. (1997) Interleukin-1. Cytokine Growth Factor Rev 8: 253-265.
Doble, B. W. and Woodgett, J. R. (2003) GSK-3: tricks of the trade for a multi-tasking kinase. J  Cell 
Sci 116: 1175-1186.
Doepfner, K. T., Spertini, O., and Arcaro, A. (2007) Autocrine insulin-like growth factor-I signaling 
promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3- 
kinase/Akt pathway. Leukemia in press.
Domin, J., Harper, L., Aubyn, D., Wheeler, M., Florey, O., Haskard, D. et al. (2005) The class II 
phosphoinositide 3-kinase PI3K-C2beta regulates cell migration by a PtdIns3P dependent mechanism. 
J  Cell Physiol 205: 452-462.
Domin, J., Pages, F., Volinia, S., Rittenhouse, S. E., Zvelebil, M. J., Stein, R. C. et al. (1997) Cloning 
of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the 
inhibitor wortmannin. Biochem J 326: 139-147.
Domin, J., Gaidarov, I., Smith, M. E. K., Keen, J. H., and Waterfield, M. D. (2000) The class II 
phosphoinositide 3-kinase PI3K-C2alpha is concentrated in the trans-Golgi network and present in 
clathrin-coated vesicles. J  Biol Chem 275: 11943-11950.
Donaldson, D. D., Whitters, M. J., Fitz, L. J., Neben, T. Y., Finnerty, H., Henderson, S. L. et al. (1998) 
The murine IL-13 receptor {alpha}2: molecular cloning, characterization, and comparison with murine 
IL-13 receptor {alpha} 1. J  Immunol 161: 2317-2324.
Dower, S. K. and Qwamstrom, E. E. (2003) Signalling networks, inflammation and innate immunity. 
Biochem Soc Trans 31: 1462-1471.
Drazen, J. M., Israel, E., and O'Byme, P. M. (1999) Treatment of asthma with drugs modifying the 
leukotriene pathway. N Engl J  Med 340: 197-206.
171
Chapter 8 -  References
Duan, W., guinaldo Datiles, A. M., Leung, B. P., Vlahos, C. J., and Wong, W. S. (2005) An anti­
inflammatory role for a phosphoinositide 3-kinase inhibitor LY294002 in a mouse asthma model. Int 
Immunopharmacol 5: 495-502.
Dummler, B., Tschopp, O., Hynx, D., Yang, Z. Z., Dimhofer, S., and Hemmings, B. A. (2006) Life 
with a single isoform of Akt: Mice lacking Akt2 and Akt3 are viable but display affected glucose 
homeostasis and growth deficiencies. Mol Cell Biol 26: 8042-8051.
Durham, S. R. and Kay, A. B. (1985) Eosinophils, bronchial hyperreactivity and late-phase asthmatic 
reactions. Clin Allergy 15: 411-418.
Dykxhoom, D. M., Novina, C. D., and Shaip, P. A. (2003) Killing the messenger: short RNAs that 
silence gene expression. Nat Rev Mol Cell Biol 4: 457-467.
Ekberg-Jansson, A., Andersson, B., Bake, B., Boijsen, M., Enanden, I., Rosengren, A. et al. (2001) 
Neutrophil-associated activation markers in healthy smokers relates to a fall in DL(CO) and to 
emphysematous changes on high resolution CT. Respir Med 95: 363-373.
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., and Tuschl, T. (2001) Duplexes of 
21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498.
Engelman, J. A., Lisanti, M. P., and Scherer, P. E. (1998) Specific inhibitors ofp38 mitogen-activated 
protein kinase block 3T3-L1 adipogenesis. J  Biol Chem 273: 32111-32120.
Erickson, S. L., de Sauvage, F. J., Kikly, K., Carver-Moore, K., Pitts-Meek, S., Gillett, N. et al. (1994) 
Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2 - 
deficient mice. Nature 372: 560-563.
Erjefalt, J. S., Eijefalt, I., Sundler, F., and Persson, C. G. (1995) In vivo restitution of airway 
epithelium. Cell Tissue Res 281: 305-316.
Eynott, P. R., Nath, P., Leung, S. Y., Adcock, I. M., Bennett, B. L., and Chung, K. F. (2003) Allergen- 
induced inflammation and airway epithelial and smooth muscle cell proliferation: role of Jun N- 
terminal kinase. Br J  Pharmacol 140: 1373-1380.
Ezeamuzie, C. I., Sukumaran, J., and Philips, E. (2001) Effect of wortmannin on human eosinophil 
responses in vitro and on bronchial inflammation and airway hyperresponsiveness in Guinea pigs in
vivo. Am J  Respir Crit Care Med 164: 1633-1639.
Fan, J., Ye, R. D., and Malik, A. B. (2001) Transcriptional mechanisms of acute lung injury. Am J
Physiol Lung Cell Mol Physiol 281: L1037-L1050.
Fiedler, M. A., Wemke-Dollries, K., and Stark, J. M. (1998) Inhibition of TNF-alpha -induced NF- 
kappa B activation and IL-8 release in A549 cells with the proteasome inhibitor MG-132. Am J  Respir 
Cell Mol Biol 19: 259-268.
Finan, P. M. and Thomas, M. J. (2004) PI 3-kinase inhibition: a therapeutic target for respiratory 
disease. Biochem Soc Trans 32: 378-382.
Foresi, A., Bertorelli, G., Pesci, A., Chetta, A., and Olivieri, D. (1990) Inflammatory markers in 
bronchoalveolar lavage and in bronchial biopsy in asthma during remission. Chest 98: 528-535.
Foster, K. A., Oster, C. G., Mayer, M. M., Avery, M. L., and Audus, K. L. (1998) Characterization of 
the A549 cell line as a type II pulmonary epithelial cell model for drug metabolism. Exp Cell Res 243: 
359-366.
Franchimont, D., Martens, H., Hagelstein, M. T., Louis, E., Dewe, W., Chrousos, G. P. et al. (1999) 
Tumor necrosis factor alpha decreases, and interleukin-10 increases, the sensitivity of human
172
Chapter 8 -  References
monocytes to dexamethasone: potential regulation of the glucocorticoid receptor. J  Clin Endocrinol 
Metab 84: 2834-2839.
Frey, R. S., Gao, X., Javaid, K., Siddiqui, S. S., Rahman, A., and Malik, A. B. (2006) 
Phosphatidylinositol 3-kinase gamma signaling through protein kinase Czeta induces NADPH oxidase- 
mediated oxidant generation and NF-kappaB activation in endothelial cells. J  Biol Chem 281: 16128- 
16138.
Fujihara, S., Ward, C., Dransfield, I., Hay, R. T., Uings, I. J., Hayes, B. et al. (2002) Inhibition of 
nuclear factor-kappaB activation un-masks the ability of TNF-alpha to induce human eosinophil 
apoptosis. Eur J  Immunol 32: 457-466.
Gao, X. P., Zhu, X., Fu, J., Liu, Q., Frey, R. S., and Malik, A. B. (2007) Blockade of class IA 
phosphoinositide 3-kinase in neutrophils prevents NADPH oxidase activation- and adhesion-dependent 
inflammation. J  Biol Chem 282: 6116-6125.
Gauvreau, G. M., Watson, R. M., and O'Byme, P. M. (1999) Protective effects of inhaled PGE2 on 
allergen-induced airway responses and airway inflammation. Am J  Respir Crit Care Med 159: 31-36.
Gavett, S. H., Madison, S. L., Chulada, P. C., Scarborough, P. E., Qu, W., Boyle, J. E. et a l (1999) 
Allergic lung responses are increased in prostaglandin H synthase-deficient mice. J  Clin Invest 104: 
721-732.
Ghosh, S., Wu, Y., Li, R., and Hu, Y. (2005) Jun proteins modulate the ovary-specific promoter of 
aromatase gene in ovarian granulosa cells via a cAMP-responsive element. Oncogene 24: 2236-2246.
Giard, D. J., Aaronson, S. A., Todaro, G. J., Amstein, P., Kersey, J. H., Dosik, H. et al. (1973) In vitro 
cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. JNatl 
Cancer Inst 51: 1417-1423.
Go, Y. M., Park, H., Maland, M. C., rley-Usmar, V. M., Stoyanov, B., Wetzker, R. et al. (1998) 
Phosphatidylinositol 3-kinase gamma mediates shear stress-dependent activation of JNK in endothelial 
cells. Am J  Physiol 275: H1898-H1904.
Goodman, R. B., Pugin, J., Lee, J. S., and Matthay, M. A. (2003) Cytokine-mediated inflammation in 
acute lung injury. Cytokine Growth Factor Rev 14: 523-535.
Goodman, R. B., Strieter, R. M., Martin, D. P., Steinberg, K. P., Milberg, J. A., Maunder, R. J. et al.
(1996) Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. 
Am J  Respir Crit Care Med 154: 602-611.
Gordon, J. R., Li, F., Zhang, X., Wang, W., Zhao, X., and Nayyar, A. (2005) The combined 
CXCR1/CXCR2 antagonist CXCL8(3-74)K11R/G31P blocks neutrophil infiltration, pyrexia, and 
pulmonary vascular pathology in endotoxemic animals. JLeukoc Biol 78: 1265-1272.
Gosens, R., Bromhaar, M. M., Tonkes, A., Schaafsma, D., Zaagsma, J., Nelemans, S. A. et al. (2004) 
Muscarinic M(3) receptor-dependent regulation of airway smooth muscle contractile phenotype. B rJ  
Pharmacol 141: 943-950.
Graber, P., Gretener, D., Herren, S., Aubry, J. P., Elson, G., Poudrier, J. et al. (1998) The distribution 
of IL-13 receptor alpha 1 expression on B cells, T cells and monocytes and its regulation by IL-13 and 
IL-4. European Journal o f Immunology 28: 4286-4298.
Grau, R., Punzon, C., Fresno, M., and Iniguez, M. A. (2006) Peroxisome-proliferator-activated receptor 
alpha agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional 
activation in human colorectal carcinoma cells via inhibition of activator protein-1. Biochem J  395: 81- 
88 .
173
Chapter 8 -  References
Green, S. P., Chuntharapai, A., and Cumutte, J. T. (1996) Interleukin-8 (IL-8), melanoma growth- 
stimulatory activity, and neutrophil-activating peptide selectively mediate priming of the neutrophil 
NADPH oxidase through the type A or type B IL-8 receptor. J  Biol Chem 271: 25400-25405.
Grell, M., Douni, E., Wajant, H., Lohden, M., Clauss, M., Maxeiner, B. et al. (1995) The 
transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor 
necrosis factor receptor. Cell 83: 793-802.
Gross, T. J. and Hunninghake, G. W. (2001) Idiopathic pulmonary fibrosis. NEngl J  Med 345: 517- 
525.
Grunstein, M. M., Hakonarson, H., Leiter, J., Chen, M., Whelan, R., Grunstein, J. S. et al. (2002) IL- 
13-dependent autocrine signaling mediates altered responsiveness of IgE-sensitized airway smooth 
muscle. American Journal o f Physiology-Lung Cellular and Molecular Physiology 282: L520-L528.
Grunweller, A. and Hartmann, R. K. (2005) RNA interference as a gene-specific approach for 
molecular medicine. Curr Med Chem 12: 3143-3161.
Guo, B. and Rothstein, T. L. (2005) B cell receptor (BCR) cross-talk: IL-4 creates an alternate pathway 
for BCR-induced ERK activation that is phosphatidylinositol 3-kinase independent. J  Immunol 174: 
5375-5381.
Guo, Y. S., Hellmich, M. R., Wen, X. D., and Townsend, C. M., Jr. (2001) Activator protein-1 
transcription factor mediates bombesin-stimulated cyclooxygenase-2 expression in intestinal epithelial 
cells. J  Biol Chem 276: 22941-22947.
Gustin, J. A., Maehama, T., Dixon, J. E., and Donner, D. B. (2001) The PTEN tumor suppressor 
protein inhibits tumor necrosis factor-induced nuclear factor kappa B activity. J  Biol Chem 276: 27740- 
27744.
Ha, H., Lee, J. H., Kim, H. N., Kim, H. M., Kwak, H. B., Lee, S. et al. (2006) alpha-Lipoic acid 
inhibits inflammatory bone resorption by suppressing prostaglandin E2 synthesis. J Immunol 176: 111- 
117.
Hahn, E. L. and Gamelli, R. L. (2000) Prostaglandin E2 synthesis and metabolism in bum injury and 
trauma. J  Trauma 49: 1147-1154.
Hai, T. and Hartman, M. G. (2001) The molecular biology and nomenclature of the activating 
transcription factor/cAMP responsive element binding family of transcription factors: activating 
transcription factor proteins and homeostasis. Gene 273: 1-11.
Halayko, A. J., Kartha, S., Stelmack, G. L., McConville, J., Tam, J., Camoretti-Mercado, B. et al. 
(2004) Phophatidylinositol-3 kinase/mammalian target of rapamycin/p70S6K regulates contractile 
protein accumulation in airway myocyte differentiation. Am J  Respir Cell Mol Biol 31: 266-275.
Hamilton, A. J. and Baulcombe, D. C. (1999) A species of small antisense RNA in posttranscriptional 
gene silencing in plants. Science 286: 950-952.
Hanna, A. N., Chan, E. Y., Xu, J., Stone, J. C., and Brindley, D. N. (1999) A novel pathway for tumor 
necrosis factor-alpha and ceramide signaling involving sequential activation of tyrosine kinase, 
p21(ras), and phosphatidylinositol 3-kinase. J  Biol Chem 274: 12722-12729.
Harada, K., Truong, A. B., Cai, T., and Khavari, P. A. (2005) The class II phosphoinositide 3-kinase 
C2beta is not essential for epidermal differentiation. Mol Cell Biol 25: 11122-11130.
Hata, S., Shimizu, T., and Fujimoto, M. (2000) A short region containing an AP-1 binding site is 
essential for transforming growth factor-beta-induced c-jun gene expression in osteoblastic cells. 
IUBMB Life 49: 229-234.
174
Chapter 8  -  References
Heaney, L. G., Lindsay, J. T., and McGarvey, L. P. (2007) Inflammation in chronic obstructive 
pulmonary disease: implications for new treatment strategies. Curr Med Chem 14: 787-796.
Heijink, I. H. and Van Oosterhout, A. J. (2005) Targeting T cells for asthma. Curr Opin Pharmacol 5: 
227-231.
Held, H. D., Boettcher, S., Hamann, L., and Uhlig, S. (2001) Ventilation-induced chemokine and 
cytokine release is associated with activation of nuclear factor-kappaB and is blocked by steroids. Am J  
Respir Crit Care Med 163: 711-716.
Henderson, W. R., Jr., Chi, E. Y., Teo, J. L., Nguyen, C., and Kahn, M. (2002) A small molecule 
inhibitor of redox-regulated NF-kappa B and activator protein-1 transcription blocks allergic airway 
inflammation in a mouse asthma model. J  Immunol 169: 5294-5299.
Henriquet, C., Gougat, C., Combes, A., Lazennec, G., and Mathieu, M. (2007) Differential regulation 
of RANTES and IL-8 expression in lung adenocarcinoma cells. Lung Cancer 56: 167-174.
Hess, J., Angel, P., and Schorpp-Kistner, M. (2004) AP-1 subunits: quarrel and harmony among 
siblings. J  Cell Sci 117: 5965-5973.
Heuer, H. O., Wenz, B., Jennewein, H. M., and Urich, K. (1994) Dissociation of airway responsiveness 
and bronchoalveolar lavage (BAL) cell composition in sensitized guinea-pigs after daily inhalation of 
ovalbumin. Clin Exp Allergy 24: 682-689.
Hildt, E. and Oess, S. (1999) Identification of Grb2 as a novel binding partner of tumor necrosis factor 
(TNF) receptor I. J  Exp Med 189: 1707-1714.
Hirsch, E., Bosco, O., Tropel, P., Laffargue, M., Calvez, R., Altruda, F. et al. (2001) Resistance to 
thromboembolism in PI3Kgamma-deficient mice. FASEB J 15: 2019-2021.
Hirsch, E., Katanaev, V. L., Garlanda, C., Azzolino, O., Pirola, L., Silengo, L. et al. (2000) Central role 
for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 287: 1049-1053.
Hoeflich, K. P., Luo, J., Rubie, E. A., Tsao, M. S., Jin, O., and Woodgett, J. R. (2000) Requirement for 
glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 406: 86-90.
Hoffmann, E., ttrich-Breiholz, O., Holtmann, H., and Kracht, M. (2002) Multiple control of interleukin- 
8 gene expression. JLeukoc Biol 72: 847-855.
Holgate, S. T., Bums, G. B., Robinson, C., and Church, M. K. (1984) Anaphylactic- and calcium- 
dependent generation of prostaglandin D2 (PGD2), thromboxane B2, and other cyclooxygenase 
products of arachidonic acid by dispersed human lung cells and relationship to histamine release. J  
Immunol 133: 2138-2144.
Holmes, W. E., Lee, J., Kuang, W. J., Rice, G. C., and Wood, W. I. (1991) Structure and functional 
expression of a human interleukin-8 receptor. Science 253: 1278-1280.
Honda, T., Segi-Nishida, E., Miyachi, Y., and Narumiya, S. (2006) Prostacyclin-IP signaling and 
prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced 
arthritis. J  Exp Med 203: 325-335.
Hsieh, H. L., Wu, C. B., Sun, C. C., Liao, C. H., Lau, Y. T., and Yang, C. M. (2006) Sphingosine-1- 
phosphate induces COX-2 expression via PI3K/Akt and p42/p44 MAPK pathways in rat vascular 
smooth muscle cells. J  Cell Physiol 207: 757-766.
Hsu, H., Huang, J., Shu, H. B., Baichwal, V., and Goeddel, D. V. (1996a) TNF-dependent recruitment 
of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 4: 387-396.
175
Chapter 8  -  References
Hsu, H., Shu, H. B., Pan, M. G., and Goeddel, D. V. (1996b) TRADD-TRAF2 and TRADD-FADD 
interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84: 299-308.
Hsu, H., Xiong, J., and Goeddel, D. V. (1995) The TNF receptor 1-associated protein TRADD signals 
cell death and NF-kappa B activation. Cell 81: 495-504.
Huang, W. C. and Chen, C. C. (2005) Akt phosphorylation of p300 at Ser-1834 is essential for its 
histone acetyltransferase and transcriptional activity. Mol Cell Biol 25: 6592-6602.
Igishi, T., Fukuhara, S., Patel, V., Katz, B. Z., Yamada, K. M., and Gutkind, J. S. (1999) Divergent 
signaling pathways link focal adhesion kinase to mitogen-activated protein kinase cascades. Evidence 
for a role of Paxillin in c-Jun NH2-terminal kinase activation. J  Biol Chem 274: 30738-30746.
Inoue, H., Yokoyama, C., Hara, S., Tone, Y., and Tanabe, T. (1995) Transcriptional regulation of 
human prostaglanain-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in 
vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and 
cAMP response element. J  Biol Chem 270: 24965-24971.
Ishida, K., Thomson, R. J., Beattie, L. L., Wiggs, B., and Schellenberg, R. R. (1990) Inhibition of 
antigen-induced airway hyperresponsiveness, but not acute hypoxia nor airway eosinophilia, by an 
antagonist of platelet-activating factor. J  Immunol 144: 3907-3911.
Ito, K., Caramori, G., and Adcock, I. M. (2007) Therapeutic potential of phosphatidylinositol 3-kinase 
inhibitors in inflammatory respiratory disease. J  Pharmacol Exp Ther 321: 1-8.
Ivanov, A. I. and Romanovsky, A. A. (2004) Prostaglandin E2 as a mediator of fever: synthesis and 
catabolism. Front Biosci 9:1977-93.: 1977-1993.
Jacobs, M. D., Black, J., Futer, O., Swenson, L., Hare, B., Fleming, M. et al. (2005) Pim-1 ligand- 
bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002. J  Biol 
Chem 2S0: 13728-13734.
Jayaprakash, V., Menezes, R. J., Javle, M. M., McCann, S. E., Baker, J. A., Reid, M. E. et al. (2006) 
Regular aspirin use and esophageal cancer risk. Int J  Cancer 119: 202-207.
Jiang, Y., Woronicz, J. D., Liu, W., and Goeddel, D. V. (1999) Prevention of constitutive TNF receptor 
1 signaling by silencer of death domains. Science 283: 543-546.
Jou, S. T., Carpino, N., Takahashi, Y., Piekorz, R., Chao, J. R., Carpino, N. et al. (2002) Essential, 
nonredundant role for the phosphoinositide 3-kinase p i lOdelta in signaling by the B-cell receptor 
complex. Mol Cell Biol 22: 8580-8591.
Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., and MacLachlan, I. (2005) Sequence- 
dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Bio techno I 
23: 457-462.
Kaltschmidt, B., Linker, R., Deng, J., and Kaltschmidt, C. (2002) Cyclooxygenase-2 is a neuronal 
target gene of NF-kappaB. BMC Molecular Biology 3: 16.
Kanda, S., Hodgkin, M. N., Woodfield, R. J., Wakelam, M. J., Thomas, G., and Claesson-Welsh, L.
(1997) Phosphatidylinositol 3'-kinase-independent p70 S6 kinase activation by fibroblast growth factor 
receptor-1 is important for proliferation but not differentiation of endothelial cells. J  Biol Chem 272: 
23347-23353.
Kang, K. W., Cho, I. J., Lee, C. H., and Kim, S. G. (2003) Essential role of phosphatidylinositol 3- 
kinase-dependent CCAAT/enhancer binding protein beta activation in the induction of glutathione S- 
transferase by oltipraz. JN atl Cancer Inst 95: 53-66.
176
Chapter 8 — References
Kang, S., Song, J., Kang, J., Kang, H., Lee, D., Lee, Y. et al. (2005) Suppression of the alpha-isoform 
of class II phosphoinositide 3-kinase gene expression leads to apoptotic cell death. Biochem Biophys 
Res Commun 329: 6-10.
Kay, A. B. (1991) Asthma and inflammation. J  Allergy Clin Immunol 87: 893-910.
Ke, J., Long, X., Liu, Y., Zhang, Y. F., Li, J., Fang, W. et a l (2007) Role of NF-kappaB in TNF-alpha- 
induced COX-2 expression in synovial fibroblasts from human TMJ. J  Dent Res 86: 363-367.
Keatings, V. M., Collins, P. D., Scott, D. M., and Barnes, P. J. (1996) Differences in interleukin-8 and 
tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary 
disease or asthma. Am J  Respir Crit Care Med 153: 530-534.
Kelliher, M. A., Grimm, S., Ishida, Y., Kuo, F., Stanger, B. Z., and Leder, P. (1998) The death domain 
kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity 8: 297-303.
Kim, Y. D., Jeon, J. Y., Woo, H. J., Lee, J. C., Chung, J. H., Song, S. Y. et al. (2002) Interleukin-1 beta 
induces MUC2 gene expression and mucin secretion via activation of PKC-MEK/ERK, and PI3K in 
human airway epithelial cells. J  Korean Med Sci 17: 765-771.
Kim, Y. D., Kwon, E. J., Kwon, T. K., Baek, S. H., Song, S. Y., and Suh, J. S. (2000) Regulation of 1L- 
1 beta-mediated MUC2 gene in NCI-H292 human airway epithelial cells. Biochem Biophys Res 
Commun 274: 112-116.
King, G. G., Pare, P. D., and Seow, C. Y. (1999) The mechanics of exaggerated airway narrowing in 
asthma: the role of smooth muscle. Respir Physiol 118: 1-13.
Kita, H., bu-Ghazaleh, R. I., Gleich, G. J., and Abraham, R. T. (1991) Regulation of Ig-induced 
eosinophil degranulation by adenosine 3',5'-cyclic monophosphate. J  Immunol 146: 2712-2718.
Knight, Z. A., Gonzalez, B., Feldman, M. E., Zunder, E. R., Goldenberg, D. D., Williams, O. et al. 
(2006) A pharmacological map of the PI3-K family defines a role for pi lOalpha in insulin signaling. 
Cell 125: 733-747.
Kollias, G., Douni, E., Kassiotis, G., and Kontoyiannis, D. (1999) On the role of tumor necrosis factor 
and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory 
bowel disease. Immunol Rev 169:175-94.: 175-194.
Korenaga, R., Ando, J., Kosaki, K., Isshiki, M., Takada, Y., and Kamiya, A. (1997) Negative 
transcriptional regulation of the VCAM-1 gene by fluid shear stress in murine endothelial cells. Am J  
Physiol 273: C1506-C1515.
Krieg, J., Hofsteenge, J., and Thomas, G. (1988) Identification of the 40 S ribosomal protein S6 
phosphorylation sites induced by cycloheximide. J  Biol Chem 263: 11473-11477.
Kroegel, C. and Matthys, H. (1993) Platelet-activating factor-induced human eosinophil activation. 
Generation and release of cyclo-oxygenase metabolites in human blood eosinophils from asthmatics. 
Immunology 78: 279-285.
Krymskaya, V. P., Ammit, A. J., Hoffman, R. K., Eszterhas, A. J., and Panettieri, R. A., Jr. (2001) 
Activation of class IA PI3K stimulates DNA synthesis in human airway smooth muscle cells. Am J  
Physiol Lung Cell Mol Physiol 280: L1009-L1018.
Krymskaya, V. P., Penn, R. B., Orsini, M. J., Scott, P. H., Plevin, R. J., Walker, T. R. et al. (1999) 
Phosphatidylinositol 3-kinase mediates mitogen-induced human airway smooth muscle cell 
proliferation. Am J  Physiol 111". L65-L78.
177
Chapter 8 -  References
Kuebler, W. M., Uhlig, U., Goldmann, T., Schael, G., Kerem, A., Exner, K. et al. (2003) Stretch 
activates nitric oxide production in pulmonary vascular endothelial cells in situ. Am J  Respir Crit Care 
Med 168: 1391-1398.
Kumar, R. K. and Foster, P. S. (2002) Modeling allergic asthma in mice: pitfalls and opportunities. Am 
J  Respir Cell Mol Biol 27: 267-272.
Kunikata, T., Yamane, H., Segi, E., Matsuoka, T., Sugimoto, Y., Tanaka, S. et al. (2005) Suppression 
of allergic inflammation by the prostaglandin E receptor subtype EP3. Nat Immunol 6: 524-531.
Kuo, C. C., Lin, W. T., Liang, C. M., and Liang, S. M. (2006) Class I and III phosphatidylinositol 3'- 
kinase play distinct roles in TLR signaling pathway. J  Immunol 176: 5943-5949.
Kuperman, D. A., Huang, X., Koth, L. L., Chang, G. H., Dolganov, G. M., Zhu, Z. et al. (2002) Direct 
effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in 
asthma. Nat Med 8: 885-889.
Kwak, Y. G., Song, C. H., Yi, H. K., Hwang, P. H., Kim, J. S., Lee, K. S. et al. (2003) Involvement of 
PTEN in airway hyperresponsiveness and inflammation in bronchial asthma. J  Clin Invest 111: 1083- 
1092.
Kwan, M. L., Habel, L. A., Slattery, M. L., and Caan, B. (2007) NSAIDs and breast cancer recurrence 
in a prospective cohort study. Cancer Causes Control 18: 613-620.
Kwon, O. J., Au, B. T., Collins, P. D., Adcock, I. M., Mak, J. C., Robbins, R. R. et al. (1994) Tumor 
necrosis factor-induced interleukin-8 expression in cultured human airway epithelial cells. Am J  
Physiol Lung Cell Mol Physiol 267: L398-L405.
Laffargue, M., Calvez, R., Finan, P., Trifilieff, A., Barbier, M., Altruda, F. et al. (2002) 
Phosphoinositide 3-kinase gamma is an essential amplifier of mast cell function. Immunity 16: 441- 
451.
Lam, K., Carpenter, C. L., Ruderman, N. B., Friel, J. C., and Kelly, K. L. (1994) The 
phosphatidylinositol 3-kinase serine kinase phosphorylates IRS-1. Stimulation by insulin and inhibition 
by Wortmannin. J  Biol Chem 269: 20648-20652.
Laoukili, J., Perret, E., Willems, T., Minty, A., Parthoens, E., Houcine, O. et al. (2001) IL-13 alters 
mucociliary differentiation and ciliary beating of human respiratory epithelial cells. J  Clin Invest 108: 
1817-1824.
Lappalainen, U., Whitsett, J. A., Wert, S. E., Tichelaar, J. W., and Bry, K. (2005) Interleukin-1 {beta} 
causes pulmonary inflammation, emphysema, and airway remodeling in the adult murine lung. Am J 
Respir Cell Mol Biol 32: 311-318.
Lassalle, P., Delneste, Y., Gosset, P., Tonnel, A. B., and Capron, A. (1991) Potential implication of 
endothelial cells in bronchial asthma. Int Arch Allergy Appl Immunol 94: 233-238.
Lassalle, P., Gosset, P., Delneste, Y., Tsicopoulos, A., Capron, A., Joseph, M. et al. (1993) Modulation 
of adhesion molecule expression on endothelial cells during the late asthmatic reaction: role of 
macrophage-derived tumour necrosis factor-alpha. Clin Exp Immunol 94: 105-110.
Lawler, S., Fleming, Y., Goedert, M., and Cohen, P. (1998) Synergistic activation of SAPK1/JNK1 by 
two MAP kinase kinases in vitro. Curr Biol 8: 1387-1390.
Lee, J. W., Soung, Y. H., Kim, S. Y., Lee, H. W., Park, W. S., Nam, S. W. et al. (2005) PIK3CA gene 
is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24: 1477-1480.
178
Chapter 8 -  References
Lee, K. S., Lee, H. K., Hayflick, J. S., Lee, Y. C., and Puri, K. D. (2006) Inhibition of phosphoinositide 
3-kinase delta attenuates allergic airway inflammation and hyperresponsiveness in murine asthma 
model. FASEB J20: 455-465.
Lee, S. Y., Reichlin, A., Santana, A., Sokol, K. A., Nussenzweig, M. C., and Choi, Y. (1997) TRAF2 is 
essential for JNK but not NF-kappaB activation and regulates lymphocyte proliferation and survival. 
Immunity 7: 703-713.
Levine, S. J., Larivee, P., Logun, C., Angus, C. W., Ognibene, F. P., and Shelhamer, J. H. (1995)
Tumor necrosis factor-alpha induces mucin hypersecretion and MUC-2 gene expression by human 
airway epithelial cells. Am J  Respir Cell Mol Biol 12: 196-204.
Levy, B. D. (2005) Lipoxins and lipoxin analogs in asthma. Prostaglandins, Leukotrienes and Essential 
Fatty Acids 73: 231-237.
Levy, B. D., De Sanctis, G. T., Devchand, P. R., Kim, E., Ackerman, K., Schmidt, B. A. et al. (2002) 
Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A4. Nat Med 8: 
1018-1023.
Li, J. D., Dohrman, A. F., Gallup, M., Miyata, S., Gum, J. R., Kim, Y. S. et al. (1997) Transcriptional 
activation of mucin by Pseudomonas aeruginosa lipopolysaccharide in the pathogenesis of cystic 
fibrosis lung disease. Proc Natl Acad Sci U SA  94: 967-972.
Li, Q. and Verma, I. M. (2002) NF-kappaB regulation in the immune system. Nat Rev Immunol 2: 725- 
734.
Li, Z., Jiang, H., Xie, W., Zhang, Z., Smrcka, A. V., and Wu, D. (2000) Roles of PLC-beta2 and -beta3 
and PI3Kgamma in chemoattractant-mediated signal transduction. Science 287: 1046-1049.
Libby, P., Warner, S. J., and Friedman, G. B. (1988) Interleukin 1: a mitogen for human vascular 
smooth muscle cells that induces the release of growth-inhibitory prostanoids. J  Clin Invest 81: 487- 
498.
Lim, S., Roche, N., Oliver, B. G., Mattos, W., Barnes, P. J., and Chung, K. F. (2000) Balance of matrix 
metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette 
smokers. Regulation by interleukin-10. Am J  Respir Crit Care Med 162: 1355-1360.
Lionetti, V., Lisi, A., Patrucco, E., De, G. P., Milazzo, M. G., Ceci, S. et al. (2006) Lack of 
phosphoinositide 3-kinase-gamma attenuates ventilator-induced lung injury. Crit Care M ed34: 134- 
141.
Liu, C. H., Chang, S. H., Narko, K., Trifan, O. C., Wu, M. T., Smith, E. et al. (2001) Overexpression of 
cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J  Biol Chem 276: 18563- 
18569.
Liu, Z. G. and Han, J. (2001) Cellular responses to tumor necrosis factor. Curr Issues Mol Biol 3: 79- 
90.
Lomas-Neira, J. L., Chung, C. S., Wesche, D. E., Perl, M., and Ayala, A. (2005) In vivo gene silencing 
(with siRNA) of pulmonary expression of MIP-2 versus KC results in divergent effects on hemorrhage- 
induced, neutrophil-mediated septic acute lung injury. JLeukoc Biol 77: 846-853.
Lugogo, N. L. and Kraft, M. (2006) Epidemiology of asthma. Clin Chest Med 27: 1-15.
Lukacs, N. W., Strieter, R. M., Chensue, S. W., Widmer, M., and Kunkel, S. L. (1995) TNF-alpha 
mediates recruitment of neutrophils and eosinophils during airway inflammation. J  Immunol 154: 
5411-5417.
179
Chapter 8 -  References
Luster, A. D. and Tager, A. M. (2004) T-cell trafficking in asthma: lipid mediators grease the way. Nat 
Rev Immunol 4:711 -724.
Mabuchi, T., Kojima, H., Abe, T., Takagi, K., Sakurai, M., Ohmiya, Y. et al. (2004) Membrane- 
associated prostaglandin E synthase-1 is required for neuropathic pain. Neuroreport 15: 1395-1398.
MacDonald, P. E., Joseph, J. W., Yau, D., Diao, J., Asghar, Z., Dai, F. et al. (2004) Impaired glucose- 
stimulated insulin secretion, enhanced intraperitoneal insulin tolerance, and increased beta-cell mass in 
mice lacking the p i lOgamma isoform of phosphoinositide 3-kinase. Endocrinology 145: 4078-4083.
MacDougall, L. K., Domin, J., and Waterfield, M. D. (1995) A family of phosphoinositide 3-kinases in 
Drosophila identifies a new mediator of signal transduction. Curr Biol 5: 1404-1415.
Maffucci, T., Cooke, F. T., Foster, F. M., Traer, C. J., Fry, M. J., and Falasca, M. (2005) Class II 
phosphoinositide 3-kinase defines a novel signaling pathway in cell migration. J  Cell Biol 169: 789- 
799.
Mahoney, C. W., Shuman, J., McKnight, S. L., Chen, H. C., and Huang, K. P. (1992) Phosphorylation 
of CCAAT-enhancer binding protein by protein kinase C attenuates site-selective DNA binding. J  Biol 
Chem 267: 19396-19403.
Maneechotesuwan, K., Essilfie-Quaye, S., Kharitonov, S. A., Adcock, I. M., and Barnes, P. J. (2007) 
Loss of control of asthma following inhaled corticosteroid withdrawal is associated with increased 
sputum inteleukin-8 and neutrophils. Chest in press.
Manoukian, A. S. and Woodgett, J. R. (2002) Role of glycogen synthase kinase-3 in cancer: regulation 
by Wnts and other signaling pathways. Adv Cancer Res 84: 203-229.
Marcet, B., Libert, F., Boeynaems, J. M., and Communi, D. (2007) Extracellular nucleotides induce 
COX-2 up-regulation and prostaglandin E2 production in human A549 alveolar type II epithelial cells. 
Eur J  Pharmacol 566: 167-171.
Martin, T. R. (1999) Lung cytokines and ARDS: Roger S. Mitchell lecture. Chest 116: 2S-8.
Masoli, M., Fabian, D., Holt, S., and Beasley, R. (2004) The global burden of asthma: executive 
summary of the GINA Dissemination Committee report. Allergy 59: 469-478.
Matsuse, T., Thomson, R. J., Chen, X. R., Salari, H., and Schellenberg, R. R. (1991) Capsaicin inhibits 
airway hyperresponsiveness but not lipoxygenase activity or eosinophilia after repeated aerosolized 
antigen in guinea pigs. Am Rev Respir Dis 144: 368-372.
Mayo, M. W., Madrid, L. V., Westerheide, S. D., Jones, D. R., Yuan, X. J., Baldwin, A. S., Jr. et al. 
(2002) PTEN blocks tumor necrosis factor-induced NF-kappa B-dependent transcription by inhibiting 
the transactivation potential of the p65 subunit. JBiol Chem 277: 11116-11125.
Mayr, B. and Montminy, M. (2001) Transcriptional regulation by the phosphorylation-dependent factor 
CREB. Nat Rev Mol Cell Biol 2: 599-609.
Mechta-Grigoriou, F., Gerald, D., and Yaniv, M. (2001) The mammalian Jun proteins: redundancy and 
specificity. Oncogene 20: 2378-2389.
Medina-Tato, D. A., Ward, S. G., and Watson, M. L. (2007) Phosphoinositide 3-kinase signalling in 
lung disease: leucocytes and beyond. Immunology 121: 448-461.
Mitchell, J. A., Belvisi, M. G., Akarasereenont, P., Robbins, R. A., Kwon, O. J., Croxtall, J. et al. 
(1994) Induction of cyclo-oxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by 
dexamethasone. Br J  Pharmacol 113: 1008-1014.
180
Chapter 8 -  References
Mitchell, J. A., Larkin, S., and Williams, T. J. (1995) Cyclooxygenase-2: regulation and relevance in 
inflammation. Biochem Pharmacol 50: 1535-1542.
Miyahara, T., Hamanaka, K., Weber, D. S., Drake, D., Anghelescu, M., and Parker, J. C. (2007) 
Phosphoinositide 3-Kinase, Src and Akt modulate acute ventilation induced vascular permeability 
increases in mouse lungs. Am J  Physiol Lung Cell Mol Physiol in press.
Moller, B. and Villiger, P. M. (2006) Inhibition of IL-1, IL-6, and TNF-alpha in immune-mediated 
inflammatory diseases. Springer Semin Immunopathol 27: 391-408.
Molton, S. A., Todd, D. E., and Cook, S. J. (2003) Selective activation of the c-Jun N-terminal kinase 
(JNK) pathway fails to elicit Bax activation or apoptosis unless the phosphoinositide 3-kinase (PI3K) 
pathway is inhibited. Oncogene 22: 4690-4701.
Moore, M. L. and Peebles, R. S., Jr. (2006) Update on the role of prostaglandins in allergic lung 
inflammation: separating friends from foes, harder than you might think. J  Allergy Clin Immunol 117: 
1036-1039.
Mori, A., Kaminuma, O., Ogawa, K., Okudaira, H., and Akiyama, K. (2000) Transcriptional regulation 
of IL-5 gene by nontransformed human T cells through the proximal promoter element. Intern Med 39: 
618-625.
Moriguchi, T., Toyoshima, F., Masuyama, N., Hanafusa, H., Gotoh, Y., and Nishida, E. (1997) A novel 
SAPK/JNK kinase, MKK7, stimulated by TNFalpha and cellular stresses. EMBO J 16: 7045-7053.
Moule, S. K. and Denton, R. M. (1997) Multiple signaling pathways involved in the metabolic effects 
of insulin. Am J Cardiol 80: 41A-49A.
Muller, G., Storz, P., Bourteele, S., Doppler, H., Pfizenmaier, K., Mischak, H. et al. (1998) Regulation 
of Raf-1 kinase by TNF via its second messenger ceramide and cross-talk with mitogenic signalling. 
EMBO J 17: 732-742.
Murakami, T., Takagi, H., Suzuma, K., Suzuma, I., Ohashi, H., Watanabe, D. et al. (2005) 
Angiopoietin-1 attenuates H202-induced SEK1/JNK phosphorylation through the phosphatidylinositol 
3-kinase/Akt pathway in vascular endothelial cells. J  Biol Chem 280: 31841-31849.
Myou, S., Leff, A. R., Myo, S., Boetticher, E., Tong, J., Meliton, A. Y. et al. (2003) Blockade of 
inflammation and airway hyperresponsiveness in immune-sensitized mice by dominant-negative 
phosphoinositide 3-kinase-TAT. J  Exp Med 198: 1573-1582.
Namkoong, S., Lee, S. J., Kim, C. K., Kim, Y. M., Chung, H. T., Lee, H. et al. (2005) Prostaglandin E2 
stimulates angiogenesis by activating the nitric oxide/cGMP pathway in human umbilical vein 
endothelial cells. Exp Mol Med 37: 588-600.
Nanua, S., Zick, S. M., Andrade, J. E., Sajjan, U. S., Burgess, J. R., Lukacs, N. W. et al. (2006) 
Quercetin blocks airway epithelial cell chemokine expression. Am JRespir Cell Mol Biol 35: 602-610.
Nardone, L. L. and Andrews, S. B. (1979) Cell line A549 as a model of the type II pneumocyte. 
Phospholipid biosynthesis from native and organometallic precursors. Biochim Biophys Acta 573: 276- 
295.
Nath, P., Eynott, P., Leung, S. Y., Adcock, I. M., Bennett, B. L., and Chung, K. F. (2005) Potential role 
of c-Jun NH2-terminal kinase in allergic airway inflammation and remodelling: effects of SP600125. 
Eur J  Pharmacol 506: 273-283.
Newton, R., Stevens, D. A., Hart, L. A., Lindsay, M., Adcock, I. M., and Barnes, P. J. (1997) 
Superinduction of COX-2 mRNA by cycloheximide and interleukin-1 beta involves increased 
transcription and correlates with increased NF-kappaB and JNK activation. FEBS Lett 418: 135-138.
181
Chapter 8  -  References
Ogawa, Y. and Calhoun, W. J. (2006) The role of leukotrienes in airway inflammation. J  Allergy Clin 
Immunol 118: 789-798.
Okkenhaug, K., Bilancio, A., Farjot, G., Priddle, H., Sancho, S., Peskett, E. et al. (2002) Impaired B 
and T cell antigen receptor signaling in pi lOdelta PI 3-kinase mutant mice. Science 297: 1031-1034.
Ong, E., Gao, X. P., Predescu, D., Broman, M., and Malik, A. B. (2005) Role of phosphatidylinositol 
3-kinase-gamma in mediating lung neutrophil sequestration and vascular injury induced by E. coli 
sepsis. Am J Physiol Lung Cell Mol Physiol 289: L1094-L1103.
Ono, H., Ichiki, T., Fukuyama, K., lino, N., Masuda, S., Egashira, K. et al. (2004) cAMP-response 
element-binding protein mediates tumor necrosis factor-alpha-induced vascular smooth muscle cell 
migration. Arterioscler Thromb Vase Biol 24: 1634-1639.
Orr, A. W., Pallero, M. A., and Murphy-Ullrich, J. E. (2002) Thrombospondin stimulates focal 
adhesion disassembly through Gi- and phosphoinositide 3-kinase-dependent ERK activation. J  Biol 
Chem 111'. 20453-20460.
Orsini, M. J., Krymskaya, V. P., Eszterhas, A. J., Benovic, J. L., Panettieri, R. A., Jr., and Penn, R. B.
(1999) MAPK superfamily activation in human airway smooth muscle: mitogenesis requires prolonged 
p42/p44 activation. Am J  Physiol 211: L479-L488.
Osawa, Y., Nagaki, M., Banno, Y., Brenner, D. A., Asano, T., Nozawa, Y. et al. (2002) Tumor necrosis 
factor alpha-induced interleukin-8 production via NF-{kappa}B and phosphatidylinositol 3-kinase/Akt 
pathways inhibits cell apoptosis in human hepatocytes. Infect Immun 70: 6294-6301.
Oshima, H., Oshima, M., Inaba, K., and Taketo, M. M. (2004) Hyperplastic gastric tumors induced by 
activated macrophages in COX-2/mPGES-l transgenic mice. EMBO J  23: 1669-1678.
Ougolkov, A. V. and Billadeau, D. D. (2006) Targeting GSK-3: a promising approach for cancer 
therapy? Future Oncol 2: 91-100.
Ozes, O. N., Mayo, L. D., Gustin, J. A., Pfeffer, S. R., Pfeffer, L. M., and Donner, D. B. (1999) NF- 
kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401: 82- 
85.
Palframan, R. T., Collins, P. D., Severs, N. J., Rothery, S., Williams, T. J., and Rankin, S. M. (1998a) 
Mechanisms of acute eosinophil mobilization from the bone marrow stimulated by interleukin 5: the 
role of specific adhesion molecules and phosphatidylinositol 3-kinase. J  Exp Med 188: 1621-1632.
Palframan, R. T., Collins, P. D., Williams, T. J., and Rankin, S. M. (1998b) Eotaxin induces a rapid 
release of eosinophils and their progenitors from the bone marrow. Blood 91: 2240-2248.
Panaretou, C., Domin, J., Cockcroft, S., and Waterfield, M. D. (1997) Characterization of pl50, an 
adaptor protein for the human phosphatidylinositol (Ptdlns) 3-kinase. Substrate presentation by 
phosphatidylinositol transfer protein to the pl50.Ptdins 3-kinase complex. J  Biol Chem 212: 2477- 
2485.
Park, W. Y., Goodman, R. B., Steinberg, K. P., Ruzinski, J. T., Radella, F., Park, D. R. et al. (2001) 
Cytokine balance in the lungs of patients with acute respiratory distress syndrome. Am J  Respir Crit 
Care Med 164: 1896-1903.
Parry, R. V., Riley, J. L., and Ward, S. G. (2007) Signalling to suit function: tailoring phosphoinositide 
3-kinase during T-cell activation. Trends Immunol 28: 161-168.
Patel, K. M., Wright, K. L., Whittaker, P., Chakravarty, P., Watson, M. L., and Ward, S. G. (2005) 
Differential modulation of COX-2 expression in A549 airway epithelial cells by structurally distinct 
PPAR(gamma) agonists: evidence for disparate functional effects which are independent of NF- 
(kappa)B and PPAR(gamma). Cell Signal 17: 1098-1110.
182
Chapter 8  -  References
Patrucco, E., Notte, A., Barberis, L., Selvetella, G., Maffei, A., Brancaccio, M. et al. (2004) 
PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent 
and -independent effects. Cell 118: 375-387.
Pearson, G., Robinson, F., Beers Gibson, T., Xu, B., Karandikar, M., Berman, K. et al. (2001) 
Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr 
Rev 22: 153-183.
Peebles, R. S., Jr., Hashimoto, K., Morrow, J. D., Dworski, R., Collins, R. D., Hashimoto, Y. et al. 
(2002) Selective cyclooxygenase-1 and -2 inhibitors each increase allergic inflammation and airway 
hyperresponsiveness in mice. Am JRespir Crit Care Med 165: 1154-1160.
Pende, M., Um, S. H., Mieulet, V., Sticker, M., Goss, V. L., Mestan, J. et al. (2004) S6K1-/-/S6K2-/- 
mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation 
and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol Cell Biol 24: 3112- 
3124.
Perez, A., Rogers, R. M., and Dauber, J. H. (2003) The prognosis of idiopathic pulmonary fibrosis. Am 
J  Respir Cell Mol Biol 29: S19-S26.
Perkins, N. D. (2000) The Rel/NF-kappa B family: friend and foe. Trends Biochem Sci 25: 434-440.
Peters, S. P., Schulman, E. S., Schleimer, R. P., MacGlashan, D. W., Jr., Newball, H. H., and 
Lichtenstein, L. M. (1982) Dispersed human lung mast cells. Pharmacologic aspects and comparison 
with human lung tissue fragments. Am Rev Respir Dis 126: 1034-1039.
Petrovic, N., Knight, D. A., Bomalaski, J. S., Thompson, P. J., and Misso, N. L. (2006) Concomitant 
activation of extracellular signal-regulated kinase and induction of COX-2 stimulates maximum 
prostaglandin E2 synthesis in human airway epithelial cells. Prostaglandins Other Lipid Mediat 81: 
126-135.
Pfeffer, K., Matsuyama, T., Kundig, T. M., Wakeham, A., Kishihara, K., Shahinian, A. et al. (1993) 
Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet 
succumb to L. monocytogenes infection. Cell 73: 457-467.
Phillips, R. J., Burdick, M. D., Hong, K., Lutz, M. A., Murray, L. A., Xue, Y. Y. et al. (2004) 
Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J  Clin Invest 
114:438-446.
Pignatti, P., Moscato, G., Casarini, S., Delmastro, M., Poppa, M., Brunetti, G. et al. (2005) 
Downmodulation of CXCL8/IL-8 receptors on neutrophils after recruitment in the airways. J  Allergy 
Clin Immunol 115: 88-94.
Poli, V. (1998) The role of C/EBP isoforms in the control of inflammatory and native immunity 
functions. J  Biol Chem 273: 29279-29282.
Pope, S. M., Brandt, E. B., Mishra, A., Hogan, S. P., Zimmermann, N., Matthaei, K. I. et al. (2001) IL- 
13 induces eosinophil recruitment into the lung by an IL-5- and eotaxin-dependent mechanism. J  
Allergy Clin Immunol 108: 594-601.
Portanova, J. P., Zhang, Y., Anderson, G. D., Hauser, S. D., Masferrer, J. L., Seibert, K. et al. (1996) 
Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 
production in vivo. J  Exp Med 184: 883-891.
Puneet, P., Moochhala, S., and Bhatia, M. (2005) Chemokines in acute respiratory distress syndrome. 
Am J  Physiol Lung Cell Mol Physiol 288: L3-15.
Puri, K. D., Doggett, T. A., Douangpanya, J., Hou, Y., Tino, W. T., Wilson, T. et al. (2004) 
Mechanisms and implications of phosphoinositide 3-kinase delta in promoting neutrophil trafficking 
into inflamed tissue. Blood 103: 3448-3456.
183
Chapter 8 -  References
Puri, K. D., Doggett, T. A., Huang, C. Y., Douangpanya, J., Hayflick, J. S., Turner, M. et al. (2005)
The role of endothelial PI3Kgamma activity in neutrophil trafficking. Blood 106: 150-157.
Qiu, Y., Zhu, J., Bandi, V., Atmar, R. L., Hattotuwa, K., Guntupalli, K. K. et al. (2003) Biopsy 
neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic 
obstructive pulmonary disease. Am J  Respir Crit Care Med 168: 968-975.
Rahaman, S. O., Sharma, P., Harbor, P. C., Aman, M. J., Vogelbaum, M. A., and Haque, S. J. (2002) 
IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in 
glioblastoma cells. Cancer Res 62: 1103-1109.
Rahman, I., Gilmour, P. S., Jimenez, L. A., and MacNee, W. (2002) Oxidative stress and TNF-alpha 
induce histone acetylation and NF-kappaB/AP-1 activation in alveolar epithelial cells: potential 
mechanism in gene transcription in lung inflammation. Mol CellBiochem 234: 239-248.
Rameh, L. E. and Cantley, L. C. (1999) The role of phosphoinositide 3-kinase lipid products in cell 
function. J  Biol Chem 274: 8347-8350.
Reddy, R., Buckley, S., Doerken, M., Barsky, L., Weinberg, K., Anderson, K. D. et al. (2004) Isolation 
of a putative progenitor subpopulation of alveolar epithelial type 2 cells. Am J  Physiol Lung Cell Mol 
Physiol 286: L658-L667.
Reddy, S. A., Huang, J. H., and Liao, W. S. (2000) Phosphatidylinositol 3-kinase as a mediator of 
TNF-induced NF-kappa B activation. J  Immunol 164: 1355-1363.
Rieck, P. W., Cholidis, S., and Hartmann, C. (2001) Intracellular signaling pathway of FGF-2- 
modulated corneal endothelial cell migration during wound healing in vitro. Exp Eye Res 73: 639-650.
Robertson, L. K., Mireau, L. R., and Ostergaard, H. L. (2005) A role for phosphatidylinositol 3-kinase 
in TCR-stimulated ERK activation leading to paxillin phosphorylation and CTL degranulation. J  
Immunol 175: 8138-8145.
Rodriguez-Barbero, A., Dorado, F., Velasco, S., Pandiella, A., Banas, B., and Lopez-Novoa, J. M.
(2006) TGF-betal induces COX-2 expression and PGE2 synthesis through MAPK and PI3K pathways 
in human mesangial cells. Kidney Int 70: 901-909.
Rolin, S., Masereel, B., and Dogne, J. M. (2006) Prostanoids as pharmacological targets in COPD and 
asthma. European Journal o f Pharmacology 533: 89-100.
Rondinone, C. M., Carvalho, E., Rahn, T., Manganiello, V. C., Degerman, E., and Smith, U. P. (2000) 
Phosphorylation of PDE3B by phosphatidylinositol 3-kinase associated with the insulin receptor. J  Biol 
Chem 275: 10093-10098.
Rooney, J. W., Hoey, T., and Glimcher, L. H. (1995) Coordinate and cooperative roles for NF-AT and 
AP-1 in the regulation of the murine IL-4 gene. Immunity 2: 473-483.
Ross, S. E., Erickson, R. L., Hemati, N., and MacDougald, O. A. (1999) Glycogen synthase kinase 3 is 
an insulin-regulated C/EBPalpha kinase. Mol Cell Biol 19: 8433-8441.
Rothman, B. L., Despins, A. W., and Kreutzer, D. L. (1990) Cytokine regulation of C3 and C5 
production by the human type II pneumocyte cell line, A549. J  Immunol 145: 592-598.
Ruckle, T., Schwarz, M. K., and Rommel, C. (2006) PI3Kgamma inhibition: towards an 'aspirin of the 
21 st century'? Nat Rev Drug Discov 5: 903-918.
Rudmann, D. G., Moore, M. W., Tepper, J. S., Aldrich, M. C., Pfeiffer, J. W., Hogenesch, H. et al. 
(2000) Modulation of allergic inflammation in mice deficient in TNF receptors. Am J  Physiol Lung 
Cell Mol Physiol 279: LI 047-L1057.
184
Chapter 8 -  References
Russo, C. and Polosa, R. (2005) TNF-alpha as a promising therapeutic target in chronic asthma: a 
lesson from rheumatoid arthritis. Clin Sci (Lond) 109: 135-142.
Rusznak, C., Mills, P. R., Devalia, J. L., Sapsford, R. J., Davies, R. J., and Lozewicz, S. (2000) Effect 
of cigarette smoke on the permeability and IL-lbeta and sICAM-1 release from cultured human 
bronchial epithelial cells of never-smokers, smokers, and patients with chronic obstructive pulmonary 
disease. Am J  Respir Cell Mol Biol 23: 530-536.
Ruvinsky, I. and Meyuhas, O. (2006) Ribosomal protein S6 phosphorylation: from protein synthesis to 
cell size. Trends in Biochemical Sciences 31: 342-348.
Sadhu, C., Masinovsky, B., Dick, K., Sowell, C. G., and Staunton, D. E. (2003) Essential role of 
phosphoinositide 3-kinase delta in neutrophil directional movement. J  Immunol 170: 2647-2654.
Salazar, M., Rojo, A. I., Velasco, D., de Sagarra, R. M., and Cuadrado, A. (2006) Glycogen synthase 
kinase-3beta inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear 
exclusion of the transcription factor Nrf2. J  Biol Chem 281: 14841-14851.
Sarbassov, D. D., Guertin, D. A., Ali, S. M., and Sabatini, D. M. (2005) Phosphorylation and regulation 
of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101.
Sasaki, T., Irie-Sasaki, J., Jones, R. G., Oliveira-dos-Santos, A. J., Stanford, W. L., Bolon, B. et al.
(2000) Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. 
Science 287: 1040-1046.
Scheurich, P., Thoma, B., Ucer, U., and Pflzenmaier, K. (1987) Immunoregulatory activity of 
recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells 
and TNF-alpha-mediated enhancement of T cell responses. J  Immunol 138: 1786-1790.
Schievella, A. R., Chen, J. H., Graham, J. R., and Lin, L. L. (1997) MADD, a novel death domain 
protein that interacts with the type 1 tumor necrosis factor receptor and activates mitogen-activated 
protein kinase. J  Biol Chem 272: 12069-12075.
Schreml, S., Lehle, K., Bimbaum, D. E., and Preuner, J. G. (2007) mTOR-inhibitors simultaneously 
inhibit proliferation and basal IL-6 synthesis of human coronary artery endothelial cells. Int 
Immunopharmacol I: 781-790.
Schroer, K., Zhu, Y., Saunders, M. A., Deng, W. G., Xu, X. M., Meyer-Kirchrath, J. et al. (2002) 
Obligatory role of cyclic adenosine monophosphate response element in cyclooxygenase-2 promoter 
induction and feedback regulation by inflammatory mediators. Circulation 105: 2760-2765.
Schulze-Osthoff, K., Ferrari, D., Los, M., Wesselborg, S., and Peter, M. E. (1998) Apoptosis signaling 
by death receptors. Eur JBiochem 254: 439-459.
Schwingshackl, A., Duszyk, M., Brown, N., and Moqbel, R. (1999) Human eosinophils release matrix 
metalloproteinase-9 on stimulation with TNF-alpha. J  Allergy Clin Immunol 104: 983-989.
Scott, P. H., Belham, C. M., al-Hafidh, J., Chilvers, E. R., Peacock, A. J., Gould, G. W. etal. (1996) A 
regulatory role for cAMP in phosphatidylinositol 3-kinase/p70 ribosomal S6 kinase-mediated DNA 
synthesis in platelet-derived-growth-factor-stimulated bovine airway smooth-muscle cells. Biochem J  
318: 965-971.
Seagrave, J. C. and Nikula, K. J. (2000) Multiple modes of responses to air pollution particulate 
materials in A549 alveolar type II cells. Inhal Toxicol 12: 247-260.
Selman, M. and Pardo, A. (2006) Role of epithelial cells in idiopathic pulmonary fibrosis: from 
innocent targets to serial killers. Proc Am Thorac Soc 3: 364-372.
185
Chapter 8 -  References
Shahabuddin, S., Ji, R., Wang, P., Brailoiu, E., Dun, N., Yang, Y. et al. (2006) CXCR3 chemokine 
receptor-induced chemotaxis in human airway epithelial cells: role of p38 MAPK and PI3K signaling 
pathways. Am J  Physiol Cell Physiol 291: C34-C39.
Shannon, J. M. and Hyatt, B. A. (2004) Epithelial-mesenchymal interactions in the developing lung. 
Annu Rev Physiol 66: 625-645.
Shapiro, D. L., Nardone, L. L., Rooney, S. A., Motoyama, E. K., and Munoz, J. L. (1978) Phospholipid 
biosynthesis and secretion by a cell line (A549) which resembles type II aleveolar epithelial cells. 
Biochim Biophys Acta 530: 197-207.
Shepherd, P. R., Nave, B. T., Rincon, J., Haigh, R. J., Foulstone, E., Proud, C. et al. (1997)
Involvement of phosphoinositide 3-kinase in insulin stimulation of MAP-kinase and phosphorylation of 
protein kinase-B in human skeletal muscle: implications for glucose metabolism. Diabetologia 40: 
1172-1177.
Sheu, M. L., Chao, K. F., Sung, Y. J., Lin, W. W., Lin-Shiau, S. Y., and Liu, S. H. (2005) Activation of 
phosphoinositide 3-kinase in response to inflammation and nitric oxide leads to the up-regulation of 
cyclooxygenase-2 expression and subsequent cell proliferation in mesangial cells. Cell Signal 17: 975- 
984.
Shimabukuro, D. W., Sawa, T., and Gropper, M. A. (2003) Injury and repair in lung and airways. Crit 
Care Med 31: S524-S531.
Shishodia, S., Koul, D., and Aggarwal, B. B. (2004) Cyclooxygenase (COX)-2 inhibitor celecoxib 
abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha 
kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 
synthesis. J  Immunol 173: 2011-2022.
Shuchman, M. (2006) Trading restenosis for thrombosis? New questions about drug-eluting stents. N  
Engl J  Med 355: 1949-1952.
Siler, T. M., Swierkosz, J. E., Hyers, T. M., Fowler, A. A., and Webster, R. O. (1989) Immunoreactive 
interleukin-1 in bronchoalveolar lavage fluid of high-risk patients and patients with the adult 
respiratory distress syndrome. Exp Lung Res 15: 881-894.
Sizemore, N., Lemer, N., Dombrowski, N., Sakurai, H., and Stark, G. R. (2002) Distinct roles of the 
Ikappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa B) from Ikappa 
B and in phosphorylating the p65 subunit of NF-kappa B. JBiol Chem 277: 3863-3869.
Sliva, D. (2004) Signaling pathways responsible for cancer cell invasion as targets for cancer therapy. 
Curr Cancer Drug Targets 4: 327-336.
Slungaard, A., Vercellotti, G. M., Walker, G., Nelson, R. D., and Jacob, H. S. (1990) Tumor necrosis 
factor alpha/cachectin stimulates eosinophil oxidant production and toxicity towards human 
endothelium. J  Exp Med 171: 2025-2041.
Smith, A. J., Surviladze, Z., Gaudet, E. A., Backer, J. M., Mitchell, C. A., and Wilson, B. S. (2001) 
pi lObeta and pi lOdelta phosphatidylinositol 3-kinases up-regulate Fc(epsilon)RI-activated Ca2+ 
influx by enhancing inositol 1,4,5-trisphosphate production. J  Biol Chem 276: 17213-17220.
Smith, B. T. (1977) Cell line A549: a model system for the study o f alveolar type II cell function. Am 
Rev Respir Dis 115: 285-293.
Smith, W. L., Garavito, R. M., and DeWitt, D. L. (1996) Prostaglandin endoperoxide H synthases 
(cyclooxygenases)-l and -2. J  Biol Chem 271: 33157-33160.
Solomon, K. A., Pesti, N., Wu, G., and Newton, R. C. (1999) Cutting edge: a dominant negative form 
of TNF-alpha converting enzyme inhibits proTNF and TNFRII secretion. J  Immunol 163: 4105-4108.
186
Chapter 8 -  References
Somwar, R., Sumitani, S., Taha, C., Sweeney, G., and Klip, A. (1998) Temporal activation of p70 S6 
kinase and Aktl by insulin: PI 3-kinase-dependent and -independent mechanisms. Am J  Physiol 275: 
E618-E625.
Song, E., Lee, S. K., Wang, J., Ince, N., Ouyang, N., Min, J. et al. (2003) RNA interference targeting 
Fas protects mice from fulminant hepatitis. Nat Med 9: 347-351.
Sorli, C. H., Zhang, H. J., Armstrong, M. B., Rajotte, R. V., Maclouf, J., and Robertson, R. P. (1998) 
Basal expression of cyclooxygenase-2 and nuclear factor-interleukin 6 are dominant and coordinately 
regulated by interleukin 1 in the pancreatic islet. Proc Natl Acad Sci U SA  95: 1788-1793.
Sousa, A. R., Lane, S. J., Nakhosteen, J. A., Lee, T. H., and Poston, R. N. (1996) Expression of 
interleukin-1 beta (IL-lbeta) and interleukin-1 receptor antagonist (IL-lra) on asthmatic bronchial 
epithelium. Am J  Respir Crit Care Med 154: 1061-1066.
Stockley, R. A. (2002) Neutrophils and the pathogenesis of COPD. Chest 121: 151S-155S.
Stokoe, D. (2005) The phosphoinositide 3-kinase pathway and cancer. Expert Rev Mol Med 7: 1-22.
Subbaramaiah, K., Yoshimatsu, K., Scherl, E., Das, K. M., Glazier, K. D., Golijanin, D. et al. (2004) 
Microsomal prostaglandin E synthase-1 is overexpressed in inflammatory bowel disease. Evidence for 
involvement of the transcription factor Egr-1. J  Biol Chem 279: 12647-12658.
Sugahara, K., Sadohara, T., Sugita, M., Iyama, K., and Takiguchi, M. (1999) Differential expression of 
CCAAT enhancer binding protein family in rat alveolar epithelial cell proliferation and in acute lung 
injury. Cell Tissue Res 297: 261-270.
Sujobert, P., Bardet, V., Comillet-Lefebvre, P., Hayflick, J. S., Prie, N., Verdier, F. et al. (2005) 
Essential role for the pi lOdelta isoform in phosphoinositide 3-kinase activation and cell proliferation in 
acute myeloid leukemia. Blood 106: 1063-1066.
Sullivan, D. E., Ferris, M., Pociask, D., and Brody, A. R. (2005) Tumor necrosis factor-alpha induces 
transforming growth factor-betal expression in lung fibroblasts through the extracellular signal- 
regulated kinase pathway. Am J  Respir Cell Mol Biol 32: 342-349.
Suter, P. M., Suter, S., Girardin, E., Roux-Lombard, P., Grau, G. E., and Dayer, J. M. (1992) High 
bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, 
in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. Am Rev Respir Dis 
145: 1016-1022.
Swat, W., Montgrain, V., Doggett, T. A., Douangpanya, J., Puri, K., Vermi, W. et al. (2006) Essential 
role of PI3Kdelta and PI3Kgamma in thymocyte survival. Blood 107: 2415-2422.
Takayama, K., Garcia-Cardena, G., Sukhova, G. K., Comander, J., Gimbrone, M. A., Jr., and Libby, P. 
(2002) Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 
receptor. J  Biol Chem 211'. 44147-44154.
Tetley, T. D. (2002) Macrophages and the pathogenesis of COPD. Chest 121: 156S-159S.
Thomas, M. J., Smith, A., Head, D. H., Milne, L., Nicholls, A., Pearce, W. et al. (2005) Airway 
inflammation: chemokine-induced neutrophilia and the class I phosphoinositide 3-kinases. EurJ  
Immunol 35: 1283-1291.
Thomas, P. S. (2001) Tumour necrosis factor-alpha: the role of this multifunctional cytokine in asthma. 
Immunol Cell Biol 79: 132-140.
Thomas, P. S. and Heywood, G. (2002) Effects of inhaled tumour necrosis factor alpha in subjects with 
mild asthma. Thorax 57: 774-778.
187
Chapter 8 — References
Thomas, P. S., Yates, D. H., and Bames, P. J. (1995) Tumor necrosis factor-alpha increases airway 
responsiveness and sputum neutrophilia in normal human subjects. Am J  Respir Crit Care Med 152: 
76-80.
Tiano, H. F., Loftin, C. D., Akunda, J., Lee, C. A., Spalding, J., Sessoms, A. et al. (2002) Deficiency of 
either cyclooxygenase (COX)-l or COX-2 alters epidermal differentiation and reduces mouse skin 
tumorigenesis. Cancer Res 62: 3395-3401.
Tigani, B., Hannon, J. P., Mazzoni, L., and Fozard, J. R. (2001) Effects of wortmannin on airways 
inflammation induced by allergen in actively sensitised Brown Norway rats. Eur J  Pharmacol 433: 
217-223.
Toews, G. B. (2001) Cytokines and the lung. Eur Respir J 18: 3S-17S.
Tong, M., Ding, Y., and Tai, H. H. (2006) Reciprocal regulation of cyclooxygenase-2 and 15- 
hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells. 
Carcinogenesis 27: 2170-2179.
Toumier, C., Dong, C., Turner, T. K., Jones, S. N., Flavell, R. A., and Davis, R. J. (2001) MKK7 is an 
essential component of the JNK signal transduction pathway activated by proinflammatory cytokines. 
Genes Dev 15: 1419-1426.
Tran, H., Brunet, A., Griffith, E. C., and Greenberg, M. E. (2003) The many forks in FOXO's road. Sci 
STKE 2003: re5.
Trautwein, C., Caelles, C., van der, G. P., Hunter, T., Karin, M., and Chojkier, M. (1993) 
Transactivation by NF-IL6/LAP is enhanced by phosphorylation of its activation domain. Nature 364: 
544-547.
Tsang, C. K., Qi, H., Liu, L. F., and Zheng, X. F. S. (2007) Targeting mammalian target of rapamycin 
(mTOR) for health and diseases. Drug Discovery Today 12: 112-124.
Tsang, F., Choo, H. H., Dawe, G. S., and Wong, W. S. (2002) Inhibitors of the tyrosine kinase 
signaling cascade attenuated thrombin-induced guinea pig airway smooth muscle cell proliferation. 
Biochem Biophys Res Commun 293: 72-78.
Tsang, F. and Fred Wong, W. S. (2000) Inhibitors of tyrosine kinase signaling cascade attenuated 
antigen challenge of guinea-pig airways in vitro. Am J  Respir Crit Care Med 162: 126-133.
Tullai, J. W., Schaffer, M. E., Mullenbrock, S., Kasif, S., and Cooper, G. M. (2004) Identification of 
transcription factor binding sites upstream of human genes regulated by the phosphatidylinositol 3- 
kinase and MEK/ERK signaling pathways. J  Biol Chem 279: 20167-20177.
Uhlig, U., Fehrenbach, H., Lachmann, R. A., Goldmann, T., Lachmann, B., Vollmer, E. et al. (2004) 
Phosphoinositide 3-OH kinase inhibition prevents ventilation-induced lung cell activation. Am J  Respir 
Crit Care Med 169: 201-208.
Ulbrich, H., Eriksson, E. E., and Lindbom, L. (2003) Leukocyte and endothelial cell adhesion 
molecules as targets for therapeutic interventions in inflammatory disease. Trends Pharmacol Sci 24: 
640-647.
Urso, B., Brown, R. A., O'Rahilly, S., Shepherd, P. R., and Siddle, K. (1999) The alpha-isoform of 
class II phosphoinositide 3-kinase is more effectively activated by insulin receptors than IGF receptors, 
and activation requires receptor NPEY motifs. FEBS Lett 460: 423-426.
Vaillancourt, F., Morquette, B., Shi, Q., Fahmi, H., Lavigne, P., Di Battista, J. A. et al. (2007) 
Differential regulation of cyclooxygenase-2 and inducible nitric oxide synthase by 4-hydroxynonenal 
in human osteoarthritic chondrocytes through ATF-2/CREB-1 transactivation and concomitant 
inhibition of NF-kappaB signaling cascade. J  Cell Biochem 100: 1217-1231.
188
Chapter 8 -  References
van der Pouw Kraan, T., Boeije, L. C., Snijders, A., Smeenk, R. J., Wijdenes, J., and Aarden, L. A. 
(1996) Regulation of IL-12 production by human monocytes and the influence of prostaglandin E2.
Ann N Y  Acad Sci 795: 147-157.
Van, L. J., Agostinis, P., Vandevoorde, V., Haegeman, G., Fiers, W., Merlevede, W. et al. (1992) 
Tumor necrosis factor stimulates multiple serine/threonine protein kinases in Swiss 3T3 and L929 cells. 
Implication of casein kinase-2 and extracellular signal-regulated kinases in the tumor necrosis factor 
signal transduction pathway. J  Biol Chem 267: 25916-25921.
Van, S., I, Perrais, M., Pigny, P., Porchet, N., and Aubert, J. P. (2000) Sequence of the 5'-flanking 
region and promoter activity of the human mucin gene MUC5B in different phenotypes of colon cancer 
cells. Biochem J  348: 675-686.
Vanderslice, P., Biediger, R. J., Woodside, D. G., Berens, K. L., Holland, G. W., and Dixon, R. A. 
(2004) Development of cell adhesion molecule antagonists as therapeutics for asthma and COPD. Pulm 
Pharmacol Ther 17: 1-10.
Vanhaesebroeck, B., Ali, K., Bilancio, A., Geering, B., and Foukas, L. C. (2005) Signalling by PI3K 
isoforms: insights from gene-targeted mice. Trends Biochem Sci 30: 194-204.
Vanhaesebroeck, B., Higashi, K., Raven, C., Welham, M., Anderson, S., Brennan, P. et a l (1999) 
Autophosphorylation of p i lOdelta phosphoinositide 3-kinase: a new paradigm for the regulation of 
lipid kinases in vitro and in vivo. EMBO J 18: 1292-1302.
Vanhaesebroeck, B., Leevers, S. J., Ahmadi, K., Timms, J., Katso, R., Driscoll, P. C. et al. (2001) 
Synthesis and function 3-phosphorylated inositol lipids. Annual Review o f Biochemistry 70: 535-602.
Venkayya, R., Lam, M., Willkom, M., Grunig, G., Corry, D. B., and Erie, D. J. (2002) The Th2 
lymphocyte products IL-4 and IL-13 rapidly induce airway hyperresponsiveness through direct effects 
on resident airway cells. Am J  Respir Cell Mol Biol 26: 202-208.
Verma, I. M., Stevenson, J. K., Schwarz, E. M., Van, A. D., and Miyamoto, S. (1995) Rel/NF-kappa 
B/I kappa B family: intimate tales of association and dissociation. Genes Dev 9: 2723-2735.
Vietor, I., Schwenger, P., Li, W., Schlessinger, J., and Vilcek, J. (1993) Tumor necrosis factor-induced 
activation and increased tyrosine phosphorylation of mitogen-activated protein (MAP) kinase in human 
fibroblasts. J  Biol Chem 268: 18994-18999.
Voisard, R., Zellmann, S., Muller, F., Fahlisch, F., von, M. L., Baur, R. et al. (2007) Sirolimus inhibits 
key events of restenosis in vitro/ex vivo: evaluation of the clinical relevance of the data by SI/MPL- 
and SI/DES-ratios. BMC Cardiovasc Disord in press.
von Bethmann, A. N., Brasch, F., Nusing, R., Vogt, K., Volk, H. D., Muller, K. M. et al. (1998) 
Hyperventilation induces release of cytokines from perfused mouse lung. Am J  Respir Crit Care Med 
157: 263-272.
Wajant, H., Pfizenmaier, K., and Scheurich, P. (2003) Tumor necrosis factor signaling. Cell Death 
Differ 10: 45-65.
Walker, T. R., Moore, S. M., Lawson, M. F., Panettieri, R. A., Jr., and Chilvers, E. R. (1998) Platelet- 
derived growth factor-BB and thrombin activate phosphoinositide 3-kinase and protein kinase B: role 
in mediating airway smooth muscle proliferation. Mol Pharmacol 54: 1007-1015.
Walter, D. M., Mclntire, J. J., Berry, G., McKenzie, A. N. J., Donaldson, D. D., DeKruyff, R. H. etal.
(2001) Critical role for IL-13 in the development of allergen-induced airway hyperreactivity. J  
Immunol 167: 4668-4675.
Wang, D., Westerheide, S. D., Hanson, J. L., and Baldwin, A. S., Jr. (2000) Tumor necrosis factor 
alpha-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II. J  Biol Chem 
275: 32592-32597.
189
Chapter 8 -  References
Wang, Y., Yoshioka, K., Azam, M. A., Takuwa, N., Sakurada, S., Kayaba, Y. et al. (2006) Class II 
phosphoinositide 3-kinase alpha-isoform regulates Rho, myosin phosphatase and contraction in 
vascular smooth muscle. Biochem J 394: 581-592.
Ward, S. G. (2004) Do phosphoinositide 3-kinases direct lymphocyte navigation? Trends Immunol 25: 
67-74.
Ward, S., Sotsios, Y., Dowden, J., Bruce, I., and Finan, P. (2003) Therapeutic potential of 
phosphoinositide 3-kinase inhibitors. Chemistry & Biology 10: 207-213.
Ware, L. B. and Matthay, M. A. (2000) The acute respiratory distress syndrome. N Engl J  Med 342: 
1334-1349.
Webb, L. M., Vigorito, E., Wymann, M. P., Hirsch, E., and Turner, M. (2005) Cutting edge: T cell 
development requires the combined activities of the p i lOgamma and p i lOdelta catalytic isoforms of 
phosphatidylinositol 3-kinase. J  Immunol 175: 2783-2787.
Wenzel, S. E. and Busse, W. W. (2007) Severe asthma: Lessons from the Severe Asthma Research 
Program. Journal o f Allergy and Clinical Immunology 119: 14-21.
West, K. A., Brognard, J., Clark, A. S., Linnoila, I. R., Yang, X., Swain, S. M. et al. (2003) Rapid Akt 
activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway 
epithelial cells. J  Clin Invest 111: 81 -90.
White, A. M., Yoshimura, T., Smith, A. W., Westwick, J., and Watson, M. L. (1997) Airway 
inflammation induced by recombinant guinea pig tumor necrosis factor-alpha. Am J  Physiol 273: L524- 
L530.
Whitman, M., Downes, C. P., Keeler, M., Keller, T., and Cantley, L. (1988) Type I 
phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. 
Nature 332: 644-646.
Wills-Karp, M. (2004) Interleukin-13 in asthma pathogenesis. Immunol Rev 202: 175-190.
Wills-Karp, M., Luyimbazi, J., Xu, X., Schofield, B., Neben, T. Y., Karp, C. L. et al. (1998) 
Interleukin-13: Central mediator of allergic asthma. Science 282: 2258-2261.
Wipf, P. and Halter, R. J. (2005) Chemistry and biology of wortmannin. Org Biomol Chem 3: 2053- 
2061.
Woodgett, J. R. (2005) Recent advances in the protein kinase B signaling pathway. Curr Opin Cell Biol 
17: 150-157.
Workman, P., Clarke, P. A., Guillard, S., and Raynaud, F. I. (2006) Drugging the PI3 kinome. Nat 
Biotechnol 24: 794-796.
Wu, D. (2005) Signaling mechanisms for regulation of chemotaxis. Cell Res 15: 52-56.
Wu, J. and Janknecht, R. (2002) Regulation of the ETS transcription factor ER81 by the 90-kDa 
ribosomal S6 kinase 1 and protein kinase A. J  Biol Chem 277: 42669-42679.
Wu, Y. M., Robinson, D. R., and Kung, H. J. (2004) Signal pathways in upregulation of chemokines by 
tyrosine kinase MER/NYK in prostate cancer cells. Cancer Res 64: 7311-7320.
Wymann, M. P. and Pirola, L. (1998) Structure and function of phosphoinositide 3-kinases. Biochim 
Biophys Acta 1436: 127-150.
190
Chapter 8 -  References
Wysk, M., Yang, D. D., Lu, H. T., Flavell, R. A., and Davis, R. J. (1999) Requirement of mitogen- 
activated protein kinase kinase 3 (MKK3) for tumor necrosis factor-induced cytokine expression. Proc 
Natl Acad Sci U SA  96: 3763-3768.
Xu, H., He, Y., Yang, X., Liang, L., Zhan, Z., Ye, Y. et al. (2007) Anti-malarial agent artesunate 
inhibits TNF-{alpha}-induced production of proinflammatory cytokines via inhibition of NF-{kappa}B 
and PI3 kinase/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes. 
Rheumatology 46: 920-926.
Yamamoto, C., Yoneda, T., Yoshikawa, M., Fu, A., Tokuyama, T., Tsukaguchi, K. et al. (1997)
Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest 112: 505-510.
Yamamoto, H., Sedgwick, J. B., and Busse, W. W. (1998) Differential regulation of eosinophil 
adhesion and transmigration by pulmonary microvascular endothelial cells. J  Immunol 161: 971-977.
Yamaoka, S., Courtois, G., Bessia, C., Whiteside, S. T., Weil, R., Agou, F. et al. (1998) 
Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF- 
kappaB activation. Cell 93: 1231-1240.
Yang, M., Hogan, S. P., Henry, P. J., Matthaei, K. I., McKenzie, A. N. J., Young, I. G. et al. (2001) 
Interleukin-13 mediates airways hyperreactivity through the IL-4 receptor-alpha chain and STAT-6 
independently of IL-5 and eotaxin. Am J  Respir Cell Mol Biol 25: 522-530.
Yasunaga, S., Yuyama, N., Arima, K., Tanaka, H., Toda, S., Maeda, M. et al. (2003) The negative- 
feedback regulation of the IL-13 signal by the IL-13 receptor alpha2 chain in bronchial epithelial cells. 
Cytokine 24: 293-303.
Yeh, W. C., Shahinian, A., Speiser, D., Kraunus, J., Billia, F., Wakeham, A. et al. (1997) Early 
lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in 
TRAF2-deficient mice. Immunity 7: 715-725.
Yip, S. C., El-Sibai, M., Hill, K. M., Wu, H., Fu, Z., Condeelis, J. S. et al. (2004) Over-expression of 
the p i lObeta but not pi lOalpha isoform of PI 3-kinase inhibits motility in breast cancer cells. Cell 
Motil Cytoskeleton 59: 180-188.
Yum, H. K., Arcaroli, J., Kupfner, J., Shenkar, R., Penninger, J. M., Sasaki, T. et al. (2001) 
Involvement of phosphoinositide 3-kinases in neutrophil activation and the development of acute lung 
injury. J  Immunol 167: 6601-6608.
Zandi, E., Rothwarf, D. M., Delhase, M., Hayakawa, M., and Karin, M. (1997) The IkappaB kinase 
complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB 
phosphorylation and NF-kappaB activation. Cell 91: 243-252.
Zeidel, A., Beilin, B., Yardeni, I., Mayburd, E., Smirnov, G., and Bessler, H. (2002) Immune response 
in asymptomatic smokers. Acta Anaesthesiol Scand 46: 959-964.
Zhang, J. G., Hilton, D. J., Willson, T. A., McFarlane, C., Roberts, B. A., Moritz, R. L. et al. (1997) 
Identification, purification, and characterization of a soluble interleukin (IL)-13-binding protein. 
Evidence that it is distinct from the cloned IL-13 receptor and IL-4 receptor alpha chains. J  Biol Chem 
272: 9474-9480.
Zheng, T., Zhu, Z., Wang, Z., Homer, R. J., Ma, B., Riese, R. J., Jr. et al. (2000) Inducible targeting of 
IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J  Clin 
Invest 106: 1081-1093.
Zheng, Y., Saftig, P., Hartmann, D., and Blobel, C. (2004) Evaluation of the contribution of different 
ADAMs to tumor necrosis factor {alpha} (TNF {alpha}) shedding and of the function of the 
TNF {alpha} ectodomain in ensuring selective stimulated shedding by the TNF {alpha} convertase 
(TACE/ADAM17). J  Biol Chem 279: 42898-42906.
191
Chapter 8 -  References
Zhong, H., Shlykov, S. G., Molina, J. G., Sanborn, B. M., Jacobson, M. A., Tilley, S. L. et al. (2003) 
Activation of murine lung mast cells by the adenosine A3 receptor. J  Immunol 171: 338-345.
Zhou, X., Trudeau, J. B., Schoonover, K. J., Lundin, J. I., Barnes, S. M., Cundall, M. J. et al. (2005) 
Interleukin-13 augments transforming growth factor-betal -induced tissue inhibitor of 
metalloproteinase-1 expression in primary human airway fibroblasts. Am J  Physiol Cell Physiol 288: 
C435-C442.
Zhu, Z., Homer, R. J., Wang, Z., Chen, Q., Geba, G. P., Wang, J. et al. (1999) Pulmonary expression of 
interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic 
abnormalities, and eotaxin production. J  Clin Invest 103: 779-788.
Zlotnik, A. and Yoshie, O. (2000) Chemokines: a new classification system and their role in immunity. 
Immunity 12: 121-127.
Zor, T. and Selinger, Z. (1996) Linearization o f the Bradford protein assay increases its sensitivity: 
theoretical and experimental studies. Anal Biochem 236: 302-308.
Zuany-Amorim, C., Manlius, C., Dalum, I., Jensen, M. R., Gautam, A., Pay, G. et al. (2004) Induction 
of TNF-alpha autoantibody production by Auto Vac TNF 106: a novel therapeutic approach for the 
treatment of allergic diseases. Int Arch Allergy Immunol 133: 154-163.
Zurawski, S. M., Chomarat, P., Djossou, O., Bidaud, C., Mckenzie, A. N. J., Miossec, P. et al. (1995) 
The primary binding subunit of the human interleukin-4 receptor is also a component of the 
interleukin-13 receptor. J  Biol Chem 270: 13869-13878.
192
